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Interleukin-10 (IL-10) is a key immuno-regulatory cytokine with potent anti-
inflammatory effects. IL-10 contributes to immuno-suppression by inhibiting the 
presentation of antigen and decreasing the production of pro-inflammatory 
cytokines from innate cells such as dendritic cells and macrophages which in turn 
can suppress the activity of adaptive T cells. However, much is still unknown 
about the precise mechanisms through which this cytokine exerts its effects. This 
thesis used protein engineering techniques to explore the molecular mechanisms 
underpinning IL-10’s activities. 
 
IL-10 occurs naturally as a dimeric molecule which binds two receptor subunits: 
IL-10Rα and IL-10Rß. It has very poor affinity for the IL-10Rß receptor subunit 
and is unable to bind IL-10Rß in the absence of IL-10Rα (Walter, 2014). Using 
error-prone yeast display we were able to generate a variant of IL-10 which could 
directly bind to the IL-10Rß subunit, with affinities in the low micromolar range. 
This variant was recombinantly expressed in both the monomeric and dimeric 
conformations. Using these engineered variants in combination with the wild type 
monomeric and dimeric IL-10, allowed us to examine the contribution of both 
receptor affinity and stoichiometry to IL-10’s activities. 
 
Single particle imaging of the receptor subunits on the surface of live cells showed 
that increased affinity for IL-10Rß enhanced heterodimerisation of IL-10Rα and 
IL-10Rß for both the monomeric and dimeric variants. This increased receptor 
complex assembly translated into increased STAT1 and STAT3 activation by the 
high affinity monomer compared to the wild type monomer. The high affinity dimer 
showed a similar maximal STAT activation compared to the wild type dimer 
however, it also showed favourable activity at lower concentrations. This resulted 
in enhanced biological activities by the high affinity dimer compared to the wild 
type at sub-saturating concentrations e.g., enhanced suppression of LPS-
induced IL-6 secretion.  
 
In order to view differences between the variants on a more global level, RNA 
sequencing was performed on human primary monocytes and CD8 T cells, 




high affinity monomer had enhanced regulation of almost all transcripts compared 
to the wild type monomer however, it failed to reach dimeric expression levels. 
The wild type dimer showed poorer gene regulation when used at low doses, 
particularly when looking at suppression of pro-inflammatory cytokines and 
chemokines in monocytes. The high affinity dimer showed enhanced regulation 
of subsets of genes at low doses compared to the wild type, suggesting that 
improved receptor affinity could be used to overcome dose-dependent limitations. 
These data demonstrate that both stoichiometry and affinity play a large role in 
IL-10’s activities. 
 
A structure of the complete IL-10/IL-10Rα/IL-10Rß complex is lacking, hindering 
our understanding of the molecular interactions in this cytokine-receptor complex. 
We used our high affinity variants to attempt crystallisation of the receptor 
complex. While a stable complex was successfully purified by gel filtration, no 
crystals were generated. However, work done here lays the foundation for future 
attempts using alternate technologies such as cryogenic electron microscopy. 
 
IL-10 has also been shown, under certain conditions, to enhance the tumour 
targeting ability of CD8 T cells (Naing et al., 2018) however much is still unknown 
about this process. We used proteomics as well as RNA sequencing to examine 
the action of IL-10 in human CD8 T cells. This study showed that IL-10 can 
downregulate exhaustion markers in these cells. In addition, it highlighted 
downregulation of several enzymes in glycolysis as well as an upregulation of 
several mitochondrial components, indicating that IL-10 may be regulating 
metabolic processes in CD8 T cells. While these results are only considered 
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Cytokines are a diverse family of ligands containing interleukins, interferons, 
chemokines, and growth factors, which critically contribute to the regulation of 
mammalian physiology. A unique feature of cytokines is their ability to elicit highly 
pleiotropic activities. Most cytokines trigger a wide range of biological responses, 
making the study of this family of ligands very challenging.  
 
Cytokines are implicated in the pathologies of diseases such as asthma, arthritis 
and psoriasis (Foster et al., 2002, McInnes and Schett, 2007, Baliwag et al., 
2015). Cytokine deficiencies can also cause severe pathologies such as Severe 
Combined Immunodeficiency (SCID) and Crohn’s disease (Kovanen and 
Leonard, 2004, Correa et al., 2009). These observations highlight the importance 
of cytokines in human health. However, due to the complexity of the responses 
elicited by these ligands, our ability to translate them into the clinic is very limited, 
stressing the need for a more detailed molecular understanding of cytokine 
signalling and responses. 
 
In this thesis I will focus specifically on interleukin-10 (IL-10), however I will first 
outline some general principles shared by all cytokines to better illustrate the 
complexity of this family of ligands.  
 
1.1.1 Cytokine-receptor interactions 
 
Cytokine receptors are single-pass transmembrane proteins. Their extracellular 
domain binds the cytokine and determines affinity. The cytoplasmic domain of 
most receptors is constitutively associated with a kinase, allowing signalling to 
occur via the Janus Kinase (JAK)/Signal Transducer and Activator of 
Transcription (STAT) pathway (Figure 1.1). JAK/STAT signalling will be 
discussed in greater detail below. Cytokine receptors themselves can be sub-
divided into several families based on their structure and the cytokines they bind. 




subunit forms a complex with another identical subunit to induce signalling, e.g. 
erythropoietin (EPO) and human growth hormone (hGH) receptors. The majority 
of cytokine receptors, however, are heterodimeric, being composed of different 
receptor subunits. In addition, many receptor subunits can function in more than 
one cytokine receptor complex. For example, the glycoprotein 130 (gp130) 
receptor is a component of the IL-6, IL-27, LIF and oncostatin M cytokine receptor 
complexes (Silver and Hunter, 2010) The IL-10, IL-22, IL-26 receptors and type 
III interferons share the IL-10 receptor beta chain (IL-10Rß) subunit (Yoon et al., 
2010) and the common gamma chain (γc) receptor  functions in the IL-2, IL-4, IL-
7, IL-15 and IL-21 systems (Pulliam et al., 2016). Cytokine receptor complexes 
usually have a receptor subunit which is specific for a particular cytokine. The 
cytokine IL-6 binds to the specific IL-6Rα chain in a complex with the shared 
gp130 receptor.  IL-2 binds it’s particular IL-2Rα and IL-2ß chains in a multiplex 
with the shared γc receptor (Pulliam et al., 2016) and IL-10 binds to its distinct IL-
10Rα subunit along with the shared IL-10Rß component (Walter, 2014).  
Cytokines utilise a limited set of receptors and signalling molecules to carry out 
diverse functions in multiple cell types. This deceptively simple system of 
molecules is governed by complex biophysical interactions between the cytokine 
and its receptor as well as interactions between the receptor and intracellular 
 
Figure 1.1 Schematic of cytokine receptor structure. Cytokine receptors are composed of an 
extracellular domain which binds to the ligand. They span the membrane with a  transmembrane 
domain. The intracellular domain can vary in length depending on the cytokine.  The intracellular 
domain is usually constitutively associated with a Janus kinase (JAK) which allows downstream 













signalling molecules. These interactions determine the biological response. 
Variables such as receptor stoichiometry, geometry and affinity as well as 
regulation of receptor and kinase expression levels are crucial facets of how 
cytokines carry out their functions (Moraga et al., 2014). 
 
1.1.2 Stoichiometry of the cytokine-receptor complex 
 
In order for intracellular signalling to occur, the cytokine receptors must dimerise 
or oligomerise. There is debate in the field as to whether dimerisation of receptor 
subunits is induced upon cytokine binding or whether receptors are pre-formed 
dimers in the absence of ligand (Atanasova and Whitty, 2012). Several homo-
dimeric receptor systems have been thought to exist as pre-formed dimers where 
ligand binding induces a conformational shift to allow the intracellular kinase 
domains to interact. One example of this is the EPO receptor (EPO-R) system 
where the crystal structure of the extracellular domains in the absence of ligand 
showed EPO-R dimers (Livnah et al., 1999). Pre-formed receptor complexes 
have also been suggested for other systems such as growth hormone receptor 
(GH-R) and thrombopoietin receptor (TPO-R) (Brown et al., 2005, Matthews et 
al., 2011). 
 
Opposing this is the model of ligand-induced receptor assembly whereby 
cytokine receptors diffuse within the plasma membrane as monomers and the full 
complex is only assembled upon binding of the cytokine. In many cytokine 
systems the cytokine has preferential affinity for one receptor subunit which 
suggests a step-wise binding pattern. Experiments using single particle 
fluorescence imaging have allowed visualisation of individual receptors on the 
surface of live cells and these studies have shown that receptor subunits act as 
monomers in the absence of ligand in several cytokine-receptor systems such as 
type I interferons (IFNs), IL-13, IL-4 and EPO (Moraga et al., 2015a, Wilmes et 
al., 2015, Richter et al., 2017, Wilmes et al., 2020).  
 
It is possible that cytokine receptors transition between both a monomeric and a 
dimeric state in the absence of ligand, depending on the local concentration of 
the receptors at the cell surface, forming an equilibrium rather than two opposing 




analyse receptor systems can themselves introduce artefacts. For example, the 
use of crystal structures, while informative, use very high concentrations of 
receptor proteins which would not be reached under normal conditions on the cell 
surface. Similarly, the use of artificial systems such as tagged receptors usually 
requires large overexpression. However, in both the pre-assembled and ligand-
induced assembly models, some form of cytokine-induced receptor 
reorganisation is essential for signal transduction. While binding patterns vary 
between cytokines, it is accepted that the binding event allows the formation of 
an activated receptor complex which brings the cytoplasmic domains of the 
receptors into close proximity, allowing phosphorylation by receptor-associated 
kinases (Atanasova and Whitty, 2012, Schreiber and Walter, 2010). 
 
1.1.3 Geometry of the cytokine-receptor complex 
 
The role that cytokine-receptor binding topology plays in activating signalling is 
complex and remains an area of interest in the field. Initially it was thought that 
only receptor dimerisation was needed to induce signalling, regardless of the 
conformation of the receptor extracellular domains. Work using chimeric 
receptors reinforced this idea. Studies where the extracellular domain (ECD) of 
EPO-R was replaced with the ECD of epidermal growth factor receptor or the 
tyrosine kinase receptor c-kit showed that these hybrid receptors could induce 
signalling similar to the wildtype receptor when bound to their respective ligand. 
This suggested that once dimerisation was achieved, the precise geometry of the 
ECD was permissible to change (Ohashi et al., 1994).   
 
However, other studies have demonstrated that the geometry of the receptor 
complex can critically contribute to internal signalling. Studies have used dimeric 
coiled-coils to replace the ECD of both the EPO-R and TPO-R to further 
understanding of how receptor orientation impacts signalling (Staerk et al., 2011, 
Seubert et al., 2003). For EPO-R only one dimeric conformation allowed full 
activity with a second conformation giving only partial activity (Seubert et al., 
2003). However, for the TPO-R there were several orientations which could 
induce biological activity, suggesting that this system was more permissible to 
changes in orientation (Staerk et al., 2011). Nevertheless, different conformations 




geometry could be used to fine-tune the signalling output. More recently studies 
have demonstrated that surrogate ligands for the EPO-R could induce differential 
signalling patterns and this was dependent on the orientation of the receptor 
topology (Moraga et al., 2015b, Mohan et al., 2019).  
 
The use of synthekines, molecules designed to activate non-native pairings of 
receptor heterodimers, has also been able to give us insight into the role that 
receptor topology plays in cytokine signalling. Novel synthekines were able to 
activate unique combinations of STATs and induce biological responses (Moraga 
et al., 2017). However, the authors of this study did note that the amplitude of 
signalling induced by the synthekines was reduced compared to their parent 
cytokines. This underlines the importance of the binding topology in signal 
potency.  
 
Together these examples illustrate the importance of receptor geometry in the 
cytokine response. However, the geometry of the complex is just one facet of 
regulation of the cytokine response. The affinity and the stability of the cytokine-
receptor interaction also critically contribute to the signalling outcome. 
 
1.1.4 Affinity, stability and kinetics of the cytokine-receptor complex 
 
The stability of the cytokine-receptor complex can determine the specificity of the 
cytokine as well as the signalling patterns it induces. The ligand-receptor affinity 
is a key factor in the stability of the complex. An example of this is seen in the 
type I IFN family. This family of cytokines all utilise the same receptor complex 
(IFNAR1 and IFNAR2), however different family members can induce different 
potencies of biological effects (Piehler et al., 2012). Studies have attempted to 
delineate the root of these differences by generating ligands with altered affinity 
for IFNAR1 and IFNAR2. A study which generated IFNα2 mutants with differential 
binding affinity ratios to the receptor subunits showed that the antiproliferative 
and antiviral activity of the mutants correlated with the overall complex stability, 
rather than the affinity for a specific receptor (Kalie et al., 2008).  
 
Other examples of the influence of complex stability on biological activity include 




receptor complex (IL-4Rα and IL-13Rα) however they can induce cytokine-
specific effects (Junttila et al., 2008). This is dependent on the affinity for the 
cytokines for IL-4Rα which in turn determines the sensitivity of particular cell 
types for each cytokine based on the expression of IL-4Rα (Junttila et al., 2008). 
A recently published study from our laboratory using engineered variants of IL-6 
with differential gp130 binding affinities showed that reduced receptor binding 
affinity and hence less stable complexes, could affect the intracellular trafficking 
of the receptor complexes. This in turn lead to reduced STAT1 phosphorylation, 
highlighting how changes in affinity can translate into differential signalling 
patterns (Martinez-Fabregas et al., 2019).  
 
These examples illustrate the potential for alterations of cytokine signalling 
patterns using variants with differential binding stabilities and kinetics. Other 
factors such as actin cytoskeleton compartments, intracellular JAK interactions 
and endosome recycling can also impact stability (Moraga et al., 2015a, You et 
al., 2016, Wilmes et al., 2015). 
 
1.2 JAK/STAT signalling 
 
Although there are a broad range of cytokines activating multiple receptor 
combinations, they rely on a limited range of intracellular signalling molecules to 
induce biological responses. Specific gene induction programmes triggered by 
JAK/STAT activation allow cytokines to carry out their diverse range of functions 
and are central to the activity of both innate and adaptive immune cells. Other 
signalling pathways have also been described for cytokine systems such as 
mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase 
(PI3K)/Akt pathways. Knowledge of the exact contribution of these alternate 
pathways to IL-10 activities is lacking and outside the scope of this thesis, 
therefore, this section will focus on the role of JAK/STAT signalling in cytokine 




Associated with the cytoplasmic tail of the cytokine receptor are tyrosine kinases 




conserved domains which allow them to carry out their function (Figure 1.2). At 
the N terminus of the JAK is the FERM (band four-point-one, ezrin, radixin and 
moesin) homology domain which facilitates interaction with the cytoplasmic tail of 
the cytokine receptor (Yamaoka et al., 2004). This is adjacent to an SH2 (scr-
homology 2)-like domain, followed by a regulatory pseudokinase domain 
(Lupardus et al., 2014). The C terminus of JAKs contain the catalytic tyrosine 
kinase domain (Alicea-Velazquez and Boggon, 2011).  
Different cytokine receptors have specific JAKs associated with them. Upon the 
receptor subunits coming into close proximity the associated JAKs phosphorylate 
each other on their tyrosine residues via their kinase domain (Jatiani et al., 2010). 
The JAKs are then in an active formation and phosphorylate the receptor’s 
intracellular tyrosine residues. This provides a docking site for the STAT 
molecules.  
 
JAKs are important for signal transduction but also for receptor expression 
patterns. Many cytokine receptor surface expression levels are controlled by 
JAKs, for example Tyk2 is required for stable surface expression of IFNAR1 
(Ragimbeau et al., 2003). As well as regulating receptor expression, JAKs can 
modulate the stability of the cytokine-receptor complex. In the growth hormone 
receptor, interactions between two JAK2 molecules were shown to contribute to 
signalling (Brooks et al., 2014). Interactions between JAK1 and TYK2 were 
shown to stabilise the IFNAR complex in the IFN system (Wilmes et al., 2015). A 
recent study also showed that oncogenic mutations in JAK2 can facilitate 
receptor dimerisation of type I cytokine receptors in the absence of ligand 
(Wilmes et al., 2020). This highlights the intrinsic role that JAKs play in cytokine-




Figure 1.2 Schematic of JAK domains. JAKs can be divided into several domains based on 
their function and structure. The FERM domain at the N terminus binds to the receptor. The 
kinase domain is located at the C terminus.  
 







There are seven STATs in mammals: STAT1, STAT2, STAT3, STAT4, STAT5A, 
STAT5B, STAT6 and they reside in the cytosol in their inactivate state. Similar to 
JAKs, the specific STAT activated depends on the cytokine. STATs bind the 
receptor via their SH2 domain and become phosphorylated. This allows 
dimerisation of the STATs, either as homodimers or heterodimers. Upon 
dimerisation STATs can then translocate to the nucleus where they bind to DNA 
and induce transcription of gene expression programmes (O'Shea et al., 2013).  
 
Cytokines can activate multiple STATs and can modulate the levels to which 
these STATs are activated. This can be affected by the amount of available 
STATs within the cell or previous exposure to other cytokines. For example, IL-
10 can activate both STAT1 and STAT3, with STAT3 modulating the bulk of IL-
10’s anti-inflammatory activities (Williams et al., 2004). However, macrophages 
which have been primed with IFN-γ have a bias towards STAT1 activation and 
can suppress the ability of IL-10 to inhibit Major Histocompatibility Complex class 
II (MHC II) expression (Herrero et al., 2003).  
 
The stability of the cytokine-receptor complex can also affect STAT activation. 
Engineered IL-6 variants with differential affinities for gp130 had altered 
STAT1/STAT3 ratios, with STAT1 activation more sensitive to changes in affinity 
(Martinez-Fabregas et al., 2019). This study suggested that low affinity STATs 
require more stable cytokine-receptor complexes and larger doses to reach 
maximal signalling. This generated competition between STATs and altered the 
biological response. This is in agreement with other studies in the IFN system 
which showed that a mutation of one tyrosine residues in the IFNAR2 intracellular 
domain (ICD) could abolish both STAT1 and STAT2 activation, suggesting 
competition for receptor binding (Zhao et al., 2008). 
 
1.3 Interleukin-10  
 
IL-10 is a pleiotropic cytokine with many central immune-regulatory functions. It 
is the founding member of the IL-10 family of cytokines which include IL-19, IL-
20, IL-22, IL-24, IL-26 and IL-28 (Ouyang and O'Garra, 2019). IL-10 is the most 




termed secreted cytokine synthesis inhibitory factor (CSIF) due to its ability to 
inhibit secretion of IFNγ, IL-2 and other cytokines from Th1 cells (Fiorentino et 
al., 1989). IL-10 activates a hetero-tetrameric receptor complex, comprising two 
IL-10Rα and two IL-10Rß subunits (Figure 1.3). Upon assembly of this receptor 
complex, JAK1 and TYK2, associated with IL-10Rα and IL-10Rß respectively, 
are activated (Moore et al., 2001). This provides docking sites for STATs and 
their subsequent activation, dimerisation and nuclear translocation. IL-10 has 
been shown to activate STAT1, STAT3 and, in some cell types, STAT5 
(Wehinger et al., 1996). IL-10 receptor binding and signalling patterns will be 
discussed in detail below. 
IL-10 has been intensely studied since its discovery with huge progress being 
made characterising its effects on immune cell subsets. However, there are gaps 
in our knowledge of the molecular mechanisms underpinning some of IL-10’s 
activities as well as an incomplete structural understanding of how IL-10 binds its 
receptor complex. In the following sections I will outline what is known about IL-
 
Figure 1.3 Illustration of the IL-10 cytokine receptor complex. As a dimer, IL-10 binds two 
IL-10Rα and two IL-10Rß subunits. The kinases JAK1 and TYK2 are associated with the 
intracellular tails of IL-10Rα and IL-10Rß respectively. These are activated upon receptor 
dimerisation, phosphorylating the intracellular domain of IL-10Rα. This provides a docking site 












10 signalling, its anti-inflammatory effects and its immunostimulatory effects. I will 
also detail what is known about the structure of the IL-10 receptor complex. 
1.3.1 Interleukin-10 dimer and monomer 
 
IL-10 is a 36kDa homodimer comprised of two identical 160 amino acids 
polypeptides forming a domain-swapped dimer, similar to the structure of IFNγ 
(Zdanov et al., 1995). Each peptide chain consists of 6 alpha helices, A-F, and 
interconnect in a manner whereby helices E and F of one chain associate with 
helices A, B, C and D of the other chain (Zdanov et al., 1995) (Figure 1.4a). There 
are two disulphide bonds which connect the D-E loop to the N-terminus and helix 
C, however they do not link the two polypeptide chains together. 
While IL-10 exists as a dimer, it was shown that IL-10 monomers can form in non-
physiological conditions such as at low pH or high temperature (Syto et al., 1998). 
This study also showed that there was a correlation between the biological activity 
of IL-10 and the percentage of dimer present. To further investigate the properties 
 
Figure 1.4 IL-10 dimer and IL-10 peptide chain configuration. (a) Structural ribbon diagram 
of dimeric IL-10 (PDB 2H24) (Yoon et al., 2006). Dimeric IL-10 is composed of two interlinked 
peptide chains of six alpha helices each. Helices E and F of one chain associate with helices A-
D of the other chain to form a dimer (adapted from Walter, 2014). (b) Structural ribbon diagram 
of monomeric IL-10 (PDB 1LK3) (Josephson et al., 2002). A 6 amino acid extension between 





























of the IL-10 monomer, a stable monomeric form of IL-10 was generated 
(Josephson et al., 2000b). It was created by inserting a flexible 6 amino acid linker 
between alpha helices D and E which allowed helices E and F to fold into the cleft 
created by helices A-D (Figure 1.4b). Their study showed that the IL-10 monomer 
bound to IL-10Rα with a 1:1 stoichiometry. The IL-10 monomer had weaker 
biological activity than the wild type as shown by proliferation of cells transfected 
with either the human or murine IL-10Rα. It also had 9-18 fold less activity than 
the dimer, depending on the cell line used, however at high concentrations the 
monomer could reach the maximal activity induced by the dimer.  In addition, it 
was shown that the IL-10 monomer could not supress tumour necrosis factor 
alpha (TNF-α) secretion in a lipopolysaccharide (LPS)-stimulated macrophage 
cell line (Westerhof et al., 2012). Interestingly, the monomer is more thermally 
stable than the dimer.  
 
More recently, a more stable IL-10 dimer was generated (Minshawi et al., 2020). 
Here they used two IL-10 monomers subunits, linking the C terminus of one 
monomer and the N terminus of the second. This IL-10 variant had increased 
temperature and pH stability compared to the native dimer. Additionally, the 
stable IL-10 variant had improved biological activities at low concentrations 
compared to the wild type dimer. Together, these works demonstrate that the 
activity of IL-10 is dependent on its structure and stability. 
 
1.3.2 IL-10 receptors 
 
As mentioned previously IL-10 binds two receptor subunits, IL10Rα and IL-10Rß. 
As a dimeric molecule, IL-10 binds two IL-10Rα and two IL-10Rß subunits, to 
form a complete signalling complex (Figure 1.3). Both receptor chains are needed 
for IL-10’s activity.  
 
Human IL-10Rα is composed of three domains: an extracellular domain which 
binds IL-10, a transmembrane domain and an intracellular domain which is 
constitutively associated with JAK1 (Walter, 2014). IL-10Rα’s extracellular 
domain is formed of two ß-sandwich domains which are at an angle of 90 degrees 
to each other (Figure 1.5). The structure of IL-10 bound to the extracellular 




binds to IL-10Rα along the helix A, the AB loop and helix F and has high affinity 
for IL-10Rα, in the picomolar range. 
While IL-10Rα is specific for IL-10, IL-10Rß is termed a “promiscuous” cytokine 
receptor as it is shared between several other cytokines such as IL-22, IL-26 and 
IFN-lambda. It has a similar extracellular structure to IL-10Rα, forming two ß-
sandwich domains (Yoon et al., 2010) (Figure 1.6). However, it has a much 
shorter intracellular domain of only 83 residues, which is constitutively associated 
with TYK2. In contrast to IL-10Rα, IL-10 has very weak affinity for IL-10Rß with 
interactions in the millimolar range. Due to this weak affinity, a crystal structure 
of IL-10 in complex with both IL-10Rα and IL-10Rß has not been solved. 
However, a model has been developed based on mutagenesis studies and 
computational modelling (Yoon et al., 2010, Yoon et al., 2006). Residues that 
were involved in IL-10Rß binding mapped to the A and D helices of IL-10 (Yoon 
et al., 2006). Structure-based alignment of the IL-10 receptor complex with the 
IFN-lambda receptor complex also identified these helices as the IL-10Rß binding 
site. However, without a complete structure of the complete IL-10 ternary 




Figure 1.5 Structure of IL-10 bound to soluble IL-10Rα. IL-10Rα (magenta) has two domains, 
D1 at the N terminus (amino acids 1-98) and D2 at the C terminus (amino acids 105-205). One 










1.3.3 IL-10 receptor-complex assembly 
 
Much is still unknown about how this receptor complex is assembled, in part due 
to the lack of structural knowledge of the IL-10/IL-10Rß interaction. As mentioned 
previously, IL-10 has high affinity for IL-10Rα and much weaker affinity for IL-
10Rß (Walter, 2014). This means that IL-10Rα acts as the determining chain for 
IL-10 responsiveness and cells lacking IL-10Rα do not respond to IL-10 
(Nagalakshmi et al., 2004). While IL-10Rß has much weaker affinity for IL-10, it 
is crucial for IL-10 signalling, most likely due to its association with TYK2. This 
model of a high affinity binding receptor and a low affinity signalling receptor has 
been discussed previously in the literature and is seen in other cytokine/receptor 
systems (Schreiber and Walter, 2010). 
 
The exact mechanisms of the IL-10 receptor complex assembly are unknown, 
however two models have been proposed based on structural studies. A model 
of preformed IL-10 receptor dimers (Figure 1.7) was proposed where FRET 
analysis showed interactions between IL-10Rα and IL-10Rß in the absence of 
ligand (Krause et al., 2006). Another study supported this by demonstrating that 
the extracellular domain of IL-10Rα can be conformationally changed by co-
 
Figure 1.6 Structure of the IL-10Rß ectodomain. The structure of IL-10Rß was solved by Yoon 
et. al. 2010. (PDB 3LQM). Similar to IL-10Rα, IL-10Rß contains two domains, D1 at the N 










expression with IL-10Rß and that this was mediated by IL-10Rß’s intracellular 
domain (Wilbers et al., 2017).  
Another proposed mechanism is that of ligand-induced receptor assembly 
(Figure 1.8). Due to its high affinity for IL-10Rα it has been proposed that this is 
the first chain bound by IL-10 followed by subsequent binding of IL-10Rß. It has 
been shown that IL-10Rß has increased affinity for the IL-10/IL-10Rα complex, 
compared to IL-10 alone, supporting a stepwise assembly mechanism (Logsdon 
et al., 2002, Yoon et al., 2005).  
A further study demonstrated that IL-10Rα binding induces conformational 
changes in IL-10 which mediate IL-10Rß binding (Yoon et al., 2006). This could 
also be evidence for sequential receptor binding by IL-10. However other 
 
Figure 1.7 A model of the preformed IL-10 receptor complex. In this model IL-10Rα and IL-
10Rß are dimerised in the absence of IL-10 stimulation, with JAK1 and TYK2 inactive. Upon IL-
10 binding to this preformed receptor complex becomes activated, allowing intracellular 
phosphorylation by the associated JAK1 and TYK2. This allows the phosphorylation and 










Figure 1.8 A model of ligand-induced assembly by IL-10. This model postulates that IL-10Rα 
and IL-10Rß are not associated in the absence of IL-10. It has been proposed that IL-10 first 
binds to the high affinity IL-10Rα subunit, followed by IL-10Rß. Signalling will only occur upon 
assembly of the complete receptor complex with IL-10. Other permutations of receptor 











permutations of complex assembly are possible, such as IL-10 binding one IL-
10Rα followed by one IL-10Rß and then associating with the second chains. The 
exact pattern of receptor assembly is still unknown.  
 
1.4 IL-10 Signalling 
1.4.1 JAK/STAT signalling by IL-10 
 
The JAK/STAT activation pathway has been well characterised for the IL-10 
system. As mentioned previously, IL-10 activates JAK1 and TYK2, associated 
with IL-10Rα and IL-10Rß respectively. Macrophages from mice deficient in JAK1 
are unresponsive to IL-10 demonstrating its key function in IL-10 signalling (Rodig 
et al., 1998). The role of TYK2 however is still unclear. Some studies have shown 
that TYK2 is dispensable for known IL-10 responses such as inhibition of LPS-
induced TNF-α from macrophages (Wilbers et al., 2017, Karaghiosoff et al., 
2000). However, it has been shown to potentially play a role in modulating the 
amplitude of the response, with TYK2 knock out macrophages and dendritic cells 
(DCs) showing reduced STAT3 phosphorylation and impaired suppressor of 
cytokine signalling 3 (SOCS3) upregulation in macrophages but not DCs (Wilbers 
et al., 2017). This supports an earlier study which showed that macrophages from 
TYK2 knock out mice had reduced STAT1 and STAT3 phosphorylation,  requiring 
high concentrations of IL-10 to restore STAT3 phosphorylation (Shaw et al., 
2006). Upon activation of these constitutively associated tyrosine kinases, 
tyrosine residues Y446 and Y496 on the IL-10Rα cytoplasmic tail are 
phosphorylated (O'Farrell et al., 1998). These then act as docking sites for STAT 
binding. It has also been shown that IL-10 requires the presence of serine 
residues in the IL-10Rα cytoplasmic domain for the suppression of TNF-α, 
suggesting a docking site for additional signalling proteins, however this has not 
been explored in detail (Riley et al., 1999). 
 
STAT3 is the dominant factor activated by IL-10. Mice lacking STAT3 are 
embryonic lethal (Takeda et al., 1997) however conditional or cell-specific STAT3 
deficiencies have helped elucidate the role of this molecule in IL-10 signalling. 
When IL-10 was administered to a mouse macrophage cell line lacking the 
tyrosines needed for STAT3 recruitment, no inhibition of proliferation was seen, 




truncated STAT3 was used. However, this truncated STAT3 mutant was still able 
to inhibit LPS-induced TNF-α secretion whereas the tyrosine mutant could not, 
suggesting that certain IL-10 mediated effects had differential STAT3 
requirements (O'Farrell et al., 1998). In contrast, a subsequent study 
demonstrated that IL-10 did not inhibit LPS-induced TNF-α secretion in STAT3 
deficient macrophages (Riley et al., 1999). The key role of STAT3 in IL-10 
mediated anti-inflammatory activities was also highlighted in an elegant study in 
which they generated mice with a STAT3 deficiency in macrophages and 
neutrophils (Takeda et al., 1999). These mice presented with inflammatory 
symptoms and macrophages and neutrophils did not display IL-10 mediated 
downregulation of LPS induced TNF-α secretion. Together these studies 
demonstrate the key role that STAT3 plays in downstream IL-10 activities.  
 
IL-10 can also activate STAT1 and STAT5 (Wehinger et al., 1996). While the role 
of STAT3 is well understood, less is known about IL-10’s activation of STAT1 and 
STAT5. Phosphorylation of STAT1 was detected in macrophages, monocytes 
and T cells following IL-10 stimulation (Shaw et al., 2006, Herrero et al., 2003, 
Finbloom and Winestock, 1995). In contrast to these studies, work by Wilbers et 
al. could not detect STAT1 phosphorylation by IL-10 in bone marrow derived 
macrophages, dendritic cells or neutrophils (Wilbers et al., 2017). This study also 
showed that cells from STAT1 deficient mice responded normally to IL-10 with 
macrophages and dendritic cells showing inhibition of LPS induced TNF-α in 
addition to  inducing a survival signal in mast cells. Studies on the murine IL-10 
receptor showed that mutations of tyrosine residues in the IL-10Rα chain 
prevented activation of STAT3 but not STAT1, suggesting differential binding 
sites or indirect recruitment to the receptor (Weber-Nordt et al., 1996). 
Macrophages from mice deficient in STAT1 are able to respond to IL-10 by 
suppression of TNF-α production, confirming that STAT1 is not needed for this 
IL-10 response (Riley et al., 1999). These conflicting reports on IL-10’s ability to 
activate STAT1 may be explained in part by the influence of IFNγ on IL-10-
induced STAT1. It has been demonstrated that IFNγ can bias IL-10 towards 
STAT1 activation rather than STAT3, leading to differential gene expression 
(Herrero et al., 2003). Similarly, priming with IFNα has also been shown to 
increase IL-10 STAT1 activation (Sharif et al., 2004). The presence of other 




STAT1 and STAT3 activation by IL-10, particularly in macrophages. This also 
highlights that, while studies of purified cell populations are necessary to deduce 
cytokine functions, they may not accurately reflect the activities of the cytokine 
when in a multi-faceted immune environment. 
 
Very little work has been done examining the role that STAT5 plays in IL-10’s 
biological activities. STAT5 phosphorylation in response to IL-10 was first seen 
in BaF3 cells transfected with the murine IL-10 receptor (Wehinger et al., 1996). 
However, a similar response was not detected in neutrophils (Cassatella et al., 
1999). STAT5 activation was not detected in macrophages when stimulated with 
IL-10 but it was detected in mast cells, however only at the maximal concentration 
tested (Wilbers et al., 2017). Although in depth examination of STAT5 
phosphorylation by IL-10 in different immune cell subsets is lacking, it can be 
assumed from the work described above that STAT5 plays a limited role in 
responses to IL-10.  
 
1.4.2 Alternate IL-10 signalling pathways 
 
Activation of the JAK/STAT pathway is primarily used as a readout of IL-10 
activity. However other signalling pathways have been implicated in IL-10 activity 
such as phosphatidylinositol-3-kinase (PI3K) and AMP-activated protein kinase 
(AMPK) signalling pathways. The use of PI3K inhibitors in human primary 
macrophages decreased expression of several IL-10-inducible genes e.g. 
ARNT2. However, not all IL-10-regulated genes were affected following PI3K 
inhibition, an example being SOCS3 (Antoniv and Ivashkiv, 2011). Downstream 
of PI3K, protein kinase B (Akt) was shown to regulate expression of several IL-
10 inducible genes (Antoniv and Ivashkiv, 2011). Inhibition of PI3K partially 
suppressed the ability of IL-10 to inhibit IL-1ß however it did not impact the 
suppression of TNF-α. In addition, inhibition of PI3K did not significantly affect 
STAT3 or STAT1 phosphorylation, suggesting that these are non-reliant 
pathways (Antoniv and Ivashkiv, 2011). These results outline a distinct but 
selective role for PI3K/Akt signalling in the IL-10 response. 
 
AMPK has been shown to be activated in response to IL-10 (Sag et al., 2008).  




SOCS3 and other IL-10-inducible genes (Zhu et al., 2015). This study also 
showed that AMPK was involved in the activation of PI3K by IL-10 as well as 
mammalian target of rapamycin complex 1 (mTORC1) activation. Cells from 
AMPKα1 deficient mice showed reduced STAT3 phosphorylation and blocking 
AMPK signalling prevented STAT3 phosphorylation by IL-10 (Zhu et al., 2015). 
However, other STAT3 activating cytokines such as IL-6 do not rely on AMPK for 
STAT3 activation. This suggests that although AMPK can regulate STAT3 
phosphorylation, other signalling pathways also play a role.  
 
1.5 Anti-inflammatory effects of IL-10 
 
IL-10’s anti-inflammatory and immune-suppressive effects have been intensely 
studied and its potency as an immunoregulatory cytokine has led to repeated 
attempts to translate it into the clinic. IL-10’s main immune-regulatory functions 
are the suppression of antigen presentation and inhibition of pro-inflammatory 
cytokine production. These anti-inflammatory activities are primarily directed 
against myeloid cells such as macrophages, monocytes and dendritic cells which 
in turn lead to a decrease in T cell recruitment and activation, however IL-10 can 
also directly inhibit CD4 T cell subsets as discussed below. 
 
1.5.1 IL-10 mediated inhibition of antigen presentation 
 
IL-10 can potently inhibit antigen presentation and expression of costimulatory 
molecules by monocytes, macrophages and DCs (Mittal and Roche, 2015). The 
exact mechanisms through which it does this are still unclear however several 
explanations have been put forward. DCs constitutively express low levels of 
MHC on their cell surface which are upregulated along with co-stimulatory 
molecules by detection of pathogen associated molecular pattern molecules 
(PAMPs) via toll-like receptors (TLRs) ((Iwasaki and Medzhitov, 2004). IL-10 has 
been shown to negatively regulate TLR signalling which in turn supresses antigen 
presentation in DCs (Mittal and Roche, 2015). Monocytes and macrophages 
upregulate antigen presenting molecules after being primed with IFNγ (Keskinen 
et al., 1997). IL-10 can also negatively regulate IFNγ signalling, leading to 
inhibition of antigen presentation (Mittal and Roche, 2015). In addition, IL-10 can 




increasing expression of the ubiquitin ligase membrane-associated RING-CH 1 
(MARCH1) targeting these proteins (Thibodeau et al., 2008).  
 
This effective inhibition of antigen presentation has many knock-on effects for the 
adaptive immune response. In the absence of sufficient T-cell receptor (TCR) 
ligation by peptide/MHC molecules, T cells are unable to activate, leading to a 
reduction in effector T cells. While this can have negative impacts on the adaptive 
immune system’s ability to respond to pathogens it is also an important 
mechanism for self-tolerance and resolution of the immune response.  
 
1.5.2 Regulation of cytokine secretion by IL-10 
 
Another key facet of IL-10’s anti-inflammatory capabilities is its suppression of 
pro-inflammatory cytokine and chemokine secretion from a variety of cell types. 
As described above, the inhibition of LPS-induced TNF-α secretion from 
monocytes and macrophages by IL-10 is frequently used as a readout of IL-10 
activity. IL-10 was demonstrated to inhibit IL-1α, IL-6 and TNF-α at both the 
protein and mRNA level in LPS stimulated macrophages (Fiorentino et al., 1991). 
IL-10 can also inhibit the action of these cytokines by inducing the production of 
soluble TNF-α receptor and IL-1 receptor antagonist (Sabat et al., 2010). 
Production of soluble TNF-α receptor was observed upon IL-10 stimulation in 
monocytes (Joyce et al., 1994). The upregulation of IL-1 receptor antagonist 
occurs via stabilisation of mRNA (Cassatella et al., 1994). This blockade of 
inflammatory mediators in multiple cell types leads to the creation of an immune-
suppressive environment, preventing the activation of cells and inhibiting their 
effector functions.  
 
IL-10 has also been shown to inhibit IL-12 and IL-23 production (Schuetze et al., 
2005, D'Andrea et al., 1993). These cytokines are needed for the development 
of Th1 and Th17 cells, respectively, and so through its action on innate cells IL-
10 can hinder adaptive cell immunity. IL-10 also acts directly on T cells to inhibit 
production of cytokines, such as its ability to inhibit IFNγ secretion from Th1 cells 





IL-10 can inhibit several chemokines, leading to a reduction in cell recruitment 
and contributing to an anti-inflammatory environment. IL-10 was shown to reduce 
levels of the chemokines CCL2, CCL3 and CCL4 in the serum  (Olszyna et al., 
2000). It can also reduce the half-life of IL-8 mRNA in neutrophils (Kasama et al., 
1994). The regulation of cytokines and chemokines, particularly those that are 
pro-inflammatory, is a hallmark activity of IL-10 and allows it to dampen both the 
innate and adaptive immune responses. 
 
1.5.3 Clinical use of IL-10 as an anti-inflammatory therapeutic 
 
The above sections give a brief overview of IL-10’s anti-inflammatory capabilities. 
The regulatory effect mediated by IL-10 and its key role in immune homeostasis 
is clear when examining IL-10 deficient phenotypes. Mice deficient in IL-10 
develop chronic enterocolitis (Kuhn et al., 1993). Mutations in IL-10 or in either 
the IL-10Rα or IL-10Rß gene can be found in subsets of human patients with 
early-onset colitis (Glocker et al., 2009, Begue et al., 2011, Kotlarz et al., 2012). 
These patients have increased pro-inflammatory cytokine production from 
peripheral blood mononuclear cells (PBMCs), supporting IL-10’s role in 
controlling inflammatory cytokine secretion (Glocker et al., 2009). The link 
between defects in IL-10 and colitis were further highlighted in a genome-wide 
association study (GWAS) which found significant association between ulcerative 
colitis and a single nucleotide polymorphism (SNP) in IL-10 (Franke et al., 2008). 
Because of IL-10’s potency in controlling inflammation it was hoped that it could 
be used therapeutically in the treatment of inflammatory auto-immune diseases 
such as inflammatory bowel disease (IBD), rheumatoid arthritis and psoriasis. 
Harnessing the therapeutic potential of IL-10 has proved difficult, with only limited 
success in subsets of patients. I will outline the strategies used in IL-10 treatment, 
the outcomes seen and highlight hypotheses discussed in the literature as to why 
this promising therapeutic did not translate well into the clinic. 
 
In mouse studies, intraperitoneal introduction of splenic T cells from IL-10 
transgenic mice provided protection against the development of colitis 
(Hagenbaugh et al., 1997). When given to mice, genetically engineered IL-10 
producing bacteria reduced colitis symptoms in an induced model and could also 




suggested that administration of IL-10 could have therapeutic benefits for patients 
with IBD. However, several studies failed to prove efficacy with different variants 
of IL-10 being tested. In PBMCs isolated from healthy volunteers following 
recombinant IL-10 (Tenovil) administration, reduced levels of the pro-
inflammatory cytokines TNF-α and IL-1ß levels were observed following ex vivo 
LPS stimulation (Huhn et al., 1997). In addition, it was well tolerated and non-
toxic (Wang et al., 2019). An initial trial in Crohn’s disease patients showed that 
administration of recombinant IL-10 increased remission rates compared to a 
placebo (Fedorak et al., 2000). A subsequent larger study however showed no 
significant difference between recombinant IL-10 treated and placebo groups 
(Schreiber et al., 2000). Interestingly there was some clinical improvement in the 
8 μg/kg treatment group compared to the placebo group although not remission. 
In those that responded there was a decrease in NFкB p65 activation. A further 
study  assessing the effect of recombinant IL-10 in the prevention of recurrence 
of Crohn’s disease after surgery showed no efficacy (Colombel et al., 2001).  
 
The failure of IL-10 to act effectively as an anti-inflammatory agent in clinical trials 
for IBD may be due to the low concentrations of IL-10 reaching the 
gastrointestinal tract. This is supported by the comparatively better clinical 
response of psoriasis patients to IL-10 therapy where subcutaneous injection 
results in modest but significant improvements compared to those seen in 
Crohn’s disease patients (Al-Robaee et al., 2008, McInnes et al., 2001). IL-10 
has a short half-life of 1-5 hours (Huhn et al., 1997) meaning that sufficient 
concentrations may not reach the site of inflammation when administered 
systemically. Supporting this theory, the use of genetically engineered bacteria 
which can secrete IL-10 and deliver it directly to the gastrointestinal tract have 
shown promising results (Braat et al., 2006, Steidler et al., 2000). This was first 
shown using the bacteria Lactococcus lactis (Steidler et al., 2000) and more 
recently using Bifidobacterium bifidum bacteria (Mauras et al., 2018), highlighting 
the advantage of targeted delivery of IL-10 to mucosal sites. Further work is 
needed to design alternative strategies for IL-10 therapy in order to fully harness 





1.6 Immuno-stimulatory effect of IL-10  
 
While IL-10’s anti-inflammatory effects have been well characterised, it also 
possesses several stimulatory effects on certain immune cell subsets. It can 
enhance IgG and IgM secretion from B cells (Heine et al., 2014) and has a 
stimulatory effect on mast cells (Polukort et al., 2016), however these features 
are outside of the scope of this thesis. Several studies in recent years have 
highlighted the ability of IL-10 to enhance the function of cytotoxic effector CD8 
T cells, leading to its use in clinical trials as a cancer therapeutic, however the 
molecular basis of these properties is still being investigated (Oft, 2014).  
 
1.6.1 Effect of IL-10 on CD8 T cell cytotoxicity 
 
In contrast to its inhibitory effect on CD4 T cells, IL-10 has been shown to 
enhance the effector functions of CD8 T cells under certain conditions. This was 
first described in 1991 when recombinant IL-10 was shown to enhance IL-2 
mediated CD8 proliferation (Chen and Zlotnik, 1991). IL-10 can also prevent T 
cell apoptosis occurring after IL-2 withdrawal (Taga et al., 1993). A study 
examining the effect of recombinant IL-10 administration to Crohn’s disease 
patients reported an increase in IFNγ when whole blood cells isolated from 
patients who had been treated with a high dose of IL-10 were stimulated with 
phytohemagglutinin (PHA) ex-vivo (Tilg et al., 2002). An increase in IFNγ was 
also seen when recombinant IL-10 was given alongside LPS in healthy humans 
(Lauw et al., 2000). This induction of IFNγ by IL-10 prompted further study into 
potential stimulatory properties of this cytokine on CD8 T cells. In addition to an 
upregulation of IFNγ, IL-10 was also shown to upregulate granzyme B (Mumm et 
al., 2011).  
 
The ability of IL-10 to enhance CD8 cytotoxic functions has led to investigation of 
its use as a cancer therapeutic.  The role of endogenous IL-10 in cancer is multi-
faceted. Because of its potent anti-inflammatory properties, it was assumed that 
IL-10 levels would correlate negatively with tumour growth by generating an 
immuno-suppressive environment through inhibition of antigen presenting cells. 
Indeed, several studies have shown correlation between increased IL-10 levels 




2000). In addition, it was shown that melanoma cells can produce and secrete IL-
10 (Sato et al., 1996), suggesting that this may be a mechanism of immune 
evasion by cancerous cells. However, there are also studies which highlight a 
protective and/or anti-tumour effect mediated by IL-10. Mice deficient in IL-10 
were sensitive to tumour induction whereas mice which overexpressed IL-10 
showed protection against the same tumour induction (Mumm et al., 2011). A 
PEGylated version of IL-10 has been used to investigate whether IL-10 can 
provide a therapeutic benefit in tumour killing by CD8 T cells, both in mice and in 
humans. PEGylation of the cytokine increases its size, thereby increasing its half-
life and allowing it to be retained in circulation longer (Eliason, 2001). PEGylated 
IL-10 has been used in clinical trials and has been termed Pegilodecakin. A phase 
I trial demonstrated that it met safety and tolerability standards when 
administered to patients with solid tumours (Naing et al., 2016). A further in depth 
study was performed to assess how IL-10 influenced the CD8 T cell immune 
response in cancer patients (Naing et al., 2018). In this study they found that 
PEGylated IL-10 increased levels of IFNγ, granzyme B and IL-18 in patient serum 
as well as enhancing activity of CD8 T cells expressing immune checkpoint 
markers such as PD-1 and LAG-3. In addition, they saw increased T cell clonal 
expansion which correlated with decreased tumour burdens in patients that had 
responded positively to the treatment. When combined with anti-PD-1 therapy, 
PEGylated IL-10 gave a favourable response in eight out of nineteen patients. 
While these patients had already been treated with other therapies meaning that 
direct comparisons are hard to make, these data show a potential therapeutic 
use  for IL-10 in cancer treatment when combined with immune checkpoint 
inhibitors.   
 
This is not to say that IL-10 consistently plays a stimulatory role in CD8 T cells; it 
can inhibit CD8 T cells proliferation and induce anergy (Groux et al., 1998). 
However, these results were dependent on activation of CD8 T cells by antigen 
presenting cells (APCs). When a CD3 monoclonal Ab (mAb) was used these 
inhibitory effects were reduced, suggesting that this was a secondary effect of 
inhibition of APCs, rather than a direct CD8 effect (Groux et al., 1998). In addition, 
IL-10 has been shown to inhibit CD8 function in chronic viral infections by 
increasing glycan branching and interfering with TCR activation (Smith et al., 




activation state of the cells may also play a role in balancing inhibitory or 
stimulatory effects.  
 
Together these studies outline the complexity associated with examining the 
effect of IL-10 on CD8 T cells and highlight the need for further investigation into 
this subject.  
 
1.7 Protein engineering of cytokines 
 
In recent years protein engineering has become more common as a way of 
generating useful tools for the investigation of protein-receptor interactions as 
well as developing modified cytokines with alterative or improved activities. 
Examples include using engineered cytokines to enhance binding affinities, to 
improve structural studies, to augment signalling properties and even to alter cell 
targets (Spangler et al., 2015). Here I will discuss methods used in the literature 
to engineer cytokines with a particular focus on yeast display methodologies. 
 
Protein engineering can broadly be divided into two types: site-directed rational 
design and directed evolution. Rational design involves generating mutated 
proteins based on their known structure and protein interactions. Rational design 
of cytokines has the caveat of requiring detailed structural knowledge of the 
cytokine and its interactions with the receptor. In directed evolution, the protein 
of interest is subject to random mutagenesis followed by a selection process to 
enhance the presence of favourable mutations. This approach has the benefit of 
not requiring detailed structural knowledge of the protein interactions. A common 
method used for random mutagenesis in directed evolution is error-prone PCR 
(Cadwell and Joyce, 1992). This technique uses Taq polymerase under 
conditions which reduce its fidelity in order to introduce mutations into the gene 
of interest. The concentration of MgCl2 is usually increased, MnCl2 is added and 
the extension time is elongated. MnCl2 affects the fidelity of Taq polymerase. 
(Beckman et al., 1985) and MgCl2 acts as a cofactor for the polymerase, but at 
higher concentrations can result in decreased specificity of the polymerase and 
thus introduce mutations. During this process it is important to fine-tune the 




introduce premature stop codons or misfolded proteins, while also still generating 
enough variability for powerful selection. 
 
Once site-specific mutations or random mutations have been generated in the 
gene of interest, protein engineering then uses a selection mechanism to isolate 
favourable mutations, usually based on binding assays. There are several 
approaches which can be used for selection such as phage, bacterial or yeast 
display. For cytokine engineering, yeast display has been widely used due to its 
eukaryotic secretory apparatus which allows it to form disulphide bonds and 
glycosylate proteins (Spangler et al., 2015). The yeast display the cytokine 
variants on the cell surface. Large libraries of mutants can then be incubated with 
the receptor of interest and those with favourable binding patterns can be isolated 
using magnetic activated cell sorting and flow cytometry. Directed evolution 
provides artificial selection pressures on the library to remove unfavourable 
variants e.g. those that do not bind at a certain concentration.  
 
There are several examples of cytokines which have been moldulated using 
protein engineering techniques to alter the trafficking of the cytokine, the affinity 
of the cytokine for its receptor and the specificity of the cytokine. A series of 
studies were undertaken to improve the affinity of IFN-α2 for IFNAR1. Firstly, 
alanine mutations were used to identify the region on IFN-α2 which binds to 
IFNAR1 (Roisman et al., 2005). This identified three amino acids which, when 
substituted for alanine, increased the binding affinity and in turn increased 
biological activity. In a subsequent study these three mutations were combined 
to generate the “HEQ” IFN-α2 mutant which had comparable IFNAR1 binding 
affinity to IFNß and also similar anti-proliferative activity levels, far exceeding the  
wildtype (Jaitin et al., 2006). However, it only showed slightly increased antiviral 
activities. As this HEQ mutant had only alanine substitutions at the identified 
binding site positions, a phage library was used to generate mutants with further 
optimised amino acids at these positions (Kalie et al., 2007). The library contained 
all amino acid combinations at these positions which were then screened against 
IFNAR1, producing a mutant with 60-fold increased IFNAR1 affinity. This mutant 
displayed largely increased antiproliferative activity which had a superior anti-
tumour effect compared to wild type IFN-α2 in an in vivo tumour model. These 




ternary complex (Thomas et al., 2011). These studies highlight how protein 
engineering can be harnessed to provide information about cytokine-receptor 
activity at a myriad of levels: structural, signalling and biological activities.  
 
Attempts have been made to modulate the binding of IL-2 to its receptor 
complexes using error-prone PCR and yeast display, in order to improve its 
clinical efficacy (Levin et al., 2012). IL-2 can bind two receptor complexes: a high 
affinity ternary receptor complex containing two specific receptors, IL-2Rα and 
IL-2Rß, and the shared receptor γc or an intermediate complex of just IL-2Rß and 
γc (Wang et al., 2009). In this study a variant of IL-2 with 200-fold increased 
affinity for IL-2Rß was generated (Levin et al., 2012). This allowed the variant to 
signal through the IL-2Rß/γc complex to the same amplitude as for the high 
affinity ternary complex, ultimately allowing it to act in CD8 T cells but limiting its 
effect on regulatory T cells. This resulted in an enhanced anti-tumour response 
and decreased toxicity compared to wildtype IL-2, improving the therapeutic 
efficacy of the cytokine. This study is an elegant example of how protein 
engineering at the cytokine/receptor interface can be used to alter the specificity 
of the cytokine. 
 
This thesis uses protein engineering techniques to affinity mature the cytokine IL-





1.8 Aims and Objectives 
 
As outlined above, IL-10 is a potent immuno-regulatory cytokine which has been 
intensely studied for more than 30 years. However, there are still gaps in our 
knowledge of how this critical cytokine functions: how it interacts with its low 
affinity receptor subunit, the role stoichiometry plays in its activities, why it has 
translated poorly as a therapeutic for autoimmune disorders and finally, the 
molecular mechanisms underpinning its enhancement of CD8 activities.  
 
The first aim of this thesis was to use protein engineering techniques to generate 
a variant of IL-10 in both a monomeric and dimeric conformation, which had 
increased affinity for the IL-10Rß subunit. This gave us insight into the IL-10/IL-
10Rß binding interactions as well as providing us with ligands for use in in vitro 
systems.  
 
The second aim of the thesis was to use these variants to examine the effect of 
affinity and stoichiometry on IL-10’s activities at multiple levels of cytokine 
biology: receptor binding, receptor complex assembly, early signalling events and 
gene transcription. This provided us with information on how this cytokine 
functions at a molecular level and how changes at the receptor interface translate 
into biological activities. 
 
Due in part to its weak affinity for IL-10Rß, complete structural knowledge of the 
IL-10/IL-10Rα/IL-10Rß complex is lacking. The third aim of this thesis was to use 
the high affinity IL-10 variants as tools to further crystallisation attempts of this 
complex.  
 
IL-10 has been shown to enhance the cytotoxicity of CD8 T cells under certain 
conditions. While this effect has been well characterised at the cellular level, 
insight into the precise molecular mechanisms governing this effect are lacking. 
The final aim of the thesis was to use proteomics to observe changes induced by 
IL-10 in human CD8 T cells during activation. This highlighted a potential role for 




Chapter 2. Materials and Methods 
 
2.1 Cell Culture 
2.1.1 Growth media and buffers 
 
Complete RPMI (cRPMI): RPMI-1640 with L-glutamine (Gibco) supplemented 
with 10% foetal bovine serum (FBS) (Gibco), penicillin/streptomycin (100 U/mL) 
(Gibco). 
Hi5 media: Lonza Insect Xpress with glutamine (SLS) supplemented with 
gentamicin (10 µg/mL) (Gibco). 
SF9 media: SF9 III (Thermo) supplemented with gentamicin (10 µg/mL) (Gibco). 
PBE: Phosphate buffered saline, pH 7.2 (made in-house by SLS Central 
Technical Services, University of Dundee), 0.5% BSA (Sigma), 2 mM EDTA (SLS 
Central Technical Services)  
PBSA: Phosphate buffered saline, pH 7.2, (SLS Central Technical Services), 
0.5% BSA (Sigma) 
 
All cells were handled in laminar flow cell culture hoods. Cells were cultured in 
incubators maintained at 37⁰C, 5% CO2 with the exception of insect cells 
Trichoplusiani ni  (Hi5) (ThermoFisher) and Spodoptera frugiperda (SF9) 
(ThermoFisher) which were cultured with agitation (120 rpm) at 27-28ºC. 
 
2.1.2 Isolation of PBMCs  
 
Human buffy coats were supplied by the Scottish National Blood Transfusion 
Service (Licence agreement number 16-20, held by Dr. Ignacio Moraga). 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation (Lymphoprep, StemCell Technologies) following the manufacture’s 
protocol. Briefly, buffy coats were diluted 1:2 with pre-warmed RPMI. 25 mL of 
Lymphoprep was added to 50 mL falcon tubes (Eppendorf) and 25 mL of diluted 
buffy coat was layered on top of the Lymphoprep with care taken not to mix the 
layers. The mixture was centrifuged at 800 g for 30 minutes with no brake applied. 
After centrifugation the buffy coat layer was removed using sterile pastettes into 




were then washed twice with 50 mL of RPMI each time by centrifugation at 1200 
rpm for 5 minutes with brake applied. The total cells were then resuspended in 
50 mL cRPMI and a sample was taken for counting by flow cytometry (Beckmann 
Coulter Cytoflex S). 
 
2.1.3 CD8 T isolation 
 
From the isolated human PBMCs, CD8 T cells were isolated using two methods, 
the method used for each experiment is highlighted in the relevant figure legend 
of the results chapters.  
 
Negative cell selection was performed using the MojoSort CD8 T cell kit 
(Biolegend #480012) according to manufacturer’s protocols.  
 
The second method, used in the majority of experiments, is positive CD8 T cell 
isolation. Here PBMCs were resuspended in 500 µL cold PBE and 15 µL of anti-
FITC CD8 antibody (Biolegend) was added. Cells were incubated at 4⁰C in the 
dark for 15 minutes. Then, cells were washed with 10 mL PBE by centrifugation 
at 1200 rpm, 5 minutes. Supernatant was removed and cells were resuspended 
in 500 µL PBE and 70 µL of anti-FITC microbeads (Miltenyi #130-048-701) were 
added. Cells were incubated at 4⁰C in the dark for 15 minutes and washed as 
before. An LS column (Miltenyi #130-042-401) was placed in a QuadroMACS 
Separator (Miltenyi) and equilibrated by passing 3 mL of cold PBE through the 
column. Cells were resuspended in 500 µL of cold PBE and added to the column 
to magnetically separate the labelled CD8 T cells. Cells were washed on the 
column three times with 3 mL of PBE. The column was removed from the magnet 
and 5 mL of PBE was added to elute the cells using the plunger supplied with the 
kit. Eluted cells were counted by flow cytometry to visualise FITC CD8 staining. 
CD8 isolation gave populations that were >90% pure. 
 
2.1.4 Activation of T cells 
 
T cells were activated within a PBMC culture using the following protocol, adapted 
from the laboratory of Professor Doreen Cantrell (Division of Cell Signalling & 




106 cells/mL in cRPMI. IL-2 (20 ng/mL) (Proleukin, Novartis #709421) and anti-
CD3 (100 ng/mL) (Human UltraLEAF, Biolegend #317326) were added to the 
culture to activate the T cells present. This culture media was maintained for three 
days. On day three cells were centrifuged and media was removed and replaced 
with cRPMI/IL-2 (20 ng/mL) for a further two to three days to allow the activated 
population to expand. If cells were to be simulated for a dose response or a kinetic 
study then cells were placed in cRPMI with no IL-2 overnight before the 
experiment was performed to remove any background stimulation due to IL-2.  
 
For purified CD8 T cell cultures, the cells were activated in cRPMI with 
ImmunoCult Human CD3/CD28 T Cell Activator (1/1000 dilution) (StemCell 
#10971) and IL-2 (20 ng/mL) (Proleukin, Novartis) for three days. On day three, 
the cells were removed from this media and resuspended in cRPMI/IL-2 as above 
and cultured for a further 2-3 days.  
 
For examination of the effect of IL-10 on T cell activation, IL-10 (recombinantly 
expressed in the lab as detailed below) was added to the culture medium in 
addition to anti-CD3 and IL-2 as described above at the start of culture. On day 
three when the media was changed, fresh IL-10 was also added to the culture. 
The concentrations of IL-10 added to the media are listed in the relevant figure 
legends of the results sections.  
 
2.1.5 Isolation and culture of human monocytes 
 
A similar positive selection protocol as used for CD8 T cell isolation was used to 
isolate monocytes from buffy coats. Here an anti-CD14 FITC antibody was used 
(Biolegend) and the protocol above was followed. A >90% pure population was 
obtained. 
 
After isolation of CD14+ cells, the cells were cultured in cRPMI plus M-CSF (20 
ng/mL) (Biolegend #574804) for two days before stimulation. For experiments 
using IL-10 stimulation, the cells were treated with IL-10 for either 8 or 24 hours 






2.1.6 CAR T Cell generation and cytotoxicity assay 
 
The generation of the CAR T cells and the cytotoxicity cell assay was carried out 
by W. Warda, A Cozzani, C. Ferrand and S. Mitra, Institut pour la Recherche 
contre le Cancer de Lille, University of Lille (France). The IL-10 proteins used 
were made by the author of this thesis and sent to the University of Lille for use 
in this experiment. 
 
Lentiviral construct and genetically modified Chimeric Antigen Receptor (CAR) T-
cell transduction: The IL-1RAP (Interleukin-1 Receptor Accessory Protein) CAR 
lentiviral construct was generated as previously described (Warda et al., 2019). 
Briefly, this vector carries a 3rd generation CAR, an iCASP9 (inducible Caspase 
9) suicide gene and a delta CD19 surface gene. The mock control vector doesn’t 
contain the CAR sequence. 
 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient 
density centrifugation using Ficoll-Paque (Velizy-Villacoublay) with anonymous 
blood samples collected from healthy donors at a French blood center 
(Besançon, France). Donors provided written informed consent; the study was 
conducted in accordance with the ethical guideline (declaration of Helsinki) and 
approved by the local ethical the CPP-Est committee (France). 
 
Human tumor Monomac-6 cell line was obtained from DSMZ German collection 
of microorganisms and cell culture GmbH and stored in a master cell bank. The 
cells were cultivated in cRPMI 1640. Activated cells were established from 
healthy donors and transduced with lentiviral supernatant encoding the IL-1RAP 
CAR or Mock sequence. At day 5 post-activation, cells were put in the different 
culture conditions: IL-2 (500 UI/mL) with or without IL-10 variants at 25 nM for 3 
days. Then, IL-1RAP CAR T cells, Mock T cells and un-transduced T cells were 
used for the cytotoxicity assays. 
 
For CAR T cell cytotoxicity assay, prior to the co-culture, effector cells (un-
transduced T cells, Mock T cells and IL1RAP CAR T cells) were labeled with e-
Fluor v450 (eBioscience, #65-0842-85). Then effector cells were co-cultured with 




After 5 hours, cells were stained with 7-Aminoactinomycine D (7-AAD; BD 
Bioscience, #559925) and the percentage of alive Monomac-6 cells was 
determined by flow cytometry using a FACS Canto II (BD Bioscience). 
 
2.2 Flow Cytometry 
 
All antibodies, clones and suppliers are listed in Table 2.1 
Target Clone Fluorophore Dilution Catalogue 
Number  
Supplier 
CD3 UCHT1 BV-510 1:100 300448 Biolegend 
CD4 A161A1 PE 1:100 357404 Biolegend 
CD8a HIT8a AF700 1:100 300920 Biolegend 
CD8a HIT8a FITC 1:100 300906 Biolegend 
CD9 HI9A FITC 1:50 312103 Biolegend 
CD14 63D3 FITC 1:100 367116 Biolegend 
CD57 HNK-1 PE/Cy7 1:100 359623 Biolegend 
CD69 FN50 APC 1:50 310909 Biolegend 
CD71 A015 FITC 1:50 334103 Biolegend 
cMyc-tag 9B11 AF647 1:100 2233S CST 
GranzymeB GB11 FITC 1:100 515403 Biolegend 
HA-tag 6E2 AF647 1:100 3444S CST 
HLA-DR L243 PE 1:100 307605 Biolegend 
HLA-DR L243 APC 1:100 307609 Biolegend 
KLRG1 2F1 BV-711 1:100 138427 Biolegend 
LAG3 11C3C65 AF647 1:100 369303 Biolegend 
PD-1 EH12.2H7 AF488 1:50 329935 Biolegend 
pSTAT1 
(Y701) 
58D6 AF647 1:100 8009S CST 
pSTAT3 
(Y705) 
13A3-1 AF488 1:100 651006 Biolegend 
TIGIT A1515G3 PE 1:100 372703 Biolegend 
TIM3 F38-2E2 BV-510 1:100 345029 Biolegend 
Table 2.1 Antibodies used for flow-cytometry. 
 
2.2.1 Cell surface staining 
For live cell surface staining of cell surface molecules, the following protocol was 
used. T cells and non-adherent monocytes were removed from culture by 
centrifugation and resuspension in PBSA. Adherent monocytes were detached 




at 4⁰C or on ice during live cell surface marker staining and staining was done in 
96-well V-bottom plates (Greiner) unless otherwise stated. Cells were 
resuspended in 150 µL PBS and centrifuged at 1200 rpm for 5 minutes. FcR 
blocking was performed for 10 minutes at 4⁰C using human FcR blocking reagent 
(Miltenyi #130-059-091) diluted 1/5 in PBE to a volume of 50 µL per well. Cells 
were washed as above in 150 µL PBE and resuspend in 50 µL of antibody 
mixture, diluted in PBSA. Antibody incubation was for 30 to 60 minutes at 4⁰C in 
the dark. Cells were washed twice in PBSA before resuspension in 100 µL PBSA 
per well for analysis on the CytoFlex S flow cytometer (Beckman Coulter). 
 
2.2.2 Intracellular staining 
 
For intracellular staining cells were first fixed using a 2% final concentration of 
paraformaldehyde (Thermo) for 10 minutes at room temperature. Cells were then 
centrifuged at 1600 rpm for 5 minutes and resuspended in 150 µL PBS for 
washing. After another centrifugation step cells could then be resuspended in 
PBSA and stored at -80⁰C for analysis at a later point or else permeabilised. 
Permeabilisation was done by resuspending the cells in 500 µL 100% ice-cold 
methanol (VWR) in deep-well V-bottom blocks (Greiner) for a minimum of 30 
minutes. For granzyme B staining a different method of permeabilisation was 
used to enhance antibody staining due to reaction of the antibody to methanol. 
Here cells were incubated in 0.1% Triton-X100 (Sigma) in PBS for 10 minutes at 
room temperature.  
 
In both cases, cells were then washed in PBSA and FcR blocked as described 
above. After FcR blocking, cells were incubated in 50 µL of antibody mixture 
diluted in PBSA for an hour at room temperature before washing and analysis on 
the flow cytometer as previously described. 
 
2.2.3 Fluorescent Cell Barcoding 
 
Fluorescent cell barcoding as described in (Krutzik et al., 2011) was used to 
combine 16 different samples together for antibody staining. This increased 




and costs. Briefly, two dyes Dylight 800 (Thermo Scientific #10561664) and 
Pacific Blue (Thermo Scientific #P10163) were prepared at four concentrations 
each and mixed in 4 different ratios, providing a panel of 16 unique staining 
combinations with which individual samples could be identified. The top 
concentration of each dye was 100 µg/mL, DyLight800 was serially diluted one 
in four and Pacific Blue was diluted one in three in DMSO (Sigma). 10 μL of the 
barcoding dye set were added per well directly to the 500 μL of methanol used 
for cell permeabilisation, after 30 minutes of permeabilisation. The plate was 
vortexed briefly to ensure complete mixing and 500 μL of PBS was added per 
well to maintain the pH close to 7. The cells incubated on ice for 35 minutes. 1 
mL of PBSA was added per well to quench the dyes and cells were pelleted at 
1600 rpm for 5 minutes. Each well was resuspended in 50 μL of PBSA and each 
of the 16 wells of the shared barcode set were pooled together i.e., one pool of 
cells for each barcode dye set. Pooled cells were washed in PBSA and FcR 
blocked. Cells were then resuspended in an appropriate final volume to allow 
each pool to be divided equally between several wells for antibody staining. 
Antibody staining and analysis were done as described above. Compensation 
controls for barcoding were cells stained with the top concentration of either 
DyLight 800 or Pacific Blue (100 μg/mL). 
 
2.2.4 Mitotracker staining 
 
For analysis of mitochondrial mass MitoTracker Green FM (ThermoFisher 
#M7514) was used (provided by the Hundal laboratory, University of Dundee). 
For analysis of mitochondrial membrane potential MitoTracker Red FM was used 
(ThermoFisher #M22425). CD8 T cells were purified and activated as described 
above. Cells were then stained at day 6, 8 and 10 after activation. FCCP (carbonyl 
cyanidep-trifuoromethoxyphenylhydrazone) (provided by the Hundal laboratory, 
University of Dundee) was used as a positive control. A final concentration of 5 
μM FCCP was added to the cell culture media of the controls and incubated at 
37ºC for 45 minutes. The cells were then centrifuged and resuspended in media 
containing the MitoTracker dye. Both dyes were used at a final concentration of 
100 nM in RPMI without FBS. Cells were incubated at 37ºC for 20-30 minutes. 
The cells were then centrifuged at 1200 rpm and the MitoTracker media was 




to remove any remaining dye. This wash step was repeated a total of three times 
to reduce any background non-specific signal. Cells were then FcR blocked and 
live stained for CD8 as described above. 
 
2.2.5 Compensation and data analysis 
 
For all experiments appropriate compensation was applied to correct for spectral 
overlap. In some cases, a compensation matrix was created by staining cells with 
one of each of the fluorochromes to be used as well as an unstained cell sample. 
This was needed for compensations involving the fluorescent barcodes as 
described above. For all other experiments a compensation matrix was created 
by staining positive and negative beads (Beckman Coulter) with each of the 
fluorochromes. In all cases the compensation matrix was created using the 
CytExpert software on the CytoFlex S (Beckman Coulter).  
 
All data acquisition and gating was done using CytExpert software.  
 
2.3 Molecular Cloning 
2.3.1 Expression Vectors 
 
All bacterial growth media and agar plates were provided by SLS Central 
Technical Services, University of Dundee.  
 
During this project, several vectors for bacterial, insect and yeast protein 
expression were used. For yeast surface display a previously modified pCTCON2 
vector, pCT302, (Chao et al., 2006) was used, modified for the generation of a 
BamHI/NotI cloning site. This plasmid introduces a c-myc tag on the C-terminus 
of the displayed protein, allowing for its identification via flow cytometry and has 
a resistance marker for ampicillin.  
 
For insect expression of proteins two similar plasmids were used; the first was a 
previously modified version of pACgp67-A vector (BD Biosciences) (Levin et al., 
2012), altered to introduce a BamHI/NotI cloning site (pACgp67BN BH3). This 
plasmid introduces an N-terminal gp67 signal sequence and a hexa-histidine tag 




This plasmid also has a BH3 site for chemical biotinylation of the protein 
expressed. This BH3 site is a C-terminal biotin acceptor peptide (BAP)-
LNDIFEAQKIEWHW.  
 
The second plasmid used for insect cell expression was pACgp67 BN, differing 
only from the above by the removal of the BH3 site. 
 
For bacterial expression of proteins, the pET21 vector was used. This vector 
introduces a hexa-histidine tag at the N-terminus of the expressed protein and 
has a Lac promoter for inducible expression.  
 
2.3.2 Restriction digest, ligation and isothermal assembly 
 
Plasmids were digested at the appropriate cloning sites using restriction digest 
enzymes from New England Biolabs (BamHI, NotI, NdeI). Digests used 10x 
CutSmart buffer (NEB) and followed the manufacturer’s protocol for digestion (1 
hour at 37⁰C).  
 
Synthesised gene blocks (IDT) were used for generation of double-stranded DNA 
for insertion into expression vectors. 
 
Ligation was done using T4 Ligase (NEB) with T4 ligase buffer (NEB) according 
to the manufacturer’s protocol (1 hour at room temperature) and then used to 
transform DH5α bacteria. 
 
Isothermal assembly (ITA) was used in some cases to ligate plasmid and insert 
DNA. Gene blocks for ITA had overhanging 5’ and 3’ ends of 20-25 nucleotides 
corresponding with the vectors they were to be cloned into. Here an ITA master 
mix (see below) of 15 µL was added to 10-100 ng of purified cut plasmid and an 
equivalent of in-frame insert. The mixture was incubated at 50⁰C for 1 hour and 





5x isothermal assembly buffer: 
1M Tris-HCl pH 7.5, 1M MgCl2, 10mM dNTP mix, 1M DTT, PEG-8000 20 mg 
NAD.  
Isothermal assembly master mix:  
320uL 5x isothermal assembly buffer, 1 µL T5 exonuclease, 20uL Phusion 
polymerase, 160 uLTaq ligase, 700uLH2O. Used in 15uL aliquots. 
 
2.3.3 Bacterial Transformation 
 
For cloning and expression of vectors, the E. Coli strain DH5α was used. For 
bacterial protein expression strain BL21 (DE3) was used. The same 
transformation protocol was used for both. Frozen bacterial stocks were partially 
thawed on ice for 10 minutes. The appropriate amount of plasmid DNA was 
added to the partially thawed bacteria and incubated on ice for a further 10 
minutes. Bacteria were then heat-shocked by incubating at 45⁰C for 45 seconds 
and then returned to ice for a further 2 minutes. 1 mL of SOCS recovery media 
(SLS Central Technical Services)  was then added and the bacteria were placed 
at 37⁰C for 30 minutes to allow recovery.  
 
For single colony growth the bacteria were then centrifuged at 7000 rpm for 3 
minutes and supernatant was removed. Bacteria were resuspended in 100 µL of 
SOCS media and plated on the appropriate agar plate depending on antibiotic 
resistance (usually LB/ampicillin agar plates). 
 
For protein expression using BL21, the transformed bacteria were added to 10 
mL of terrific broth/ampicillin media and grown overnight at 37⁰C.  
 
2.3.4 Gel electrophoresis, gel extraction, PCR purification and miniprep  
 
For separation of restriction digest products or to visualise PCR products, 
agarose gel electrophoresis was used. For all gels a 1% agarose mixture was 
made by dissolving agarose (Invitrogen) in 1X TAE buffer (SLS Central Technical 
Services)  by heating. Gel red (Biotium) was added to the agarose solution at 1 
in 10,000 dilution as a nucleic acid dye. Samples were run at 110 V for 35 minutes 




For extraction of DNA and/or PCR purification, the Promega Wizard Gel and PCR 
Clean-Up Kit was used following manufacturer’s protocol. 
 
For extraction of plasmid from bacteria the Promega Wizard Miniprep Kit was 




All sequencing was performed by the in-house facility, MRC PPU DNA 
Sequencing and Services. Samples were submitted in 20 µL aliquots at 
concentrations ranging from 25-30 ng/µL, dilute in H2O. For primers used in 
sequencing please refer to table 2.2. Sequences were analysed using SnapGene 
Software, version 4.2.11. 
 
Primer Name Sequence Purpose 
AML-6 CGAGCTAAAAGTACAGTGGG Sequencing 
pCT 
Bac Fw TATTCCGGATTATTCATACCGTC Sequencing 
pAC 
Bac Rv CAACAATTGCATTCATTTTATGTTTCAGG Sequencing 
pAC 








GAGGATCCCTAGTTGCGGATTTTCATC GTCATATAGGC Cloning into 
pET vector 
NdeI WTD Fw GACATATGTCTGAGAACAGCTGCACCCACTTCC Cloning into 
pET vector 




Table 2.2 Primers used for sequencing and cloning 
 
2.4 Protein production (insect cells) 
 
Proteins produced via insect cell expression include monomeric wild type IL-10 
(Josephson et al., 2000a), monomeric high affinity variants, IL-10Rα ectodomain 







10 X HBS: 100 mM HEPES, 1.5 M Sodium Chloride, 0.2% Sodium Azide, pH 7.2 
Precipitation buffer: 1 mM NiCl2, 5 mM CaCl2, 60 mM Tris pH 8.0 
Wash buffer: 20 mM imidazole in HBS, pH 7.2 
Elution buffer: 200 mM imidazole in HBS, pH 7.2 
 
2.4.2 Generation of virus and amplification 
 
To generate a P0 virus, transfection of SF9 (Spodoptera frugiperda) cells was 
performed as follows. Cells were seeded in a 6 well plate (1 well per transfection) 
at a density of 1 x 106 cells/mL, 2 mL per well. Cells were left to adhere for a 
minimum of 30 minutes. 2 µL of BestBac 2.0 linearized virus (Expression 
Systems) was mixed with 2 µg of DNA (pACgp67 plasmid) and incubated for 5 
minutes. In a separate vial, 10 µL of TransIT (GeneFlow) was added to 100 µL of 
SF9 III media (Thermo). This solution was added to the DNA solution and 
incubated for 15-20 minutes. 1.8 mL of SF9 III media was then added to the vial. 
Media was removed from the adherent cells and replaced with the transfection 
mixture. Cells were incubated statically at 28⁰C for 5 to 8 hours after which the 
transfection media was replaced with 3 mL SF9 III media, and the plate was 
sealed with saran wrap to prevent evaporation. Cells were left for 7 to 10 days at 
28⁰C, static. For each transfection a positive mCherry control was done in parallel 
to determine transfection efficiency via fluorescence.  
 
On day 7 to 10 the media containing the virus was removed from the cells and 
centrifuged at 2000 rpm for 5 minutes and the supernatant transferred to a clean 
tube as P0 virus. 30 µL of this P0 virus was added to 30 mL of suspension SF9 
cells at a cell density of 2 x 106/mL. Cells were counted daily and media added 
to maintain cell density at 2 x 106/mL until cell division stopped (usually day 3). 
The cells were then left for 7 days to amplify the virus. After that, the cells were 






A titration of the P1 virus was done by infecting suspension Hi5 cells 
(Trichoplusiani ni) (2 x 106/mL, 2 mL/well in a 6 well plate) over a variety of 
volumes of the virus, usually 0 µL, 1 µL, 2 µL, 4 µL, 6 µL, 8µL of P1 virus per 2 
mL Hi5s. Cells were incubated for 2 days before the supernatant was harvested 
for analysis of protein production. 
 
To observe if protein was produced a “protein miniprep” was done. Here 1.8 mL 
of culture supernatant was buffered with 200 µL of 10X HBS and incubated with 
25µL Ni-NTA resin (Thermo) for a minimum of 3 hours at room temperature on 
rotation. The media was then centrifuged at 5000 rpm for 1 minute and the 
supernatant removed. The Ni-NTA was washed with 1.5 mL 10 mM imidazole 
and centrifuged again. Protein was eluted with 25 µL of 200 mM imidazole and 
this was run on an SDS-PAGE gel, followed by staining with Coomassie Blue to 
observe if protein was present.   
 
2.4.3 Infection of insect cells for protein production 
 
For production of protein, Hi5 cells were used. Cells were maintained at a density 
of 2 x 106 cells/mL in Insect-XPRESS media (Lonza), supplemented with 
gentamycin (10 µg/mL, Thermo). Cells were infected with virus at the appropriate 
dilution depending on the viral titre as determined above. Usually this was in the 
range of 1-2 mL of P1 virus per litre of Hi5 cells. Cells were infected with P1 virus 
and left to incubate with gentle shaking (120 rpm) for 2 days. 
 
2.4.4 Protein purification via His-tag 
 
Cells which had been infected with virus were centrifuged in 1L bottles at 2,000 
rpm, 15 minutes and supernatant was transferred to a clean beaker. 50 mL of 
precipitation buffer was added to this and the solution was left with spinner at 120 
rpm for 15 minutes to remove components of the media which inhibit the action 
of the Ni-NTA resin. The solution was then centrifuged at 6000 rpm for 15 minutes 
and supernatant was removed to a clean beaker. 2 mL of Ni-NTA agarose resin 
(Thermo) was added per litre of media and placed with a spinner at 120 rpm for 





The media was then filtered through a glass Buchner funnel to collect the Ni-NTA 
resin. The resin was washed with 20 mM imidazole/HBS before removal of the 
resin to a poly-prep column (Biorad). The protein of interest was eluted from the 
Ni-NTA resin by addition of 200 mM imidazole/HBS to the column. 10 fractions of 
0.5 mL each were collected. Absorbance at 280 nm (A280) was measured to 
determine which fractions contained the protein of interest and these fractions 
were then concentrated in a centrifugal filter unit (Merck). Protein concentration 
was determined using the formula below. Extinction coefficients were calculated 
using the online programme ProtParam (ExPASy) (Wilkins et al., 1999). 
 
Concentration (molarity) = A280nm / Extinction Coefficient 
Concentration (mg/mL) = (A280nm / Extinction Coefficient) x Molecular Weight 
 
2.4.5 Size exclusion chromatography 
 
After isolation via his-tag, proteins were purified via Fast Protein Liquid 
Chromatography (FPLC) and separated on the basis of size. For all proteins 
except IL-10 dimers an Enrich SEC 650 1x300 column (Biorad) was used. For 
the IL-10 dimer proteins a SuperDex 75 increase 10/300 column (Cytiva) was 
used. HBS was used as the equilibration buffer for the columns. For Enrich 
column the flow rate was 1 mL/min. For SuperDex 75 the flow rate was 0.5 
mL/minute. 0.5 mL fractions were collected for both. 
 
2.4.6 Protein Sterilisation 
 
After purification and concentration, proteins for cell stimulation were sterilised 
and aliquoted. Centrifugal filter units with a 0.22 µm filter were used to sterilise 
the proteins (Merck). Proteins were then aliquoted in sterile PCR tubes and snap 
frozen in liquid nitrogen. Aliquots were stored at -80⁰C until use. 
 
2.4.7 Protein biotinylation 
 
IL-10Rβ was biotinylated via its C-terminal Biotin Acceptor Peptide (BAP)-




(1:100) in an excess of biotin overnight at 4ºC as described in (Spangler et al., 
2019). BirA ligase was recombinantly produced by Dr. I. Moraga.  
 
IL-10Rα had poor expression when expressed with the biotin acceptor peptide 
and so biotinylation was performed using NHS-ester activated biotinylation. EZ-
Link NHS Biotin (Thermo #20217) was used according to the manufacturer’s 
protocol.  
 
The proteins were purified via FPLC after biotinylation as described above to 
separate the biotinylated protein from the excess of biotin. To confirm 
biotinylation an aliquot of protein was incubated with an excess of streptavidin 
(Thermo) and run on a non-reducing SDS-PAGE gel. Proteins which were 
biotinylated displayed a shift upwards on the gel. 
 
2.5 Protein Production (Bacterial) 
 
Human wild type dimeric IL-10 and high affinity dimeric IL-10 variants (amino 




Resuspension buffer: 50 mM Tris-HCl pH 8.0, 25% (w/v) sucrose, 1 mM Na 
EDTA, 10 mM DTT, 0.2 mM PMSF. 
2x Lysis buffer: 100 mM Tris-HCl pH 8.0, 2% (v/v) TritonX-100, 200 mM NaCl, 
Benzonase 10 µL, 10 mM DTT, 5 mM MgCl2, 0.2 mM PMSF. 
Wash buffer 1: 50mM Tris-HCl pH 8.0, 0.5% Triton X-100, 100 mM NaCl, 1 mM 
Na EDTA, 1 mM DTT, 0.2 mM PMSF. 
Wash buffer 2: 50 mM Tris-HCl pH 8.0, 1 mM Na EDTA, 1 mM DTT, 0.2 mM 
PMSF. 
Refolding Buffer: 50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5 mM EDTA, 2 mM 
reduced glutathione (GSH) and 0.2 mM oxidized glutathione (GSSG). 
 





Transformation of BL21 bacteria was done as described in section 2.3.3. The 10 
mL overnight culture was added to 1 litre of terrific broth/ampicillin media (SLS 
Central Technical Services) and grown until the OD600 reached 0.5-0.7. The 
bacteria were then induced using 1 mM final concentration of Isopropyl β-d-1-
thiogalactopyranoside (IPTG, Formedium) and incubated at 37⁰C for 3 to 5 hours. 
Cultures were centrifuged at 6000 g for 15 minutes and the supernatant was 
discarded. Cell pellets were resuspended in 25 mL of resuspension buffer per 
litre of original culture and frozen at -80⁰C until needed. 
 
Lysis was done by adding 25 mL of 2X lysis buffer (1X final concentration) to the 
cells previously resuspended in 25 ml of resuspension buffer and incubating for 
20 minutes at room temperature on a rotator. 10 mM EDTA (final concentration) 
was then added to the suspension and cells were sonicated (10 cycles of 15 
seconds on/off, 15 microns, Soniprep150) in an ice-bath. The solution was 
centrifuged at 7000 g for 15 minutes (4⁰C) and resuspended in 50-100 mL of 
wash buffer 1. Sonication was repeated as above and cells were centrifuged and 
resuspended in 50-100 mL of wash buffer 1. This washing and sonication step 
was repeated a total of three times until the preparation appeared white. The 
preparation was then washed once in wash buffer 2 (detergent-free).  
 
The pellet containing the protein of interest as inclusion bodies was solubilised in 
10 mL of 6M GuHCl per litre of original culture for 30 minutes. The solution was 
clarified by a high speed centrifugation and the supernatant was removed for 
refolding. 
 
2.5.3 Refolding, dialysis and purification of proteins 
 
The solubilised solution was added dropwise into refolding buffer (10 mL of 
solution into 200 mL of buffer) at 4⁰C and incubated with gentle spinning overnight 
at 4⁰C. The next day the solution was filtered to remove any precipitant present. 
Dialysis membranes (14,000 Da cut off, Sigma) were used to dialyse 200 mL of 
solution into 2 L of HBS. This dialysis was replaced daily for 5-7 days. After 
dialysis, the protein was isolated by incubating with Ni-NTA resin for 1 hour and 





2.5.4 Endotoxin removal 
 
The removal of endotoxin from bacterially produced proteins was done as follows 
at 4⁰C. 1 mL of Ni-NTA agarose was added to a poly-prep column and washed 
with 10 mL of HBS. The protein was added to the column and the flow through 
was collected and A280 measured to ensure all protein had bound the column. 
Any unbound protein was re-added to the column and elute was checked until 
the flow through had no protein detectable. The column was washed with 50 
column volumes of ice-cold HBS/150 mM NaCl/20 mM imidazole/ 0.1% Triton-
X114 to remove endotoxin. The column was then washed with 20 column 
volumes of HBS/20 mM imidazole. The endotoxin-free protein was eluted using 
4 column volumes of HBS/200 mM imidazole.  
 
The protein was buffer exchanged into HBS using PD-10 columns (GE 
Healthcare) following the manufacturer’s protocol.  
 
Endotoxin levels were measured using Pierce LAL Chromogenic Endotoxin 
Quantitation Kit (Thermo) following the manufacturer’s protocol. For all proteins, 
endotoxin levels were below detection levels of the kit. 
 
2.6 De-glycosylation and crystal screening 
2.6.1 De-glycosylation 
 
In order to de-glycosylate IL-10Rα the protein was treated with kifunensine 
(Carbosynth) and endoglycosidase F (EndoF). Kifunensine was added to the 
insect cell media at the same time as the P1 virus was added. A range of 
kifunensine concentrations were used as outlined in the relevant results section.  
EndoF was recombinantly produced by Dr. I. Moraga. After purification of the 
kifunensine-treated protein, EndoF was added to the protein at a concentration 
of 50 μg/mL. This was incubated overnight at 4ºC before purification via gel 
filtration. 
 





Screening of different conditions in order to generate crystals of the high affinity 
IL-10/IL-10 receptor complex was undertaken as part of this thesis. Commercial 
screens were used to test a wide range of variables such as pH, salts and 
polyethylene glycol (PEG) concentrations. Screens used in this thesis were: 
ProPlex (Molecular Dimensions), JCSG Core Suites I, II, III, IV (Quiagen) and 
PurePEGS (Molecular Dimensions). ProPlex screens a range of pHs as well as 
PEG molecular weights and concentrations. The JCSG Core Suites use a variety 
of salts, buffers and precipitants. PurePEGS uses PEGs over a range of 
molecular weights.  60 μL volumes were used in the reservoirs. 
 
Protein complexes were concentrated to a range of 3-10 mg/mL in HBS for use 
in the screens and were filtered through a 0.2 μm clarification spin column 
(Generon). Sitting drop wells were used for the screens in MRC 96-well 2 drop 
plates (Molecular Dimensions), to allow simultaneous screening of different 
complexes. A Mosquito Xtal3 (SPT Lab Tech) was used to dispense 100 nL 
volumes in a 1:1 ratio. Plates were sealed with an adhesive sheet and stored 
either in a communal temperature controlled room (21ºC) or in an incubator 
(18ºC). Plates were checked regularly for crystal growth using a light microscope. 
 
2.7 Yeast surface display library for affinity maturation of IL-10 for IL-10Rβ 
2.7.1 Buffers 
 
All media was prepared by Central Technical Services, SLS. 
YPD media: 20 g dextrose, 20 g peptone, 10 g yeast extract in deionized H2O 
to a volume of 1 litre and sterilised by filtration.  
E buffer: 1.2 g Tris base, 92.4 g sucrose, 0.2 g MgCl2 in deionized H2O to a 
volume of 1 litre, pH to 7.5 and sterilised by filtration 
SDCAA media: 20 g dextrose, 6.7 g Difco yeast nitrogen base, 5 g Bacto 
casamino acids, 5.4 g Na2HPO4, 8.56 g NaH2PO4_H2O in deionized H2O to a 
volume of 1 litre and sterilised by filtration 
SGCAA media: Prepared as for SDCAA, but use 20 g galactose instead of 
dextrose  
 





For error-prone PCR a monomeric form of IL-10 as designed by the Walter group 
(Josephson et al., 2000a) was used as a template. Error-prone PCR introduces 
random mutations into the gene, the rate of which can be altered by changing 
amounts of MgCl2 and MnCl2 in the reaction mixture. The reaction was set up as 
outlined in Table 2.3 below with primers listed in Table 2.4. 
 
Reagent Volume (µL) Final concentration 
10X Taq Polymerase Buffer 
(magnesium free) 
5 1X 
ddH20 29.5 N/A 
MgCl2 (100 nM) 3.5 7 mM 
Primer Mix (25 µM) 1 200 nM each 
Template DNA (8 ng/µL) 1 N/A 
dNTPs (10 mM each) 1 200 µM each 
dCTP/dTTP (40 mM each) 1 800 µM each 
MnCl2 (1 mM) 7.5 0.15 mM 
Taq Polymerase 0.5 N/A 
Table 2.3 Error Prone PCR 
 
Primer Name Sequence Purpose 
IL-10 Error Fw TCCGAGAACAGTTGCACGCAC Error-prone PCR (Taq 
Polymerase) 
IL-10 Error Rv GTTGCGGATTTTCATCGTCATATAGGC Error-prone PCR (Taq 
Polymerase) 





Amplify error-prone PCR 
product (Phusion PCR) 






Amplify error-prone PCR 
product (Phusion PCR) 
Table 2.4 Error PRC Primers 
 
The cycle for the PCR reaction was: 94⁰C melt for 3 minutes, 30 cycles of (94⁰C 
for 30 seconds, 60⁰C annealing for 30 seconds, 72⁰C for a 1 minute extension) 
5’ polish at 72⁰C for 5 minutes. A sample of the PCR reaction (5 µL) was run on 
a 1% agarose gel to check the size of the product which was around 500 base 




(NEB) and the product was cleaned up to remove any primer-dimers using the 
Promega Wizard PCR clean-up kit.  
 
The pCT plasmid (as described in section 2.3.1) was restriction digested at the 
BamHI/NotI cloning site to remove the insert present (had previously contained 
the sequence of Leukaemia Inhibitory Factor (LIF)) and run on a 1% agarose gel. 
The upper band of the linearized plasmid was extracted and purified.  
 
A test ligation of a sample of the error-prone PCR product with the cut plasmid 
was done and DH5α bacteria were transformed. Colonies were picked and the 
plasmid was mini-prepped. The isolated DNA was sent for sequencing to confirm 




Saccharomyces cerevisiae strain EBY100 was grown on a YPD plate at 30⁰C 
overnight. 5 mL of YPD was inoculated with 5-10 colonies of EBY100 and grown 
with agitation at 30⁰C overnight. The following day 100 mL of YPD was inoculated 
with the 5 mL culture and grown to an OD600 of 1.3 in a baffled flask. 1 mL of Tris-
DTT (2.5M DTT in 1M Tris, pH 8.0) was added to the culture and left shaking at 
30⁰C for 15 minutes. 
 
The culture was divided into two 50 mL falcon tubes and centrifuged at 2500 g 
for 3 minutes, resuspended in 25 mL of E buffer and centrifuged again. Each 
pellet was resuspended in 1 mL of E buffer and centrifuged again. One pellet was 
then resuspended in 300 µL of E buffer plus a total of 275 µL of IL-10 error PCR 
product and linearized pCT vector in a 5:1 ratio, PCR product: vector. This 
suspension was then used to resuspend the other pellet and the solution was 
aliquoted into chilled electroporation cuvettes (2 mm, VWR) and kept on ice. 
Electroporation was done at 500 V LV, resistance none, 0.025 µF. Each aliquot 
was rescued with 2 x 1 mL of YPD. All electroporated aliquots were combined 
into a baffled flask and made up to 50 mL of YPD media. This was placed at 30⁰C 
for 1 hour. The culture was then centrifuged at 2500 g for 3 minutes and 





In order to determine the size of the yeast library a titration of the yeast was done 
and several dilutions of the library were plated on SDCAA agar plates and grown 
for 3 days at 30⁰C. 
The 10 mL of the library was added to 500 mL of SDCAA (+ chloramphenicol) 
and grown at 250 rpm, 30⁰C overnight. 
 
The following day 1010 cells (as determined by OD600) were removed and placed 
into fresh SDCAA and grown overnight. 
 
On day three, 1010 cells were removed and centrifuged. They were resuspended 
into SGCAA (induction media) and grown at 20⁰C for 2 days in order to allow the 
yeast to display the protein on the cell surface. 
 
2.7.4 Yeast library screening 
 
All screening rounds started with a negative selection to remove any yeast which 
bound streptavidin in the absence of biotinylated protein. This involved incubating 
the yeast with 100 μL fluorescently labelled streptavidin (AlexaFlour647 (AF647), 
made by Dr. I. Moraga) for 1 hour at 4ºC. The yeast were then washed twice with 
cold PBE and centrifuged at 2500 g for 3 minutes. Anti-AF647 magnetic 
microbeads were added (Miltenyi #130-091-395) and incubated for 1 hour at 4ºC. 
After another wash, Magnetic Activated Cell Sorting (MACS) was performed 
using LS columns (Miltenyi) in a QuadroMACS Separator according to 
manufacturer’s protocol. Briefly, the yeast suspension was added to the column 
and flow through was collected. The column was then washed three times with 3 
mL of PBE. This flow through was collected. The column was then removed from 
the magnet and 5 mL of PBE was used to elute any yeast bound to the column. 
The flow through contained yeast which did not show non-specific streptavidin 
binding and so were taken forward for the positive selection round.  
 
The first round of positive selection was done to recover all positive binders in the 
library and also to reduce the complexity of the library. 250 μL of streptavidin 
microbeads (Miltenyi #130-048-101) were incubated with 400 nM of biotinylated 
IL-10Rß for 15 minutes. This was then incubated with the yeast at 4ºC for 2 hours. 




which were eluted were kept as these yeast displayed affinity for IL-10Rß and the 
flow through was discarded. The yeast were returned to culture and grown at 
30⁰C for 1 day in SDCAA media and changed into SGCAA media at 20⁰C for 
induction for 2 days. This growth protocol was followed for the entire screening 
process. 
The second screening round selected those yeast which displayed the c-myc tag 
on the cell surface. The c-myc tag is expressed on the C terminus of the yeast-
displayed IL-10. By selecting for c-myc expression we were removing any yeast 
which displayed truncated IL-10. A negative clearing step was performed as 
before. The flow through yeast were incubated with anti-cmyc tag AF647 antibody 
(CST, #2233S) for 2 hours at 4ºC, followed by 20 minutes incubation with anti-
AF647 microbeads. The yeast were washed and MACS separation was 
performed with the eluted yeast being taken forward for culture. 
 
The third screening round began to select for yeast which displayed IL-10 
variants with affinity for the IL-10Rβ and all subsequent rounds were performed 
following a similar protocol with decreasing concentrations of IL-10Rβ. The yeast 
were incubated with a known concentration of recombinantly expressed 
biotinylated IL-10Rβ for two hours. They were then washed and incubated with 
streptavidin-AF647 for 15 minutes and the wash was repeated followed by 
incubation with anti-AF647 beads for 20 minutes. This meant that the yeast-
displayed IL-10 which could bind IL-10Rβ could be isolated by magnetic activated 
cell sorting (MACS) and visualised using flow cytometry. Each round of selection 
used decreasing IL-10Rβ concentrations. IL-10Rα (non-biotinylated) was also 
used in early selection rounds to stabilise binding as described in the results 
section. 
 
Once the concentration of IL-10Rβ needed for binding was decreased sufficiently 
compared to wild type monomeric IL-10, the yeast were spread on SDCAA plates 
and single colonies were isolated and used for dose response experiments to 
determine the EC50 values of the mutants.  
 
Yeast colonies displaying promising mutant IL-10 variants were subject to 
Zymoprep (Zymoreserach) to isolate the pCT plasmid which was then heat 




for sequencing to observe where mutations had occurred in the monomeric IL-10 
gene. These genes were then cloned into the baculovirus expression vector 
pACgp67BN and recombinantly expressed as described above. 
 
2.8 Yeast surface display library for selection of nanobodies recognising 
the IL-10/IL-10R complex 
2.8.1 Media and buffers 
 
All media was prepared by Central Technical Services, SLS. 
YGLC-glucose/galactose: 3.8 g of –Trp drop-out media supplement, 6.7 g 
Yeast Nitrogen Base, 10.4 g Sodium Citrate, 7.4 g Citric Acid Monohydrate, 20 g 
glucose or galactose in deionized H2O to a volume of 1 litre and sterilised by 
filtration 
 
2.8.2 Yeast library preparation  
 
The nanobody yeast library as described in (McMahon et al., 2018) was used to 
isolate nanobodies capable of binding the high affinity IL-10 molecule R5A11M 
in complex with IL-10Rβ/IL-10Rα. The yeast library was thawed from frozen 
stocks into 500 mL of YGLC-glucose media and incubated overnight at 30ºC. The 
following day 1 x 1010 cells were placed into fresh YGLC-glucose media to 
remove dead cells and incubated overnight. Cells were then placed in 500 mL of 
YGLC-galactose media for 48 hours at 20ºC to induce expression of the 
nanobody protein on the yeast cell surface. Expression of the protein was 
confirmed by staining for HA-tag AF647 (CST, #3444S) by flow cytometry, 
expressed on the C terminus of the nanobody.  
 
2.8.3 Yeast library screening 
 
Screening was carried out initially with R5A11M/IL-10 receptor complex 
biotinylated alternately on IL-10Rα or IL-10Rβ and subsequently with biotinyalted 
IL-10Rα or IL-10Rβ alone. This is described in more detail in Chapter 6. 
Screening was carried out with anti-AF647 beads (Miltenyi) and MACS 
separation as for the previous library. Details of the concentrations of biotinylated 





Single colonies were isolated by spreading on YGLC-glucose plates and picking 
single colonies. The plasmids were isolated from these clones as described for 
the previous library. 
2.9 Secreted Cytokine Analysis 
2.9.1 ELISA 
 
For analysis of IL-6 from supernatants of stimulated human monocytes an  ELISA 
kit for human IL-6 was used (Biolegend). Samples for IL-6 quantification were 
diluted 1 in 6. Manufacturer’s protocols were followed with the following 
exception: half-volume flat bottom plates (Greiner) were used and so the volume 
of all reagents added per well was halved. Fluorescence was measured at 450 
nm on a CLAIROstar plate reader and standard curves were fitted using the 




Biorad’s bioplex assay was used to measure levels of IL-6, TNF-α, GM-CSF and 
IL-13 from murine BMDMs after stimulation (cells were isolated by S. Laba in 
collaboration with the Simon Arthur laboratory, University of Dundee). Cells were 
stimulated with PAM3CSK at 1 µg/mL for 8 hours in the presence or absence of 
varying concentrations of IL-10 wild type and high affinity variants. Supernatant 
was removed and frozen at -80⁰C. Manufacturer’s guidelines were followed for 
the bioplex assay (Biorad). Plates were read on a Luminex 200 instrument. Data 
was analysed using Excel and GraphPad Prism. 
 
2.10 Proteomics 
2.10.1 Cell pellet preparation 
 
CD8 T cells were submitted for proteomic analysis. CD8 T cells were activated 
and grown in a PBMC culture in the presence of IL-10 (100 nM) as described 
above. CD8 T cells were isolated by negative selection after 6 days of activation 
as described above. After cell stimulation and isolation was complete, a sample 
of the cells were stained for analysis by flow cytometry to determine the live cell 




all proteomic samples live count was >90%. The purity of the population’s cell 
type was also determined by flow cytometry by staining for CD8a (AlexaFlour700, 
Biolegend). The population was >90% positive for the correct cell type. 
Cell pellets were frozen as follows, all steps were done on ice or at 4⁰C: cells 
were centrifuged at 1500 rpm for 5 minutes and media was removed. Cells were 
resuspended in 600 µL of cold HBSS (Gibco) and this was transferred to a pre-
chilled Eppendorf. A further 600 µL of HBS was added to the original falcon tube 
which held the cells to ensure maximum cell recovery and this was added to the 
Eppendorf. This was centrifuged at 8000 rpm for 10 seconds. The tubes were 
turned 180 degrees to face the opposite way in the centrifuge and centrifuged 
again at 8000 rpm for 10 seconds. Supernatant was removed and the pellet was 
resuspended in 1 mL of HBSS. 10 µL was taken for a cell count estimate. The 
rest of the samples were centrifuged as before and the supernatant was 
removed. The pellets were snap frozen in liquid nitrogen and stored at -80⁰C until 
lysis. 
 
2.10.2 Lysis and protein digest 
 
Cell lysis and protein digest was done with the assistance of Dr. A. Howden in 
the Cantrell laboratory, University of Dundee. Filter tips, pure H20 and clean 
glassware were used during sample processing to minimise protein 
contamination. For cell lysis, digestion and preparation for mass spectrometry, 
the SP3 method was followed as described in (Howden et al., 2019).  
 
Briefly, samples were resuspended in lysis buffer (4% SDS, 10 mM TCEP, 50 
mM TEAB) and vortexed before shaking for 5 minutes at room temperature. 
Samples were then boiled for 5 minutes while shaking and cooled before 
sonicating, 15 cycles of 30 seconds on/off (Bioruptor). Benzonase was added to 
the samples to remove any nucleotides and incubated for 15 minutes at 37⁰C. 
Protein quantification was determined by EZQ Protein Quantification Kit (Thermo) 
following manufacturers protocol. A final concentration of 20 mM iodoacetic acid 
was added to each sample and incubated in the dark for 1 hour to alkylate the 
cysteines and prevent disulphide bond formation. 200 µg of SP3 (Single-Pot 
Solid-Phase-enhanced Sample Preparation) beads were added to each sample. 




surface and incubated for 8 minutes with gentle shaking. Supernatant was 
removed by placing on a magnetic rack and 1 mL of 70% ethanol was used to 
wash the beads. This was repeated with 100% acetonitrile and beads were air 
dried for 15 seconds. Digest buffer was added (0.1% SDS, 50 mM TEAB 1 M 
CaCl2) along with 1 µg LysC per 100 µg protein and incubated overnight at 37⁰C 
shaking to digest the proteins to peptides.  
 
On day two, 1 µg trypsin was added per 100 µg protein and incubated overnight 
as before. On day 3, acetonitrile was added to the samples before placing on a 
magnetic rack to remove supernatant. Acetonitrile was added again for 30 
seconds before air drying for 15 seconds. Peptides were eluted from the beads 
by addition of 189 μL of 2% DMSO and sonication (5 minutes, 30 seconds off/on). 
Samples were placed on magnetic racks and the supernatants containing the 
peptides were removed and placed into protein low-bind tubes. The samples 
were centrifuged at max speed in a table-top centrifuge to remove any non-
magnetic bead debris and the supernatant was stored at -20⁰C overnight. The 
following day 21 μL of 50% formic acid (5% final concentration) was added. 
Samples were dried using a SpeedVac (GeneVac) and resuspended in 300 μL 




Samples were fractionated before mass spectrometry to reduce sample 
complexity in order to increase protein identify. Peptides were fractionated on the 
basis of their hydrophobicity. The Pierce High-pH Reversed Phase Peptide 
Fractionation Kit (Thermo) was used according to the manufacturer’s protocol.  8 
fractions per sample were generated and dried down before mass spectrometry 
analysis.  
 
2.10.4 Mass Spectrometry Analysis 
 
Mass spectrometry was performed by the FingerPrints Proteomics facility at the 
University of Dundee as follows. 1 μg of peptide from each fraction was analysed 
on an Ultimate 3000 RSLCnano system (Thermo Scientific) coupled to a Q 




0.1% formic acid. Peptides were trapped on an Acclaim PepMap 100 (C18, 100 
μM x 2 cm) and subsequently separated on an Easy-Spray PepMap RSLC C18 
column (75 μM x 50 cm) (Thermo Scientific). The mobile phase consisted of 0.1% 
formic acid (solvent A) and 80% acetonitrile in 0.08% formic acid (solvent B). A 
constant flow rate of 0.3 μL/min was used. The sample was then transferred to 
the mass spectrometer via an Easy-Spray source with temperature set at 50ºC 
and a source voltage of 1.9 kV. A Top 40 method was used for the Q Exative HF-
X.  
 
2.10.5 Data analysis 
 
Peptides were searched using MaxQuant Software Version 1.5.8.3 with the 
assistance of Dr. A. Howden. Proteins were identified using the UniProt database 
Human2017. Search parameters for fixed modifications included 
carbamidomethylation of cysteines and variable modifications included 
methionine oxidation and acetylation of amino termini.  Data was filtered to 
remove any proteins that were identified as contaminants, reverse and only 
identified by site. Label Free Quantification (LFQ) values were used to compare 
treatments and further data analysis was done in Excel.  
 
Fold change was calculated by dividing IL-10 treated LFQ values by non-IL-10 
treated LFQ values in each donor group. The average fold change was calculated 
over three donors and the log2 of this was calculated.  For calculation of 
significance, the log2 of the fold change between IL-10 stimulated LFQ values 
and non-IL-10 treated LFQ values for each donor was calculated separately and 
a two-sample equal variance two tailed t test was used to generate the p value.  
 
2.11 Surface Plasmon Resonance 
 
Surface plasmon resonance (SPR) was used to determine the binding affinity of 
the recombinantly produced monomeric IL-10 wild type and variants to IL-10Rβ 
in the presence or absence of IL-10Rα. This was done with the assistance of Dr. 
P.K. Fyfe. Biotinylated IL-10Rβ was immobilised onto the chip surface via 
streptavidin. The chips used were Series S Sensor A Chip SA (GE Healthcare). 




Monomeric variants were flowed over the chip in a solution of HBS/ 0.5% BSA/ 
0.05% Tween-20. For measurement of IL-10Rβ affinity in the presence of IL-
10Rα monomeric IL-10 variants were incubated IL-10Rα and this complex was 
then flowed over the chip. Serial 1:3 dilutions of ligands were used. Biacore T200 
Evaluation Software 3.0 was used for curve fitting for affinity curves and surface 
bound kinetic curves.  
 
2.12 RNA Sequencing 
2.12.1 Cell Stimulation and RNA extraction 
 
The monocytes and CD8 T cells used for RNA sequencing were isolated from 
human PBMCs purchased from StemCell Technologies. Human primary 
monocytes from three donors were isolated as described above. Cells were 
rested in M-CSF containing media (20 ng/mL, Biolegend) for two days. On day 
two IL-10 wt and variants were added to the cells for 24 hours. Non-adherent 
cells were removed from media by centrifugation while adherent cells were 
removed by incubation with Accutase (Sigma) at room temperature for 5-10 
minutes. Adherent and non-adherent cell populations were combined and cells 
were washed in Hank’s balanced salt solution (HBSS, Gibco) and snap frozen for 
storage.  
 
CD8 T cells were isolated by positive selection from three donors as described 
above. Cells were activated as described above in the presence of IL-10 wt and 
variants. On day 6 of activation/expansion cells were centrifuge, washed in HBSS 
and snap frozen for storage. 
 
RNA was isolated using the RNeasy Kit (Qiagen) according to manufacturer’s 
protocol. All RNA A260/A280 ratios were above 1.9. 1 μg of RNA per sample was 
sent to Novogene for RNA sequencing.  
 
2.12.2 RNA sequencing (Novogene) 
 
Transcriptomic analysis was done by Novogene as follows; Sequencing libraries 
were generated using NEBNext® UltraTM RNALibrary Prep Kit for Illumina® 




added to attribute sequences to each sample. Briefly, mRNA was purified from 
total RNA using poly-T oligo-attached magnetic beads. Fragmentation was 
carried out using divalent cations under elevated temperature in NEBNext First 
StrandSynthesis Reaction Buffer (5X). First strand cDNA was synthesized using 
random hexamer primer and M-MuLV Reverse Transcriptase (RNase H-). 
Second strand cDNA synthesis was subsequently performed using DNA 
Polymerase I and RNase H. Remaining overhangs were converted into blunt 
ends via exonuclease/polymerase activities. After adenylation of 3’ ends of DNA 
fragments, NEBNext Adaptor with hairpin loop structure were ligated to prepare 
for hybridization. In order to select cDNA fragments of preferentially 150~200 bp 
in length, the library fragments were purified with AMPure XP system (Beckman 
Coulter, Beverly, USA). Then 3 μl USER Enzyme (NEB, USA) was used with 
size-selected, adaptor-ligated cDNA at 37 °C for 15 minutes followed by 5 
minutes at 95 °C before PCR. Then PCR was performed with Phusion High-
Fidelity DNA polymerase, Universal PCR primers and Index (X) Primer. At last, 
PCR products were purified (AMPure XP system) and library quality was 
assessed on the Agilent Bioanalyzer 2100 system. 
 
2.12.3 Data Analysis 
 
Primary data analysis for quality control, mapping to reference genome and 
quantification was conducted by Novogene as outlined below.  
 
Quality control: Raw data (raw reads) of FASTQ format were firstly processed 
through in-house scripts. In this step, clean data (clean reads) were obtained by 
removing reads containing adapter and poly-N sequences and reads with low 
quality from raw data. At the same time, Q20, Q30 and GC content of the clean 
data were calculated. All the downstream analyses were based on the clean data 
with high quality.  
 
Mapping to reference genome: Reference genome and gene model annotation 
files were downloaded from genome website browser (NCBI/UCSC/Ensembl) 
directly. Paired-end clean reads were mapped to the reference genome using 
HISAT2 software. HISAT2 uses a large set of small GFM indexes that collectively 




with several alignment strategies, enable rapid and accurate alignment of 
sequencing reads.  
 
Quantification: HTSeq was used to count the read numbers mapped of each 
gene, including known and novel genes. And then RPKM of each gene was 
calculated based on the length of the gene and reads count mapped to this gene. 
RPKM, (Reads Per Kilobase of exon model per Million mapped reads), considers 
the effect of sequencing depth and gene length for the reads count at the same 
time and is currently the most commonly used method for estimating gene 
expression levels. 
 
Statistical analysis was done by the author in Excel. The fold change was 
calculated by dividing the IL-10 stimulated expression levels by the unstimulated 
control within each donor. The average fold change was calculated across the 
three donors and the log2 of this average was then calculated. To calculate 
significance, the log2 of the fold change between IL-10–stimulated and IL-10–
unstimulated expression levels of each donor was calculated separately and a 
two sample equal variance two tailed t test was used to generate the p value. The 
negative log10 of this p value was then plotted against the previously calculated 
log2 average fold change. Genes which were significantly (p≦ 0.05) changed 
greater than 0.6 or less than -0.6 log2 fold change in the wild type IL-10 dimer 
(WTD) 50 nM condition were taken as a set list of genes against which all other 
IL-10 stimulations were compared, regardless of the level of significance in the 
other IL-10 stimulations. A list of these genes and their fold change can be found 
in the Appendix tables 1 and 2. Upregulated genes were denoted as genes ≧ 0.6 
log2 fold change and downregulated genes were denoted as genes ≦ -0.6 log2 
fold change. For comparison of WTD to other IL-10 variant stimulations the 
average log2 fold changes of the variant/unstimulated was divided by the average 
log2 fold change of WTD/unstimulated. Genes with an RPKM of less than 1 in two 
or more donors were excluded from analysis so as to remove genes with 
abundance near detection limit. 
 
Functional annotation of genes (KEGG pathways, GO terms) was done using 
DAVID Bioinformatics Resource functional annotation tool (Huang da et al., 







2.13 Real Time Quantitative PCR 
2.13.1 RT-qPCR Reactions 
 
RNA was isolated using RNeasy Kit (Qiagen) following manufacturer’s protocol. 
50 ng RNA per sample was reverse transcribed to cDNA using iScript cDNA 
synthesis kit (Biorad). This was used as template for qPCR. SYBR premix Ex-
Taq (Clontech) was used for the reaction and primers were used at 10 μM final 
concentration. A CFX96 Touch Real-Time PCR Detection System (Biorad) was 
used. 
 
2.13.2 Primers  
 
All primers used are listed in table 2.5. Sequence for granzyme B primer was 
acquired from (Morissette et al., 2007). All primers were ordered from IDT.  
 
Primer Name Sequence (5’- 3’) Purpose 
Granzyme B Fw TGGGGGACCCAGAGATTAAAA qPCR 
Granzyme B Rv TTTCGTCCATAGGAGACAATGC qPCR 
GAPDH Fw ACCCACTCCTCCACCTTTGA qPCR 
GAPDH Rv CTGTTGCTGTAGCCAAATTGGT qPCR 
18S Fw GGCCCTGTAATTGGAATGAGTC qPCR 
18S Rv CCAAGATCCAACTACGAGCTT qPCR 
Table 2.5 Primers used for qPCR 
 
2.13.3 qPCR Data Analysis 
 
GAPDH and 18S were used as housekeeping genes for normalisation. Each 







Where E is the efficiency of qPCR, u is the mRNA of interest, c is the non-IL-10 







2.14 Total internal reflection microscopy (TIRF) 
 
All TIRF experiments were conducted by Junel Sotolongo Bellón, University of 
Osnabrück using wild type and high affinity proteins made by the author in 
University of Dundee. 
 
Receptor homo- and heterodimerisation was quantified by two-colour single-
molecule co-tracking as described previously (Moraga et al., 2015b, Wilmes et 
al., 2015, Wilmes et al., 2020). Receptor dimerisation experiments were 
performed in HeLa cells transiently expressing IL-10Rα and IL-10Rβ with N-
terminally fused variants of monomeric ECFP and EGFP, respectively. Cell 
surface Labelling was achieved using anti-GFP nanobodies Minimizer (MI) and 
Enhancer (EN), respectively, site-specifically conjugated with photostable 
fluorophores via an engineered cysteine residue. For quantification of receptor 
heterodimerisation, IL-10Rα and IL-10Rβ were labelled with MIRho11 (ATTO 
Rho11, ATTO-TEC GmbH) and ENAT643 (ATTO 643, ATTO-TEC GmbH), 
respectively. For quantification of homodimerisation, either IL-10Rα was labelled 
with MIRho11 and MIAT643, or IL-10Rβ was labelled with ENRho11 and ENAT643. Over-
expression of the corresponding other receptor subunit was ensured by labelling 
with ENAT488 or MIAT488 (ATTO 488, ATTO-TEC GmbH), respectively. Time-lapse 
dual-colour imaging of individual IL-10Rα and IL-10Rβ in the plasma membrane 
was carried out by total internal reflection fluorescence microscopy with excitation 
at 561 nm and 640 nm and detection with a single EMCCD camera (Andor iXon 
Ultra 897, Andor) using an image splitter (QuadView QV2, Photometrics). 
Molecules were localised using the multiple-target tracing (MTT) algorithm (Serge 
et al., 2008). Receptor dimers were identified as molecules that co-localised 
within a distance threshold of 150 nm for at least 10 consecutive frames as 
described in detail previously (Moraga et al., 2015b, Wilmes et al., 2015, Wilmes 





Chapter 3. Generation and biophysical characterisation of IL-10 
variants with increased affinity for IL-10Rβ 
Background 
 
IL-10 carries out its diverse functions by binding a cell surface receptor comprised 
of two receptor chains: IL-10Rα and IL-10Rß. In a first step, IL-10 binds to two 
IL-10Rα subunits with high affinity (picomolar range) (Yoon et al., 2012). Two IL-
10Rß chains are then thought to be recruited to the IL-10/IL-10Rα complex in a 
second step to form the signalling active IL-10 complex. In contrast to its strong 
affinity for IL-10Rα, IL-10 binds with very weak affinity to IL-10Rß (high 
micromolar to low millimolar range) (Yoon et al., 2006). Thus, the assembly of 
the active IL-10 receptor signalling complex is likely rate limited by IL-10’s affinity 
for IL-10Rß. How this IL-10/IL-10Rß low affinity interaction contributes to IL-10’s 
biological activities is poorly understood. To address this question, we have 
engineered IL-10 variants with increased affinity for the IL-10Rß subunit. We 
envisioned that these engineered variants would provide us with key molecular 
insights into the role that complex stability plays in IL-10 biology.  
 
In order to generate high affinity variants, error-prone PCR and yeast surface 
display was used. Yeast surface display is a powerful methodology which has 
been harnessed previously for the affinity maturation of cytokines (Mendoza et 
al., 2017, Martinez-Fabregas et al., 2019, Levin et al., 2012). The secretory 
apparatus of yeast allows it to display a diverse range of proteins due to its ability 
to glycosylate proteins and form disulphide bonds (Spangler et al., 2015). Yeast 
libraries also have the advantage of being amenable to magnetic activated cell 
sorting (MACS), meaning that large libraries can been screened rapidly and 
preliminary binding characterisation can be done on-yeast without the need for 
recombinant protein expression (Spangler et al., 2015, Gai and Wittrup, 2007). 
IL-10 engineering is challenging due to the dimeric nature of this cytokine. To 
overcome this limitation, we used a monomeric version of IL-10, previously 
reported by the Walter group, as a template for our engineering platform 






• Generate high affinity variants of IL-10 with increased affinity for IL-10Rβ.  
• Recombinantly express wild type and high affinity monomeric and dimeric 
IL-10 variants. 
• Measure binding affinity of recombinant IL-10 variants for IL-10Rβ by 






3.1 Selection of IL-10 variants with increased affinity for IL-10Rβ using 
yeast surface display 
 
We used yeast surface display to enhance the binding affinity of monomeric IL-
10 for IL-10Rß. First, we confirmed that monomeric IL-10 could be displayed in a 
native conformation on the yeast surface. Error-prone PCR was then carried out 
to introduce random mutations into the IL-10 monomer gene to create the library. 
Selection rounds were performed to select for variants with high affinity for IL-
10Rß before sequencing and characterisation of individual yeast clones. 
 
3.1.1 IL-10 monomer can be correctly displayed on the yeast cell surface 
 
Display of ligands on the yeast surface can sometimes alter their original structure 
and topology leading to misfolded proteins and loss of function. Thus, in a first 
step, we transfected Saccharomyces cerevisiae strain EBY100 with the IL-10 
monomer (WTM) to examine its ability to bind both IL-10 receptor subunits in the 
context of the yeast surface. WTM was displayed as a fusion protein at the C-
terminus of the yeast cell surface protein agglutinin (Aga2) which was under the 
control of a galactose inducible promotor.  The yeast were grown in SDCAA 
(media with glucose as the carbon source) at 30ºC for 24 hours before being 
changed into SGCAA (media with galactose as the carbon source) and grown at 
20ºC for 48 hours to induce the surface display of the WTM. The lower 
temperature for induction provides slower growing conditions for the yeast, 
ensuring correct processing of the protein. Both media used lack tryptophan, 
which allows selection for the transfected clones. Expression of WTM in the yeast 
surface was monitored using an anti-c-myc tag antibody, that recognizes a c-myc 
tag encoded at the C-terminus of WTM (Figure 3.1a).  Yeast were then incubated 
with 100 nM of either biotinylated IL-10Rß or biotinylated IL-10Rα, followed by 
fluorescently labelled streptavidin (AF647) to visualise receptor binding as 
illustrated in Figure 3.1b. As expected WTM was able to bind IL-10Rα, however 
it did not bind IL-10Rß, even in the presence of non-biotinylated IL-10Rα (Figure 
3.1c). Together these data confirmed that monomeric IL-10 was displayed on the 
yeast surface and maintained the expected receptor binding properties i.e., high 






3.1.2 Error-prone PCR and generation of an IL-10 monomer yeast display 
library 
 
Currently we lack a crystal structure of IL-10 binding its beta receptor, precluding 
us from undertaking a structure-guided library designing approach to affinity 
mature IL-10. Thus, we used error-prone PCR to insert mutations into the WTM 
gene in a random and unbiased fashion. Error-prone PCR uses Taq polymerase 
which has a low fidelity rate which can be further decreased by increasing 
concentrations of MgCl2, addition of MnCl2 and adjusting the amount of 
nucleotides added (Cadwell and Joyce, 1992). A final concentration of 7 mM 
Figure 3.1 Confirmation of WTM yeast display. (a) Yeast displaying the WTM were stained 
using AF647 anti-c-myc tag antibody to confirm the induction of protein expression on the yeast 
cell surface. An unstained control is included. (b) WTM (purple) was displayed as a fusion 
protein to the yeast cell surface protein Aga2. The yeast was then incubated with biotinylated 
IL-10Rß (blue). Binding of IL-10Rß could be detected by flow cytometry using AF647-labelled 
streptavidin. (c) Detection of binding of IL-10Rα (100 nM) and IL-10Rß (100 nM) to yeast 
displayed WTM. Panel one shows yeast in the absence of receptor as an unstained control. 
Panel two shows IL-10Rα (biotinylated) binding. Panel three shows IL-10Rβ (biotinylated) 
binding in the absence of IL-10Rα. Panel four shows IL-10Rβ (biotinylated) binding in the 
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MgCl2 and 0.15 mM MnCl2 was used in the PCR along with 800 μM each of dCTP 
and dTTP and a dNTP mixture of 200 μM. To determine the mutation rate, a 
sample of the PCR product was ligated with the yeast pCT vector and used to 
transform DH5α Escherichia coli cells. The resulting colonies were then 
screened. Mutations were introduced at a rate of 7-9 nucleotides substations per 
kilobase (or 4 to 5 mutations per gene) as shown by alignments in Figure 3.2. 
This was an optimal number as too high a rate increases the chances of either 
nonsense mutations or mutations which may affect the folding or expression of 
the protein, however too few mutations would result in a poorly diverse library. 
The PCR product was then amplified and electroporated into yeast along with the 





Figure 3.2 Error-prone PCR. Sequence alignment (DNA) of wild type IL-10 monomer with four 
clones used to confirm the error rate of the PCR. WT sequence is in bold and mutations are 
highlighted in red. Each clone contained 4-5 mutations. 
 
WT          TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGA 60 
Clone1      TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGA 60 
Clone2      TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGT 60 
Clone3      TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGA 60 
Clone4      TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGA 60 
            ***********************************************************  
 
WT          GATGCGTTCTCTCGAGTGAAAACTTTCTTTCAGATGAAAGATCAGTTGGATAATTTGCTC 120 
Clone1      GATGCGTTCTCTCGAGTGAAAACTTTCTTTCAGATGAAAGATCAGTAGGATAATTTGCTC 120 
Clone2      GATGCGTTCTCTCGAGTGAAAACTTTCTTTCAGTTGAAAGATCAGTAGGATAATTTGCTC 120 
Clone3      GATGCGTTCTCTCGAGTGAAAACTTTCTTTCAGATGAAAGATCAGTTGGATAATTTGCTC 120 
Clone4      GATGCGTTCTCACGAGTGAAAACTTTCTTTCAGATGAAAGATCAGTTGGATAATTTGCTC 120 
            *********** ********************* ************ ************* 
 
WT          CTCAAGGAGTCCCTTCTCGAAGACTTTAAAGGATACCTGGGGTGCCAGGCGCTTAGCGAG 180 
Clone1      CTCAAGGAGTCCCTTCACGAAGACTTTAAAGGATACCTGGGGTGCCAGGCGCTTAGCGAG 180 
Clone2      CTCAAGGAGTCCCTTCTCGAAGACTTTAAAGGATACCTGGGGTGCCAGGCGCTTAGCGAG 180 
Clone3      CTCAAGGAGTCCCTTCTCGAAGACTTTAAAGGATACCTGGGGTGACAGGCGCTTAGCGAG 180 
Clone4      CTCAAGGAGTCCCTTCTCGAAGACTTTAAAGGATACCTGGGGTGCCAGGCGCTTAGCGAG 180 
            **************** *************************** *************** 
 
WT          ATGATACAGTTCTATCTGGAGGAAGTGATGCCCCAAGCAGAAAATCAAGATCCCGATATT 240 
Clone1      ATAATACAGTTCTATCTGGAGGAAGTGATGCCCCAAGCAGAAAATCAAGATCCCGATATT 240 
Clone2      ATGATACAGTTCTATCTGGAGGAAGTGATGCCCCAAGCAGAAAATCAAGATCCCGATATT 240 
Clone3      ATGATACAGTTCTATCTGGAGGAAGTGATGCCCCAAGCAGAAAATCAAGATCCCGATATT 240 
Clone4      ATGATACAGTTCTATCTGGAGGAAGGGATGCCCCAAGCAGAAAATCAAGAACCCGATATT 240 
            ** ********************** ************************ ********* 
 
WT          AAGGCCCATGTCAACAGCCTTGGCGAAAATTTGAAAACTCTCAGACTCCGACTTCGCCGA 300 
Clone1      AAGGCCCATGTCAACAGCCTTGGCGAAAATTTGAAAACTCTCAGACTCCGTCTTCGCCGA 300 
Clone2      AAGGCCCATGTCAACAGCCTTGGCGAAAATTTGAAAACTCTCAGACTCCGACTTCGCCGA 300 
Clone3      AAGGCCCATGTCAACAGCCTTGGCGAAAATTTGAAAACTCTCAGACTCCGACTTCGCCGA 300 
Clone4      AAGGCCCATGTCAACAGCCTTGGCGAAAATTTGAAAACTCTCAGACTCCGACTTCGCCGA 300 
            ************************************************** ********* 
 
WT          TGCCACAGGTTTTTGCCATGTGAGAATGGGGGTGGTTCCGGGGGTAAGTCCAAGGCCGTT 360 
Clone1      TGCCACAGGTTTTTGCCATGTGAGAATGGGGGTGGTTCCGGGGGTAAGTCCAAGGCCGTT 360 
Clone2      TGCCTCAGGTTTTTGCCATGTGAGAATGGGGGTGGTTCCGGGGGTAAGTCCAAGGCCGTT 360 
Clone3      TGCCACAGGTTTTTGCCATGTGAGAATGGGGGTGGTTCCGGGGGTAAGTCCAAGGCCGTT 360 
Clone4      TGCCACAGGTTTTTGCCATGTGAGAATGGGGGTGGTTCCGGGGGTAAGTCCAAGGCCGTT 360 
            **** ******************************************************* 
 
WT          GAGCAGGTGAAAAACGCTTTCAACAAACTGCAAGAAAAGGGGATCTACAAAGCGATGTCA 420 
Clone1      GAGCAGGTGAAAAACGCTTTCAACAAACTGCAAGAAAAGGGGATCTACAAAGCGATGTCA 420 
Clone2      GAGCAGGTGAAAAACGCTTTCAACAAACTGCAAGAAAAGGGGATCTACAAAGCGATGTCA 420 
Clone3      GAGCAGGTGCAAAACGCTTTCAACAAACAGCAAGAAAAGGGGATCTACACAGCGATGTCA 420 
Clone4      GAGCAGGTGAAAAACGCTTTCAACAAACTGCAAGAAATGGGGATCTACAAAGCGATGTCA 420 
            ********* ****************** ******** *********** ********** 
 
WT          GAGTTCGACATATTTATAAACTACATAGAAGCCTATATGACGATGAAAATCCGCAA 476 
Clone1      GAGTTCGACATGTTTATAAACTACATAGAAGCCTATATGACGATGAAAATCCGCAA 476 
Clone2      GAGTTCGACATATTTATAAACTACATAGATGCCTATATGACGATGAAAATCCGCAA 476 
Clone3      GAGTTCGACGTATTTATAAACTACATAGAAGCCTATATGACGATGAAAATCCGCAA 476 
Clone4      GAGTTCGACATATTTATAAACTACATAGAAGCCTATATGACGATGAAAATCCGCAA 476 
            ********* * ***************** **************************  
 
 
WT          TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGA 60 
Clone1      TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGA 60 
Clone2      TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGT 60 
Clone3      TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGA 60 
Clone4      TCCGAGAACAGTTGCACGCACTTTCCGGGCAACCTTCCTAACATGCTTCGCGACCTGCGA 60 
            ***********************************************************  
 
WT          GATGCGTTCTCTCGAGTGAAAACTTTCTTTCAGATGAAAGATCAGTTGGATAATTTGCTC 120 
Clone1      GATGCGTTCTCTCGAGTGAAAACTTTCTTTCAGATGAAAGATCAGTAGGATAATTTGCTC 120 
Clone2      GATGCGTTCTCTCGAGTGAAAACTTTCTTTCAGTTGAAAGATCAGTAGGATAATTTGCTC 120 
Clone3      GATGCGTTCTCTCGAGTGAAAACTTTCTTTCAGATGAAAGATCAGTTGGATAATTTGCTC 120 
Clone4      GATGCGTTCTCACGAGTGAAAACTTTCTTTCAGATGAAAGATCAGTTGGATAATTTGCTC 120 
           *********** ********************* ************ ************* 
 
WT          CTCAAGGAGTCCCTTCTCGAAGACTTTAAAGGATACCTGGGGTGCCAGGCGCTTAGCGAG 180 
1 A
Clone2      CTCAAGGAGTCCCTTCTCGAAGACTTTAAAGGATACCTGGGGTGCCAGGCGCTTAGCGAG 180 
3 A
Clone4      CTCAAGGAGTCCCTTCTCGAAGACTTTAAAGGATACCTGGGGTGCCAGGCGCTTAGCGAG 180 
            **************** *************************** *************** 
 




Clone4 ATGATACAGTTCTATCTGGAGGAAGGGATGCCCCAAGCAGAAAATCAAGAACCCGATATT 240 
           ** ********************** ************************ ********* 
 




Clone4 AAGGCCCATGTCAACAGCCTTGGCGAAAATTTGAAAACTCTCAGACTCCGACTTCGCCGA 300 
           ************************************************** ********* 
 




Clone4 TGCCACAGGTTTTTGCCATGTGAGAATGGGGGTGGTTCCGGGGGTAAGTCCAAGGCCGTT 360 
           **** ******************************************************* 
 
WT    
1
2 A T A
3 C A A C
Clone4 GAGCAGGTGAAAAACGCTTTCAACAAACTGCAAGAAATGGGGATCTACAAAGCGATGTCA 420 
           ********* ****************** ******** *********** ********** 
 




Clone4 GAGTTCGACATATTTATAAACTACATAGAAGCCTATATGACGATGAAAATCCGCAA 476 





3.1.3 Screening of the IL-10 monomeric yeast display library 
 
We successfully generated an IL-10 yeast library with approximately 2 x 108 
display variants. This was estimated by titrating a sample of the  electroporated 
culture on SDCAA plates. The library underwent several rounds of screening with 
the first two rounds used to ensure proper functioning of the library and the 
subsequent rounds used to affinity mature IL-10 for IL-10Rß. A summary of the 
conditions used for each screening round is shown in Figure 3.3a.  
Each screening round started with a negative selection clearing step, followed by 
a positive selection step. The negative selection was performed by incubating the 
yeast with 500 nM fluorescently labelled streptavidin (SA-AF647) (Figure 3.3b). 
 
Figure 3.3 Screening of the IL-10 yeast library. (a) Schematic outlining the conditions used 
in each selection round. Concentrations of IL-10Rß were decreased as selection progressed. 
IL-10Rα was not biotinylated. (b) Representative FACS plots for negative selection of 
streptavidin binders. For negative selection the yeast were incubated with 500 nM fluorescently 
labelled streptavidin (SA647) followed by incubation with anti-AF647 magnetic beads. Panel one 
shows the yeast after incubation with SA647, before MACS. The flow through (panel two) 
contained yeast negative for streptavidin binding and these were brought forward for positive 
selection. Panel three contains the eluate, yeast which were positive for streptavidin binding 
which were discarded. This negative selection process was repeated at the beginning of each 
round of selection. 
Round 1: SAV-IL-10Rβ clearing
Round 2: Selection for c-myc expression
Round 3: 1 µM IL-10Rβ plus 100 nM IL-10R!
Round 4: 300 nM IL-10Rβ plus 100 nM IL-10R!
Round 5: 50 nM IL-10Rβ plus 100 nM IL-10R!
Round 6: 500 nM IL-10Rβ 
Round 7: 100 nM IL-10Rβ 


















The mixture was washed and then incubated with anti-AF647 microbeads. 
Magnetic activated cell sorting (MACS) technology was used. The yeast were 
added to the MACS column and the column was washed several times. The flow 
through contained yeast which did not bind streptavidin. The column was then 
removed from the magnet and any yeast which displayed an affinity for 
streptavidin in the absence of biotinylated protein were removed in the eluate. 
The flow through was then taken forward for positive selection.  
 
Round 1: 
The first positive selection round had the aim of recovering all positive binders in 
the library while also reducing the complexity of the library. Streptavidin 
microbeads (SAV) were pre-incubated with 400 nM biotinylated IL-10Rß. These 
microbeads have very high avidity as each bead has thousands of streptavidin 
molecules bound to it and each streptavidin molecule has the capability of binding 
between 1 to 4 biotinylated IL-10Rß proteins (Figure 3.4a).  
 
 
Figure 3.4 Magnetic activated cell sorting of yeast library. (a) Each streptavidin microbead 
(SAV) can bind many biotinylated proteins i.e. biotinylated IL-10Rß. The streptavidin/IL-10Rß 
complexes are then incubated with the yeast-displayed IL-10 proteins. (b) The yeast/IL-
10Rß/SAV mixture is added to the MACS column and placed within a magnetic field. Yeast 
which display IL-10 variants incapable of binding IL-10Rß flow through and are discarded. The 
column is removed from the magnet and yeast which display IL-10 variants bound to IL-10Rß 






This significantly reduces the amount of reagent needed in this round where large 
numbers of yeast were used. After incubation of the streptavidin microbeads with 
the biotinylated protein they were then added to the yeast flow through from the 
negative selection. Another round of MACS was performed (3.4b). Here the 
eluted yeast were kept as these displayed IL-10 variants capable of IL-10Rß 
binding. The yeast were grown in SDCAA (glucose) media for 24 hours and then 




The second round was a selection for the c-myc tag which was expressed at the 
C-terminus of the yeast-displayed IL-10. This ensured that any IL-10 displayed 
on the yeast was full length.  Again, a negative selection clearing step was 
performed first to remove any streptavidin binders, as was done for round 1. 
Following this, the yeast in the flow through were incubated with an Alexa Fluor 
647 (AF647) anti-c-myc antibody, followed by incubation with anti-AF647 
magnetic beads (Figure 3.5a). The population had roughly 18% of yeast positive 
for c-myc before MACS (Figure 3.5b). Yeast which were negative for c-myc were 
removed in the flow through as shown in Figure 3.5c. The eluted fraction was 
enriched for yeast positive for c-myc (Figure 3.5d). This population was then 
cultured as described above before beginning the affinity maturation selection 
rounds.  
 
Figure 3.5 Positive selection for c-myc. (a) c-myc tag is expressed at the C-terminus of the 
yeast-displayed IL-10 monomer. The yeast are incubated with an anti-c-myc antibody (AF647) 
followed by incubation with anti-AF647 microbeads. (b) Visualisation of yeast positive for c-
myc before MACS. (c) Yeast negative for c-myc are removed in the flow through. (d) Yeast 













3.1.4 Affinity maturation of IL-10 for IL-10Rß 
 
Once the complexity of the library was reduced and it was confirmed that the IL-
10 variants being displayed were full length, affinity maturation selection could 
then be commenced. Conditions for each selection round are shown in Figure 
3.3a. As before, each round started with a negative selection step to remove any 
yeast which could bind streptavidin in the absence of biotinylated protein. The 
flow through was taken forward for positive selection. In the positive selection 
step, the yeast were pre-incubated with a known concentration of biotinylated IL-
10Rß before addition of fluorescently labelled streptavidin (AF647) (Figure 3.6a).  
This was then incubated with anti-AF647 microbeads for a second round of 
MACS. The yeast which bound IL-10Rß were recovered in the eluate. The eluted 
yeast were grown and induced over three days as previously described before 
 
 
Figure 3.6 Affinity maturation of IL-10 for IL-10Rß using yeast display (a) Example of the 
positive selection used in each affinity maturation round. The yeast isolated in the flow through of 
the negative streptavidin MACS are washed and incubated with biotinylated IL-10Rß. This is 
followed by incubation with SA647 and anti-AF647 beads. MACS is performed again. The eluate 
contains yeast capable of binding IL-10Rß.  (b) Representative histograms of IL-10Rβ binding 
(AF647) of yeast displayed wild type IL-10, round 3 selection, round 6 selection and round 8 
selection. Yeast from each round were incubated with 1 μM IL-10Rß, followed by staining with 
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commencing the next round of selection. This positive selection procedure 
commenced with a 1 μM concentration of biotinylated IL-10Rβ as well as 100 nM 
non-biotinylated IL-10Rα to stabilise the surface complex and recover low affinity 
binders. Each selection round used decreasing concentrations of IL-10Rβ as 
shown in Figure 3.3a and by round 6 the yeast-displayed IL-10 variants were able 
to bind IL-10Rβ without the need for IL-10Rα. After 8 rounds of selection the 
library was able to bind nanomolar concentrations of IL-10Rß. Figure 3.6b shows 
a representative histogram of IL-10Rβ binding by the library throughout the 
selection rounds, visualised by flow cytometry using fluorescently labelled 
streptavidin (AF647). The shift in fluorescence demonstrates the biasing of the 
library towards variants which display enhanced affinity for IL-10Rβ. 
 
3.1.5 Characterisation of yeast-displayed high affinity clones 
 
After 8 selection rounds, single yeast colonies were grown by spreading on 
SDCAA (glucose) agar plates. An initial screen was done to select colonies which 
displayed enhanced IL-10Rß binding. 24 single yeast colonies (12 from round 7 
and 12 from round 8) were grown in SDCAA (glucose) media for 24 hours and 
induced in SGCAA (galactose) media for 2 days. These cultures were then 
incubated with 100 nM IL-10Rß (biotinylated) followed by addition of streptavidin-
AF647. Comparative binding between the 24 colonies was assessed by flow 
cytometry. 6 colonies (A1, A8, A11, B5, B10, B11) showed promising binding 
patterns (Figure 3.7a). These colonies were sent for DNA sequence analysis. 
Two unique variants were identified: A11 and B11, indicating convergency of the 
library. Sequence comparison with the wild type IL-10 monomer showed 
mutations at several points in the sequence, many of which were conserved 
between the variants indicating possible areas of importance for IL-10Rβ binding 
e.g. N36Y, N110I. (Figure 3.7b).  
 
To get an estimation of the apparent binding affinity of the IL-10 variants for IL-
10Rß an on-yeast binding dose response study was performed. A11 and B11 
showed a large increase in affinity for IL-10Rß compared to the WT (Figure 3.7c). 
In order to confirm that the variants maintained binding to IL-10Rß in the presence 
of IL-10Rα the dose response was repeated using biotinylated IL-10Rβ as well 




stepwise binding pattern of IL-10. Figure 3.7c shows that there was a decrease 
in IL-10Rß binding in the presence of IL-10Rα. This suggested that the introduced 
mutations may be contributing to competition for binding between IL-10Rß and 
IL-10Rα receptor subunits on the yeast surface, perhaps due to a change in the 




Figure 3.7 Selection and screening of colonies. (a) 24 individual colonies from round 7 and 
round 8 of selection were incubated with 100 nM of biotinylated IL-10Rß followed by incubation 
with SA647. Binding of the yeast colonies to IL-10Rß is indicated by increased AF647 
fluorescence. WT monomeric yeast on the left is compared to the 6 colonies which showed 
enhanced affinity for IL-10Rß. (b) Table for amino acid changes found in high affinity variants. 
Wild type sequence is shown in yellow and is based on the amino acid sequence reported for IL-
10 on the UniProt database (P22301), with the addition of the 6 amino acid linker at position 134 
allowing the formation of the monomer. Conserved changes between mutants are shown in blue. 
Individual mutations are shown in white. (c) Yeast displayed IL-10 mutants A11 and B11 and wild 
type monomer were incubated with three-fold serial dilutions of biotinylated IL-10Rβ, top 
concentration 1 µM. Receptor binding was visualised and quantified using AF647 labelled 
streptavidin. Panel 2 shows yeast treated as in panel 1 with un-biotinylated IL-10Rα added at a 












WT N36 D73 I87 N110 N115 K117 R128 N172 
A11 Y     I   N   H 
B11 Y V M I K   W   
 









































In order to retain the natural affinity for IL-10Rα we returned to the 5th round of 
selection, the last round where a constant concentration of IL-10Rα had been 
used during the screening (Figure 3.3a). From this round we plated and isolated 
colonies and screened them against IL-10Rß in the presence of non-biotinylated 
IL-10Rα. The dose responses are shown in Figure 3.8a. All R5 clones showed 
weaker responses to IL-10Rß alone compared to A11 and B11, however their IL-
10Rß binding was significantly improved upon the addition of IL-10Rα, mimicking 
Figure 3.8 Round 5 colonies (a) Yeast displayed IL-10 mutants A11 and B11 and wild type monomer 
along with variants from round 5 (R5) were incubated with three-fold dilutions of biotinylated IL-10Rβ, 
top concentration 1 µM. Receptor binding was visualised and quantified using AF647 labelled 
streptavidin. Panel 2 shows yeast treated as in panel 1 with un-biotinylated IL-10Rα added at a 
constant concentration of 100 nM. (b) Table for amino acid changes found in high affinity variants. 
Wild type sequence is shown in yellow and is based on the amino acid sequence reported for IL-10 
including on the UniProt database (P22301) with the addition of the 6 amino acid linker at position 
134 allowing the formation of the monomer. Conserved changes between mutants are shown in blue. 
Individual mutations are shown in white. (c) Cartoon representation of wild type IL-10 and R5A11 with 
the predicted IL-10Rβ binding site in red and mutations highlighted in purple. 
 














































WT F33 N36 N73 I87 Q88 N100 N110 N115 K117 R120 H127 R128 F129 N172 I174
A11 Y I N H
B11 Y V M I K W
R5A2 L I N L
R5B2 H I I N
R5A4 Y N N
R5B4 I D S
R5A8 Y L N



















a natural IL-10 binding pattern. These round 5 variants were sequenced and their 
mutations are displayed in Figure 3.8b.  
Many of the mutations are conserved between both round 5 and round 8 variants, 
in particular mutations at N36, N110 and K117. The majority of these conserved 
mutations occurred along the A and D helices of IL-10, highlighted in Figure 3.8c. 
This is the area previously predicted to be the IL-10Rβ binding site (Mendoza et 
al., 2017, Yoon et al., 2010), validating the selection process. In summary, 
several high affinity IL-10 variants were successfully generated using a yeast 
display affinity maturation library. These variants were taken forward for further 
characterisation. 
 
3.2 Recombinant expression of wild type and mutant IL-10 in monomeric 
and dimeric form 
 
After screening of the yeast library clones, we had several high affinity variants 
to take forward for further biophysical analyses. We chose to take forward A11, 
B11 and R5A11 based on their IL-10Rß binding patterns. We firstly needed to 
recombinantly express these proteins in addition to the wild type IL-10. The 
monomeric IL-10 variants were cloned into the baculovirus system and 
expressed in insect cells as described in the Materials and Methods. Proteins 
contained a His tag at the C-terminus and were purified by batch binding using 
Ni-NTA agarose beads and eluted in a high concentration imidazole buffer. Size 
exclusion chromatography was then used to further purify the proteins. The 
chromatograms for size exclusion chromatography for the A11 and B11 variants 
are shown in Figure 3.9a.  
 
In addition to the monomeric variants, we wanted to express the variants in the 
natural dimeric conformation. This would allow us to use wild type dimeric IL-10, 
wild type monomeric IL-10, high affinity dimeric variants and high affinity 
monomeric variants in further characterisation studies. By having both the 
monomeric and dimeric forms of IL-10 we could examine how receptor 
stoichiometry as well as receptor affinity influence IL-10 activities. Of the variants 
we chose R5A11 to express in the dimeric conformation due to its apparent 
enhanced ability to bind IL-10Rß in the presence of IL-10Rα, mimicking the 




In order to recombinantly express the dimeric forms of the high affinity variants, 
the 6 amino acid linker between helices D and E was removed during cloning into 
the recombinant expression vectors to allow the protein to form its domain 
swapped dimer conformation. However, using insect cell expression for the 
dimeric versions of the proteins gave poor yields. The wild type IL-10 dimer had 
previously been expressed in bacterial cells via inclusion bodies (Zdanov et al., 
1995) and so this was the approach taken forward. As shown in Figure 3.9b, 
when R5A11 and wild type IL-10 were recombinantly expressed and run in a gel 
filtration column there was a clear distinction between the monomeric and dimeric 
versions.  
 
Figure 3.9 Recombinant expression of wild type and high affinity IL-10 monomeric and 
dimeric variants. (a) Gel filtration chromatogram for monomeric high affinity variants A11 and 
B11. Proteins were run on an S200 column. (b) Gel filtration chromatogram for wild type and 
variant monomer and dimer. Proteins were run on a S75 column (c) A sample of the gel 
filtration-purified proteins were run on a 10% SDS-PAGE gel. Lane one contains the molecular 
weight marker (MW). 
 





















































When run on a reducing SDS-PAGE gel, dimeric and monomeric proteins ran at 
the same molecular weight as expected (Figure 3.9c). We used these monomeric 
and dimeric high affinity variants to compare against the monomeric and the 
dimeric wild type IL-10 in further biophysical and bioactivity studies. 
3.3 Engineered IL-10 variants bind IL-10Rβ with nanomolar affinities 
 
To validate the apparent binding affinities seen in the on-yeast binding titration 
experiments, surface plasmon resonance (SPR) was performed using the 
recombinantly produced cytokines. SPR studies were done using the monomeric 
version of IL-10 (wild type and high affinity variants). The monomeric versions 
were chosen as they provided a monovalent ligand flow on the Biacore chip. This 
gave a 1:1 ratio of ligand: receptor binding, allowing binding curves to be fitted. 
The dimeric forms of IL-10 are bivalent ligands and rebinding may have occurred 
if these were used, leading to inaccurate KD measurements. 
 
3.3.1 Affinity measurement of wild type and variant IL-10 binding to IL-10Rß 
 
Biotinylated IL-10Rβ was immobilised onto the chip surface through attachment 
to streptavidin molecules on the chip surface. Monomeric wild type and high 
affinity IL-10 variants were then flowed across the chip in solution (Figure 3.10a). 
At the range of doses used here (13-0.06 μM) we could not detect substantial 
binding of wild type monomeric IL-10 (WTM) to IL-10Rβ, in agreement with IL-
10’s previously reported weak affinity for IL-10Rβ (Figure 3.10b, c). The upper 
concentration of all variants was determined and limited by recombinant protein 
yield. High affinity variants A11, B11 and R5A11 were tested for IL-10Rβ binding 
under the same conditions as the wild type. All variants were capable of binding 
IL-10Rβ at the concentrations tested (Figure 3.10b, c). High affinity variants 
bound with a KD value in the low micromolar range (Figure 3.10b). This confirmed 
the on-yeast dose response studies, validating that our IL-10 variants were 
capable of enhanced IL-10Rβ binding compared to wild type. Although R5A11 
did not display binding affinity for IL-10Rß in the absence of IL-10Rα in the on-
yeast dose responses, it showed comparable affinity with A11 and B11 in SPR. 
This discrepancy may be due to increased steric hinderance when the proteins 
are displayed on the yeast surface or poor sensitivity of the yeast dose response 






3.3.2 High affinity IL-10 variants retain cooperative receptor binding 
patterns 
 
IL-10 displays cooperative binding to its receptor subunits whereby its affinity for 
IL-10Rβ is increased once pre-bound to IL-10Rα (Walter, 2014). To confirm that 
the affinity matured IL-10 variants retained this cooperative binding property we 
repeated SPR measurements using the IL-10 wild type and high affinity variants 
pre-bound to soluble IL-10Rα (Figure 3.11a). We could not detect significant 
binding of the wild type IL-10 monomer/IL-10Rα complex to IL-10Rβ, again 
mimicking what was seen in yeast-displayed wild type IL-10 (Figure 3.11b, c). All 
the high affinity variants tested exhibited enhanced binding to IL-10Rβ when pre-
bound to IL-10Rα, with KD values in the nanomolar range: A11= 23 nM, B11= 170 
nM, R5A11= 50 nM (Figure 3.11b, c). This confirmed that the high affinity variants 
maintained a cooperative binding pattern and suggested that the canonical IL-10 
receptor complex binding topology had not been perturbed by the mutations 
introduced. This was in contrast to what was observed in the yeast where A11 
and B11 had reduced binding affinity to IL-10Rß when IL-10Rα was present. This 
Figure 3.10 Measurement of binding affinity of monomeric variants to IL-10Rß (a) For 
SPR measurement IL-10Rβ is immobilised on the chip surface via a biotin-streptavidin 
interaction and IL-10 variants are flowed across the chip in solution. (b) KD values for IL-10Rβ 
binding for wild type and high affinity variants. ND= no data measured. (c) Kinetic charts for 
IL-10Rβ binding for wild type and high affinity IL-10 with inserts for equilibrium analysis. 
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may be due to increased steric hinderance when the proteins were displayed on 





Figure 3.11 Measurement of binding affinity of monomeric variants to IL-10Rß in the 
presence of IL-10Rα  (a) IL-10Rβ is immobilised on the chip surface and IL-10 variants pre-
bound to IL-10Rα are flowed across the chip surface in solution. Concentrations used are 
shown on curves. (b) KD values for IL-10Rβ binding when IL-10 proteins are pre-bound to IL-
10Rα. (c) Kinetic curves for IL-10Rβ binding in the presence of IL-10Rα. Affinity curves are 
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Protein engineering techniques have previously been used to successfully affinity 
mature cytokines for their receptors, for example in the cases of IFN-α2, IFN-λ, 
IL-13 and IL-2 (Mendoza et al., 2017, Moraga et al., 2015a, Levin et al., 2012, 
Kalie et al., 2007). These affinity matured variants act as tools with which to 
investigate how early events in cytokines’ interactions with their receptors can 
shape the cellular response. Thus far no attempt had been made to enhance IL-
10’s receptor affinity, despite its poor affinity for IL-10Rβ. This may be due to the 
dimeric nature of the cytokine which makes manipulation by protein engineering 
difficult. By using the monomeric version of IL-10 generated previously 
(Josephson et al., 2000b) as a template we overcame this difficulty. We could 
then investigate the biophysical properties of high affinity IL-10 in both a 
monomeric and dimeric conformation.  
 
Amino acid mutations in high affinity IL-10 variants give insight into the IL-
10/IL-10Rß binding interface 
 
Here we used error-prone PCR and yeast surface display to affinity mature 
monomeric IL-10 for IL-10Rß. When the sequences of the high affinity variants 
were compared to wild type IL-10 many of the mutated residues were highly 
conserved. In particular residues N36, N110 and K117 were mutated in nearly all 
variants. The majority of the conserved mutations occurred on the outward facing 
amino acids, suggesting that the structure of the cytokine remained intact with no 
changes to the hydrophobic core. Without a structure of IL-10 bound to IL-10Rß 
no definitive conclusions can be drawn about the nature of the mutations and how 
they enhance binding. However, by comparing the sites where the mutations 
arise with previously published models of IL-10Rß binding we can see that these 
conserved mutation sites occurred primarily along the A and D helices of IL-10 
which has been reported to be the IL-10Rß binding site (Pletnev et al., 2005). 
Previous studies used IL-10Rß alanine mutants as well as computational docking 
models to examine the IL-10/IL-10Rß binding interface (Yoon et al., 2010, Yoon 
et al., 2006). Here helices A and D were identified as a probable IL-10Rß binding 
site, in particular M40, a hydrophobic residue, was identified as the centre of the 




was mutated to tyrosine in variants A11 and B11 and to isoleucine in R5A11. 
Both tyrosine and isoleucine have hydrophobic side chains, similar to methionine 
at position 40, suggesting that this conversion to a hydrophobic residue may be 
important for binding. In addition, N110 is converted to isoleucine in all high 
affinity variants from our library. This residue is beside S111 which was previously 
shown to make contact with Y56 on IL-10Rß (Yoon et al., 2010). This conversion 
of a polar residue to a hydrophobic residue may allow tighter binding through 
expansion of the hydrophobic pocket where IL-10Rß docks. 
 
Other studies have modelled IL-10/IL-10Rß binding by using IL-10Rß’s property 
as a shared cytokine receptor between IL-10, IL-22 and IFN-λ. Modelling of the 
IL-10/IL-10Rß binding interface based on the binding of IFN-λ3/IL-10Rß also 
predicted binding sites on helices A, C and D of IL-10 (Mendoza et al., 2017). 
Despite the lack of conservation between the sequences of IFN-λ3, IL-22 and IL-
10 which map to the IL-10Rß binding site, Mendoza et al. showed that they do 
share common hydrophobic areas which contact the tyrosine residues of IL-10Rß 
predicted to be involved in binding (Y59, Y82, Y140), again highlighting the 
importance of these hydrophobic areas for IL-10Rß binding. 
 
Previous work on the human growth hormone (hGH) has shown that increased 
affinity can arise from “energetic remodelling” of the complex due to a 
combinatorial effect of several mutations (Pal et al., 2005, Spangler et al., 2015). 
Shotgun alanine scanning of hGH demonstrated that it was an additive effect of 
several interactions which form the site I interaction between hGH and its 
receptor. Therefore, while analysis of the positions of the mutations arisen in the 
high affinity variants can give insight into the IL-10Rß binding site we must be 
cautious about assigning the increased affinity to any one residue substitution 
without a crystal structure of the mutant IL-10/IL-10 receptor complex to inform 
us of the specific cytokine-receptor interactions.  
 
Another aspect to consider when examining the effect of amino acid substitutions 
to IL-10 receptor affinity is the viral IL-10 homolog produced by the Epstein-Barr 
virus, ebvIL10, which has 84% amino acid sequence similarity with human IL-10 
(Moore et al., 1990). The main differences in sequence are at the N terminus, the 




properties in its ability to inhibit proinflammatory cytokine production and antigen 
presentation from monocytes (de Waal Malefyt et al., 1991). However, it is unable 
to stimulate proliferation of mast cells or the upregulation of MHC II on murine B 
cells, suggesting that its differences at the amino acid levels translate into 
functional differences (Vieira et al., 1991, Go et al., 1990). In addition it was 
shown that ebvIL10 has much lower affinity for IL-10R1 than human IL-10 (Liu et 
al., 1997). Work by Ding et al. showed that, similar to human IL-10, ebvIL-10 does 
not bind to IL-10Rß alone (Ding et al., 2001). This work also demonstrated that 
the poor responses of ebvIL-10 could be restored to human IL-10 levels by 
increasing levels of IL-10Rα on the cell surface. It was later shown that this is due 
to the ebvIL-10 displaying monomeric IL-10Rα binding properties at low IL-10Rα 
levels, which is restored to dimeric binding at high IL-10Rα levels (Yoon et al., 
2012). The altered amino acid residues in ebvIL-10 compared to human IL-10 
resulted in a change in binding energy and kinetics to IL-10Rα however, replacing 
single ebvIL-10 amino acids with human IL-10 amino acids did not substantially 
enhance binding to IL-10Rα, suggesting that it is not a single substitution 
responsible for the binding activities (Yoon et al., 2012). The mutation of alanine 
to isoleucine at position 105 in ebvIL-10 was shown to have the greatest effect 
on biological activities, with its replacement restoring it to activity similar to human 
IL-10 immuno-stimulatory effects (Ding et al., 2000). In the same study this 
mutation also significantly changed the binding affinity of IL-10 for IL-10R, in 
contrast to what was reported by Yoon et al. This may be due to the use of murine 
IL-10Rα in the study by Ding et al. When comparing the mutations in our high 
affinity IL-10 to ebvIL-10 the N110I substitution is in close proximity to the I105A 
substitution. This supports the idea that an isoleucine residue in this area may 
confer an advantage. However, while position 110 is on helix D, 105 is in the CD 
loop region and so the ability to draw comparisons is limited.  
 
Conclusions and future perspectives 
 
Here we have successfully demonstrated the generation and biophysical 
characterisation of IL-10 variants with increased affinity for IL-10Rß. This 
increased receptor affinity has several implications for the study of IL-10. Firstly, 
it indicates that R5A11 may be a good candidate for attempts to crystallise the 




complex would be able to form. Secondly, the increased receptor affinity may 
have implications for downstream signalling. IL-10Rα and IL-10Rß are 
constitutively associated with JAK1 and TYK2 respectively. The interaction of the 
receptors activates these kinases and allows the phosphorylation of intracellular 
domains on IL-10Rα, providing docking sites for STAT molecules and their 
subsequent phosphorylation, dimerisation and activation. The ability of R5A11 to 
more effectively bind IL-10Rß may enhance formation of these active complexes 
and lead to increased STAT activation. Previous studies have shown that 
changes in the stability and thus the lifetime of cytokine-receptor complexes can 
alter the potency of intracellular signalling as well as downstream biological 
activities (Martinez-Fabregas et al., 2019). In the IL-6 system it was shown that 
by using IL-6 variants with a range of binding affinities for gp130, graded 
responses could be generated such as differential pSTAT1: pSTAT3 ratios. This 
in turn led to differential cell responses i.e. biasing of Treg/Th17 differentiation 
(Martinez-Fabregas et al., 2019). This link between cytokine receptor binding 
stability and biological output has also been investigated in systems such as type 
I interferons, IL-4 and IL-13 (Moraga et al., 2015a, Roisman et al., 2005, Junttila 
et al., 2012), however thus far reports using IL-10 are lacking. These high affinity 
IL-10 variants in both monomeric and dimeric conformations provide unique tools 
with which to probe the molecular basis of IL-10’s activity. This will be further 






Chapter 4. Investigating the link between IL-10 receptor binding 




This chapter will describe the use of the previously generated high affinity IL-10 
variant R5A11 to examine how changes in receptor binding affinity alter known 
IL-10 biological effects. R5A11 and wild type IL-10 were used in both their 
monomeric and dimeric conformations. This allowed us to also assess the 
contribution that receptor stoichiometry played in the IL-10 response.  
 
IL-10 is a key anti-inflammatory and immuno-regulatory cytokine. It can potently 
suppress the ability of innate cells such as macrophages and dendritic cells to 
present antigen and produce pro-inflammatory cytokines. This in turn inhibits the 
activity of the adaptive arm of the immune response, particularly Th1 cells. IL-10 
can also act directly to suppress adaptive cell responses, for example, by its 
action on Th17 cells (Huber et al., 2011). The central role that IL-10’s anti-
inflammatory activities play in the regulation of the immune response is seen in 
patients deficient in IL-10 or with defects in the receptor. These patients develop 
auto-immune diseases such as Crohn’s disease and colitis (Correa et al., 2009, 
Zhu et al., 2017), emphasising the importance of effective IL-10 production and 
response. Despite promising in vitro activity, IL-10 based therapies have so far 
shown poor clinical efficacy in the treatment of auto-immune diseases, hindered 
by IL-10’s short half-life and difficulties in targeted delivery (Saraiva et al., 2020) 
 
In recent years several studies have highlighted another key IL-10 activity. It has 
been shown that, under certain conditions, IL-10 can enhance the cytotoxicity of 
CD8 T cells, leading to enhanced tumour cell targeting (Mumm et al., 2011). A 
PEGylated version of IL-10 is currently in clinical trials as a cancer therapeutic, 
with initial studies showing promising results (Naing et al., 2019).  
 
We hypothesised that an IL-10 variant with enhanced receptor binding affinity has 
the potential to improve the efficacy of the IL-10 response. In this chapter I outline 




receptor binding affinity as well as receptor complex stoichiometry to IL-10 
biology. Monocytes and CD8 T cells isolated from human buffy coats were used 
for experiments in this chapter. IL-10’s ability to potently suppress pro-
inflammatory responses in monocytes has been well characterised (Moore et al., 
2001). The ability of IL-10 to enhance CD8 cytotoxicity has also been described 
in detail in recent studies (Mumm and Oft, 2013). This, along with their ability to 
be easily isolated and cultured, made these cells ideal for studying how high 
affinity changes influence IL-10 activities in both an innate and an adaptive cell 
setting. Wild type IL-10 was used in its native conformation as a dimer (WTD) 
and also as a monomer (WTM). R5A11 was used in dimeric (R5A11D) and 
monomeric (R5A11M) forms (Figure 4.0). 
 
Results discussed in this chapter form the basis for the publication “Engineered 
IL-10 variants elicit potent immunomodulatory effects at low ligand doses”, Gorby 




Figure 4.0 Schematic of IL-10 variants used. Four variants of IL-10 were used in this study. 
Wild type IL-10 was used in its natural dimeric conformation (WTD) and in a monomeric 
conformation (WTM) as described by (Josephson et al., 2000b). The high affinity IL-10 variant 














• Assess the effect of receptor affinity on assembly of the IL-10 receptor 
complex 
• Examine early signalling events (i.e., STAT activation) by wild type and 
high affinity IL-10 monomers and dimers. 
• Test the known IL-10 cellular response to high affinity variants (inhibition 
of antigen presentation, granzyme B production). 
• Analyse gene expression in monocytes and CD8 T cells after stimulation 





4.1 Increased affinity for IL-10Rß enhances assembly of the complete IL-10 
receptor complex 
 
All experiments in this section (4.1) were conducted by Junel Sotolongo Bellón in 
the lab of Jacob Piehler at University of Osnabrück. The Piehler lab has extensive 
experience with multi-colour single-molecule fluorescence TIRF imaging of 
cytokine receptors. The wild type and high affinity IL-10 variants were produced 
and provided by the author in the University of Dundee. 
 
IL-10 carries out its biological functions by binding to IL-10Rα and IL-10Rβ on the 
cell surface, forming a hexameric complex, i.e. one IL-10 dimer, bound to two 
copies of IL-10Rα and two copies of IL-10Rβ. According to the law of mass action, 
IL-10 would first bind IL-10Rα via the receptor’s high-affinity binding site. In a 
subsequent step, IL-10Rβ is recruited into the complex leading to a dynamic 
equilibrium of receptor complex assembly and dissociation. This equilibrium is 
largely defined by the affinity of IL-10 toward IL-10Rβ, as this is the weakest 
interaction in the complex. As our engineered IL-10 variants had increased affinity 
for IL-10Rβ we wanted to investigate how this change in affinity would affect the 
assembly of the signalling complex in the context of the plasma membrane of live 
 
Figure 4.1 TIRF microscopy. Simplified representation of the differential excitation of fluorophores 
by traditional epifluorescence versus TIRF microscopy. Using epifluorescence, the incident light 
travels straight through the coverslip into the sample and all fluorophores in this path are excited. 
Using TIRF microscopy, the incident light is reflected back off the coverslip. This generates an 
evanescent wave at the solid-liquid interface with is the same frequency as the exciting beam. Only 
fluorophores within this range are excited, reducing background signal. Figure adapted from 














cells. We took advantage of Total Internal Reflection Fluorescence (TIRF) 
microscopy to do this (Figure 4.1).  
TIRF microscopy allows selective excitation of fluorophores proximal to the basal 
membrane of adherently growing cells which significantly reduces background 
signals. Using super-resolution imaging algorithms, individual fluorescence 
emitters can be localised with high spatial accuracy (~20nm), allowing single 
molecule co-localisation and co-tracking experiments of fluorescently labelled cell 
surface receptors. 
 
4.1.1 Labelling of IL-10Rα and IL-10Rß for single molecule co-localisation 
studies 
 
For visualisation of IL-10Rα and IL-10Rβ engineered versions of the receptors 
were expressed in HeLa cells as follows (Figure 4.2a). IL-10Rα and IL-10Rß were 
tagged at their N-terminus with non-fluorescent variants of either monomeric 
ECFP (enhanced cyan fluorescent protein) or EGFP (enhanced green 
fluorescent protein) respectively, each of which carry a Y66F mutation. This 
mutation impairs chromophore formation and thus these variants are non-
fluorescent. ECFP and EGFP were used  as GFP and CFP have low intrinsic 
affinities which may affect dimerisation. These tags were designed to be 
specifically recognised by either one of two different anti-GFP nanobodies; 
minimiser (MI) or enhancer (EN), for IL-10Rα and IL-10Rß respectively (Figure 
4.2a). These anti-GFP nanobodies were previously generated using a phagemid 
library (Kirchhofer et al., 2010). The nanobodies (NBs) were conjugated to the 
photostable organic fluorophores ATTO Rho11 and ATTO 643 (referred to in the 
figures as Rho11 and AT643 respectively). This allowed simultaneous dual-
colour single molecule tracking of IL-10Rα and IL-10Rβ in the plasma membrane 
of live cells with high spatio-temporal accuracy as shown previously in other 
cytokine receptor systems such as IL-6, IL-13, erythropoietin and thrombopoietin 
(Martinez-Fabregas et al., 2019, Moraga et al., 2015a, Wilmes et al., 2020, 
Moraga et al., 2015b).  
 
In the dimeric conformation we expected that IL-10 would interact with two 
molecules of IL-10Rα and two molecules of IL-10Rß while the monomeric 




reported cytokine-receptor stoichiometry (Josephson et al., 2000b). A schematic 
of receptor assembly is shown in Figure 4.2b. As this is a dynamic system, 
several permutations of the dimeric complex assembly are possible e.g. 1:2:1, 
1:1:2 for IL-10:IL-10Rα:IL-10Rß. However, for illustration of the labelling strategy 
only one configuration is shown. 
 
After quantitative cell surface labelling, single-molecule co-localisation of IL-10Rα 
and IL-10Rß can be taken as a readout for interaction of the two receptor chains. 




Figure 4.2 Labelling strategy for probing receptor co-localisation. (a) Schematic of receptor 
labelling. IL-10Rα is tagged with an ECFP non-fluorescent variant. This is recognised by an anti-
GFP nanobody conjugated to the fluorophore Rho11. IL-10Rß is tagged with an EGFP non-
fluorescent variant which is recognised by an anti-GFP nanobody conjugated to the fluorophore 
AT643. (b) Quantifying receptor dimerisation in the plasma membrane by dual-colour single 
molecule co-localisation and co-tracking. IL-10Rα and IL-10Rβ were labelled with nanobodies 
MIRho11, ENAT643 respectively allowing visualisation of single receptor molecules and co-
localisation events. This experiment was performed and analysed by J. Sotolongo Bellón, 
University of Osnabrück. 
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localisations, only persistent co-localisation (threshold 150nm for ³ 10 
consecutive steps » 320ms) of receptor chains was taken as readout for receptor 
complex assembly. This labelling and evaluation strategy was applied to both the 
monomeric and the dimeric variants of IL-10 (Figure 4.2b). 
 
4.1.2 High affinity IL-10 variants display enhanced IL-10 receptor 
dimerisation 
 
Cells expressing both receptor subunits were treated with saturating doses of the 
respective IL-10 variants, ensuring that each high-affinity IL-10Rα subunit would 
be occupied by the ligand. Only cells showing a mild excess of IL-10Rß were 
considered for analysis (Figure 4.3a), so that maximal receptor assembly would 
only be limited by the affinity of IL-10 towards IL-10Rß, not the availability of IL-
10Rα, as recently shown for the Type I interferon system (Wilmes et al., 2015). 
Both receptor subunits diffused randomly in the plasma membrane as shown in 
Figure 4.3b. In absence of IL-10 stimulation, no heterodimers of IL-10Rα and IL-
10Rß could be detected. After IL-10 stimulation, a significant fraction of dimers 
was observed, as shown in Figure 4.3b.  
Data by J. Sotolongo Bellón 
 
Figure 4.3 Visualisation of hetero- and homodimerisation of IL-10 receptor subunits.  
(a) Cell surface receptor density of ectopically expressed IL-10Rα (blue) and IL-10Rβ (red). Each dot 
represents one cell. (b) Trajectories of IL-10Rα (blue), IL-10Rß (red) and co-localized IL-10Rα:IL-
10Rß (magenta) in the absence of IL-10 (left column) and in the presence of WTD (middle column) 
and R5A11D (right column), respectively. This experiment was performed and analysed by J. 









































Interestingly, the R5A11 dimer (R5A11D) induced a significantly higher level of 
receptor heterodimers compared to WTD (Figure 4.4a, panel 1). We also 
compared the wild type IL-10 monomer (WTM) with the monomeric high affinity 
variant (R5A11M). Similar to the dimeric variants, WTM  induced lower levels of 
heterodimerisation than R5A11M (Figure 4.4b, panel 1). 
 
Next, we quantitatively examined the homodimerisation of the two receptor 
subunits. In order to do this either receptor chain was stochastically labelled with 
both dyes, showing a 1:1 ratio as demonstrated in Figure 4.4c. Because of this 
binomial distribution of stochastic receptor labelling, only half of the formed 
dimers would be picked up by co-tracking analysis and quantification was 
mathematically corrected for this. For homodimerisation of IL-10Rα no significant 
difference was seen between WTD and R5A11D (Figure 4.4a, panel 2). In 
contrast, R5A11D induced significantly more homodimerisation of IL-10Rß 
compared to WTD (Figure 4.4a, panel 3), in agreement with its higher affinity for 
IL-10Rß. As expected, no homodimerisation events were detected for the 
monomeric cytokines, verifying their monomeric nature (Figure 4.4b, panel 2-3). 
 
In summary, the high affinity variants of IL-10 in both monomeric and dimeric 
conformations displayed enhanced heterodimerisation of the IL-10 receptor 






Figure 4.4 Quantification of hetero- and homodimerisation of IL-10 receptor subunits  
(a) Heterodimerisation of IL-10Rα and IL-10Rß (left), and homodimerisation of IL-10Rα (centre) 
and IL-10Rß (right) induced by dimeric IL-10 variants, quantified by co-locomotion analysis. Each 
data point represents one cell. (b) Homo- and heterodimerisation of IL-10Rα and IL-10Rß induced 
by monomeric IL-10 variants quantified by co-locomotion analysis. (c) Cell surface density for 
homodimerisation experiments. Each data point represents a cell. P value is calculated by two-
tailed student’s t test. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. n.s., not significant. This 














































































































4.2 High affinity IL-10 regulation of innate (monocyte) immune responses 
 
As R5A11 showed enhanced assembly of the receptor complex we next wanted 
to see how this would affect other aspects of IL-10 biology. We examined the 
effect of receptor affinity and receptor stoichiometry on IL-10’s ability to activate 
STATs, the IL-10 transcriptome and known IL-10 biological activities. As IL-10 
has very well characterised activities in innate cells we chose monocytes to work 
with. The response of these cells to IL-10 has been previously studied in depth, 
giving us a broad range of literature to work from. These cells are also easily 
isolated from human buffy coats, allowing us to examine the effect of our high 
affinity variants in primary human cells. 
 
4.2.1 Increased affinity enhances STAT activation in monocytes 
 
IL-10’s activation of the JAK/STAT pathway is the primary way in which signals 
from the receptor complex are transmitted within the target cell. JAK1 and TYK2 
are associated with IL-10Rα and IL-10Rß respectively. Upon ligand stimulation 
these kinases are activated and phosphorylate tyrosines in the intracellular 
domain of the receptor tails. This provides a docking site for STAT molecules and 
allows their dimerisation and activation upon Tyr phosphorylation by JAKs. Once 
dimerised, STATs translocate to the nucleus to induce gene expression 
programmes. Both STAT1 and STAT3 have been shown to be activated in 
response to IL-10 (Finbloom and Winestock, 1995). In order to assess how 
increased receptor affinity affected early signalling events, phospho-flow 
cytometry was used to measure tyrosine phosphorylation of STAT1 and STAT3 
 
Figure 4.5 Isolation and treatment of monocytes for STAT activation. Monocytes (CD14+) 
were isolated by positive selection (MACS) from human buffy coats. The cells were then 


















in human monocytes. Monocytes were isolated from human buffy coats 
stimulated with a range of IL-10 concentrations for 15 minutes (Figure 4.5).  
Cells were stimulated with wild type and high affinity monomers and dimers over 
a large range of concentrations, from 200 nM to 12.8 pM. 
 
Dose response curves were generated from these experiments with the log10 of 
the concentration of the IL-10 variants on the x-axis and the pSTAT response 
(normalised) on the y-axis. The curves are sigmoidal in nature as the response 
reaches saturation at high concentrations where, despite increased cytokine 
concentration, no increase in STAT activation is seen. This allows us to compare 
the EC50 of the IL-10 variants, giving an insight into the relative potency of the 
variants. The dose response curves for pSTAT1 and pSTAT3 are shown in Figure 
4.6a-b respectively. We first compared the WTD dose response curves with those 
of the high affinity dimer, R5A11D. At high concentrations for both WTD and 
R5A11D there was an apparent decrease in pSTAT1 activity which was not seen 
for pSTAT3. In addition, R5A11D showed a non-significant but enhanced 
pSTAT1 response at high concentrations compared to WTD. When we examined 
the ability of WTD and R5A11D to activate STAT3 we saw that R5A11D 
phosphorylated STAT3 to a very similar level as WTD at saturation. Despite 
showing an almost identical pattern of STAT3 activation to WTD at high 
concentrations, R5A11D appeared to show enhanced STAT1 and STAT3 
phosphorylation at low concentrations, leading to a shift in the dose response 
curves. When the EC50 values were plotted, R5A11D had a non-significant but 
consistently lower EC50 for both pSTAT1 and pSTAT3 compared to WTD, 
suggesting enhanced activity by the high affinity variant (Figure 4.6c-d).  
 
We next examined STAT activation by the monomeric variants to gain an 
understanding of the role that receptor stoichiometry plays in STAT signalling. 
The wild type monomer (WTM) activated both STAT1 and STAT3 poorly, with 
less than 25% of maximal STAT1 activity and 35% of STAT3 activity compared 
to WTD at saturating levels (Figure 4.6a-b). This also led to apparently higher 
EC50 levels than WTD for both STAT1 and STAT3 (Figure 4.6c-d). When we 
compared WTM to the high affinity monomer (R5A11M) we saw that the increase 




STAT3. At saturating concentrations, R5A11M activated STAT1 to a similar 
extent to WTD and STAT3 reached 80% of the dimeric activity (Figure 4.6a-b).  
 
Although the STAT response was similar to the level of the dimeric cytokine at 
saturating concentrations, there appeared to be a shift in the dose response 
 
Figure 4.6 STAT1 and STAT3 activation by high affinity IL-10 variants. (a-b) Human CD14 
positive monocytes were stimulated with IL-10 variants over a range of concentrations for 15 
minutes. Phosphorylation of STAT1 and STAT3 was measured by flow cytometry. Data shown is 
the mean of 5 biological replicates with error bars showing the standard error of the mean. Each 
replicate is normalised by assigning the highest MFI value of the top concentration as 100% and 
the lowest MFI value of the bottom concentration as 0%. (c-d) Log10 EC50 values for pSTAT1 and 
pSTAT3 from the corresponding dose response curves in (a-b). (e) Ratio of pSTAT1 to pSTAT3 
in monocytes upon IL-10 variant stimulation. Ratio was calculated by taking the percentage 
activation of pSTAT1 and pSTAT3 at 40 nM and dividing the pSTAT1 by pSTAT3 values. P values 
were calculated using paired t tests. 

















































































































































curves at low concentrations, particularly for STAT3. This was reflected when the 
EC50 values were plotted, with apparently higher EC50 values for R5A11M for 
STAT1 and STAT3 than WTD (Figure 4.6c-d).  
 
We also noted that WTM had increased STAT3 activity compared to STAT1. 
When the ratios of pSTAT1 to pSTAT3 levels were examined it was clear that 
WTM showed a bias towards STAT3 activation, whereas WTD, R5A11D and 
R5A11M had 1:1 ratios (Figure 4.6e). This will be examined further in the 
discussion. 
 
In summary, increased affinity significantly enhances the ability of monomeric IL-
10 to activate STAT1 and STAT3 at high concentrations. Increased affinity in the 
dimeric form of IL-10 does not enhance the STAT activation at saturation, 
however, it does appear to improve the EC50 of the response, suggesting 
enhanced activity at low concentrations compared to WTD. 
 
4.2.2 Changes in receptor affinity and stoichiometry do not affect the 
kinetics of the IL-10 response in monocytes 
 
We next wanted to see if the change in affinity for IL-10Rß by the R5A11 variants 
would impact the kinetics of the IL-10 response. Human monocytes were isolated 
as described previously. Cells were stimulated for the denoted time periods 
between 15 minutes and 3 hours and phosphorylation of STAT1 and STAT3 was 
examined. The pSTAT1 and pSTAT3 response peaked at 15 mins after 
stimulation and decreased thereafter with levels returning to basal after 2 hours 
for pSTAT1 and 3 hours for pSTAT3 (Figure 4.7). The amplitudes of signalling 
match with those seen in the dose response studies. WTM again showed poor 
activation of both pSTAT1 and pSTAT3. While the amplitudes of the response 
appeared to differ between the variants there was no significant changes in the 
kinetics between either high affinity vs wild type or dimeric vs monomeric 
molecules, concluding that changes in affinity for IL-10Rß do not affect the 






4.2.3 Increased affinity enhances known IL-10 biological activities at low 
concentrations in monocytes 
 
Activation of STATs is the primary signalling step in the IL-10 response. As we 
observed differences in the amplitude of STAT phosphorylation between the IL-
10 variants we next wanted to see if this would translate into any differences in 
cellular responses. To investigate this, we examined two well characterised IL-
10 responses in monocytes: suppression of antigen presentation molecules and 
inhibition of pro-inflammatory cytokine production.  
 
Human leukocyte antigen-DR (HLA-DR) is a cell surface receptor, analogous to 
major histocompatibility class II (MHC-II) in mice. It is a molecule which allows 
presentation of processed antigens to CD4 T helper cells, via interaction with the 
T cell receptor (TCR). This is a key step in the activation of the adaptive immune 
response. A key characteristic of IL-10 is its ability to inhibit antigen presentation 
by innate cells, dampening the immune response. IL-10 reduces MHC II via 
regulation at the protein level, reducing exocytosis of MHC II and also inhibiting 
the recycling mechanisms used to return these molecules to the cell surface 
(Koppelman et al., 1997). Measurement of surface HLA-DR expression on 
human monocytes was used as a proxy to examine the ability of our high affinity 
variants to modulate the innate immune response. Monocytes (CD14+) were 
isolated from human buffy coats and rested for two days as shown in in Figure 
4.8a. Cells were placed in media containing either WTD, WTM, R5A11D or 
 
Figure 4.7 Kinetics of pSTAT1 and pSTAT3 response to IL-10 variants in monocytes. 
Monocytes were stimulated with 50 nM IL-10 for the indicated time periods before fixation. Data 
shown is the mean of four biological replicates with error bars depicting the standard error of 
the mean. Each biological replicate is normalised by assigning the highest MFI value at 15 
minutes as 100% and the lowest MFI value of an untreated control as 0%.  































































































































R5A11M at a saturating dose of 50 nM for 24 hours. After 24 hours of treatment, 
cell surface HLA-DR was measured by flow cytometry. All data were normalised 
to a non-IL-10 treated control within each donor. Figure 4.8b shows that, as 
expected, WTD induced a decrease of almost 50% in HLA-DR compared to non-
IL-10 treated controls. In line with its ability to activate STAT signalling at levels 
equivalent to WTD at saturating concentrations, R5A11D also showed a 50% 
decrease in cell-surface HLA-DR. WTM induced only a 20% reduction in HLA-
DR molecules, in keeping with its poor STAT activation. R5A11M showed a 30% 
inhibition of HLA-DR, demonstrating a better response than WTM but not 
reaching dimeric levels of inhibition, despite having similar STAT activation as 
the dimeric variants at this saturating concentration.  
 
As R5A11D appeared to show enhanced STAT activation compared to WTD at 
sub-saturating concentrations, we tested inhibition of HLA-DR using a low dose 
of 0.1 nM of the IL-10 variants. Figure 4.8c shows that at this low concentration 
 
Figure 4.8 Measurement of cell surface HLA-DR upon IL-10 stimulation. CD14+ 
monocytes were isolated from human buffy coats by positive selection and rested for 2 days 
in media containing M-CSF (20 ng/mL). The cells were then stimulated with IL-10 variants for 
24 hours at either a high concentration ((b) 50 nM) or a low concentration ((c) 0.1 nM) for 24 
hours. HLA-DR was measured on the cell surface of live cells by flow cytometry. Each point 
represents one biological replicate (n=4). Fold change is calculated by dividing the MFI of each 















































































R5A11D appeared to display slightly stronger inhibition of HLA-DR compared to 
WTD. Again, R5A11M and WTM failed to reach the levels of inhibition induced 
by the dimeric cytokines. These results are in keeping with the trends seen in 
STAT1 and STAT3 activation by the IL-10 variants and suggest that the high 
affinity dimeric IL-10 may provide an advantage over the wild type at low doses. 
 
A key feature of IL-10’s anti-inflammatory activities is its ability to suppress 
secretion of pro-inflammatory cytokines from a myriad of cell types such as 
monocytes, dendritic cells and Th1 cells. IL-10 was shown to potently inhibit LPS 
and PMA-induced IL-6 secretion from monocytes at the level of RNA (Takeshita 
et al., 1996). We decided to use this known response to IL-10 to further examine 
if the high affinity variant R5A11D displayed a dose-dependent advantage over 
the wild type IL-10 (WTD). CD14+ monocytes isolated from human buffy coats 
were stimulated with LPS in the absence or presence of WTD or R5A11D at 
varying concentrations for 8 hours before the supernatant was collected and IL-
6 secretion was measured.  
 
Upon LPS stimulation a large increase in IL-6 secretion was seen which could be 
potently inhibited by co-incubation with either WTD or R5A11D at 50 nM (Figure 
4.9a). When a low dose of IL-10 was used, 0.01 nM, R5A11D inhibited 
significantly more IL-6 secretion compared to WTD (Figure 4.9b). This 
corresponds to its stronger STAT activation at low doses. Again, this suggests 
that increased affinity provides an advantage to IL-10 when used at low doses, 
in keeping with what was seen at the level of STAT activation.  
 
Figure 4.9 WTD and R5A11D inhibition of LPS-induced IL-6 secretion. CD14+ human 
monocytes were stimulated with LPS (100 ng/mL) alone or with WTD or R5A11D at the denoted 
concentrations for 8 hours.  (a)= 50 nM, (b)= 0.01 nM. An ELISA was used to measure IL-6 
secretion. Each point represents one biological replicate (n=3) and error bars indicate the 


































4.3 Comparison of transcriptional activity induced by IL-10 and high affinity 
variants in monocytes 
 
Our comparisons between the IL-10 variants had so far focussed on two classical 
markers of IL-10 activity in monocytes: suppression of antigen presentation and 
pro-inflammatory cytokine production. We wanted to gain a broader 
understanding of how the differences in affinity, receptor complex assembly and 
STAT activation would regulate monocyte activity. The phosphorylation of STAT1 
and STAT3 by IL-10 allows the dimerisation and translocation of these 
transcription factors to the nucleus where they can induce gene transcription 
programmes. We decided to use RNA sequencing to examine in depth the 
transcriptional activity induced by our IL-10 variants in human monocytes. This 
gave us a global view of this cytokine’s regulation of monocyte activity and 
allowed us to compare the effect of our variants in an unbiased fashion. The effect 
of IL-10 on monocytes and myeloid cells has been well characterised however 
the sensitivity of these activities to changes in ligand concentration and/ or 
receptor binding affinity is less well understood. We envisioned that our 
transcriptomic studies would further our understanding of IL-10 biology under 
different ligand conditions.  
 
Monocytes (CD14+) were isolated from human PBMCs (StemCell Technologies) 
(3 donors) and rested for two days in M-CSF containing media before 24 hours 
of stimulation with IL-10 variants as shown in Figure 4.10.  
All variants (WTD, R5A11D, WTM, R5A11M) were used at a saturating 
concentration of 50 nM. In addition, WTD and R5A11D were used at a low 
Figure 4.10 Isolation and treatment of monocytes for RNA sequencing. Monocytes 
(CD14+) were isolated by positive selection from human PBMCs (n=3) and rested in M-CSF 
containing media (20 ng/mL) for two days. The cells were then stimulated with IL-10 wild 
type and variants for 24 hours. WTD and R5A11D were used at 50 nM and 0.1 nM each. 


















concentration of 0.1 nM due to the previously demonstrated apparent enhanced 
activity displayed by R5A11D compared to WTD at this concentration. Each 
biological replicate contained an untreated control against which the IL-10 
variants could be compared. 
 
Cells were stimulated and RNA was isolated by the author. RNA sequencing and 
primary data analysis for quality control, mapping to reference genome and 
quantification was conducted by an external company (Novogene) as detailed in 
the “Materials & Methods” chapter. Statistical analysis and comparison of gene 
regulation between the IL-10 variants was done by the author.  
 
4.3.1 Characterising the transcriptional effect of WTD on human monocytes  
 
First, we wanted to fully characterise the effect of high concentration (50 nM) 
WTD on monocytes so as to generate a template of IL-10 regulated genes 
against which we could compare the other ligand and concentration conditions. 
We compiled a list of those genes whose expression was changed by WTD (50 
nM) compared to unstimulated cells more than 1.5 fold or less than 0.67 fold (>0.6 
log2 fold change or <-0.6 log2 fold change). This list can be found in Appendix 
Table 1. We excluded any genes which were non-significantly regulated (p value 
> 0.05). This filtering of data is described in more detail in the “Materials & 
Methods” chapter. There was a strong transcriptional regulation by WTD with 
1825 genes significantly changed compared to unstimulated controls, as shown 
in the volcano plot in Figure 4.11a. Of these 41% were upregulated genes (741) 
and 59% were downregulated (1084) compared to non-IL-10 treated controls 
(Figure 4.11b).  
 
Cytokines and chemokines can act as key drivers of inflammation. The ability of 
IL-10 to supress production of pro-inflammatory cytokines and chemokines as 
well as their receptors is an important aspect of its immune-suppressive 
capabilities.  We saw downregulation of IL-24, IL-18 and IL-8 transcripts by WTD 
in our study (Figure 4.12a). IL-24 is an IL-10 family member cytokine with diverse 
effects. Of note is its ability to induce secretion of pro-inflammatory cytokines 
such as IL-6 and TNF-α in PBMC cultures (Caudell et al., 2002). It has also been 




bowel disease (Chen et al., 2018). IL-18 has been shown to stimulate 
granulocytes such as mast cells to produce histamines and can also act in 
concert with IL-12 to induce IFNγ secretion from T cells (Yasuda et al., 2019). 
Many TNF-associated genes such as TNFAIP3, TNFRSF18 and TNFRSF4 were 
also downregulated. Together this significant downregulation of pro-inflammatory 
cytokines by WTD supports IL-10’s known role in limiting the inflammatory 
response by monocytes.  
IL-8 transcripts were also downregulated by WTD. IL-8, also known as CXCL8, 
is a potent chemo-attractant for neutrophils (Yoshimura et al., 1987) again 
confirming the immune-suppressive role of IL-10. Several other chemokine 
transcripts were also downregulated by WTD such as CXCL10 and CXCL11 
(Figure 4.12a). These are both pro-inflammatory chemo-attractants, known to 
effect cells such as activated T cells and NK cells (Vazirinejad et al., 2014, 
Metzemaekers et al., 2017). 
 
However not all cytokines and chemokines were inhibited by WTD. We observed 
a large upregulation of IL-7 and its receptor (Figure 4.12a). IL-7 plays a role in 
the maintenance of survival of T cells, suggesting that WTD may be modulating 
 
Figure 4.11 Regulation of monocyte gene transcription by WTD. (a) Volcano plot of 
monocytes genes significantly upregulated by WTD > 0.6 log2 fold change (red) and significantly 
downregulated by WTD <-0.6 log2 fold change (blue) compared to non-IL-10 treated cells. Fold 
change was calculated by dividing WTD 50 nM values by unstimulated values for each donor. 
The average fold change was calculated for three donors and the log2 of this value is plotted. P 
values were calculated by two-tailed two sample equal variance t test of the log2 fold change of 
WTD 50 nM/ unstimulated genes for each donor. Genes which were not significantly changed 
or were <0.6 >-0.6 log2 fold change were excluded. (b) Proportion of genes significantly up or 
down regulated by WTD in monocytes. 



























the T cell response via changes in monocyte cytokine secretion. WTD also 
induced the upregulation of IL-21R in monocytes. IL-21 has previously been 
shown to enhance phagocytosis of opsonised targets in human monocytes 
(Vallieres and Girard, 2017). 
Phagocytosis is one of the primary functions of monocytes. The phagocytosis of 
bacteria or damaged/infected cells limits infections. It also induces further pro-
inflammatory responses by monocytes such as antigen presentation and the 
production of cytokines and chemokines which activate other facets of the 
immune system. IL-10 has been shown to enhance the phagocytic activity of 
monocytes. Previous studies have demonstrated the upregulation of genes 
encoding receptors and signalling molecules involved in phagocytosis as well as 
scavenger functions by IL-10. For example, it has been observed that monocytes 
incubated with IL-10 showed increased expression of FC gamma receptor 1 
(FCγR1) and complement receptors 1 and 3 (CR1, CR3) which resulted in 
increased uptake of opsonised particles (Capsoni et al., 1995). Similar results 
were observed in monocyte derived macrophages where IL-10 stimulated 
macrophages had enhanced levels of phagocytosis (Schulz et al., 2019). A 
 
Figure 4.12 Regulation by WTD 50 nM of genes previously reported to be changed upon 
IL-10 stimulation in monocytes. (a) Heatmap of regulation of genes encoding cytokines, 
chemokines and their receptors by WTD. (b) Regulation of genes associated with phagocytosis 
by WTD. (c) Regulation of genes associated with metabolic pathways by WTD. For all genes 
the log2 fold change was calculated by dividing values for WTD 50 nM by untreated controls for 


























































































previous study characterised gene expression in IL-10-treated CD14+ cells 
isolated from human PBMCs (Jung et al., 2004). They identified the IL-10 
mediated upregulation of genes encoding cell surface receptors for phagocytosis 
and scavenger functions and also genes associated with phagocytosis signalling. 
We compared these previously reported genes to our WTD regulated genes and 
found many similar expression patterns. These are shown in Figure 4.12b. The 
FC gamma receptors FCGR1, 2 and 3 (also known as CD64, CD32 and CD16), 
the complement receptor 1 (CR1) as well as the scavenger receptor MARCO 
were all upregulated upon WTD treatment. Genes known to be involved in 
phagocytosis signalling such as LYN, a Src family member associated with 
FcyR1, and the Rho GTPase RhoC were also upregulated by WTD stimulation. 
In line with what was previous reported VASP, a regulator of actin dynamics 
known to mediate FcyR phagocytosis was upregulated (Garcia-Garcia and 
Rosales, 2002). Overall, these data support the previously reported ability of IL-
10 to enhance phagocytosis in monocytes. 
 
IL-10 has also been shown to regulate the metabolic state of myeloid cells. IL-10 
downregulates glycolysis and promotes oxidative phosphorylation in 
macrophages as well as enhancing the removal of damaged mitochondria (Ip et 
al., 2017). We examined the genes significantly regulated by WTD in our study 
and found many genes involved in metabolic regulation (Figure 4.12c). Genes 
associated with fatty acid metabolism, ACSL1, ACSL4 and ACSS2 were 
significantly upregulated upon IL-10 stimulation (Figure 4.12c). ACSL1 and 
ACSL4 are isoforms of long chain fatty acid CoA ligases (Tang et al., 2018) which 
catalyse the conversion of long chain fatty acids into acyl CoA. ACSS2 is acetyl 
coenzyme A synthase and converts short chain fatty acids into acetyl CoA.  
Several other genes involved in metabolic pathways were also regulated by IL-
10 such as hexokinase-2 (HK2) and hexokinase-3 (HK3) which convert glucose 
to glucose-6-phosphate, a rate limiting step in glycolysis (Figure 4.12c). We saw 
an upregulation of hexokinase-3 but a strong downregulation of hexokinase-2. 
The opposing regulation of these two kinases by WTD is interesting given their 
similar function. In addition to its role in glycolysis, HK2 has been shown to 
regulate apoptosis via association with the mitochondria and suppression of 
cytochrome C (Mathupala et al., 2006). HK3 is less well studied but one report 




production and maintaining membrane potential (Wyatt et al., 2010). WTD also 
induced the downregulation of another key enzyme in glycolysis, lactate 
dehydrogenase B (LDHB), the enzyme which catalyses the conversion of 
pyruvate to lactate. Lactate has been shown to have immune-modulatory 
functions with high levels of lactate inhibiting in vitro monocyte migration and pro-
inflammatory cytokine release (Goetze et al., 2011). Although these results will 
need to be confirmed by alternative methods such as qPCR and investigated at 
the protein level, it suggests that IL-10 may be inducing metabolic changes in 
monocytes, consistent with the previous study by Ip et al. 
 
Together this demonstrated that our WTD treatment could robustly reproduce 
known IL-10 activities in monocytes i.e. downregulation of pro-inflammatory 
cytokines and chemokines, upregulation of phagocytosis-associated genes and 
modulation of key metabolic enzymes. This gave us a template against which we 
could then compare the abilities of our variants to induce these known IL-10 
activities. 
 
4.3.2 WTD loses its ability to induce key anti-inflammatory transcriptional 
activities at low doses 
 
As mentioned previously, a leading hypothesis for the failure of IL-10 therapies 
in the clinic is the low local concentration of IL-10 in the gut upon systemic 
administration. We wanted to examine how sensitive the different activities 
exhibited by IL-10 were to changes in ligand concentration. For that, we 
compared expression levels of genes significantly up and downregulated by WTD 
at 50 nM (1825 genes) to their corresponding regulation by WTD at 0.1 nM. The 
majority of the genes regulated by WTD at 50 nM were induced to a similar level 
at the low concentration, indicating that the IL-10 response is very robust. 
However, roughly a quarter of genes (490 genes) regulated by WTD showed 
poorer expression levels when the low concentration was used. 
 
To gain a more in depth view of the genes being differentially regulated by WTD 
at different doses we directly compared regulation of the three sets of genes 
outlined previously: cytokines and chemokines, phagocytosis-related genes and 




inflammatory cytokines and chemokines showed poorer downregulation by WTD 
at the low dose (Figure 4.13a). This was particularly evident for very highly 
downregulated genes such as IL-24 and CXCL11 (Figure 4.13b). This trend was 
not seen for genes associated with phagocytosis (Figure 4.13c). Here there was 
almost identical regulation by WTD at 50 nM and 0.1 nM, with genes such as 
CR1 and LYN showing resilience to changes in concentration (Figure 4.13d). 
Examining genes associated with metabolic pathways we saw that the majority 
were unaffected by a change in concentration (Figure 4.13e), although there were 
exceptions such as ACSS1 and AK4 which showed somewhat poorer regulation 
by low dose WTD (Figure 4.13f).  
This provided us with insight into how changes in dose affected IL-10’s activities 
at the transcriptional level. The majority of genes were unaffected or only slightly 
impeded by using a low dose of IL-10. However, of note is that many of the 
 
Figure 4.13 Comparison of WTD activity at 50 nM and 0.1 nM. (a) Heatmap of regulation of 
genes encoding cytokines, chemokines and their receptors by WTD at 50 nM and 0.1 nM. (b) 
Log2 fold change for IL-24 and CXCL11 stimulated with WTD at 50 nM and 0.1 nM. (c) Heatmap 
of expression of genes associated with phagocytosis by WTD at 50 nM and 0.1 nM. (d) Log2 
fold change for CR1 and LYN stimulated with WTD at 50 nM and 0.1 nM. (e) Regulation of 
genes associated with metabolic pathways by WTD at 50 nM and 0.1 nM. (f) Log2 fold change 
for ACSS and AK4 stimulated with WTD at 50 nM and 0.1 nM. For all genes the log2 fold change 
was calculated by dividing values for WTD 50 nM or 0.1 nM by untreated controls for each 
donor. Heatmap values are the average of three biological replicates (a, c, e). For dot plots, 
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inflammatory cytokines, chemokines and receptors showed much weaker 
regulation at the low concentration. An inability to perform these activities at low 
doses could significantly impede IL-10’s anti-inflammatory functions. This 
supports the hypothesis that IL-10’s inability to inhibit inflammation in the clinic 
may be due to a dose-dependent effect.  
 
4.3.3 High affinity dimeric IL-10 displays enhanced transcriptional activity 
at low doses compared to wild type IL-10 in monocytes 
 
We next wanted to compare the activity of WTD with our high affinity dimeric 
variant R5A11D. As described above, we stimulated cells with both WTD and 
R5A11D at 50 nM and 0.1 nM each, allowing us to compare their activities at high 
and low concentrations. We took genes shown to be significantly regulated by 
WTD at 50 nM (1825 genes) and compared the activity of these genes across 
the other treatments. As before, we focussed on sets of genes with known 
regulation by IL-10: proinflammatory cytokines and chemokines, phagocytosis 
and metabolic pathways.  
 
We first compared the activity of WTD and R5A11D at 50 nM.  Pro-inflammatory 
cytokines and chemokines overall showed similar levels of regulation by WTD 
and R5A11D (Figure 4.14a), with some exceptions such as TNFRSF18 and IL18 
showing weaker downregulation by R5A11D (Figure 4.14b). Genes involved in 
phagocytosis also showed largely similar patterns of regulation between the two 
variants (Figure 4.14c-d). When looking at metabolic pathway genes we saw that 
many of the genes downregulated by WTD showed poorer downregulation by 
R5A11D e.g. COX10, ATP5G1 (Figure 4.14e-f).  
 
R5A11D showed consistently stronger responses than WTD in STAT activation 
and biological activities when both were used at low concentrations. We next 
wanted to investigate whether this increased receptor assembly and increased 
STAT activation would result in an enhanced transcriptional response. 
Comparing the WTD and R5A11D 0.1 nM treatments, both displayed similar 
proportions of genes up and downregulated by IL-10 (Figure 4.15a) however 
examining the numbers of genes significantly regulated, R5A11D had 1389 




whereas WTD 0.1 nM had 1226 genes significantly regulated (67% of those 
regulated at 50 nM), again showing that at low concentrations WTD performed 
more poorly. We compared expression levels of genes induced by WTD and 
R5A11D at 0.1 nM. Figure 4.15b shows that R5A11D had decreased expression 
of only 6% of genes compared to WTD and enhanced expression of 19% of 
genes, with the majority of genes (75%) remaining unchanged.   
We next examined regulation of the three sets of genes outlined before. R5A11D 
showed stronger downregulation of many cytokine and chemokine genes than 
WTD at 0.1 nM (Figure 4.15c).  As outlined previously, WTD showed poorer 
regulation of these genes at the low dose compared to the high dose. Unlike 
WTD, regulation of these genes by R5A11D did not appear to be affected by a 
 
Figure 4.14 Comparison of gene regulation by WTD and R5A11D at 50 nM. (a) Heatmap of 
regulation of genes encoding cytokines, chemokines and their receptors by WTD and R5A11D 
at 50 nM. (b) Log2 fold change for TNFRSF18 and IL-18 stimulated with WTD and R5A11D at 
50 nM.  (c) Regulation of genes associated with phagocytosis by WTD and R5A11D at 50 nM. 
(d) Log2 fold change for CD163 and PTX3 stimulated with WTD and R5A11D at 50 nM. (e) 
Regulation of genes associated with metabolic pathways by WTD and R5A11D at 50 nM. (f) 
Log2 fold change for COX10 and ATP5G1 stimulated with WTD and R5A11D at 50 nM. For all 
genes the log2 fold change was calculated by dividing values for WTD 50 nM or R5A11D 50 nM 
by untreated controls for each donor. Heatmap values are the average of three biological 

































































































































































































































change in dose. For phagocytosis and metabolic pathways, we saw an overall 
enhanced regulation by R5A11D compared to WTD at 0.1 nM, with some 
exceptions. From the three sets of genes examined, cytokines and chemokines 
appear the most changed between WTD and R5A11D, suggesting that the 
sensitivity of these genes to changes in concentration can be rescued to some 
extent by an increase in receptor affinity (Figure 4.15c). 
 
To take a more unbiased sample of genes we examined expression levels of the 
top 10 most up or downregulated genes by WTD at 0.1nM. Figure 4.15d shows 
that the majority of these highly up and downregulated genes had enhanced 
regulation by R5A11D compared to WTD. Together this suggests that increased 







Figure 4.15 Comparison of gene regulation by R5A11D and WTD at 0.1 nM. (a) Volcano plot 
of genes regulated by WTD (blue) and R5A11D (green) at 0.1 nM each. Only genes which had 
been shown previously to be significantly regulated by WTD at 50 nM are plotted. Numbers of 
significant genes up and downregulated by each treatment are shown on the plot in their respective 
colours. (b) Percentage activity of R5A11D compared to WTD at 0.1 nM. The log2 fold change of 
R5A11D/unstimulated was divided by the log2 fold change of WTD/unstimulated. Enhanced 
expression denotes genes which had expression increased in R5A11D by more than 1.5 fold 
compared to WTD. Decreased expression denotes genes with less than 0.67 fold change.  (c) 
Comparison of gene regulation by WTD and R5A11D at 0.1 nM for genes associated with 
proinflammatory cytokines and chemokines, phagocytosis and metabolic pathways, with values for 
individual replicates plotted for CXCL10, PTX3 and HK2 shown. (d) Heatmap of top 10 up and 
down regulated genes by WTD at 0.1 nM are compared to R5A11D 0.1 nM. For all genes shown 
the average of three biological replicates is plotted. 
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4.3.4 Monomeric IL-10 variants induce poorer transcriptional responses in 
monocytes compared to dimeric variants 
 
Our previous work had shown that WTM displayed poor STAT activation while 
R5A11M showed STAT activation of 80-100% of the dimeric levels at saturating 
concentrations. We next wanted to see if this improvement in STAT activation 
translated into an increased transcriptional response. Cells were stimulated with 
a high concentration (50 nM) of both the wild type monomer (WTM) and high 
affinity monomer (R5A11M). When we compared the activity of WTM to WTD, 
WTM induced poorer regulation of 85% of genes (Figure 4.16a). This is in line 
with its very low levels of STAT activation. R5A11M showed much better 
transcriptional activity than WTM however it still showed poorer activity than 
WTD, with diminished regulation of 40% of genes (Figure 4.16b). These patterns 
of activity did not seem to be specific to a particular set of genes or pathways. 
When comparing cytokines and chemokines, phagocytosis and metabolic 
pathways across the conditions, we saw consistently poorer responses in the 
monomeric variants compared to WTD, with R5A11M showing an enhanced 
response over WTM but a poorer response compared to WTD (Figure 4.16c). 
Examples of this include genes such as IL-24, MARCO and ACSS1 (Figure 
4.16d). This demonstrates that although increased affinity can greatly enhance 
activity of the monomeric IL-10, the transcriptional response does not reach 
dimeric levels. This suggests that stoichiometry contributes to IL-10’s activity 




   
 
Figure 4.16 Comparison of monomeric transcriptional activity. (a) Comparison of 
regulation of monocyte genes by WTM and WTD at 50 nM. The log2 fold change of 
WTM/unstimulated was divided by the log2 fold change of WTD/unstimulated. Enhanced 
expression denotes genes which had expression increased in WTM by more than 1.5 fold 
compared to WTD. Decreased expression denotes genes with less than 0.67 fold change. (b) 
Comparison of regulation of monocyte genes by R5A11M and WTD at 50 nM. Gene regulation 
was determined as in (a). (c) Heatmap of log2 fold change for WTD, WTM, R5A11M at 50 nM 
compared to unstimulated cells for genes associated with proinflammatory cytokines and 
chemokines, phagocytosis and metabolic pathways. All values shown are the average of three 
biological replicates. (d) Log2 fold change for IL-24, MARCO and ACSS1 for WTD, WTM and 










































































































































































































































4.4 High affinity IL-10 regulation of adaptive (CD8 T cell) immune responses  
 
IL-10Rß affinity and receptor stoichiometry had profound effects on the response 
of monocytes to IL-10. We wanted to see if this held true in adaptive immune 
cells. As mentioned previously, IL-10 enhances the cytotoxicity of CD8 T cells, 
leading to its potential use as a cancer therapeutic (Emmerich et al., 2012). We 
chose to assess the effect of IL-10 on these cells due to their relevancy for human 
health.   
 
4.4.1 Increased affinity enhances STAT activation in CD8 T cells 
 
As was done in monocytes, we first examined differences in STAT activation by 
the IL-10 variants. Peripheral blood mononuclear cells (PBMCs) were isolated 
from human buffy coats and CD8 T cells were activated within this population. 
Media supplemented with anti-CD3 was used along with IL-2 to activate these 
cells for three days after which the media was changed to that with IL-2 alone to 
allow further expansion of activated populations for two more days as shown in 
Figure 4.17. Cells were then rested in media with no IL-2 overnight to reduce 
background levels of STAT activation. The cells were stimulated with the IL-10 
variants (WTD, R5A11D, WTM, R5A11M) over a range of concentrations for 15 
minutes before fixation in order to examine STAT1 and STAT3 activation. 
The dose response curves for CD8 cells are shown in Figure 4.18a-b. First 
comparing WTD with R5A11D, we saw patterns similar to those seen in 
monocytes. R5A11D and WTD showed comparable patterns of STAT activation 
at saturation however R5A11D displayed an apparent enhanced activity at very 
low doses, leading to a non-significant but decreased EC50 for both STAT1 and 
 
Figure 4.17 Activation and stimulation of CD8 T cells in a PBMC culture. PBMCs were 
isolated from human buffy coats and activated for three days using anti-CD3 (100 ng/mL) and IL-
2 (20 ng/mL). Media was replaced to media containing only IL-2 for a further 2 days. Cells were 


















STAT3 (Figure 4.18c-d). Similar to the results in monocytes, we saw that R5A11D 
had higher although non-significant, pSTAT1 levels at high concentrations.  
 
When looking at the monomeric IL-10 variants we again saw similar results to 
those in monocytes. WTM displayed very poor activation of STAT1, reaching only 
10% of the dimeric activity even at high concentrations. It also had very poor 
 
Figure 4.18 STAT1 and STAT3 activation by high affinity IL-10 variants. (a-b) Activated 
human CD8 cells in a PBMC culture were stimulated with IL-10 variants for 15 minutes. 
Phosphorylation of STAT1 and STAT3 was measured by flow cytometry. Data shown is the 
mean of 4 biological replicates. Each replicate is normalised by assigning the highest MFI 
value of the top concentration as 100% and the lowest MFI value of the bottom concentration 
as 0%. Error bars represent the standard error of the mean. (c-d) Log10 EC50 values for 
pSTAT1 and pSTAT3 from the corresponding dose response curves in (a-b). (e) Ratio of 
pSTAT1 to pSTAT3 in CD8 cells upon IL-10 variant stimulation. Ratio was calculated by taking 
the percentage activation of pSTAT1 and pSTAT3 at 40 nM and dividing the pSTAT1 by 
pSTAT3 values. P values were calculated using paired t tests. 
 

























































































































































STAT3 activity at 25% of WTD activation levels (Figure 4.18a-b). This resulted in 
an apparent much higher EC50 values for WTM compared to the dimeric variants 
(Figure 4.18c-d). When we compare this to the high affinity monomer, R5A11M, 
it showed greatly enhanced STAT activation, reaching 70% of the dimeric activity 
at saturation (Figure 4.18a-b). However, it performed much poorer than the 
dimers at low concentrations, leading to higher EC50 values (Figure 4.18c-d).  
 
When we examined the differences between the variants in activating STAT1 and 
STAT3 we saw that WTM had a clear bias for STAT3 activity, with a low 
pSTAT1:pSTAT3 ratio as was seen in monocytes (Figure 4.18e). WTD and 
R5A11M had a 1:1 ratio but interestingly R5A11D showed a significantly higher 
ratio.  
 
Results seen in CD8 T cells are broadly in keeping with those seen in monocytes. 
Increased affinity greatly enhanced activation of STAT1 and STAT3 at saturating 
concentrations by the monomeric variant. The high affinity dimer showed an 
apparent improved activity compared to the wild type at low concentrations but 
acted similarly at saturation. This suggests that STAT activation by IL-10 follows 
broadly similar patterns in both monocytes and CD8 T cells. 
 
4.4.2 Changes in receptor affinity and stoichiometry do not affect the 
kinetics of the IL-10 response in CD8 T cells 
 
As receptor affinity and stoichiometry played a role in the activation of STAT1 and 
STAT3 in CD8 T cells, we next wanted to see if they would induce any change in 
the kinetics of STAT activation. CD8 T cells in a PBMC population were 
stimulated with the IL-10 variants at a constant concentration for specified times 
between 15 minutes and 3 hours. As shown in Figure 4.19, activation of both 
STAT1 and STAT3 peaked at 15 minutes. STAT1 was dephosphorylated faster 
than STAT3, with levels returning to basal after 1 hour. While the amplitude of 
STAT activation varied between the IL-10 variants, the kinetics of the response 
was consistent. As was seen in the dose response studies, R5A11D activated 




activation. However, dephosphorylation happened at an identical rate for all 
variants. 
In summary, as was seen in monocytes, changes in receptor affinity or 
stoichiometry do not alter the kinetics of the IL-10 response. When compared to 
monocytes, dephosphorylation of STAT1 occurred at a faster rate in CD8 T cells, 
suggesting differential mechanisms regulating the resolution of the response in 
these cells. 
 
4.4.3 High affinity dimeric variant R5A11D enhances granzyme B 
production in CD8 T cells at low cytokine concentrations 
 
Several studies in recent years have investigated the effect of IL-10 on cytotoxic 
CD8 T cells. It has been shown that IL-10 can enhance the cytotoxicity of these 
cells, leading to greater rates of tumour clearance in both mice and human 
patients (Naing et al., 2019). It does this, in part, by increasing the production of 
cytotoxic effector molecules such as granzyme B and IFNγ. This was 
demonstrated in vitro in PBMCs and also in patients treated with PEGylated IL-
10 (Chan et al., 2015, Naing et al., 2018). We used this known IL-10 response in 
CD8 T cells to see if the improved STAT activation by R5A11D in CD8 T cells 
translated into an improvement in biological activity. Human CD8 T cells were 
activated in a PBMC population as shown in Figure 4.20. Cells were activated in 
 
 
Figure 4.19 Kinetics of pSTAT1 and pSTAT3 response to IL-10 variants in CD8 T cells. 
CD8 T cells in a PBMC population were stimulated with IL-10 variants at a constant 
concentration of 50 nM for the specified time periods before fixation. Three biological replicates 
were used. Error bars represent the standard error of the mean. Data was normalised by 
assigning the highest value at 15 mins as 100% and the lowest value of an untreated control 
as 0%. 



























































the absence or presence of IL-10 variants. Two different concentrations of IL-10 
variants were used: 50 nM and 0.1 nM. Granzyme B protein levels were then 
measured after the 6 days of activation using flow cytometry. 
At a high concentration of IL-10 (50 nM), both WTD and R5A11D induced a 2.5-
fold upregulation of granzyme B compared to cells grown without IL-10 
stimulation (Figure 4.21). WTM induced a very poor granzyme B upregulation, 
with many donors showing no increase. This is in line with WTM’s poor STAT 
activation and its poor activity in monocytes. R5A11M showed a variable 
response: in half the donors tested granzyme B was upregulated to a similar level 
as seen in the dimeric molecules. However, half of the donors showed a poor 
response, similar to WTM. When the low dose of IL-10 was used R5A11D 
induced significantly more granzyme B compared to WTD, in keeping with its 
enhanced STAT activation at this concentration (Figure 4.21).  
 
 
Figure 4.20 Activation and stimulation of CD8 T cells in a PBMC culture in the presence of 
IL-10 variants. PBMCs were isolated from human buffy coats and activated for three days using 
anti-CD3 (100 ng/mL) and IL-2 (20 ng/mL). Media was replaced to that containing IL-2 only for a 
further 2 days. IL-10 variants WTD, R5A11D, WTM, R5A11M, were added to the media at the 
start of culture and again at day 3, each at 50 nM and 0.1 nM final concentration. Cells from each 















Figure 4.21 Comparison of granzyme B upregulation by IL-10 variants. CD8 T cells were 
activated in a PBMC population using anti-CD3 and IL-2 for three days followed by IL-2 for 3 days. 
IL-10 wild type and variants were added to the media at the above concentrations at day 1 and 
day 3 of activation. Granzyme B protein was measured at day 6 by flow cytometry after 
permeabilisation. Each point represents one biological replicate (n=8). Fold change was 
calculated by dividing the granzyme B MFI of treated cells by non-IL-10 treated control cells within. 









































4.5 Characterisation of the transcriptional activity induced by IL-10 and 
high affinity variants in CD8 T cells 
 
Our analysis of transcriptional regulation in monocytes by our high affinity 
variants supported our previous observations that increased affinity provided an 
advantage at low doses. It also highlighted that, although the high affinity 
monomer showed STAT activation levels similar to those induced by the dimeric 
variants, this did not linearly translate into similar levels of gene regulation. We 
had shown that, in CD8 T cells, R5A11D also displayed enhanced activity at low 
doses compared to WTD. We wanted to see if this advantageous effect held true 
at a global level of cell regulation and so we used RNA sequencing to 
characterise the response of human CD8 T cells to our IL-10 variants. As 
mentioned previously recent studies have shown that IL-10 can enhance the 
cytotoxicity and tumour-targeting activity of CD8 T cells both in vitro and in vivo. 
However, much less is known about the molecular mechanisms which underpin 
the effect. We envisioned that our transcriptional data would provide an unbiased 
comparison of the transcriptional activities of our high affinity variants and offer 
new insights into the molecular basis through which IL-10 carries out its 
pleiotropic effects.  
 
Human CD8 positive T cells were isolated from human PBMCs (StemCell 
Technologies) from three donors and activated using anti-CD3/CD28 and IL-2 
over 6 days as shown in Figure 4.22. IL-10 wild type and high affinity monomeric 
and dimeric variants were added to the media at day one of activation and again 
at day three. The monomeric variants (WTM, R5A11M) were used at the high 
dose of 50 nM and the dimeric variants (WTD, R5A11D) were used at 50 nM and 
a low dose of 0.1 nM as well. Cells were also activated in a similar manner but 
left without IL-10 stimulation within each donor group to act as controls. 
 
Cells were stimulated and RNA was isolated by the author. RNA sequencing and 
primary data analysis for quality control, mapping to reference genome and 
quantification was conducted by an external company, Novogene as detailed in 
the “Materials & Methods” chapter. Statistical analysis and comparison of gene 




4.5.1 Characterising the transcriptional effect of WTD on human CD8 T cells 
 
A similar analysis methodology was used on the RNA sequencing data from CD8 
T cells as was done for monocytes. First, we examined the effect of WTD on CD8 
T cell gene transcription programmes. We generated a list of gene transcripts 
whose expression was significantly changed by WTD more than 1.5 fold or less 
 
 
Figure 4.22 Activation and stimulation of purified CD8 T cells presence of IL-10 variants for 
RNA sequencing. CD8 T cells were isolated from PBMCs (n=3) and activated for three days 
using anti-CD3/CD28 beads and IL-2 (20 ng/mL). Media was replaced to IL-2 only for a further 2 
days. IL-10 variants were added to the media at day 1 and again at day 3 when the media was 
changed. IL-10 variants used were WTD, R5A11D, WTM, R5A11M. WTD and R5A11D were used 
each at 50 nM and 0.1 nM final concentration and WTM and R5A11M were used at 50 nM. Cells 
from each donor were also activated in the absence of IL-10 as a control. 
 













Figure 4.23 Regulation of CD8 transcription by WTD. (a) Volcano plot of CD8 genes 
significantly upregulated by WTD > 0.6 log2 fold change (red) and significantly downregulated 
by WTD <-0.6 log2 fold change compared to non-IL-10 treated cells. Fold change was 
calculated by dividing WTD 50 nM by unstimulated values for each donor. The average fold 
change was calculated for three donors and the log2 of this value is plotted. P values< 0.05 
were calculated by two-tailed two sample equal variance t test of the log2 fold change of WTD 
50 nM/ unstimulated genes for each donor. Genes which were not significantly changed or 
were <0.6 >-0.6 log2 fold change were excluded. N=3. (b) Proportion of genes significantly up 































































































































































































































































































































































































than 0.67 fold compared to unstimulated cells (>0.6 log2 fold change or <-0.6 log2 
fold change). This list can be found in Appendix Table 2.  
There were 1050 genes significantly up or down regulated by WTD (Figure 
4.23a). 78% of these significantly regulated genes were downregulated by WTD 
(Figure 4.23b).  
 
When looking at subsets of downregulated genes we saw the significant inhibition 
of the classical exhaustion markers EOMES, TOX and TIGIT by WTD as well as 
HAVCR-2 (encoding the protein TIM-3) although this did not reach significance 
(Figure 4.24a). This led us to speculate that WTD may regulate the exhaustion 
state of CD8 T cells. An in depth profile of exhausted CD8 T cells at both the 
transcriptional, epigenetic and protein level was previously characterised using 
RNA sequencing and mass cytometry (Bengsch et al., 2018). We used their list 
of genes shown to be up and downregulated in exhausted CD8 T cells by this 
study to compare the exhaustion signature in our WTD treated cells. We could 
detect 97 genes regulated by WTD that also appeared in the exhaustion 
signature previously published (this list is shown in Appendix Table 3). When we 
compared regulation of these genes, they could be grouped into four clusters: 
cluster 1 comprises genes upregulated in exhausted T cells and by WTD 
treatment, cluster 2 are genes upregulated in exhausted T cells and 
downregulated by WTD, cluster 3 are genes downregulated in exhausted T cells 
and upregulated by WTD and cluster 4 are genes downregulated in both 
exhausted and IL-10 treated cells (Figure 4.24b). A sample of genes from each 
cluster is shown in Figure 4.24c. Cluster 2 is the largest cluster, showing genes 
which are upregulated in exhausted cells but downregulated by WTD. This 
suggests that IL-10 may be preventing, to some extent, T cell exhaustion 







We also noted a significant downregulation in the levels of the IL2RA gene 
(Figure 4.25a), which could also be confirmed at the level of protein expression 
by flow cytometry of similarly treated cells (Figure 4.25b). IL-2 is a key regulator 
of T cell function and was used in our study as a growth factor for CD8 T cells, 
 
Figure 4.24 Regulation of exhaustion-associated genes by WTD. (a) Log2 fold change of 
exhaustion markers downregulated by WTD (50 nM) compared to unstimulated. Each point 
represents one biological replicate and error bars indicate the standard deviation. (b) 
Heatmap of genes previously reported to be present in exhausted T cells. A list of exhaustion 
specific genes from (Bengsch et al., 2018) was used as a comparison for genes significantly 
up or down regulated by WTD 50 nM. Previously reported genes were given a nominal value 
of 1 for upregulated genes and -1 for downregulated genes. Log2 fold change for WTD 50 nM 
was plotted. The gene names and their log2 fold change can be found in Appendix Table 3. 
(c) The log2 fold change induced by WTD (50 nM) for a sample of genes from each cluster is 





































































































































































































































along with stimulation of the T cell receptor. We speculated whether a decrease 
in IL2RA was moderating the response of these cells to IL-2.  
The effect of IL-2 on the CD8 T cell proteome was previously examined using 
quantitative high resolution mass spectrometry (Rollings et al., 2018). We 
compared the many proteins in their study which were shown to be modulated by 
IL-2 to transcripts significantly regulated by WTD in our study. Figure 4.25c shows 
that WTD treatment downregulated several IL-2 regulated genes such as IL-13, 
LIF, SLC1A4 and NFIL3 but enhanced expression of GZMB. While a direct 
comparison between gene regulation and protein expression cannot be made as 
 
Figure 4.25 Modulation of IL-2 receptor and IL-2 associated genes in CD8 T cells by WTD. 
(a) Expression of IL2RA RNA measured by RNA sequence analysis. Each point represents one 
biological replicate. P value was calculated by a paired t test. (b) IL2RA protein levels measured 
by flow cytometry. CD8 T cells were activated in a PBMC population for three days using anti-
CD3 and IL-2 in the presence or absence of IL-10 (WTD, 50nM), followed by two days expansion 
with IL-2 in the presence or absence of IL-10. Fold change was calculated by dividing IL2RA 
levels of IL-10 stimulated by non-IL-10 stimulated control values for each donor. Each point 
represents one biological replicate. P value was calculated by paired t test. (c) Heatmap showing 
the log2 fold change induced by WTD at 50 nM for genes previously reported to be regulated by 
































































































changes at the level of RNA do not always translate into changes at the level of 
protein, it suggests that IL-10 could be limiting the sensitivity to IL-2 via a 
downregulation in IL2RA levels, perhaps delaying or protecting these cells from 
exhaustion. Much further work will need to be done to investigate this hypothesis 
further.  
 
4.5.2 WTD loses potency at low concentrations in CD8 T cells 
 
Together these data gave us an insight into how IL-10 modulates CD8 T cell 
activity. This list of 1050 significantly regulated genes then acted as a template 
against which we could compare our other IL-10 variants and doses. As was done 
in monocytes, we wanted to see if these genes were sensitive to changes in WTD 
concentration. We compared regulation of these genes by WTD at 50 nM and 
also at 0.1 nM. As shown in Figure 4.26a, 813 genes showed activity of 75% or 
less at low dose WTD compared to high dose WTD. Of this large set of dose-
dependent genes, 77% of those were genes that were downregulated by IL-10. 
We identified several genes involved in the IL-2 or exhaustion response such as 
IL-13, LIF and TOX which were poorly regulated by WTD at 0.1 nM (Figure 
4.26b). This poorer regulation of subsets of genes at low doses is in keeping with 




Figure 4.26 Comparison of WTD activity at 0.1 nM vs 50 nM. (a) Percentage activity of low 
dose WTD compared to high dose WTD. Points within the red box are those which show <75% 
activity at low dose compared to high dose WTD (813 genes). The percentage activity was 
calculated by dividing the log2 fold change of WTD 50 nM/US by the log2 fold change WTD 0.1 
nM/US and multiplying by 100. Insert shows the percentage of those 813 genes which were 
up or downregulated by WTD compared to unstimulated controls. (b) Average log2 fold change 





































































4.5.3 High affinity dimeric IL-10 displays enhanced transcriptional activity 
at low doses compared to wild type IL-10 in CD8 T cells 
 
In monocytes, R5A11D showed improved gene regulation at low concentrations 
compared to WTD. When we compared the activity of R5A11D at 0.1 nM with 
WTD at 0.1 nM we saw that this held true in CD8 T cells. Firstly, we compared 
the distribution of significantly regulated genes. Figure 4.27a shows that for both 
WTD and R5A11D at 0.1 nM, the majority of genes were downregulated. R5A11D 
showed more significantly downregulated genes than WTD at 0.1 nM (480 genes 
compared to 235). When we compared expression levels of genes, we saw that 
R5A11D displayed a large advantage over WTD at 0.1 nM, with 39% of genes 
showing enhanced regulation by R5A11D and only 8% showing better activity by 
WTD (Figure 4.27b). 
 
Again, to take an unbiased sample of genes we looked at the expression of the 
top 10 up and down regulated genes by WTD at 0.1 nM and compared this to 
R5A11D at 0.1 nM (Figure 4.27c). Similar to what was seen in monocytes, the 
majority of these highly regulated genes showed enhanced expression by 
R5A11D. This held true when we looked at subsets of genes such as CD markers 
and cytokines and chemokines (Figure 4.27d-f). This data supports what was 
seen in monocytes, confirming that R5A11D displays enhanced activity at low 
doses compared to WTD. 
 
4.5.4 Monomeric IL-10 variants induce poorer transcriptional responses in 
CD8 T cells compared to dimeric variants 
 
As the WTM had a decreased transcriptional response in monocytes we wanted 
to see if this also held true in CD8 T cells. WTM consistently showed poor STAT 
activation at all doses tested in CD8 T cells, as well as a poor upregulation of 
granzyme B. STAT activation could be enhanced greatly by increased affinity as 
shown by R5A11M however upregulation of granzyme B by R5A11M was 
variable between the donors tested. We hoped that by comparing the 
transcriptional response of CD8 T cells to WTD, WTM and R5A11M we could 







Figure 4.27 Comparison of R5A11D and WTD at 0.1 nM. (a) Volcano plot of genes regulated 
by WTD (blue) and R5A11D (green) at 0.1 nM each. Only genes which had been shown 
previously to be significantly regulated by WTD at 50 nM are plotted. Numbers of significant 
genes up and downregulated by each treatment are shown on the graph in their respective 
colours. (b) Percentage activity of R5A11D compared to WTD at 0.1 nM. The log2 fold change 
of R5A11D/unstimulated was divided by the log2 fold change of WTD/unstimulated. Enhanced 
expression denotes genes which had expression increased in R5A11D by more than 1.5 fold 
compared to WTD. Decreased expression denotes genes with less than 0.67 fold change. (c) 
Heatmap of top 10 up and down regulated genes by WTD at 0.1 nM compared to R5A11D 0.1 
nM. (d) Heatmap of inflammatory cytokines and chemokine genes regulated by WTD and 
R5A11D at 0.1 nM. each (e) Regulation of genes encoding CD markers by WTD and R5A11D 
at 0.1 nM. (f) Log2 fold change of IL-17RB and CD109 by WTD and R5A11D at 0.1 nM. 
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When cells were stimulated with WTM we saw a very poor response compared 
to WTD activity at the same concentration with 96% showing a diminished 
response (Figure 4.28a). R5A11M showed better regulation than WTM, with 42% 
of genes showing similar levels of regulation to WTD however over half of the 
genes (58%) had diminished activity (Figure 4.28b). This pattern of activity 
appeared consistent across groups of genes such as cytokine and chemokines 
and CD markers (Figure 4.28c-d). In nearly all genes analysed R5A11M 
enhanced expression compared to WTM however it failed to reach dimeric levels 
of activity, suggesting that stoichiometry as well as receptor affinity plays a crucial 




Figure 4.28 Comparison of monomeric transcriptional activity. (a) Comparison of 
regulation of CD8 T cell genes by WTM and WTD. The log2 fold change of WTM/unstimulated 
was divided by the log2 fold change of WTD/unstimulated. Enhanced expression denotes genes 
which had expression increased in WTM by more than 1.5 fold compared to WTD. Decreased 
expression denotes genes with less than 0.67 fold change. (b) Comparison of regulation of 
monocyte genes by R5A11M and WTD. Gene regulation was determined as in (a). (c) Heatmap 
of log2 fold change for WTD, WTM, R5A11M compared to unstimulated cells for cytokines and 
chemokine genes and genes encoding CD markers. (d) Log2 fold change of CCL3 and CD109 
by WTD, WTM and R5A11M at 50 nM. 








































































































































4.6 High affinity IL-10 enhances target cell killing by CAR T cells in vitro 
 
Work in this section was carried out in the University of Lille by W. Warda, A 
Cozzani, C. Ferrand and S. Mitra as they had previously developed the CAR T 
cell model used here targeting acute myeloid leukemic cells (Warda et al., 2019). 
The IL-10 proteins were made by the author of this thesis and sent to the 
University of Lille for use in this experiment.  
 
Our high affinity dimeric IL-10 (R5A11D) proved advantageous over its wild type 
counterpart (WTD) in receptor assembly, STAT activation and transcriptional 
activity. We also noted that it induced higher levels of the cytotoxic effector 
molecule granzyme B. IL-10 has been shown to boost the cytotoxicity of CD8 T 
cells both in vitro and in vivo, leading to enhanced tumour targeting and clearing 
(Mumm and Oft, 2013). Chimeric antigen receptor (CAR) T cells are another 
promising immune-therapeutic in cancer treatment which has already translated 
into the clinic for treatment of blood cancers such as acute lymphoblastic 
leukaemia (ALL). Due to IL-10’s known ability to enhance the anti-tumour 
response of CD8 T cells we speculated whether this could be applied to CAR T 
cells. In addition, we wanted to investigate if R5A11D would show enhanced 
efficacy over WTD in this clinically-relevant scenario.  
 
A CAR T cell model targeting acute myeloid leukemic cells was used to address 
these questions. In this CAR T cell model, cells were generated which target the 
interleukin-1 receptor accessory protein (IL-1RAP) (Warda et al., 2019). IL-1RAP 
is expressed on leukemic stem cells but absent on normal haematopoietic stem 
cells, making it a promising therapeutic target. They demonstrated that 
generation of anti-IL1RAP CAR T cells showed efficacy in targeted killing in an in 
vitro setting using either an IL-1RAP expressing cell line and primary cells as well 
as in vivo efficacy in a murine model. We used anti-IL-1RAP CAR T cells as a 
model to investigate if changes in IL-10 receptor affinity affected targeted killing 






4.6.1 Activation, transduction and culture of anti-IL-1RAP CAR T Cells 
 
The protocol developed by Warda et al. was used here to generate anti-IL-1RAP 
CAR T cells as shown in Figure 4.29a. Briefly, PBMCs were isolated from healthy 
donors and activated using anti-CD3/CD28 for 2 days. These cells were then 
transduced with supernatant containing lentivirus which encoded either the anti-
IL-1RAP CAR or a mock CAR with no anti-IL-1RAP. A sample of cells were also 
left un-transduced as a control. The cells were grown for 5 days after transduction 
in media containing IL-2. The cells were then transferred into three IL-10 different 
 
Figure 4.29 Generation and IL-10 stimulation of anti-IL-1RAP CAR T cells. (a) Schematic 
of CAR T cell cytotoxicity assay. Total T cells in PBMC culture were activated with anti-
CD3/CD28 Dynabeads for 2-3 days. The cells were then transduced with lentivirus-containing 
supernatant (un-transduced, mock CAR vector, anti-IL-1RAP CAR vector). Cells were cultivated 
for three days in media devoid of IL-10 or containing WTD (25 nM) or R5A11D (25 nM). The 
target cells, Mono-Mac-6 cells (IL-1RAP positive leukemic cell line), were co-cultured at various 
Effector: Target (E:T) ratios. After 5 hours, the percentage of alive Mono-Mac-6 cells were 
measured by 7-AAD staining using flow cytometry. (b) Representative dot plots of CAR 
expression profiles on anti-IL-1RAP CAR T cells and Mock T cells cultured in the presence of 
IL-2 with or without WTD or R5A11D (25nM) for 3 days. This experiment was performed and 













































culture conditions: WTD (25 nM), R5A11D (25 nM) or no IL-10. IL-2 was also 
present in the media of all cultures.  
The cells were kept in these conditions for a further 3 days before killing activity 
was tested. 
 
Figure 4.29b shows efficacy of the Lentiviral transduction. The plots show 
expression of CD3 as well as CD19. A truncated CD19 is included in both the 
mock and the anti-IL-1RAP CAR T cell vectors as a selection marker. Both mock 
and anti-IL-1RAP CAR T cell vectors showed high rates of transduction. 
 
4.6.2 R5A11D has a greater rate of target cell killing than WTD 
 
After the CAR T cells had been cultured under the different IL-10 conditions they 
could then be tested for target cell killing activity. The cells were co-cultured with 
Mono-Mac-6 cells, a human leukemic cell line which is positive for IL-1RAP. Cells 
were cultured at three Effector: Target ratios; 1:1, 2:1, 4:1 as well as a target cell 
only control (0:1). Killing activity was determined by assessing the viability of the 
Mono-Mac-6 cells after 5 hours co-culture. Viability was normalised within each 
donor as a percentage of the live cells in the 0:1 effector: target cell condition.  
 
Figure 4.30 Effect of WTD and R5A11D on anti-IL-1RAP CAR T cell target killing. Target 
cells viability after 5 hours co-culture with effector cells at the denoted Effector: Target cell 
ratios. Viability was measured by 7-ADD staining by flow cytometry and the percentage of live 
cells was calculated. Data are presented as mean ±SEM, n=3. *p<0.001, **p<0.0001 (IL-2 
alone or IL-2+WTD vs. IL-2+R5A11D). This experiment was performed and analysed by A. 
Cozzani, University of Lille. 



































Figure 4.30 shows that the anti-IL-1RAP CAR T cells showed greater killing 
capabilities than the mock T cells, confirming the efficacy of the anti-IL-1RAP 
CAR vector.  
When we examined the effect of IL-10 on target cell killing, R5A11D showed 
enhanced killing compared to either IL-2 alone or WTD at all Effector: Target cell 
ratios tested. This confirms that in an in vitro environment R5A11D can enhance 






In this chapter I have outlined how we used our high affinity IL-10 variants to 
examine the effect of receptor affinity and receptor stoichiometry on IL-10’s 
activities. We took a step-wise approach, studying how changes in early events, 
i.e., receptor assembly and STAT activation, affected downstream activities such 
as transcriptional regulation and known IL-10 biological effects. Using human 
primary monocytes and CD8 T cells provided us with insights into the molecular 
basis of IL-10’s activity in these cells which are highly relevant for human health.  
 
Increased affinity for IL-10Rß enhanced the stability of the IL-10/IL-10 
receptor complex 
 
Once recombinantly expressed, we were able to use our high affinity variants in 
both monomeric and dimeric conformations to assess the contribution of receptor 
affinity to cytokine-receptor complex stability in the IL-10 system. By examining 
homodimerisation of the receptor subunits we clarified that our monomeric 
variants were indeed acting as monomers and confirmed the 1:1 stoichiometry of 
IL-10 monomer/IL-10Rα previously reported by the study in which the monomeric 
IL-10 molecule was generated (Josephson et al., 2000b). In their study they did 
not examine binding of monomeric IL-10 to IL-10Rß, however from visualisation 
of the assembly of the receptor complex in our body of work we see that 
monomeric IL-10 also binds one molecule of IL-10Rß, forming a 1:1:1 complex 
stoichiometry between IL-10 monomer: IL-10Rα: IL-10Rß. 
 
Both the high affinity monomeric and dimeric variants showed a significant 
improvement in receptor heterodimerisation compared to the wild type monomer 
and dimer respectively. The increase in homodimerisation of IL-10Rß by R5A11D 
was significant compared to WTD homodimerisation, consistent with the increase 
in receptor affinity. Of note is that R5A11D and WTD showed similar levels of IL-
10Rα homodimerisation, in keeping with the idea that the engineered R5A11D 
variant would exclusively improve binding to IL-10Rß and not disrupt binding to 
IL-10Rα. This validates our yeast selection model and supports the idea that the 





The use of TIRF microscopy to visualise single molecules of the receptor on the 
surface of live cells also allowed us to examine the state of the receptors in the 
absence of IL-10 i.e. whether the receptor complex was pre-assembled. This 
question of whether cytokine receptors exist as pre-assembled inactive 
complexes or if they are monomeric and randomly diffusing in the plasma 
membrane has been highly contested in the field. For several homo-dimeric 
molecules such as erythropoietin receptor (EpoR) and the growth hormone 
receptor (GHR), preassembled receptor complexes have been reported. Crystals 
of EpoR in the absence of ligand showed dimerisation of the receptor (Livnah et 
al., 1999). For the GHR, a tagged receptor subunit could be co-
immunoprecipitated with the wild type receptor (Gent et al., 2002). One study has 
provided evidence for pre-assembled IL-10 receptor complexes in the absence 
of the cytokine (Krause et al., 2006). In this study fluorescence resonance energy 
transfer (FRET) was used to show that IL-10Rα and IL-10Rß existed as a dimer 
in the absence of IL-10. However, these models lack a comprehensive 
explanation as to why a preformed dimer would not be able to signal. In addition, 
artefacts may be introduced by the methodologies used, such as the very high 
concentrations used for crystallisation. FRET uses over-expression of the 
receptor subunits. Physiological levels of cytokine receptors on the cell surface 
are usually only a few hundred copies per cells (Moraga et al., 2014). This means 
that the receptor affinities and interaction rates are fine-tuned to these expression 
levels. Overexpression of receptor components may shift the equilibrium of 
monomers and dimers towards dimers even in the absence of ligand. The use of 
TIRF microscopy allows examination of interactions at physiologically relevant 
receptor densities as well as co-tracking analysis to ensure that only true 
dimerisation events are captured. Single particle fluorescence imaging studies 
have been invaluable in determining the stoichiometry of cytokine receptor 
complexes and to date have shown a model of ligand-induced dimerisation for 
many cytokines such as IL-4 and Type I IFNs (Richter et al., 2017, Wilmes et al., 
2015). We have used this technique here to show that the IL-10 receptor does 
not exist as a preformed dimer in the absence of ligand stimulation in our hands.  
 





STAT activation is one of the first events triggered by cytokine-receptor binding 
and acts as a key translator of events at the cytokine-receptor interface into 
biological outputs. Here we were able to use our high affinity monomeric and 
dimeric variants for comparison with their wild type counterparts to examine the 
role of IL-10 receptor affinity and stoichiometry in STAT activation. WTM showed 
very poor activation of STAT1 and STAT3, even at very high doses (200 nM). 
WTM has previously been shown to bind IL-10Rα 60 times weaker than WTD 
(Josephson et al., 2000b). This was also seen in our studies of receptor complex 
assembly where WTM had poorer heterodimerisation of the receptor complex 
than WTD, suggesting that stoichiometry plays an integral role in amplitude of the 
IL-10 response. When we examined the activity of R5A11M which retains a 
monomeric conformation but has increased IL-10Rß binding affinity, we saw a 
large increase in the ability of a monomeric IL-10 to activate STATs, with activity 
of 70-100% of WTD at high concentrations. This implied that deficiencies in 
receptor stoichiometry could be supplemented by increased receptor affinity. 
However, this ability of R5A11M to reach dimeric levels of activity did not extend 
past STAT activation. R5A11M showed a consistently weaker transcriptional 
response as well as poorer biological activity compared to the dimeric variants in 
both monocytes and CD8 T cells, even when used at high concentrations. 
Together this suggests that the receptor stoichiometry of the IL-10 complex 
contributes to the potency of the IL-10 response beyond STAT activation.  
 
This is supported by the fact that the dimeric viral homolog of IL-10 produced by 
the Epstein-Barr virus (vIL-10) has significantly lower affinity for IL-10Rα than 
WTD but can still suppress pro-inflammatory cytokine production and antigen 
presentation at levels equivalent to WTD (Liu et al., 1997). This suggests that 
receptor stoichiometry can supplement weak receptor affinity. Interestingly, 
previous work has shown that, in cells with low levels of IL-10Rα, vIL-10 acts like 
a monomer due to its poor ability to assemble a complex of one vIL-10 with two 
IL-10Rα subunits (Yoon et al., 2012). This co-opting of receptor stoichiometry 
biases by the virus highlights the advantage that the dimeric cytokine shows over 
the monomeric version, despite increased affinity. However, R5A11M did show 
much greater transcriptional activity than WTM, indicating that this high affinity 




preferable e.g., generation of a fusion protein with other cytokines or chemical 
modification such as PEGylation. 
 
A possible explanation for the enhanced activity of dimeric variants over 
monomeric variants may be the differences in the number of phospho-tyrosines 
activated. Previous work in our laboratory demonstrated that, in the IL-6 system, 
differential receptor binding capability triggered differential phosphorylation of the 
intracellular tyrosines of gp130 (Martinez-Fabregas et al., 2019). Those variants 
which only triggered partial tyrosine phosphorylation showed biased STAT3 
activation over STAT1. The study outlined that the number of phospho-tyrosines 
is a determinant in the cytokine’s signalling capabilities. In the IL-10 system WTM 
also showed a biased STAT3 response compared to STAT1 in both CD8 T cells 
and monocytes, suggesting that similar mechanisms may be at play here. The 
dimeric variants may activate different patterns of phospho-tyrosines in the IL-10 
receptor subunits compared to the monomeric variants, triggering additional 
signalling pathways.  However, further work will need to be done to fully 
understand the reasons behind the weaker biological activities of the monomeric 
variants.  
 
Increased receptor affinity enhances IL-10’s activity at low doses 
 
The translation of IL-10 therapies into the clinic has been very poor. Its use as a 
treatment for Crohn’s disease showed efficacy in only limited numbers of 
patients. One of the key factors in the poor response to IL-10 treatment discussed 
in the literature may be the very low local concentrations of IL-10 in the gut when 
it is given systemically. In mouse studies, it was reported that IL-10 
concentrations can reach between 1-5ng/ml depending on the stimuli used 
(Elcombe et al., 2013, Yamaguchi et al., 2000). In humans, similar results are 
observed. In therapies where 25 μg/kg of IL-10 were used, IL-10 serum levels at 
3 hours were around 20 ng/mL and fell to 3 ng/mL at 6 hours, returning to basal 
levels at 24 hours (Chernoff et al., 1995). Interestingly, studies have shown that 
a targeted delivery of IL-10 can enhance efficacy such as the use of IL-10-
producing lactobacillus (Braat et al., 2006), agreeing with the idea that low local 
IL-10 concentrations significantly hinder IL-10 therapies. Another barrier to IL-10 




vivo meaning that treatments using IL-10 require frequent administration with 
high doses, usually in the range of 10-20 μg/kg of body weight with daily injection. 
A PEGylated version of IL-10 has shown enhanced tumour killing in human 
cancer patients in early clinical trials (Naing et al., 2019). PEGylation of the 
cytokine increases its size, leading to a longer retention in circulation by delaying 
its filtration by the kidneys (Alvarez et al., 2012). Together this highlights that 
effective IL-10 responses in vivo require high and sustained concentrations.  
 
We showed that our high affinity dimeric IL-10 variant displayed enhanced 
efficacy at low doses. The low dose of IL-10 used was 0.1 nM, equivalent to 
roughly 3.6 ng/mL. This corresponds to the amount of IL-10 present in serum 
after 6 hours of high dose IL-10 injection in the study outlined above. Therefore, 
this low dose represents the equivalent serum IL-10 levels seen after systemic 
administration of this cytokine. We demonstrated that, at this concentration, WTD 
showed significantly reduced transcriptional activity across a large portion of its 
genes. In particular at the low dose WTD showed poorer regulation of 
inflammatory cytokines and chemokines compared to the high dose in 
monocytes. The crucial anti-inflammatory activities of IL-10 are compromised by 
these dose-dependent effects, perhaps contributing in part to the poor efficacy of 
IL-10 treatments for Crohn’s disease. This in turn supports the assumption that 
R5A11D may demonstrate a therapeutic advantage over WTD as the majority of 
its activities are not affected by use at this low concentration. 
 
R5A11D also showed advantage over WTD in improving the target cell killing 
activity of CAR T cells in vitro when used at a high dose of 40 nM. WTD showed 
no significant difference compared to the control. This improvement in activity at 
a high dose was unexpected as in all other tests R5A11D only showed advantage 
at low doses and, in some cases, performed poorer than WTD at high doses. In 
experiments comparing doses we were looking directly at primary effects on the 
cell i.e. protein production or gene transcription. Target cell killing by CAR T cells 
comes from a variety of factors such as secretion of granzymes, cytokine release 
and Fas ligand activation. It may be that the enhanced activity of R5A11D on CD8 
T cells is more visible in these secondary effects. Small changes in gene 
expression may lead to amplification of secondary effects. Another possible 




activity. After three days of incubation the levels of WTD in the media may not 
have been sufficient to induce an effect however R5A11D could still act effectively 
at low doses. While the mechanism underpinning this enhanced CAR T cell killing 
is unclear, it demonstrates another possible therapeutic use for R5A11D. 
 
High affinity variants may show a disadvantage at high concentrations due 
to a “bell-shaped” response 
 
While R5A11D showed consistently improved activities compared to WTD at low 
doses, the results at high doses were more variable. In cell-based assays 
R5A11D appeared to act similarly to WTD at 50 nM however we did observe that 
many genes showed stronger regulation by WTD rather than R5A11D at 50 nM, 
for example those involved in metabolism such as AK4 and COX10. One 
potential explanation for poorer activity by R5A11D at high concentrations may 
be the higher affinity for IL-10Rß. WTD is unable to bind IL-10Rß in the absence 
of IL-10Rα however R5A11D can bind IL-10Rß alone. At high concentrations of 
R5A11D this may mean that single chains of IL-10Rß are bound by R5A11D 
without IL-10Rα being present, sequestering them and inhibiting dimerisation-
induced signalling (Figure 4.31).  Bell shaped binding curves have previously 
been reported for cytokine-receptor systems such as hGH and EPO where homo-
dimeric receptor assembly is seen. In hGH, high concentrations led to decreased 
activity as individual receptors are occupied by individual cytokines with no 
secondary interactions between the receptor chains (Whitty and Borysenko, 
1999, Pearce et al., 1999). Similar bell shaped curves were seen in EPO when 
EPO-Rs were triggered with an agonist antibody, indicating that each receptor 
was bound separately and thus couldn’t form an active dimeric complex 
(Middleton et al., 1999). It may be that the ability of R5A11D to bind IL-10Rß in 
the absence of IL-10Rα means that it displays characteristics similar to a homo-
dimeric receptor system at high concentrations such as a bell shaped curve. Even 
though R5A11D could promote dimerisation of IL-10Rß it has been shown that 
dimerisation of IL-10Rß or IL-10Rα alone is not sufficient to trigger signalling. IL-
10Rß KO mice develop colitis and defective Treg and anti-inflammatory 




increased pro-inflammatory cytokine production and enhanced colitis 
susceptibility (Pils et al., 2010).  
 
Examination of alternative signalling pathways by high affinity variants 
 
In this thesis I focussed on activation of the JAK/STAT pathway by IL-10. This is 
the most well studied downstream signalling pathway for IL-10 and the majority 
of IL-10’s responses have been shown to be STAT3-dependent. Because of IL-
10’s well characterised JAK/STAT activation this was the best way to compare 
activities of our high affinity variants. R5A11D showed enhanced STAT activation 
at low concentrations and more potent biological responses compared to WTD. 
However, IL-10 has been also been shown to activate AMPK, PI3K and mTORC1 
in macrophages (Zhu et al., 2015, Antoniv and Ivashkiv, 2011). In one study 
AMPK activation occurred even in the presence of a JAK inhibitor and a PI3K 
inhibitor (Zhu et al., 2015). In addition, STAT3 phosphorylation was inhibited in 
 
 
Figure 4.31 Schematic of potential differential receptor binding patterns for WTD and 
R5A11D. (a) WTD binds to IL-10Rα and recruits IL-10Rß in a second step as it is unable to 
bind IL-10Rß in the absence of IL-10Rα. The assembly of the WTD/IL-10Rα/IL-10Rß complex 
is the activate conformation, allowing signalling to occur. (b) R5A11D can bind both IL-10Rα 
and IL-10Rß alone. At high concentrations it is possible that R5A11D may bind to both IL-10Rα 










AMPKα1 deficient macrophages and these macrophages were also unable to 
inhibit LPS-induced pro-inflammatory cytokine production (Zhu et al., 2015). This 
suggests that AMPK may play a role in IL-10 signalling.  
 
The use of a PI3K inhibitor in human primary macrophages demonstrated that 
some IL-10 inducible genes required PI3K activation however other genes such 
as SOCS3 were PI3K independent (Antoniv and Ivashkiv, 2011). In contrast to 
AMPK, STAT activation was not broadly affected by inhibition of PI3K. In addition 
to the activation of PI3K, IL-10 has been shown to activate p70 S6 kinase which 
could be inhibited by rapamycin, an mTORC inhibitor (Crawley et al., 1996). The 
use of rapamycin resulted in an inhibition of proliferation of D23 cells but did not 
disrupt anti-inflammatory activities in monocytes, suggesting that different facets 
of the IL-10 response may be under the control of different signalling pathways 
(Crawley et al., 1996). 
  
Activation of alternate signalling pathways by our IL-10 variants was not 
examined during this project. Differential activation of AMPK, PI3K or mTORC by 
our IL-10 variants may help to further explain differences in biological responses. 
Further work will need to be done to explore this hypothesis such as examining 
levels of STAT3 phosphorylation in combination with inhibitors of AMPK, PI3K 
and mTORC.  
 
Conclusions and future perspectives 
 
Our study has shown that increased affinity for IL-10Rß has wide ranging effects 
on the activities of this well studied cytokine. Increased affinity can alter receptor 
complex assembly, STAT activation, transcriptional programmes and known 
biological activities.  
 
Despite R5A11M displaying poorer responses than the dimeric cytokine, its large 
improvement in activity compared to WTM means it is an ideal candidate for 
further study. A monomeric conformation can be advantageous over the dimeric 
conformation in many ways. It provides a simpler system for structural studies as 
the 1:1:1 IL-10:IL-1Rα:IL-10Rß stoichiometry means structural modelling may 




cytokine, for example by generating fusion proteins with other cytokines. As 
mentioned previously, manipulation of IL-10 is difficult due to its dimeric nature 
and the wild type monomeric IL-10 variant has weak biological activity, limiting its 
use. The enhanced activity of R5A11M in a monomeric conformation would allow 
for its easy manipulation through PEGylation, forming linkers with other cytokines 
and other modifications.  
 
Our high affinity dimer, R5A11D, displayed enhanced activities at low 
concentrations, suggesting that it may provide a therapeutic advantage over 
WTD. Ideally, we would assess this in vivo, for example in mouse models of 
colitis. However, this proved difficult as we were using human IL-10 and its 
receptors in all our studies. Human IL-10 and mouse IL-10 share 73% amino acid 
similarities and human IL-10 can induce activity in mouse cells however mouse 
IL-10 does not function in human cells (Windsor et al., 1993). Human and mouse 
IL-10Rα have 60% amino acid similarity and IL-10Rß is 69% similar between the 
species (Liu et al., 1994, Gibbs and Pennica, 1997). As R5A11D was affinity 
matured against the human IL-10Rß we did not know if this enhanced affinity 
would translate into enhanced affinity for the murine IL-10Rß. A preliminary in 
vitro assay using murine macrophages demonstrated that, while both WTD and 
R5A11D could suppress TLR-induced cytokine production from these cells, 
R5A11D did not display an advantage over WTD at any concentration tested 
(Figure 4.32) (This experiment was conducted in collaboration with S. Laba in the 
Arthur laboratory, University of Dundee). This suggests that the amino acid 
mutations which give R5A11D enhanced affinity for the human IL-10Rß do not 
confer an advantage in the mouse system. This is not unsurprising given the 
differences in sequences between the mouse and human systems however, it 
does limit our ability to test the efficacy of R5A11D in vivo. The use of human 
CAR T cells demonstrated the ability of R5A11D to enhance IL-10 responses in 
a clinically relevant setting, suggesting that further study into the translational 
applications of this high affinity cytokine may be merited, however how this will 
be done poses many questions. 
 
As well as highlighting differences between the engineered variants, our RNA 
sequencing study indicated potential regulation of exhaustion markers and the 




poorly understood and these results highlight areas for further study which will be 






Figure 4.32 Comparison of efficacy of WTD and R5A11D in murine cells. Murine BMDMs 
were stimulated with the PAM3CSK (1μg/mL) ± WTD and R5A11D at the concentrations listed 
above for 8 hours. Supernatants were harvested and cytokine secretion was measured using 
a bioplex assay. HK= heat-killed controls where WTD and R5A11D were boiled for 30 minutes. 
Asterisks indicate values outside of the range of the graph and in these cases the values are 
shown in text above the corresponding bar. N=4. This experiment was done with the help 

























































































































































































































































































































































Chapter 5. Examining the molecular basis of IL-10’s effect on 




As discussed in Chapter 4, IL-10 has been shown to enhance the cytotoxicity of 
CD8 T cells, improving their tumour targeting abilities and leading to clinical trials 
using a PEGylated recombinant human IL-10 in the treatment of cancer (Naing 
et al., 2019). Supporting this, it has also been shown that IL-10 deficient mice are 
more susceptible to induced cancers and children with IL-10 receptor deficiencies 
have higher rates of B cell lymphomas with less tumour infiltrating CD8 T cells 
(Neven et al., 2013). Work shown in Chapter 4 demonstrated that stimulation with 
wild type IL-10, as well as our high affinity variants, increased granzyme B 
production in human CD8 T cells. Our transcriptomic analysis of IL-10 treated 
CD8 T cells also showed the downregulation of exhaustion markers such as TOX 
and TIGIT suggesting that IL-10 may limit the transition of CD8 T cells into an 
exhausted phenotype. In addition, we observed an IL-10-mediated 
downregulation of IL-2Rα as well as a reduction in mRNA levels for many IL-2 
dependent genes such as IL-13 and LIF. It is possible that this regulation of 
exhaustion and IL-2 responses may contribute to the enhanced cytotoxicity of IL-
10 treated CD8 T cells. However, at this point this model remains very speculative 
and more work is required to address how IL-10 enhances CD8 T cells cytotoxic 
activities. 
 
To understand in greater detail how IL-10 tunes CD8 cytotoxic activities, we 
studied how classical markers of T cell activation were regulated by IL-10 
treatment. We also performed unbiased proteomics studies to better understand 
how IL-10 regulates CD8 T cells activities. Our proteomic study highlighted 
significant metabolic proteins altered upon IL-10 stimulation. Key proteins 
involved in glycolysis were downregulated by IL-10. In addition, we saw large 
subsets of mitochondrial proteins upregulated by IL-10, specifically those 
involved in the electron transport chain. These results suggested that IL-10 could 
modulate the metabolic response of CD8 T cells which may contribute towards 




response in CD8 T cells and gives a solid foundation upon which further studies 
can be based. 
 
Aims: 
• Characterise the IL-10-treated CD8 T cell phenotype  
• Use proteomics to gain an understanding of how IL-10 enhances the 
cytotoxic functions of CD8 T cells 





5.1 Phenotyping of CD8 T cells activated in the presence of IL-10 
 
There are many conflicting reports about the effect of IL-10 in CD8 T cells. It has 
been reported that IL-10 can affect CD8 T cell proliferation, activation, exhaustion 
and memory cell development (Smith et al., 2018, Blackburn and Wherry, 2007, 
Walk et al., 2012, Taga and Tosato, 1992). Other reports have shown opposing 
results, indicating that IL-10 does not negatively impact CD8 T cell activation or 
exhaustion (Rowbottom et al., 1999, Emmerich et al., 2012). These disparities 
may arise due to different methods of activation, different growth conditions and 
the addition of IL-10 at different time points during culture. We first wanted to gain 
a more accurate understanding of the phenotype of IL-10 treated CD8 T cells. As 
our previous work was performed using CD8 T cells activated in the presence of 
IL-10 and IL-2 we chose to use the same conditions going forward for further 
phenotyping. We examined the early activation marker CD69 and the late 
activation marker CD71. We also measured levels of several exhaustion markers 
as well as granzyme B production.  
 
CD8 T cells were activated within a PBMC environment using anti-CD3 and IL-2 
± IL-10 for three days, followed by IL-2 ± IL-10 for a further 3 days to allow the 
population to expand. This activation protocol is referred to as “TCR (T Cell 
Receptor) stimulated” in the results below. IL-10 was added to the media at day 
1 and again at day 3 when the media was changed (Figure 5.1).  
 
 
Figure 5.1 Activation and IL-10 stimulation of CD8 T cells. CD8 T cells were activated either 
in a PBMC population or in a purified CD8 T cell population. For CD8 T cells in a PBMC 
population cells were activated with anti-CD3 and IL-2 ± IL-10 (50-100 nM) for three days 
followed by three days in media containing IL-2 ± IL-10. For isolated CD8 T cells, activation was 
performed using anti-CD3/CD28 and IL-2 ±IL-10 (50-100 nM) for three days followed by three 
days in media containing IL-2 ± IL-10. Cells were harvested on day 6 for analysis by flow 
cytometry. 
 
Isolation of PBMCs 














Purified CD8 T cells were also used to uncouple the direct effect of IL-10 on the 
cells from any secondary effect via other cells in the PBMC population. In these 
purified populations the cells required activation with anti-CD3/CD28 beads plus 
the presence of IL-2. IL-10 was added at day 1 and day 3 as was done for the 
PBMC population. This activation and growth protocol was used throughout the 
experiments outlined in this chapter to gain an insight into how the presence of 
IL-10 during activation and expansion would affect the CD8 T cell phenotype.  
 
5.1.1 IL-10 does not inhibit CD8 T cell proliferation 
 
The effect of IL-10 on T cell proliferation is highly contested in the literature. 
Reports have shown that it can inhibit the proliferation of both CD4 and CD8 T 
cells while others have shown that it does not effect CD8 T cell proliferation 
(Groux et al., 1998). It is difficult to uncouple the direct effect of IL-10 on T cells 
from secondary effects of IL-10 on other cells in the immunological environment. 
Work by Giroux et al. demonstrated that the negative effect of IL-10 on T cell 
proliferation may be a result of the inhibitory effect of IL-10 on antigen presenting 
cells, limiting their ability to activate T cells. We wanted to investigate an IL-10 
mediated effect on proliferation in our system. We activated T cells within a PBMC 
culture for 6 days as described above. While this chapter focuses on CD8 T cells 
we also examined CD4 T cell proliferation within the same PBMC population as 
a control. Figure 5.2 shows that in the IL-10 treated population there were 
significantly less CD4 T cells compared to the non-IL-10 treated group. In contrast 
to this, IL-10 had little to no effect on the proliferation of CD8 T cells.  
 
 
Figure 5.2 Examination of T cell proliferation upon activation in the presence of IL-10. 
PBMCs were activated using anti-CD3 and IL-2 ± IL-10 (100 nM) for three days followed by 
three days with IL-2 ± IL-10. CD4 and CD8 T cells were counted on day 6 by flow cytometry. 
Fold change was calculated by dividing the number of IL-10 treated cells by non-IL-10 treated 




























5.1.2 IL-10 does not inhibit activation of CD8 T cells 
 
We chose to add IL-10 to the cell media throughout activation rather than at only 
one point to mimic a physiological setting where cells may be exposed to IL-10 
over long time periods e.g., during persistent viral infections. This was done to 
give us an insight into how the presence of IL-10 would affect activation of the 
cells. CD69 is an early activation marker in T cells (Sancho et al., 2005). Figure 
5.3a shows the cell surface levels of CD69 on CD8 T cells 24 hours after 
activation in both a PBMC culture and a purified CD8 T cell culture. There was 
no significant change in CD69 levels between IL-10 treated and non-IL-10 treated 
for either population, suggesting that at early stages of activation IL-10 does not 
hinder CD8 T cell activation.  
 
We examined activation again at day 6, this time measuring levels of the late 
activation maker CD71 (Figure 5.3b). There were two large outliers in the data, 
one donor with greatly increased CD71 upon IL-10 stimulation and one donor 
with decreased CD71. However, overall, there was no significant difference in 
CD71 in IL-10 treated CD8 T cells in either a PBMC population or a purified 
population. Together these data show that under the above conditions, IL-10 
does not significantly affect the classical markers of activation in CD8 T cells.  
 
Figure 5.3 Effect of IL-10 on CD8 activation. (a) CD8 T cells in a PBMC population or in 
purified population were activated using anti-CD3 (PBMC population) or anti-CD3/CD28 
(purified) and IL-2 in the presence or absence of IL-10 (100 nM). CD69 cell surface levels were 
measured 24 hours after activation by flow cytometry. (b) CD71 cell surface levels were 
measured by flow cytometry 6 days after activation. N=8. Error bars represent standard 
deviation. Fold change was calculated by dividing IL-10 treated MFI by non-IL-10 treated MFI 








































































5.1.3 IL-10 does not increase the level of classical exhaustion markers on 
CD8 T cells 
 
As described in Chapter 4, we saw a decrease in mRNA levels of exhaustion 
markers such as TIGIT and TOX in our IL-10 treated CD8 T cells.  Exhaustion of 
CD8 T cells has been implicated in cancer and viral progression. The role of IL-
10 in T cell exhaustion is complex and it is difficult to uncouple the direct effect of 
IL-10 on CD8 T cells from indirect effects via other cells in the environment. We 
wanted to look at exhaustion markers at the level of protein to complement our 
transcriptomic study. We chose a panel of commonly used T cell exhaustion and 
inhibitory markers comprising of CD57, KLRG1, LAG3, PD-1, TIGIT and TIM3 
and examined the cell surface levels of these exhaustion markers after 6 days of 
activation in the presence of IL-10. This experiment (Figure 5.4) was performed 
by Dr. J. Martinez-Fabregas, due to time constraints. 
As shown in Figure 5.4 we observed a 50% reduction in the levels of KLRG1, 
TIGIT and TIM3 after activation in the presence of IL-10 compared to non-IL-10 
treated controls. PD-1 showed no change upon IL-10 treatment and CD57 had a 
small increase (~20%) in two donors and a decrease in the third donor. 
 
 
Figure 5.4 Effect of IL-10 on exhaustion markers. Purified CD8 T cells were activated with anti-
CD3/CD28 and IL-2 in the presence or absence of IL-10 (50 nM) for three days followed by 
expansion in IL-2 ± IL-10 for three days. Cell surface expression levels of classic exhaustion 
markers were measured by flow cytometry on day 6. Error bars represent standard deviation. Fold 
change was calculated by dividing IL-10 treated MFI by non-IL-10 treated MFI for each donor. N=3. 


































Interestingly, we saw an increase in LAG3 expression after IL-10 treatment. 
Although LAG3 and PD-1 are inhibitory receptors which are implicated in T cell 
exhaustion (Du et al., 2020), it has been shown that treatment with PEGylated IL-
10 expanded populations of LAG3+ PD-1+ CD8 T cells with increased functional 
responses (Naing et al., 2018). This suggests that, although PD-1 and LAG3 are 
exhaustion markers, expression of these markers does not preclude functionally 
active T cells. The substantial decrease in expression of TIGIT and TIM-3 aligns 
with our RNA sequencing data and supports the hypothesis that IL-10 does not 
directly induce exhaustion in CD8 T cells, however further functional assays will 
need to be performed to confirm this. 
 
5.1.4 IL-10 upregulates granzyme B production in CD8 T cells 
 
In Chapter 4 we showed an increase in granzyme B protein and mRNA in CD8 T 
cells stimulated with both wild type and mutant IL-10. As mentioned previously, 
IL-10 has been shown to boost the cytotoxicity of CD8 T cells, leading to 
enhanced tumour clearing in both mouse models and human patients (Naing et 
al., 2018, Emmerich et al., 2012). The studies showed that administration of IL-
10 enhanced the presence of effector molecules such as granzyme B. We 
wanted to confirm these results in both purified and PBMC populations of CD8 T 
cells. We saw a large increase in granzyme B induced by IL-10 in CD8 T cells 
grown in a PBMC culture (Figure 5.5a), similar to the results from Chapter 4 
Figure 5.5b shows that IL-10 also induced a significant increase in granzyme B 
in the purified population, confirming a direct effect. In our RNA sequencing study 
we noted a significant increase in granzyme B transcripts when the cells were 
stimulated with IL-10 and this was confirmed by RT-qPCR in separate donors. As 
shown in Figure 5.5c, IL-10 induced a five-fold upregulation of granzyme B mRNA 
compared to cells activated in the absence of IL-10, demonstrating that IL-10 
enhances transcription of this cytotoxic effector molecule and confirming the 
results seen in our transcriptomic study. These high levels of granzyme B induced 
by IL-10 are in keeping with previously published reports (Mumm et al., 2011), 







5.2 Examining the proteome of an IL-10 treated CD8 T cell 
 
Thus far we had shown that CD8 T cells activated in the presence of IL-10 did 
not display inhibition of proliferation, or activation or a consistent upregulation of 
exhaustion markers. These cells also showed an increase in effector molecules, 
in line with published results. We next used quantitative mass spectrometry to 
gain insight into how IL-10 treatment regulated the CD8 T cell proteome. This 
gave us an unbiased and global overview of how IL-10 affects these cells and 
allowed us to compare how changes in the CD8 transcriptome induced by IL-10 
translated into changes at the protein level.  
 
As shown in Figure 5.6, CD8 T cells were activated within a PBMC population 
using anti-CD3 and IL-2 for three days, followed by expansion of the population 
with IL-2 for another three days. On day 6 CD8 T cells were isolated from the 
population by negative selection and samples were lysed and prepared for mass 
spectrometry. IL-10 was added to the culture media at the start of activation and 
again at day 3 when the media was changed. Three human donors were used 




Figure 5.5 Effect of IL-10 on CD8 granzyme B production. (a) Granzyme B fold change in 
CD8 T cells activated in a PBMC population. Cells were activated in the presence or absence 
of IL-10 (50 nM) and granzyme B levels were measured by flow cytometry on day 6. Fold 
change was calculated by dividing the granzyme B MFI of IL-10 treated cells by that of 
untreated cells. N= 4. (b) Granzyme B fold change in CD8 T cells activated in a purified CD8 
population. CD8 cells were isolated and activated for three days ± IL-10 (50 nM) followed by 
three days with IL-2 ± IL-10. Granzyme B levels were measured by flow cytometry on day 6. 
Fold change was calculated by dividing the granzyme B MFI of IL-10 treated cells by that of 
untreated cells. N=5. (c) Fold change of GZMB mRNA measured by RT-qPCR. Purified CD8 
T cells were isolated and activated over 6 days as above, n=3. Error bars represent the 

















































































































5.2.1 Overview of IL-10 treated CD8 T cell proteome 
 
6643 proteins were detected in total, with 4868 detected in all three donors. The 
fold change was calculated by dividing the label free quantification (LFQ) values 
for the IL-10 treated cells by non-IL-10 treated (i.e. unstimulated) values within 
each donor group. The significance was calculated by two-tailed two sample 
equal variance t test of the log2 fold change of IL-10/ unstimulated genes for each 
donor. The fold change for all proteins and their corresponding p-value is plotted 
in Figure 5.7a. The majority of proteins were unchanged by IL-10 stimulation 
however 80 proteins were significantly upregulated by IL-10 stimulation (>0.6 log2 
fold change) and 58 were significantly downregulated (<-0.6 log2 fold change). 
This corresponded to 7% of significantly regulated proteins being upregulated 
and 10% being downregulated (Figure 5.7b). This small shift in proteins whose 
expression is changed by IL-10 is in contrast to the large number of genes 
(>1000) which were significantly up or down regulated by IL-10. There are several 
possible explanations for this. Firstly, both the transcriptomic and the proteomic 
data come from cells harvested after 6 days of IL-10 treatment. This may mean 
that more time is needed to fully see the changes from mRNA translate into 
changes in protein. The discrepancy between mRNA and protein may also arise 
 
Figure 5.6 IL-10 treatment of CD8 T cells within a PBMC population for proteomic 
analysis. PBMCs were isolated from three human buffy coats. Cells were activated for three 
days using anti-CD3 and IL-2 in the presence or absence of IL-10 (100 nM). After three days 
the media was changed to IL-2 ± IL-10 for a further three days. On day 6, CD8 T cells were 
purified by negative selection before peptides were isolated. Cells were lysed and peptides 
were isolated as described in the Materials and Methods. The peptides were fractionated and 
analysed by mass spectrometry.  
 
Isolation of PBMCs 
from human blood 
sample 
(3 individual donors)





















due to the degradation or fast turnover of some proteins or as a result of the lower 




Figure 5.7 Proteome of CD8 T cells activated in the presence of IL-10. (a) Volcano plot 
of proteins significantly upregulated by IL-10 > 0.6 log2 fold change (green) and significantly 
downregulated by IL-10 <-0.6 log2 fold change (red) compared to non-IL-10 treated cells. 
Proteins marked in black are proteins significantly regulated in both the proteomics and 
transcriptomic datasets. Fold change was calculated by dividing IL-10 treated values by 
unstimulated values for each donor. The average fold change was calculated for three 
donors and the log2 of this value is plotted. P values were calculated by two-tailed two 
sample equal variance t test of the log2 fold change of IL-10/ unstimulated genes for each 
donor. Proteins which were not significantly changed or were  >-0.6<0.6 log2 fold change 
are in grey. (b) Proportion of proteins significantly upregulated > 0.6 log2 fold change 
(green) or downregulated <-0.6 log2 fold change (red) by IL-10. Unchanged proteins are 
those which reached significance but fell within >-0.6<0.6 log2 fold change. (c) Comparison 
of log2 fold change of datapoints shared between proteomic and transcriptomic studies. 




























































































The proteins significantly regulated at the level of protein expression which were 
also significantly regulated at the level of mRNA from our transcriptomic dataset 
are highlighted within the volcano plot. Figure 5.7c shows the regulation of these 
shared proteins. With the exception of HIS1H1E, all shared datapoints between 
the proteomic and transcriptomic studies showed similar regulation by IL-10. 
Examining these proteins we see, as expected, granzyme B being upregulated, 
confirming our previous data. We also saw a significant upregulation of CD9 in 
our proteomic data. CD9 is a tetraspanin protein which is widely expressed by 
many immune cells including T cells, NK cells, dendritic cells and macrophages 
and has been implicated in many processes such as cell migration, adhesion and 
survival (Reyes et al., 2018). In CD8 T cells CD9 has been shown to play a role 
in T cell activation by modulating interactions at the immunological synapse and 
cells transduced with shCD9 showed reduced CD69 levels and reduced IL-2 
secretion (Rocha-Perugini et al., 2014).  
 
The Major Vault Protein (MVP) was highly upregulated in the proteome of all 
donors tested and was also highly upregulated in our transcriptomic dataset. 
MVP is involved in regulation of intracellular signalling and has been shown to be 
IFNγ-inducible (Steiner et al., 2006). JAK3 was also upregulated by IL-10 in our 
proteomic and transcriptomic datasets. While IL-10 does not activate JAK3 
directly, JAK3 is essential for IL-2 signalling (Kirken et al., 1995). IL-2 was added 
to the culture media to enhance CD8 T cell proliferation and so the upregulation 
of JAK3 by IL-10 suggested the potential for IL-10 mediated regulation of IL-2 
signalling.  
 
5.2.2 IL-10 downregulates many proteins involved in glycolysis 
 
We used GO and KEGG analysis on those proteins significantly up or 
downregulated by IL-10 to better understand how IL-10 regulated CD8 T cells 
biology. KEGG pathway analysis showed that the glycolysis/gluconeogenesis 
and fructose/mannose metabolism pathways were significantly represented in 
the downregulated group of proteins (Figure 5.8a). GO biological processes 
highlighted glycolytic processes, canonical glycolysis and gluconeogenesis 




proteins are shown in Figure 5.8c with their fold change compared to non-IL-10 
treated controls shown in Figure 5.8d.  
 
Figure 5.8 IL-10 regulation of glycolysis-associated proteins in CD8 T cells. (a-b) The 58 
significantly downregulated proteins following IL-10 treatment were subject to KEGG and GO 
pathway analysis using DAVID online software (Huang da et al., 2009). Pathways are ranked 
by p value. (c) Glycolysis associated proteins LFQ values are plotted. (d) Fold change of LFQ 
values shown in (c), n=3. (e) Schematic displaying proteins upregulated by IL-10 (green) and 
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We saw a significant downregulation of hexokinase-2 (HK2), triosephosphate 
isomerase 1 (TPI1) and fructose bisphosphate aldolase C (ALDOC) by IL-10 
treatment.  
 
These are key proteins and enzymes in glycolysis, suggesting that IL-10 may be 
inhibiting this pathway in CD8 T cells. The metabolic processes these proteins 
are involved in are highlighted in Figure 5.8e. HK2 catalyses the conversion of 
glucose to glucose-6-phosphate, a rate limiting step in glycolysis. ALDOC and 
TPI1 are both involved in the conversion of glucose-6-phosphate to 
glyceraldehyde-3 phosphate which is then converted to pyruvate. In addition, we 
also observed a downregulation in the lactate transporter SLC16A3 (MCT4). 
Interestingly we saw upregulation of the enzyme OGT which catalyses the 
OGlcNAcylation of proteins. A study by Swamy et al. demonstrated that 
OGlcNAcylation is key for T cell expansion and function (Swamy et al., 2016). IL-
10 mediated regulation of glycosylation has also been demonstrated in CD8 T 
cells where IL-10 induced N-glycan branching via  MGAT5 which downregulated 
TCR signalling, leading to inhibition of CD8 T cells (Smith et al., 2018).  
 
We next wanted to see if the apparent upregulation of the OGT enzyme by IL-10 
corresponded to a change in the level of OGlcNAcylation of the cell. CD8 T cells 
in either a PBMC or a purified population were activated over 6 days in the 
presence or absence of IL-10 as above and OGlcNAcylation was measured on 
day 6. As seen in Figure 5.9a there was a small but significant decrease in 
OGlcNAc levels in IL-10 treated CD8 cells activated in a PBMC population. In the 
IL-10 treated purified CD8 population there was also a small decrease in two out 
of three donors however this was non-significant (Figure 5.9b). It is important to 
mention that separate donors were used for the PBMC and purified populations 
and experiments were carried out separately which may have led to differences 
in the amplitudes of the MFI signals between the two populations. The decrease 
in OGlcNAcylation, while only minimal, opposes the upregulation of OGT seen in 






5.2.3 IL-10 upregulates many mitochondrial proteins 
 
GO cellular compartment analysis revealed that upregulated proteins were 
significantly associated with the mitochondria and specifically the inner 
mitochondrial membrane (Figure 5.10a). Several proteins comprising complex I 
in the mitochondrial electron transport chain were upregulated by IL-10 treatment, 
namely NDUFB9, NDUFB10, NDUFB11, NDUFB13 and TMEM126B (Figure 
5.10b-c). Although they were upregulated NDUFB9, NDUFB11 and TMEM126B 
did not reach significance due to variation between donors as well as NDUFB11 
and TMEM126B being undetected in the untreated samples in two donors. 
Complex I transfers electrons from NADH to the respiratory chain and is the 
largest component in oxidative phosphorylation. Inhibition of complex I in T cells 
has been shown to reduce proliferation, IFNγ production and degranulation (Yi et 
al., 2006). COX5A, a component of Complex IV in the mitochondrial electron 





Figure 5.9 Effect of IL-10 on OGlcNAcylation in CD8 T cells. (a) PBMCs were activated using 
anti-CD3 and IL-2 ± IL-10 (50 nM) for three days followed by three days with IL-2 ± IL-10. 
OGlcNAc levels were measured on day 6 of activation using flow cytometry. P values were 
calculated by paired t test. N=4 (b) CD8 T cells were purified from a PBMC population and 
activated using anti-CD3/CD28 and IL-2 ± IL-10 (50 nM) for three days followed by three days 

































As with those proteins involved in glycolysis, none of the mitochondrial proteins 
upregulated by IL-10 were shown to be significantly regulated by IL-10 at the 
mRNA level in the transcriptomic dataset, again suggesting post-translational 
modulation. This strong mitochondrial signature induced by IL-10 prompts many 
questions about what effect IL-10 could be having. Some potential hypotheses 
are that IL-10 may be increasing oxidative phosphorylation or altering reactive 
oxygen species (ROS) production which may enhance CD8 T cell activity. The 
proteins altered by IL-10 that are involved in metabolic processes are highlighted 
in Figure 5.11.  
  
 
Figure 5.10 Regulation of oxidative-phosphorylation-associated proteins by IL-10 in CD8 
T cells. (a) The 80 proteins upregulated by IL-10 were subject to GO cellular component analysis 
using the DAVID online software . Components are ranked by p value. (b) Oxidative-
phosphorylation associated proteins LFQ values are plotted. N=3. (c) Fold change of LFQ values 
shown in (b). For NDUFB11 and TMEM126B only one point is shown as these proteins were not 















































































































Due to the large amount of mitochondrial complex I proteins altered by IL-10 in 
our proteomic dataset, we wanted to examine the effect of IL-10 on mitochondrial 
mass and membrane potential. Purified CD8 T cells were activated and cultured 
in the presence of IL-10 over ten days in a preliminary experiment. Mitochondrial 
mass and membrane potential were examined using MitoGreen and MitoRed 
stains respectively at two timepoints, day 6 and day 10. Day 6 is the same 
timepoint used for the proteomic study however we wanted to use a later 
timepoint in addition to this to gain more information about the longer effect of IL-
10 on the cultures. At both timepoints a sample of non-IL-10 treated cells were 
incubated with the ionophore FCCP as a positive control. FCCP uncouples 
oxidative phosphorylation by transporting protons across the inner membrane 
(Benz and McLaughlin, 1983).  
 
The reduction in MitoGreen staining seen upon FCCP treatment was unexpected. 
MitoGreen should be membrane potential independent (Figure 5.12a) (Ip et al., 
 
Figure 5.11 Schematic of IL-10 mediated regulation of metabolic processes in CD8 T cells. 
Simplified schematic of glycolysis and oxidative phosphorylation. Proteins upregulated by IL-10 
are highlighted in green, proteins downregulated by IL-10 are highlighted in red. Image 




2017). However a study has shown that the fluorescence of this dye can vary 
with the production of reactive oxygen species (Doherty and Perl, 2017) and 
FCCP was previously shown to reduce high glucose-induced ROS production 
(Yu et al., 2006). Therefore, the reduction seen in the present study may be an 
artefact of this and further research will be required to confirm this.  On day 10 
there was a decrease seen in mitochondrial mass in the IL-10 treated cells 
compared to the non-IL-10 treated controls however this was minimal (15%) 
(Figure 5.12a).  
 
As expected FCCP induced a reduction in MitoRed fluorescence, denoting a 
decrease in membrane potential (Figure 5.12b). A small reduction (10%) in 
 
Figure 5.12 Examination of the effect of IL-10 on mitochondrial mass and membrane 
potential. CD8 T cells were purified from a PBMC population and activated using anti-CD3/CD28 
and IL-2 ± IL-10 (50 nM) for three days followed by three days with IL-2 ± IL-10. For growth to day 
10, cells were placed in fresh media with IL-2 and IL-10 on day 6 and day 8. Samples were taken at 
day 6 and day 10 for analysis by flow cytometry of mitochondrial mass using MitoGreen (a) and 
mitochondrial membrane potential using MitoRed (b). A sample of non-IL-10 treated cells were 
stimulated with FCCP (5 μM) for 45 minutes before mitotracker staining as a positive control for 



























































































MitoRed fluorescence was seen in the IL-10 treated cells compared to the control 
cells on day 6 and this difference increased by day 10 to 25% (Figure 5.12b). 
While this experiment was only performed twice, it suggests that IL-10 may be 
decreasing the mitochondrial membrane potential. However further work will 








In this chapter I explored the effect of IL-10 on CD8 T cells. We confirmed 
previously published work demonstrating that IL-10 can enhance effector 
functions of CD8 T cells. IL-10 treatment of CD8 T cells did not inhibit activation 
or induce exhaustion. The proteomic study gave an in-depth view of how IL-10 
affected protein regulation in CD8 T cells during activation. This highlighted a 
metabolic signature induced by IL-10 which had previously not been reported in 
CD8 T cells. The regulation of key metabolic pathways by IL-10 may provide an 
explanation for the molecular basis of how IL-10 increases the fitness of these 
cells, however much further work will need to be done to confirm these results. 
 
Regulation of CD8 T cell exhaustion via IL-2Rα levels by IL-10 as a potential 
mechanism for enhancing cytotoxic activity 
 
In Chapter 4 we used RNA sequencing to examine the effect of IL-10 on CD8 T 
cells. This, alongside the proteomic data presented in this chapter, gives us an 
in-depth insight into regulation of both RNA and protein in CD8 T cells by IL-10. 
One caveat in comparing these two datasets is the differences in CD8 T cell 
cultures used. For the proteomic dataset, CD8 T cells were activated and grown 
in a PBMC culture before isolation. In the RNA sequencing study, CD8 T cells 
were activated and grown in a purified population. Despite these differences both 
populations were activated for the same time length and IL-10 was added to the 
cultures at the same time points. This means that, although some differences will 
arise due to the culture conditions, both data sets describe how the presence of 
IL-10 during activation affects CD8 T cells.  
 
In the RNA sequencing study, we showed that IL-10 significantly decreased 
levels of exhaustion marker transcripts TOX and TIM-3. Changes in these were 
not detected at the level of protein expression in our proteomic dataset. However, 
using flow cytometry, we saw that IL-10 did reduce cell surface levels of TIGIT, 
TIM-3 and KLRG1 compared to non-IL-10 treated activated controls. The 
discrepancies between RNA and protein levels may be explained by the 





The role of IL-10 in T cell exhaustion is complex. Several studies have shown 
that the presence of IL-10 can contribute to poor CD8 responses and T cell 
exhaustion. Sawant et al. demonstrated that IL-10/IL-35 producing Treg cells 
enhance exhaustion in T cells within the tumour microenvironment (Sawant et al., 
2019). CD8 T cells from IL-10 deficient mice in LCMV infection had increased 
production of effector cytokines and these mice showed enhanced viral 
clearance, suggesting that IL-10 contributes to chronic viral persistence (Brooks 
et al., 2006).  
 
In contrast to this, treatment of RCC patients with PEGylated IL-10 led to an 
increase in CD8 T cells expressing PD-1 and LAG-3 which positively correlated 
with tumour clearance (Naing et al., 2018). These cells had increased effector 
molecules and, despite high levels of PD-1 and LAG-3, they did not display an 
exhausted phenotype. Importantly these cells did not display TIM-3. The authors 
suggested that IL-10 treatment led to an expansion of tumour-specific activated 
PD-1/LAG-3 positive CD8 T cells which were key for tumour clearance. In 
addition, a study using IL-10 KO mice challenged with Trypanosoma cruzi 
showed that, in the absence IL-10, there was an increase in exhausted CD8 T 
cells, characterised by less proliferation and cytotoxic activities (Pino-Martinez et 
al., 2019).  
 
These conflicting reports on the link between IL-10 and CD8 T cell exhaustion 
may be due differences in the length of exposure to IL-10, the timing of IL-10 
administration, the sources of IL-10, the viral or cancer challenge used, the 
cytokine environment of the cells or the activation state of the cells. Our results 
suggest that the presence of IL-10 during activation may downregulate 
exhaustion in CD8 T cells, as shown by a decrease in exhaustion markers, an 
increase in granzyme B and no inhibition in proliferation. This may be a potential 
mechanism by which IL-10 enhances the cytotoxicity of CD8 T cells, by limiting 
their functional exhaustion. 
 
In the RNA sequencing study, we saw that IL-10 downregulated IL-2Rα and this 
was confirmed by flow cytometry at the protein level. In our proteomic dataset, 
IL-2Rα was downregulated by ~25% in two donors but not detected in the third 




(3 for RNA sequence analysis, 3 for flow cytometry and 2 out of 3 for proteomics) 
in both purified and PBMC cultures suggests that this is a key feature of IL-10 
stimulation in CD8 T cells. IL-2Rα is the key subunit in the IL-2 receptor which 
determines sensitivity to IL-2 and is upregulated by T cells upon activation. IL-2 
was present in the T cell culture at every stage during activation to allow the 
growth and proliferation of the activated populations and so changes to sensitivity 
to IL-2 may be important in the IL-10-treated phenotype. We saw in our RNA 
sequencing study that known IL-2 regulated cytokines such as LIF and IL-13 were 
downregulated by IL-10 treatment and we proposed that this may be due to 
downregulation of IL-2Rα. In addition, comparison of an IL-2 treated and 
untreated activated CD8 T cell proteome by Rollings et al. showed increased 
levels of TIM-3 by IL-2 (Rollings et al., 2018), an inhibitory receptor that was also 
downregulated in our study by IL-10 treatment. 
 
We hypothesise that this dampening of IL-2 signalling by IL-10 may be linked to 
the decrease in exhaustion markers. Links between IL-2 and CD8 T cell function 
have already been explored in the literature (Kalia et al., 2010). Here it was 
demonstrated that CD25lo CD8 T cells tend towards a memory cell phenotype 
and are long lived whereas CD25hi CD8 T cells are terminally differentiated with 
higher rates of apoptosis. Another study showed that removal of the IL-2Rß chain 
reduced inhibitory receptor levels on CD8 T cells, suggesting a positive role for 
IL-2 and/or IL-15 in T cell exhaustion (Beltra et al., 2016). Further work will need 
to be done to confirm the data seen in both our transcriptomic and proteomic 
data, however the initial results provide new insights into the regulation of CD8 T 
cell activities by IL-10. 
 
IL-10 regulates key metabolic proteins in CD8 T cells 
 
Our proteomic dataset showed regulation of several key metabolic proteins by IL-
10 in CD8 T cells. Glycolysis is upregulated upon T cell activation expanding the 
capability for rapid protein production, allowing expansion of the population and 
production of effector molecules (van der Windt and Pearce, 2012). However, in 
our IL-10 treated cells we saw a downregulation of hexokinase-2, 
triosephosphate isomerase 1 and fructose-bisphosphate aldolase C, key 




regulator of nutrient transporters and specifically plays a role in maintaining 
glucose uptake in activated CD8 T cells via regulation of glucose transporters 
(Ross et al., 2016). It is possible that the downregulation of IL-2Rα by IL-10 may 
contribute to a metabolic shift in CD8 T cells. We also saw a large upregulation 
of many components of the mitochondrial electron transport chain by IL-10, in 
particular those associated with complex I. This is a key step in ATP production 
during oxidative phosphorylation (OXPHOS) with complex I being the rate limiting 
step. Together these data  support the importance of IL-10 in mediating regulation 
of significant components of CD8 T cell metabolism. 
 
A study examining the metabolic effect of IL-10 on macrophages saw that IL-10 
inhibited glycolysis and promoted OXPHOS (Ip et al., 2017). Here this was linked 
to IL-10’s anti-inflammatory properties in macrophages. While we see regulation 
of key glycolysis and mitochondrial proteins which suggest that IL-10 may be 
mediating a similar metabolic shift in CD8 T cells, we link this to an increase in 
the effector functions of these cells. It has been shown that inhibition of glycolysis 
using 2-deoxyglucose promotes the generation of memory T cells and can 
enhance tumour targeting (Sukumar et al., 2013).  In addition, studies have 
reported that increased OXPHOS can enhance memory T cell generation (van 
der Windt et al., 2012). We hypothesise that the IL-10 induced shift in metabolism 
in CD8 T cells may be increasing their cytotoxic potential by stabilising the cells 
and allowing them to continue to produce effector molecules but preventing over-
activation and transition into exhaustion. 
 
Conclusions and Future Perspectives 
 
In this chapter I have demonstrated that IL-10 induces key changes in CD8 T 
cells. I confirmed previously published work showing that IL-10 can enhance 
production of the effector molecule granzyme B. I then used proteomics to gain 
insight into the molecular mechanisms that underpin this activity. This highlighted 
the potential role that IL-10 may play in regulation of IL-2 signalling and CD8 T 
cell metabolism. Much further work is needed to investigate this. Measurement 
of rates of glycolysis and OXPHOS using Seahorse assays are needed to confirm 
if the changes in metabolic pathways seen at the protein level are impacting the 




10 merit further investigation into what changes, if any, IL-10 is inducing in CD8 
T cell mitochondria. Further measurement of mitochondrial mass and membrane 
potential perhaps using isolated mitochondria is needed to confirm the 
preliminary results shown here. Investigation into ROS production in IL-10 treated 
CD8 T cells would also help to determine if IL-10 is positively or negatively 
affecting mitochondrial function. Another interesting aspect to consider for future 
work is the potential role of mTOR in the activities we are seeing. mTOR is a key 
regulator of metabolic programmes in CD8 T cells (Howden et al., 2019). Using 
rapamycin, an mTOR inhibitor, would allow us to assess the contribution of 
mTOR to IL-10’s activities in CD8 T cells. 
 
The results presented here reliably reproduce published work outlining the 
enhancement of CD8 T cell activities by IL-10. These results also provide a 
potential molecular mechanism for this enhancing effect, suggesting that IL-10 
could regulate the response to IL-2 and the metabolism of CD8 T cells. While 
further studies are needed to confirm this hypothesis, these results provide a solid 






Chapter 6. The use of high affinity IL-10 variants to enable 




The crystal structures have been obtained for IL-10 and IL-10Rß as individual 
polypeptides, as well as for the IL-10/IL-10Rα complex (Walter and 
Nagabhushan, 1995, Josephson et al., 2001, Zdanov et al., 1995, Yoon et al., 
2010, Hoover et al., 1999). Thus far however, the structure of IL-10 in complex 
with both IL-10Rα and IL-10Rß has remained unresolved. This is probably at 
least in part due to the weak affinity of IL-10 for IL-10Rß, making purification of a 
stable complex difficult (Yoon et al., 2010, Freeze and Kranz, 2010b, Pletnev et 
al., 2005). The availability of a complete structure for the assembled IL-10 
cytokine-receptor complex remains an important step in allowing a full 
understanding of the early molecular events which trigger the IL-10 response.  
 
The work to develop the high affinity IL-10 variant, R5A11, in both a monomeric 
(R5A11M) and dimeric (R5A11D) conformation (Chapter 3), provided us with 
unique tools with which it was hoped we would be able to generate stable IL-
10/IL-10 receptor complexes which could then be used for crystallisation screens. 
This chapter describes the attempts to develop a platform for structural 
characterisation of these complexes.  
 
Aims: 
• Generate stable IL-10/IL-10Rα/IL-10Rß complexes using high affinity IL-
10 monomer and dimer 
• Attempt to de-glycosylate IL-10Rα and IL-10Rß 
• Attempt crystallisation of high affinity IL-10/IL-10 receptor complexes 
• Screen for nanobodies which bind the R5A11M/IL-10 receptor complex 





6.1 Generation of purified R5A11M/IL-10Rß  and R5A11M/IL-10Rß/IL-10Ra 
complexes  
 
The engineered monomeric high affinity variant (R5A11M) was shown to bind IL-
10Rß with several fold higher affinity than its wild type counterpart by SPR 
(Chapter 3). To generate the binary complex R5A11M and IL-10Rß were 
incubated at 4 ºC in a 1:1 ratio before purification via gel filtration (S200 column). 
This complex eluted as a single peak, confirming that R5A11M can form a stable 
complex with IL-10Rß (Figure 6.1a). The R5A11M/IL-10Ra/IL-10Rß ternary 
complex was generated by incubation at 4 ºC of R5A11M with IL-10Rß and IL-
10Rα in a 1:1:1 ratio followed by purification via gel filtration (S200 column). This 
complex eluted at a volume of 14.4 mL  (Figure 6.1a).  
 
The earlier elution volume for the ternary complex was expected due to its 
increased size compared to the binary complex. Protein fractions from the ternary 
and binary IL-10-receptor complexes were run on an SDS-PAGE gel to determine 
the polypeptide species present within each peak (Figure 6.1b). However, while 
R5A11M runs as a band around 18 kDa, detection of the individual receptor 
ectodomains is complicated somewhat due to their similar molecular weights (IL-
 
Figure 6.1 Formation of a stable complex of R5A11M with IL-10 receptor subunits. (a) 
R5A11M and IL-10Rß were incubated at a 1:1 ratio before purification via gel filtration. 
R5A11M, IL-10Rα and IL-10Rß were incubated at a 1:1:1 ratio before purification via gel 
filtration. Gel filtration was performed on an S200 column (b) A sample from the peak of each 
complex was run on a 12% SDS-PAGE gel. R5M= R5A11M. MW= molecular weight marker. 
 




































10Rα at 24 kDa and IL-10Rß at 23.5 kDa respectively) and the multiple 
glycosylation sites on each subunit.  
 
Crystal screens were set (ProPlex (Molecular Dimensions), JCSG Core Suite I, 
JCSG Core Suite II and JCSG Core Suite IV (Qiagen)) using both the binary and 
the ternary complex. Sitting MRC 96-well 2 drop plates were used. 100 nL 
volumes were dispensed in a 1:1 ratio of protein: crystallisation condition. 
Screens were placed in a temperature controlled room (~21ºC) and periodically 
checked however, no crystal were obtained. 
 
6.1.1 De-glycosylation of receptor proteins 
 
A common barrier to the generation of crystals for structure determination is the 
glycosylation of proteins as the presence of the sugars reduces the homogeneity 
of the protein (Nettleship, 2012). Human IL-10 is not glycosylated however both 
IL-10Rα and IL-10Rß contain several N-linked glycosylation sites (Hoover et al., 
1999, Yoon et al., 2010, Pletnev et al., 2005). As an extension of the purification 
process, and to provide further samples for crystallisation, attempts were made 
to produce components devoid of glycosylation.  
 
De-glycosylation of IL-10Rb 
 
A non-glycosylated mutant of the IL-10Rß ectodomain had previously been 
designed by the Walter group (Yoon et al., 2010). This mutant had asparagine to 
glutamine substitutions at four sites: N49Q, N68Q, N102Q, N161Q (Figure 6.2.a) 
and was used to generate a 2.14Å resolution structure of IL-10Rß (Yoon et al., 
2010). This same IL-10Rß glycosylation mutant was generated for use in the IL-
10 cytokine-receptor complexes going forward. As shown in Figure 6.2b when 
the glycosylation mutant was purified by gel filtration it eluted at a slightly higher 
volume than the wild type, suggesting a reduction in mass due to the lack of 
glycosylation. When run on an SDS-PAGE gel, the reduction in apparent mass 
from ~35 kDa to ~25 kDa indicated that the mutations had indeed removed the 






De-glycosylation of IL-10Rα 
 
Similarly to IL-10Rß, a glycosylation mutant of the IL-10Rα ectodomain had 
previously been generated by the Walter group where asparagine residues were 
mutated to glutamine at 6 positions (N29Q, N53Q, N89Q, N133Q, N156Q, 
N168Q) (Josephson et al., 2001). The production of this glycosylation mutant in 
both Hi5 cells and Drosophila S2 cells was attempted however adequate 
expression levels of the protein were not achieved. In order to de-glycosylate IL-
10Rα, kifunensine was added to the insect cell culture when the protein was 
being expressed. Kifunensine inhibits the α-mannosidase enzyme, blocking the 
branching of the N-linked glycans, resulting in glycosylation limited to just simple 
high mannose residues (Elbein et al., 1990) (Figure 6.3a). After purification the 
protein was treated with endoglycosidase F (EndoF). This enzyme cleaves the 
oligosaccharide between two GlcNAc subunits which are adjacent to the 
asparagine residue of the protein, leaving only one GlcNAc residue on the protein 
 
Figure 6.2 Expression of IL-10Rß glycosylation mutant. (a) Sequence of IL-10Rß 
glycosylation mutant with the N to Q substitutions highlighted in red. (b) Overlay of GF 
chromatograms for IL-10Rß wild type and glycosylation mutant, each run on an S200 
column. (c) IL-10Rß wild type and glycosylation mutant run on a 10% SDS-PAGE gel. 
Both IL-10Rß WT and GM were run at 5 μL and 15 μL each (first and second lane of each 








































IL-10Rβ (WT vs GM)
IL-10RB (GM)
IL-10RB (WT)






(Freeze and Kranz, 2010a) (Figure 6.3a). A titration of kifunensine over a range 
of 5-100 μM was performed to determine the optimal concentration needed 
(Figure 6.3b). As shown by the separation pattern in SDS-PAGE, the addition of 
kifunensine, followed by incubation with a constant concentration of EndoF (50 
μg/mL) successfully reduced the glycosylation from the purified  IL-10Rα. When 
purified by GF and compared to previous non-treated samples, both the 
glycosylated (WT) and Kifu/EndoF treated IL-10Rα eluted at similar volumes 
(15.4 mL and 15.5 mL  respectively), suggesting that some glycosylation still 




Figure 6.3 De-glycosylation of IL-10Rα. (a) Simplified cartoon representation of the effect of 
kifunensine and EndoH treatment on oligosaccharide residues adapted from (Freeze and 
Kranz, 2010b). Image generated using BioRender. (b) IL-10Rα was expressed in the presence 
of kifunensine (Kifu) followed by EndoF treatment. The concentration of kifunensine used 
increased from left to right (5 μM, 10 μM, 50 μM and 100 μM). Each concentration condition 
was then either treated (+) with EndoF or untreated (-). A constant concentration of EndoF was 
used (50 μg/mL). MW= molecular weight marker. (c) GF traces of IL-10Rα compared to a 
kifunensine/EndoH treated IL-10Rα. S200 columns were used for gel filtration. 
 

























6.2 Purification of R5A11D/IL-10Rα/IL-10Rß Complex 
 
We had previously generated the high affinity IL-10 in the dimeric confirmation 
(R5A11D). We next attempted crystallisation of the dimeric variant as it was 
hoped that the symmetry of the dimeric complex would further improve the 
chances of crystallisation. We did not attempt crystallisation of the monomer with 
the de-glycosylated receptor subunits nor did we attempt to crystallisation of the 
dimer with the glycosylated receptor subunits due to time constraints.  
 
As a dimer, R5A11D will bind two IL-10Rα and two IL-10Rß subunits in a 1:2:2 
stoichiometry, different to the 1:1:1 stoichiometry of the monomer. R5A11D was 
complexed with the IL-10Rß glycosylation mutant alone to form the binary 
complex, as well as with the kifunensine/EndoH treated IL-10Rα and the IL-10Rß 
glycosylation mutant for ternary complex formation. Each complex was then 
purified by GF. As expected, a difference in the elution volumes was seen 
between the binary and the ternary complex, with the binary complex eluting at 
14 mL and the ternary at 13.3 mL (Figure 6.4a). 
 
Unlike the monomeric-receptor complexes, the dimeric-receptor complexes did 
not run as a monodispersed peak, with two distinct peaks seen in both the binary 
and the ternary complex. Overlaying the ternary complex GF trace with that of 
the individual receptor components highlights that the second peak resembles 
the elution volumes of the receptors (Figure 6.4b). To examine these peaks more 
closely each was analysed by SDS-PAGE. The early fraction which eluted at 13.4 
mL (EF) corresponded to the R5A11D/IL-10Rα/IL-10Rß complex, while the late 
fraction (LF) which eluted at 15.9 mL contained the receptor subunits (Figure 
6.4c). This fraction of unbound receptor was unexpected as the complex 
components were incubated according to the 1:2:2 IL-10:IL-10Rα:IL-10Rß ratio. 
It may be that some R5A11D was lost in the column due to non-specific binding, 
altering the ratio. In future, re-running the early fraction peak on a gel filtration 
column would be advised, in order to ensure that the complex is not dissociating. 
Additionally, our stock concentration of IL-10Rß is very high, meaning that very 




This may mean that a small deviation in the volume of IL-10Rß added results in 
a substantial excess of protein in the complex.  
  
 
Figure 6.4 R5A11D/IL-10Rß/IL-10Rα complex. (a) Overlay of the GF traces of the binary 
and ternary complexes. Each complex was run on an S200 column, (b) GF trace of the 
R5A11D/IL-10Rα/IL-10Rß complex overlaid with the receptor subunits run on an S200 
column. (c) A sample from the early fraction (EF) and late fraction (LF) separated by GF in 






























































6.3 Crystallisation Screening of R5A11D complex 
 
6.3.1 Initial rounds 
 
Having demonstrated the ability to generate stable complexes which remained 
intact through GF as well as reducing the glycosylation of the receptors we next 
attempted to prepare crystals for structure determination. We performed 
crystallisation screening with samples of R5A11D/IL-10Rß and R5A11D/IL-
10Rα/IL-10Rß. Concentrations of each complex ranging from 3-10 mg/mL were 
used in various commercially available screens: PurePEG, ProPlex (Molecular 
Dimensions), JCSG Core Suite I, JCSG Core Suite III and JCSG Core Suite IV 
(Qiagen). 60 μL of crystallisation conditions were used and sitting MRC 96-well 
2 drop plates were used. 100 nL volumes were dispensed in a 1:1 ratio of protein: 
crystallisation condition. Screens were placed in a temperature controlled room 
(~21ºC) or in an incubator maintained at 18°C with humidity control however 
neither condition produced crystals.  
 
6.3.2 Follow-up  
 
Methylation of lysine residues has been shown to improve the success rate of 
crystallisation (Sledz et al., 2010). This process involves adding a methyl group 
to the exposed primary amines (i.e., lysine residues and the N-terminus of the 
protein). Why this process can enhance the generation of crystals is unclear 
however several explanations have been proposed such as the increase in 
hydrophobic surfaces or a reduction in the isoelectric point (Walter et al., 2006). 
We methylated a complex of R5A11D/IL-10Rα/IL-10Rß for use in screens 
however no crystals were observed. 
 
All efforts thus far had used proteins in an HBS solution (100 mM HEPES, 1.5 M 
NaCl). We buffer exchanged a sample of R5A11D/IL-10Rß/IL-10Rα complex into 
a low salt buffer (10 mM HEPES, 50 mM NaCl) and set up screening plates using 
this protein solution. After 3 days incubation at 18ºC two small crystal fragments 
were visible in well 8E of the JCSG Core III suite (Figure 6.5). This well contained 
the following conditions: 0.2 M calcium acetate, 0.1 M sodium cacodylate, pH 6.5, 




variations of these conditions, varying the pH of sodium cacodylate, the molarity 
of calcium acetate and the percentage of PEG8000. Unfortunately, despite 
multiple attempts we could not repeat the generation of these crystal fragments, 
even when repeating the original screen conditions.  
6.4 Generation of nanobodies which recognise the R5A11M/IL-10Rα/IL-
10Rß complex 
 
Work done in this section (6.5) was carried out by Rachael Brown during her 
honours project in the Moraga lab, supervised and assisted by the author of this 
thesis. 
 
Due to our inability to crystallise high affinity IL-10 with its receptor components 
through the traditional pathway, we decided to generate nanobodies capable of 
binding the ligand-receptor complex. Nanobodies have previously shown efficacy 
in acting as chaperones in the crystallisation of protein complexes. A synthetic 
nanobody yeast display library, previously generated by McMahon et al., was 
used here to isolate nanobodies capable of recognising the high affinity IL-10 
variant in complex with the receptor subunits (McMahon et al., 2018).  
 
Conventional antibodies are comprised of two chains: a heavy chain and a light 
chain (Figure 6.6). Each chain has a constant domain and a variable domain and 
it is the variable domain that recognises the epitope and gives the antibody 
specificity. Camelids produce antibodies which consist only of heavy chains, with 
one variable domain and two constant domains (Muyldermans, 2013). The 
 
 
Figure 6.5 Crystallisation attempts of the IL-10 receptor complex. Image of fragments 
seen when the R5A11/IL-10Rα/IL-10Rß complex was placed in a low salt buffer in well 8E of 





variable heavy chain alone can be recombinantly expressed as a nanobody. 
Nanobodies retain the antigen binding site but have a greatly reduced size 
compared to antibodies, with a mass of approximately 15 kDa.  
Their antigen specificity, small size and ease of expression means they have 
been used in many applications, both as research tools and as therapeutics 
(Muyldermans, 2013). Of interest to this thesis, nanobodies have been 
successfully used to stabilise ligand-G-protein coupled receptor (GPCR) 
complexes, allowing their crystallisation and structure determination (Manglik et 
al., 2017). Traditional production of nanobodies involves the costly and time-
consuming process of immunising camelids. Pioneering work by the Kruse 
laboratory generated a synthetic yeast-display nanobody library which can be 
used to isolate nanobodies capable of binding a target antigen (McMahon et al., 
2018). We took advantage of this technology to isolate nanobodies which 
recognise the R5A11M/IL-10Rα/IL-10Rß complex. We used the monomeric 
version of our high affinity IL-10 variant as the 1:1:1 IL-10: receptor stoichiometry 
represented a more efficient system to express and was a more economical use 




Figure 6.6 Antibody and nanobody structure. Conventional antibodies are comprised of 
heavy and light chains. These can be divided up into variable domains and constant domains. 
VL= variable light chain, VH= variable heavy chain, CL= constant light chain, VH= variable heavy 
chain. Camelid antibodies are comprised only of heavy chains with a variable domain (VHH) and 














6.4.1 Nanobody library screening  
 
The screening process used magnetic activated cell sorting (MACS) following a 
very similar process to the one used for the affinity maturation of IL-10 in Chapter 
1 (Figure 6.7). Briefly, the yeast library displaying the nanobody variants on the 
yeast cell surface is incubated with the biotinylated protein of interest. This is 
followed by incubation with Alexa Fluor647 (AF647)-labelled streptavidin. Anti-
AF647 magnetic beads are then used to isolate yeast which display nanobodies 
capable of binding the protein.  This process is repeated with decreasing 
concentrations of protein until single clones with high affinity can be isolated. We 
generated two variations of the R5A11M/IL-10Rα/IL-10Rß complex for use in 
screening rounds: one where IL-10Rα was biotinylated and the second where IL-
10Rß was biotinylated. These could then be alternated during the early selection 
rounds to ensure that the nanobodies were binding to an epitope within the 
complex, rather than just on the receptor subunit alone.  
The conditions used for the screening rounds are outlined in Figure 6.8. The first 
round was a clearing selection round using streptavidin beads (SAV) bound to 
high concentrations of complex (400 nM) to recover all positive binders and 
reduce the complexity of the library. As was done for the IL-10 library, we also 
performed an additional negative clearing step at the start of each selection 
 
Figure 6.7 Isolation of nanobodies. Yeast displaying nanobodies on their cell surface were 
incubated with biotinylated R5A11M/IL-10 receptor complex. This could then be recognised by 






















round, incubating the yeast with Alexa Fluor647 (AF647)-labelled streptavidin in 
the absence of biotinylated protein in order to remove any yeast displaying 
nanobodies which were capable of binding streptavidin.  
For round 2 of positive selection, we used a 100 nM concentration of the complete 
IL-10/receptor complex (R5A11M/IL-10Rα/IL-10Rß) where IL-10Rß was 
biotinylated. In order to increase avidity, we used this complex as a tetramer with 
the fluorescently labelled streptavidin. This meant that each streptavidin molecule 
could bind to four IL-10 receptor complexes. The same concentration of tetramer  
was repeated for the third selection round however this round used a complex 
which was biotinylated at IL-10Rα. After this section round we then divided the 
library in two: one library would proceed with selection using IL-10Rß alone and 
the other would use IL-10Rα alone (Figure 6.8) as it was assumed that all single 
receptor binders were removed in the previous rounds. It was hoped that this 
would generate a wider range of nanobodies which could bind the complex over 
a variety of epitopes. A monomeric compound of the receptor bound to 
streptavidin was used i.e., 1:1 receptor: streptavidin stoichiometry with the 
concentrations shown in Figure 6.8. As the selection rounds progressed, the 
concentration of the biotinylated receptor subunits was decreased from 250 nM 
to 5 nM.  
 
Figure 6.8 Screening conditions to isolate nanobodies capable of binding the R5A11M/IL-
10 receptor complex. Selection rounds used decreasing concentrations of biotinylated protein 
to isolate high affinity nanobodies. For rounds two and three a tetramer was used: each 
streptavidin molecule was bound to four biotinylated R5A11M/IL-10Rß/IL-10Rα complexes. For 
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6.4.2 Isolation and identification of nanobody clones 
 
After the final round at just 5nM IL-10 receptor concentration, individual yeast 
colonies were isolated by plating on glucose agar, following a similar protocol to 
that in Chapter 3. These clones were then used in a dose response experiment 
to determine the approximate on-yeast affinity of the nanobodies for the receptor 
complex. The yeast clones from the library which had used biotinylated IL-10Rα 
were denoted as “A” nanobodies and those from the biotinylated IL-10Rß library 
were denoted as “B” nanobodies. Two dose response experiments were 
performed using both A and B nanobodies. In one dose response experiment, 
the yeast clones were titrated against the R5A11M/IL-10Rα/IL-10Rß complex 
which was biotinylated at IL-10Rα (Figure 6.9a). In the second dose response, 
the yeast clones were titrated against the R5A11M/IL-10Rα/IL-10Rß complex 
which was biotinylated at IL-10Rß (Figure 6.9b). Several variants from each 
library displayed promising binding patterns: A7, A9, A12, B4, B9, B10 and B12. 
The plasmids encoding these nanobodies were isolated and sent for sequence 
identification. Figure 6.10 shows the alignment of the nanobody sequences. As 
expected, the variations between the nanobodies occured at three distinct sites, 
corresponding to the complementarity determining regions (CDRs) and not the 
backbone structure of the nanobody. Due to the combinatorial effect of the amino 
acid variations at the CDRs, no conclusion can be made about specific amino 
acid substitutions between the nanobody variants. 
 
 
Figure 6.9 Dose response of nanobody clones. Yeast displaying the nanobody clones were 
incubated with decreasing concentrations of R5A11M/IL-10 receptor complex (top 
concentration of 1000 nM, 1/3 serial dilution). Complex binding was measured by fluorescence 
of AF647-labelled streptavidin by flow cytometry. (a) R5A11M/IL-10 receptor complex was 
biotinylated at IL-10Rα. (b) R5A11M/IL-10 receptor complex was biotinylated at IL-10Rß.  
 

















































Much further work will need to be done before these can be used for 
crystallisation attempts. Firstly, the nanobodies will need to be recombinantly 
expressed. Nanobodies have been expressed in both bacterial and mammalian 
systems giving us several options for expression. Once expressed, it would be 
pertinent to determine the binding affinity of the nanobodies to the cytokine-
receptor complex using SPR to validate the on-yeast affinities. The nanobodies 
could then be bound to the complex alone or in combinations. As the sequences 
of R5A11M and R5A11D are identical apart from the glycine-serine linker, it may 
also be possible to use the nanobodies with the R5A11D-receptor complex. It is 
hoped that the nanobodies could act as chaperones to promote crystallisation as 




The generation of a high affinity IL-10 variant in both monomeric and dimeric 
conformations opened new avenues to further explore IL-10 biology. Here we 
used the high affinity variants to attempt crystallisation of the IL-10 receptor 
complex. Although crystallisation attempts were unsuccessful, we did succeed in 
generating stable complexes of IL-10 bound to both IL-10Rα and IL-10Rß. In 
addition, the use of a synthetic nanobody yeast display library allowed the 
 
Figure 6.10 Sequences of nanobodies capable of bind the R5A11M/IL-10 receptor 
complex. Sequences of the nanobodies isolated from the synthetic library are aligned against 
the template nanobody sequence from (McMahon et al., 2018). The sequence variations 





isolation of nanobodies with affinity for the R5A11M/IL-10 receptor complex. 
These will hopefully be used in future work to enhance the chances of generating 




The stable complexes generated here failed to produce crystals, suggesting that 
it is not only the low affinity for IL-10Rß that is preventing crystallisation. 
Difficulties usually arise with crystallisation of proteins when ordered, 
heterogenous proteins cannot be obtained.  Because of this, glycosylation of 
proteins often presents a barrier to crystallisation. This is due to the mobility and 
flexibility of the sugar residues which introduces structural and conformational 
disorder. In order to combat this we expressed a mutant of the IL-10Rß 
ectodomain which effectively removed N-linked glycosylation from this receptor 
subunit by the conversion of asparagine to glutamine residues at several sites, 
as previously described (Yoon et al., 2010). We were unable to express IL-10Rα 
with similar mutations at N-linked glycosylation sites. Why this failed is unknown 
however it may be due to differences in cell culture or in expression induction 
from that done by Josephson et al. A previous study which attempted 
crystallisation of the IL-10 receptor complex observed precipitation of the IL-10Rα 
protein upon de-glycosylation which was attributed to reduced solubility (Hoover 
et al., 1999), suggesting that there are intrinsic difficulties in the expression of a 
de-glycosylated IL-10Rα variant. Due to the myriad of factors which affect the 
crystallisation process it is often not possible to say why a particular protein fails 
to crystallise and so this explanation act only as a suggestion. 
 
Conclusions and future work  
 
The ability of nanobodies to aid in the crystallisation process remains untested 
for our complexes due to time constraints. While significant effort will be required 
to get these into a crystallisation campaign, specific nanobodies have been 
successfully identified for the complex.  
 
Although crystallisation has historically been the favourable method for structure 




be a favourable strategy to use going forward for examination of the complete IL-
10 receptor complex. This technique has the advantage of not requiring crystals 
and using smaller amounts of sample, although access to specialised facilities is 
required. Since completion of this thesis, work has continued on this project by 
Dr. P.K Fyfe in collaboration with the Scottish Centre for Macro-molecular 
Imaging (SCMI, University of Glasgow). A limited number of cryoEM grids 
containing R5A11D in complex with IL-10Rα and IL-10Rß were prepared by the 
SCMI and the preliminary image collected is shown in Figure 6.11. Initial analysis 
suggests that there could be aggregates or that the particles are overlapping on 
the grid, however there are some standalone particles which appear promising. 
Much more optimisation will need to be undertaken however we are hopeful that 






Figure 6.11 Preliminary cryoEM attempt of R5A11D/IL-10Rα/IL-10Rß complex. R5A11D in 
complex with IL-10Rα and IL-10Rß in a 1:2:2 ratio was purified via gel filtration (S200 column) by 
the author of the thesis. Quantifoil 2/2 grids were glow discharged twice at 25 mA for 30 seconds. 
3.5 μL of sample was applied to the grid and backside blotting was performed in the Leica GP2 
with 85% humidity at 18ºC. Grids were set and images were collected by SCMI, University 




Chapter 7. Conclusions and Future Perspectives 
 
It has been over 30 years since IL-10 was first described and since then much 
work has been done to characterise the effects of this potent cytokine (Vieira et 
al., 1991). While its anti-inflammatory functions have been well described, there 
is still a dearth of knowledge of how this cytokine carries out its effects at a 
structural and molecular level. This lack of understanding was brought into sharp 
focus when attempts to use it as an anti-inflammatory therapeutic failed in the 
clinic despite promising in vitro studies (Saraiva et al., 2020). The primary aim of 
this thesis was to generate a high affinity variant of IL-10 for use in both structural 
and immunological studies to gain a better understanding of the molecular 
mechanisms this cytokine employs to carry out its activities.  
 
In order to generate a high affinity variant of IL-10 we took advantage of 
previously described yeast display technologies (Spangler et al., 2015). This 
allowed us to engineer a variant of IL-10 which had increased affinity for the IL-
10Rß subunit, without the structural knowledge of the IL-10/IL-10Rß interaction 
site. Identifying the sites where mutations occurs gave us insight into the IL-10/IL-
10Rß binding interface. Mutations occurred primarily along the A and D helices, 
which is in keeping with previously published binding models and validates our 
selection process (Pletnev et al., 2005, Mendoza et al., 2017).  
 
While the mutations shed light on the potential interaction of IL-10 with IL-10Rß, 
a full structure of the IL-10/IL-10Rα/IL-10Rß ternary complex is still lacking. 
Previous work suggested that the difficulty in generating a crystal structure was 
due to the weak affinity between IL-10 and IL-10Rß (Pletnev et al., 2005). The 
generation of an IL-10 variant with the capability of binding IL-10Rß, even in the 
absence of IL-10Rα, presented a unique opportunity to attempt to crystalise this 
complex. The R5A11 variant could form stable complexes with IL-10Rß alone 
and in combination with IL-10Rα. This is, to our knowledge, the first time an IL-
10/IL-10Rß complex sufficiently stable to be purified by gel filtration has been 
reported. Although large amounts of purified complex could be generated, 
crystallisation of the complex was not achieved despite multiple screening 
attempts. In order to provide more options for future structural studies, we used 




(McMahon et al., 2018) to isolate several nanobodies with the apparent capability 
to bind the high affinity IL-10/IL-10 receptor complex. Much further work will need 
to be done to confirm if the nanobodies bind the complex when recombinantly 
expressed. Future experiments would include the optimisation of recombinant 
expression of the nanobody variants and SPR to accurately determine the 
binding affinities. The nanobodies could then be bound to the complex, in the 
hope that they could act as crystallisation chaperones. Future work in this project 
will also include using cryoEM as an alternative approach for structure 
determination.   
 
The generation of a high affinity IL-10 variant also allowed us to investigate the 
role that receptor affinity plays in this cytokine’s biological activities. This work 
demonstrates that wild type IL-10 loses key activities at low concentrations, in 
particular its ability to regulate pro-inflammatory cytokines and chemokines. It has 
been speculated that low local concentrations of IL-10 when give systemically in 
clinical trials for Crohn’s disease contributed to the lack of efficacy (Saraiva et al., 
2020), which supports these results. Our high affinity variant was able to retain 
better activity at low concentrations. This improved affinity at sub-saturating 
concentrations held true at multiple levels of IL-10 activity: STAT activation, 
transcription and cellular effects such as decreased pro-inflammatory cytokine 
production. This improved efficacy suggests that this variant could provide a 
therapeutic advantage over wild type IL-10. However, without in vivo data, this 
can only be considered speculative.  
 
Ideally future work would investigate if our high affinity variant out-performed wild 
type IL-10 in vivo. Experiments such as measuring levels of LPS-induced pro-
inflammatory cytokine production in the serum of mice in the presence of IL-10 
would provide good evidence for any differential dose-dependent effects between 
the wild type and high affinity variant. However, as our high affinity variant is 
based on the human IL-10 amino acid sequence, use of a murine system is 
problematic. A preliminary test showed that the wild type and high affinity variant 
had very similar activities in murine macrophage cultures. While human IL-10 can 
act in murine cells, it only has 73% amino acid similarity with murine IL-10 
(Windsor et al., 1993), which may explain why the high affinity variant failed to 




models, in vivo experimental options are very limited. While the data presented 
here highlights the favourable activity of the high affinity variant over wild type, 
these results can only be viewed in the context of controlled cell culture 
environments, without the myriad of cell types, cytokines and growth factors 
which play large roles in an in vivo setting. As highlighted by clinical trials using 
IL-10 in the past, efficacy in vitro regularly does not translate well to an in vivo 
system. However, our use of human cells does avoid the common pitfall of 
discrepancies arising between murine models and human systems (Masopust et 
al., 2017). Culturing of human organoids, particularly those which recapitulate the 
gut environment, may be an option for use in future studies which would provide 
us with information about how the high affinity variant acts in a multi-faceted 
environment (Wallach and Bayrer, 2017). 
 
The use of the high affinity variant in both monomeric and dimeric confirmations 
provided us with unique tools to also examine the contribution of stoichiometry to 
IL-10’s molecular activities.  Data presented in this thesis showed that, while the 
high affinity monomer outperformed the wild type monomer, it could not reach the 
levels of transcriptional activity seen in the dimeric molecules. This was 
unexpected as at saturating concentrations, the high affinity monomer activated 
STATs to approximately 80% of the dimeric level. This result suggests that the 
potency of the IL-10 response is not linearly associated with STAT activation. 
There are several possible explanations to this, for example, the ability of IL-10 
to activate alternate signalling pathways  such as PI3K and AMPK which were 
not examined in this thesis (Antoniv and Ivashkiv, 2011, Sag et al., 2008). It may 
be that these pathways are more sensitive to changes in receptor stoichiometry 
than the JAK/STAT pathways. Differing numbers of phospho-tyrosine activated 
between the monomers and dimers may also play a role, similar to what was 
seen in the IL-6/gp130 system (Martinez-Fabregas et al., 2019). Future work 
would include signalling analysis of non-JAK/STAT pathways activated by the IL-
10 variants as well as examining internal phosphorylation of tyrosines on the IL-
10 receptor.  
 
Despite having a poorer response than the dimeric variants, the high affinity 
monomer still far outperformed the wild type monomer in receptor assembly, 




activities. This opens future opportunities for further engineering of this variant 
where a monomeric confirmation may be preferable, for example, generating 
fusion proteins with other cytokines and antibodies.  
 
Work presented in this thesis also shed light on some of IL-10’s less well 
understood effects, namely its enhancement of CD8 T cell activity. While the 
ability of IL-10 to improve the tumour targeting ability of CD8 T cells has been 
well characterised (Oft, 2014, Naing et al., 2019) the mechanisms underpinning 
this remain elusive and differing protocols used to activate and culture CD8 T 
cells make direct comparisons in the literature difficult. Using a combination of 
transcriptomics and proteomics we characterised in-depth the CD8 response to 
the presence of IL-10 during activation. Although IL-10 has been implicated in T 
cell exhaustion previously (Sawant et al., 2019), we saw a decrease in several 
markers of T cell exhaustion at both the protein and mRNA level in IL-10 treated 
CD8 T cells. Interestingly, we also observed a decrease in expression of IL-2Rα 
at both the mRNA and protein level. The data presented in this thesis suggests 
that IL-10 may be limiting the transition to an exhausted state, perhaps by 
decreasing the responsiveness of the cells to IL-2. However, expression of 
exhaustion markers is only one facet of exhausted T cells. In order to confirm this 
effect, additional characterisations will need to be carried out such as measuring 
cytokine section, proliferation and response to re-stimulation. In addition, the link 
between IL-2Rα expression and exhaustion will need to be studied further to 
investigate whether it is a correlation or a causation effect.  
 
Our proteomic data also suggested a possible role for IL-10 in the metabolic 
regulation of CD8 T cells. In macrophages IL-10 has previously been shown to 
alter the cell’s metabolic state (Ip et al., 2017) and it is possible that a similar 
mechanism is at play in CD8 T cells. As these results were seen in our proteomic 
dataset, further experimental work will be needed to investigate this. The use of 
a Seahorse analyser to measure rates of oxidative phosphorylation and 
glycolysis will be a key experiment in this project going forward. 
 
In summary this thesis has generated novel high affinity monomeric and dimeric 
variants of IL-10, acting as tools with which to probe the molecular basis of IL-10 




stoichiometry in this cytokine’s biological effects. The use of high throughput 
methodologies such as transcriptomics and proteomics has also highlighted 
potential new angles on the effect of IL-10 on CD8 T cells, laying the foundation 
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Appendix Table 1. Monocyte RNA sequencing. Log2 fold change of genes 
significantly upregulated by WTD 50 nM > 0.6 log2 fold change and significantly 
downregulated by WTD 50 nM <-0.6 log2 fold change compared to non-IL-10 
treated cells and their corresponding regulation by the IL-10 variants. Only those 
in the WTD 50 nM were filtered for significance, other conditions were not filtered 
for significance. Fold change is the average of three biological replicates. 
WTD50= WTD 50 nM, R5D50= R5A11D 50 nM, WTM50= WTM 50 nM, R5M50= 
R5A11M 50nM, WTD01= WTD 0.1 nM, R5D01= R5A11D 0.1 nM 
Gene Name WTD50/US R5D50/US WTM50/US R5M50/US WTD01/US R5D01/US 
TNIP3 9.3183 9.5838 6.5489 8.8555 8.9489 10.1695 
CLEC4GP1 8.0675 8.1438 2.4937 6.1780 7.3157 7.5454 
C3orf70 7.8293 8.3823 3.6545 6.9244 8.0584 9.0313 
APCDD1 7.7724 7.9390 3.4811 6.2680 8.5247 9.8225 
IL12RB2 7.6135 7.7576 3.6630 6.4518 7.2733 8.8677 
HSD11B1 6.8381 6.7419 1.7010 5.2596 6.2260 7.2444 
KIAA1199 6.8165 6.3328 1.7275 5.2549 6.4143 7.4655 
HCAR3 6.3585 5.0589 0.8301 3.6943 5.6989 7.4603 
RP11-439A17.9 6.3261 6.4223 3.1739 5.6263 5.8541 6.6833 
CASP5 6.1590 5.9596 3.3079 5.5741 5.8825 6.5811 
TNFAIP8L3 6.0959 6.0843 2.3803 5.0793 6.0726 7.6656 
ENPP2 6.0856 6.2212 3.1416 5.6382 5.9516 6.7174 
TNFSF18 6.0114 5.9923 1.0842 5.1666 5.8461 7.3461 
TMEM163 5.9236 5.3177 2.1320 4.8964 5.0517 6.6487 
RP11-79H23.3 5.8787 6.0480 1.9773 4.5763 4.8394 6.4951 
PLTP 5.8744 6.1212 2.7187 5.0217 5.7811 6.3703 
RP11-1080G15.1 5.8236 6.0386 3.6477 5.5361 5.4139 6.9441 
KREMEN1 5.7746 6.0445 3.7986 5.1957 5.4264 6.0678 
MCTP2 5.7590 5.6352 3.0199 4.7711 5.1686 5.8749 
TMEM158 5.7191 6.1802 3.2222 4.7318 5.8123 6.6033 
RP13-52K8.1 5.6439 6.1430 2.0000 5.8989 5.9425 6.9049 
SLC16A10 5.5611 5.5941 2.3183 4.5639 5.5459 6.5773 
FPR1 5.4881 5.8024 2.9345 4.7845 5.5440 6.4822 
NEURL2 5.4638 6.0102 1.4054 4.8253 5.4306 5.9226 
C10orf10 5.4129 5.0148 3.9124 4.6431 4.8661 5.4451 
FAM20A 5.0874 5.4373 3.1406 4.8637 5.1150 5.4926 
CCL18 5.0546 5.0069 3.0994 4.6885 5.3974 5.3877 
DACT1 5.0305 5.6032 2.5267 4.8055 5.0076 5.7564 
PDGFA 5.0290 5.6026 1.7370 3.8289 4.9117 6.0851 
MAT1A 5.0285 4.2395 1.1699 4.5656 5.4127 5.4567 




FCGR1B 4.9361 5.4168 2.7332 4.5528 5.0247 5.7273 
SLCO4A1 4.9332 5.2863 1.9203 4.1133 4.7109 5.7252 
SOCS3 4.8260 4.6285 4.4777 4.5669 4.4343 4.6569 
LILRA3 4.7499 4.9816 1.8649 3.7680 4.5153 5.3857 
NEDD9 4.7112 4.8616 0.4131 3.5849 4.8024 6.1215 
DCHS1 4.6241 4.5696 1.7465 3.9321 4.5865 4.9400 
SPATA25 4.6141 4.7973 1.0377 3.7409 4.4454 4.6658 
GPR85 4.5820 4.7942 2.8870 4.2399 4.6050 5.0258 
FCGR1C 4.5177 4.9319 2.3644 4.0349 4.2271 4.9603 
FPR2 4.4814 4.5107 1.8938 3.4606 4.0267 5.4332 
FCGR1A 4.4322 4.8573 2.4980 4.2689 4.4554 5.0026 
RP11-424I19.2 4.3299 5.0379 4.4883 5.0232 4.8310 4.4619 
CD72 4.3081 3.9361 2.0907 3.7008 3.9980 4.1064 
ABCA8 4.2864 4.5394 2.7464 4.0133 4.3264 4.4985 
IL21R 4.2221 4.2279 1.8281 3.7238 4.1618 4.6767 
RP1-28O10.1 4.2044 3.7460 -0.0067 3.1186 3.7142 4.0855 
PIM1 4.1976 4.4413 2.5419 3.9176 4.2183 4.8779 
S100A8 4.1184 4.6907 1.8752 3.7312 4.0536 4.5758 
ABHD17C 4.0371 4.6872 1.8472 4.0927 4.3126 5.0796 
FEZ1 4.0353 4.1452 1.1726 3.3028 4.0973 4.9691 
PTX3 4.0189 4.0318 2.2953 3.5469 4.4470 5.4881 
RP4-647J21.1 4.0034 4.3261 2.6194 3.7945 3.8600 4.2355 
CX3CR1 3.9938 4.1170 0.8902 2.3607 4.2370 5.1960 
AC079325.6 3.9499 4.1828 1.2000 3.5065 3.5334 4.7323 
CCL23 3.9355 3.6236 2.7021 4.1592 3.9087 4.1661 
IL7 3.9290 3.8203 0.8931 3.0352 3.2442 4.2276 
AC010507.5 3.8781 4.7409 1.2116 6.0617 4.2597 4.5151 
AMIGO2 3.8424 4.1488 2.4871 4.0516 4.0713 4.1974 
IL7R 3.7939 3.8014 1.4057 2.9113 3.0512 4.0762 
SH3PXD2B 3.7713 3.7706 1.5445 2.8339 3.3706 3.8086 
GPR124 3.7620 4.0542 0.3627 2.0984 3.4935 4.8212 
PROS1 3.7168 3.8829 1.9196 3.4204 3.9304 4.2650 
AC008746.10 3.7057 3.8782 2.5914 3.4553 4.1571 4.1951 
PCDH12 3.6961 3.9627 1.1519 2.5062 3.8513 4.6534 
AC006129.4 3.6571 3.7620 3.1007 3.6987 3.6993 3.6480 
ARG2 3.6278 3.4484 1.6212 2.7386 3.4891 4.3027 
CLEC4G 3.5794 3.3257 1.0817 3.3004 3.4195 4.0995 
SERPINA1 3.5750 3.6627 1.4848 3.3099 3.6536 3.9971 
SLAMF1 3.5411 3.7655 0.7962 2.8986 3.0323 4.4449 
JAK3 3.5358 3.6748 2.5663 3.5060 3.5914 3.6981 
RP11-242C19.2 3.5269 2.9727 1.9572 3.0854 3.1892 2.8513 
ADAMTS2 3.5106 2.9400 2.0805 3.4300 3.7536 3.6601 




ABLIM3 3.4448 3.9410 1.5174 3.1700 3.5797 4.0544 
ELANE 3.4363 3.7082 2.5002 3.1202 3.7676 4.4363 
CH25H 3.4287 3.7350 1.3326 3.1247 3.2813 3.1684 
MS4A6E 3.4190 3.0705 2.0987 3.0762 3.1691 3.4457 
CTD-2006K23.1 3.3450 3.9615 1.5508 3.5547 3.3580 4.3679 
DLL1 3.3220 3.3280 1.6164 2.6796 2.8232 3.2947 
TUBA1A 3.3004 3.5394 1.2331 2.8597 3.3064 4.1997 
CR1 3.2975 3.2881 1.4714 2.9028 3.3226 3.6777 
EMR2 3.2803 3.2691 1.4608 2.6845 3.0072 3.4977 
FAM129A 3.2786 2.8150 0.7534 2.3660 2.7971 3.5648 
RP11-47I22.2 3.2236 3.2624 1.5398 3.0608 3.0307 3.2531 
CHI3L2 3.2018 4.2329 1.4047 2.3505 2.8719 2.8726 
G0S2 3.1710 3.6608 0.9700 2.7409 3.3538 4.3963 
XCR1 3.1681 2.6581 2.7440 3.0538 3.1126 3.2451 
VCAN 3.1623 2.9383 1.5680 2.8612 3.0557 3.4379 
CDYL2 3.1472 3.2124 1.4291 2.8361 3.2143 3.7800 
EPHB3 3.0565 2.9847 2.0720 2.9378 3.1638 3.2613 
RP11-25K19.1 3.0473 3.8128 0.7059 2.8970 3.7427 4.8912 
GK-AS1 3.0213 2.6769 1.6201 2.4601 2.7461 3.1881 
GZMB 3.0066 3.2320 1.7467 2.4828 2.4852 3.1438 
FFAR2 2.9820 3.2764 1.4308 2.7160 2.8446 4.1765 
NFKBIZ 2.9652 2.6643 1.1738 2.2522 2.6638 3.3880 
TIFA 2.9387 3.0073 1.3415 2.6384 2.8864 3.3816 
GK 2.9386 2.8554 1.6911 2.5198 2.6133 2.9334 
SEBOX 2.9362 2.3623 1.7656 2.0237 2.6197 2.5708 
GNG2 2.9324 3.2714 0.7039 2.1376 3.1431 4.1277 
MARCO 2.8538 3.5869 0.8034 1.7196 2.5277 2.9322 
LAMB3 2.8317 3.2586 0.8082 2.4379 2.7950 3.5595 
FCGR3A 2.8202 3.0514 1.6921 2.6775 2.9712 3.3349 
C1orf21 2.8168 2.8544 1.2237 2.5836 2.7488 3.4706 
FAM157A 2.7997 2.8466 -0.3313 1.7618 2.2944 3.0382 
PGLYRP4 2.7863 2.7644 1.1722 2.8920 2.5501 3.0291 
RP11-211G3.2 2.7810 2.6032 1.8011 2.0662 2.8462 2.3061 
CHRNE 2.7685 2.7187 0.4011 2.1217 2.9532 3.5752 
AFAP1 2.7284 2.7866 1.2998 2.3113 2.6824 3.0075 
NAMPT 2.7207 2.8326 1.3066 2.2893 2.4315 3.3901 
PCBP3 2.7161 2.6371 1.9197 1.9402 2.6274 2.8438 
LILRA5 2.7109 2.7854 1.0700 2.3125 2.7934 3.7808 
EHD1 2.6949 2.9295 0.9193 2.3425 2.8512 3.9328 
HEG1 2.6886 3.0560 0.9154 2.3811 2.5941 3.3772 
TFRC 2.6709 2.6577 1.0727 2.0263 2.2670 2.7329 
RP11-430K21.2 2.6540 2.9637 2.0408 3.7923 2.7484 2.3491 




FOLR3 2.6347 2.3222 2.3033 2.5830 2.1433 2.3401 
SDC2 2.6170 2.6464 1.5293 2.2579 2.7497 3.2802 
SH2B2 2.6165 2.8340 1.3619 2.2907 2.6743 3.1126 
AC005795.2 2.6146 2.5782 2.1715 2.4898 2.6520 2.5908 
PCED1B 2.6075 2.9490 1.2756 2.3086 2.7825 2.8258 
NAMPTL 2.6057 2.7991 1.1397 2.0628 2.3022 3.2850 
NLRP6 2.5859 2.7971 1.4946 1.5173 1.9733 2.8486 
TPBGL 2.5822 2.9980 1.5576 2.2602 2.6199 3.0664 
S100A9 2.5715 3.0655 1.5406 2.5667 2.6227 2.9178 
ACE 2.5353 2.2976 1.2387 1.9269 2.3337 2.3741 
LILRB1 2.5347 2.6229 1.1563 2.3372 2.5473 3.0932 
STMN3 2.5311 2.6168 0.8835 1.8970 2.4662 2.9359 
MAOA 2.5299 1.9828 1.7673 2.4065 2.3454 2.6470 
KIAA0226L 2.5195 3.0320 1.2665 2.2593 2.5761 3.0998 
UGCG 2.5104 2.5880 0.6545 2.0001 2.2602 2.9245 
KIFC3 2.4986 2.7963 1.8234 2.5258 2.6575 2.7626 
TUBB2A 2.4760 2.8858 1.2735 2.0992 2.3629 2.8585 
HIVEP2 2.4755 2.3304 0.7037 1.7712 1.9947 2.8132 
PDE4B 2.4729 1.9768 0.6772 1.4805 1.7760 2.5550 
MAPK11 2.4697 2.2768 1.1969 2.0449 2.2265 2.5603 
EDNRB 2.4488 2.5901 1.9095 2.1862 2.3226 2.3206 
SHB 2.4308 2.7674 1.1793 2.1140 2.3737 2.5586 
CEACAM4 2.4283 2.7605 0.9839 1.9398 2.0028 2.7953 
ICAM5 2.4251 2.2412 1.1571 1.8184 2.3998 2.3404 
ETS1 2.3982 2.6395 0.8622 2.1112 2.3198 3.0582 
SPATA6 2.3893 2.4911 0.4117 1.4686 2.5036 3.3449 
PSD3 2.3606 2.2757 0.8720 2.0151 2.1178 2.8073 
AL627309.1 2.3564 2.6608 1.2901 2.2149 2.1064 2.3660 
OLFML2B 2.3557 2.2400 1.6079 2.0595 2.3932 2.4060 
AC074011.2 2.3417 2.2667 1.5482 2.0478 2.2292 2.3761 
RP11-398A8.3 2.3368 2.5063 1.0062 2.0915 2.4098 3.0764 
SLC16A7 2.3326 2.4533 0.5389 1.6091 2.3965 2.9528 
LINC00085 2.3270 2.3573 1.9230 2.2305 1.9639 2.2559 
EMR1 2.3226 2.7457 1.1247 2.1120 2.1973 2.5783 
SRGAP1 2.3186 2.9803 0.9039 2.3318 2.7312 3.0917 
MPP3 2.3184 2.6347 2.1648 2.1293 2.2811 1.7718 
SLC8A1 2.3067 2.2287 0.6699 1.8730 2.1245 2.8600 
LGI2 2.2996 2.7165 1.0852 2.0112 2.5787 3.5324 
GRIN3B 2.2979 2.7845 0.7110 2.0349 2.4250 2.4741 
HIST1H2BC 2.2928 2.1302 1.9218 2.4797 2.3026 2.3219 
CBS 2.2928 2.8858 1.8115 2.6326 2.5051 2.2444 
FAM157C 2.2909 2.4126 0.4975 2.1762 1.8818 2.1671 




CD93 2.2624 2.8325 1.0260 1.8628 1.9988 2.5379 
TUBB2B 2.2586 2.8122 1.0270 1.8883 2.3656 2.9487 
TSPAN9 2.2453 2.0761 0.5626 1.3757 1.8801 2.4222 
GLUL 2.2423 2.4068 1.0782 1.9629 2.0603 2.5941 
ADM 2.2322 2.1354 1.1006 1.9918 2.1893 2.5894 
UTF1 2.2305 2.1048 1.8499 1.6901 2.1470 2.9203 
RP11-18F14.2 2.2293 2.3209 0.7002 1.7690 2.0840 2.6839 
STARD8 2.2278 2.5334 0.8112 1.8876 2.2387 2.7254 
PLB1 2.2147 2.4290 1.2102 2.0498 2.3073 2.4932 
NFATC2 2.1774 2.2694 0.9483 1.7943 2.2817 2.6443 
LILRB2 2.1672 2.2139 0.7744 1.7349 2.1053 2.7981 
RP11-67C2.2 2.1633 2.7052 1.4733 1.9114 2.1658 2.8682 
ANKS1A 2.1621 2.2741 0.7108 1.5779 2.1476 2.6266 
DSE 2.1600 2.2705 1.2260 1.9668 2.1400 2.5458 
FCGBP 2.1452 2.1921 0.3449 1.3612 2.4859 3.2458 
IFITM2 2.1447 2.1848 1.0574 1.9029 2.2415 2.5819 
VAMP5 2.1234 2.1417 1.2340 2.1622 2.1245 2.3239 
CHPF 2.1216 1.9414 0.7943 1.5351 2.0645 2.4573 
GNG12 2.1160 2.5770 0.8794 2.4396 2.8427 3.0130 
LDLRAD3 2.1156 2.0190 0.5795 1.7587 1.8523 2.3867 
HRH2 2.1015 2.4095 0.8419 1.8330 2.0892 2.4159 
FZD5 2.0819 2.3460 1.0176 1.8888 1.9651 2.5258 
SQLE 2.0804 2.1753 0.8838 1.9252 2.2476 2.8255 
PRKCA 2.0700 2.3930 0.5168 1.6156 2.0278 2.8966 
CDCP1 2.0560 2.1786 1.2126 1.8962 2.2946 2.3663 
PDPN 2.0548 2.6470 1.0735 1.3747 1.4714 1.9206 
CEACAM21 2.0262 2.1632 1.2434 1.5899 1.8512 2.2614 
ADAMTS10 2.0144 1.9867 1.2634 2.0507 2.2251 1.8402 
MAP3K8 2.0105 2.2345 1.1642 1.9987 2.1108 2.5063 
DSC2 2.0070 1.9238 1.4496 1.7945 1.9823 1.9253 
TMEM173 2.0023 2.4045 0.9477 1.6192 2.0055 2.4362 
PRR5L 1.9918 2.2760 0.4848 1.7148 2.1420 2.7435 
PCBP1-AS1 1.9831 2.2523 1.2493 2.0166 2.0886 2.3879 
PTPN2 1.9719 2.0789 0.8720 1.6236 1.8786 2.3473 
S1PR2 1.9647 2.0774 0.7527 1.3227 1.7225 2.2715 
SPATA13 1.9620 2.3080 0.7472 1.6231 1.8008 2.4734 
MS4A4A 1.9607 2.2141 0.9952 1.6193 1.9828 2.1824 
RP11-206L10.11 1.9552 2.0542 0.5174 1.2643 1.4261 2.5613 
TMEM2 1.9498 2.0622 1.1645 1.7847 1.9865 2.1924 
RP11-304M2.2 1.9453 2.2829 1.1272 1.6728 1.6655 1.9068 
TGFA 1.9424 2.1305 1.3789 1.9084 2.0510 2.5817 
RP11-792D21.2 1.9338 1.8547 1.1438 1.6645 1.8129 2.1612 




RP11-363E6.3 1.9260 1.4030 0.9566 0.9062 1.4930 2.3262 
C1QB 1.9060 2.2271 1.2918 1.9644 2.1034 2.2251 
Mar-02 1.9058 2.0220 0.7775 1.5692 1.7790 2.2092 
CCR5 1.9049 1.9158 0.9015 1.6884 1.8224 2.3303 
C1RL 1.8923 2.3131 1.4002 2.0266 2.1903 2.3861 
VNN2 1.8894 2.0893 1.2682 1.6610 1.9716 2.1726 
CHCHD7 1.8878 2.1173 0.9599 1.7683 1.8652 2.4270 
LTBP2 1.8776 1.8230 1.0358 1.4047 1.8368 1.8190 
GAL3ST4 1.8771 1.6163 0.7899 1.1529 1.5186 1.7153 
CD209 1.8696 1.9909 0.7937 1.6079 1.8116 2.1229 
RP11-400F19.18 1.8651 1.4359 1.0764 1.5189 1.2501 1.4246 
PPM1N 1.8551 2.1511 0.6863 1.6001 1.7755 2.0805 
ARHGAP12 1.8501 2.0069 0.3116 1.3097 1.6565 2.4521 
GPR27 1.8493 1.7964 0.8768 1.4065 1.7172 2.1567 
SBNO2 1.8488 2.0838 1.0220 1.7037 1.8082 2.0614 
SMAGP 1.8422 2.2770 0.5323 1.1490 1.9518 2.5281 
FABP5P7 1.8389 2.1081 0.4146 1.5685 2.1497 3.0625 
BCL6 1.8289 1.9699 0.7680 1.7616 1.8101 2.0422 
RP11-536K7.3 1.8284 1.9265 1.4583 1.9690 1.8901 2.0121 
NAV1 1.8102 1.6890 0.5132 1.1368 1.5464 1.8366 
FABP5 1.8095 1.9426 0.2337 1.4388 2.1759 2.9597 
HFE 1.8053 1.9245 0.7920 1.5381 1.9035 2.1625 
SIGLEC10 1.8041 2.1305 1.1844 1.1868 1.3174 1.5240 
CD163 1.8019 1.7679 0.6880 1.4793 1.7618 2.0583 
ALOX5 1.7985 1.9498 0.9009 1.5920 1.8721 2.2176 
ACPP 1.7957 1.7813 0.5465 1.0894 1.8638 2.6873 
PRDM8 1.7951 2.0048 0.4716 1.3875 1.7070 2.0605 
GPR146 1.7945 1.5614 0.0926 0.5657 1.5863 1.9103 
TLN2 1.7896 1.6150 0.7273 1.3518 1.4288 0.9491 
RP11-65J3.1 1.7824 1.9881 0.7483 1.4224 1.7133 2.1301 
ATP2B4 1.7809 1.7140 0.6416 1.3181 1.6672 1.7014 
ASPH 1.7766 1.8967 0.8132 1.5796 1.7633 2.1192 
LIMA1 1.7566 1.9930 0.9642 1.7607 2.0207 2.4618 
BHLHE41 1.7511 1.7263 -0.6484 1.0107 1.8692 2.5188 
SMCO4 1.7495 1.8069 0.8228 1.6437 1.9796 2.1980 
RHPN1 1.7494 1.9729 0.7709 1.6720 1.7107 1.9978 
S1PR1 1.7472 1.7116 1.0281 1.4600 1.7206 1.8857 
F13A1 1.7419 2.1406 1.2675 1.7796 1.8546 2.0254 
CDKN1A 1.7392 1.8491 1.0434 1.4516 1.6066 1.9259 
DHCR7 1.7265 2.0108 0.6241 1.5718 2.0557 2.7525 
CDH13 1.7259 1.7228 0.8830 1.8147 1.8834 2.1543 
GLT1D1 1.7147 2.3720 1.0266 1.9329 1.8094 2.3533 




ALDH1A2 1.7082 1.3099 0.6201 2.0522 2.0422 1.7282 
AC046143.7 1.7056 1.6456 0.4101 1.0669 1.7625 2.3296 
LIMK2 1.6906 2.1739 0.4662 1.4985 1.4046 1.8353 
TUBA1B 1.6903 1.9082 0.6247 1.4710 1.7995 2.2366 
FCGR2B 1.6850 1.6666 1.1294 1.5949 1.6130 1.8253 
PTPN1 1.6813 1.7118 0.5545 1.2767 1.5438 1.9415 
HLX 1.6801 1.6322 0.8794 1.3617 1.6675 1.8704 
RP11-351I24.3 1.6781 1.8726 0.3356 1.6521 1.8461 2.3904 
RASSF4 1.6773 1.9245 0.4867 1.3646 1.4809 2.0190 
BASP1 1.6680 1.6784 0.7563 1.3010 1.6667 1.9094 
RARRES1 1.6594 1.7743 1.4919 1.8715 1.7852 1.3935 
TMEM14A 1.6538 1.8481 1.7122 1.8926 2.0232 1.7584 
RP11-282O18.3 1.6530 1.7601 1.4799 1.7244 1.8813 1.9008 
NLGN2 1.6511 1.7232 0.8560 1.4453 1.6431 1.9361 
DNAJB4 1.6498 1.5786 0.5971 1.0636 1.5240 2.2066 
TNS3 1.6477 1.6883 1.0596 1.5041 1.6657 1.7457 
GUCY1B3 1.6471 1.0780 0.6527 0.9068 1.4080 1.8903 
SDC3 1.6409 1.6903 1.1160 1.7127 1.8380 1.9560 
RHOBTB3 1.6211 1.9201 0.7854 1.2359 1.7910 2.1637 
VSIG4 1.6198 1.8622 1.0628 1.6049 1.8215 2.0034 
RP11-63E5.6 1.6076 1.8109 0.6355 1.1657 1.6798 2.3144 
FLVCR2 1.6038 1.8000 0.8148 1.4810 1.5121 1.9379 
SGMS2 1.5979 2.3058 1.0857 1.3652 1.6812 2.3457 
CNTNAP1 1.5944 1.9498 0.4205 1.1633 1.1876 1.1958 
CHSY1 1.5875 1.9380 1.1366 1.5409 1.6920 2.0712 
TMEM26 1.5850 2.7114 0.7532 1.6583 1.6195 2.8252 
FKBP5 1.5834 1.7095 0.2727 1.0739 1.3384 2.0687 
TRIB1 1.5794 1.8397 0.9402 1.2391 1.6452 1.9895 
SNX9 1.5792 1.8285 0.6193 1.3522 1.6692 2.2936 
AK4 1.5790 1.0922 0.1848 0.6872 1.0932 1.9971 
RP11-24F11.2 1.5786 1.5976 0.7613 1.4408 1.4328 1.8373 
SLC2A3 1.5784 1.9302 1.3333 1.5386 1.6101 1.7560 
TSPAN33 1.5782 1.7384 0.7317 1.4667 1.5714 1.7754 
SPP1 1.5762 1.0064 -0.3860 0.4051 1.3270 1.8752 
CMTM4 1.5599 1.8597 0.6581 1.2268 1.4981 2.1066 
PTPRJ 1.5577 1.7352 0.4414 1.2585 1.5905 2.1769 
HK3 1.5388 1.9656 0.6159 1.2566 1.5520 1.8040 
CD55 1.5366 1.5286 0.9293 1.2162 1.5599 1.8526 
CTD-2587H19.1 1.5329 1.7717 0.7208 1.4988 1.7167 1.9336 
KLF6 1.5326 1.7623 0.8215 1.4777 1.5836 2.0213 
XBP1 1.5285 1.6575 0.6817 1.3300 1.3423 1.7865 
MTL5 1.5251 1.0490 1.1696 1.0571 1.2359 1.3714 




TLR8 1.5053 1.4668 0.6443 1.0769 1.3455 1.8045 
VMO1 1.5001 0.7461 1.1153 0.7603 1.1794 1.2469 
CTD-2369P2.2 1.4914 1.7530 0.4730 1.1932 1.3762 1.9368 
S100A12 1.4892 2.0803 1.0493 1.1055 0.9464 1.6468 
B3GNT7 1.4851 2.3849 1.4821 1.8677 1.7565 1.7065 
BCL3 1.4829 1.6853 1.2237 1.5461 1.6248 1.8018 
PIK3R6 1.4812 1.5951 0.6529 1.1418 1.3386 1.5054 
CDKN2D 1.4739 1.8775 1.0169 1.2180 1.5130 1.7876 
TLR1 1.4722 1.6270 0.6147 1.1690 1.4532 1.9232 
MAP3K6 1.4702 1.8637 1.1075 1.5804 1.5692 1.6442 
AC006129.1 1.4701 2.1006 1.6682 0.6966 1.9745 1.4295 
ABCA6 1.4632 0.9632 0.9271 1.6273 2.0182 1.9147 
PCED1B-AS1 1.4606 1.9251 0.7976 1.4395 1.9357 1.9944 
KANK2 1.4558 1.6470 0.6750 1.3948 1.5454 1.9144 
GGN 1.4540 2.4519 1.5118 1.7662 2.1487 2.4513 
SCD 1.4482 1.5518 0.5233 1.2567 1.5766 2.0805 
RALGPS2 1.4353 1.3749 0.5086 0.9894 1.2399 1.6313 
CFH 1.4339 1.1182 0.3748 1.2920 1.3288 1.5392 
DERL3 1.4337 1.6234 0.7376 1.6784 1.8848 1.9779 
MBOAT2 1.4337 1.7078 0.9054 1.5918 1.6693 1.8746 
PVRL2 1.4291 1.5864 0.9840 1.4170 1.5045 1.7864 
NRP1 1.4219 1.7963 0.8028 1.3522 1.5541 1.8253 
ID3 1.4206 1.4859 0.6699 1.1432 1.1571 1.2878 
LMNB1 1.4073 1.6647 0.5032 1.1193 1.2815 1.8941 
AC144831.1 1.4038 1.7877 1.0038 1.3180 1.3459 1.5476 
RP11-84C10.2 1.3971 1.5383 1.6649 1.4920 1.6206 1.9124 
TBC1D30 1.3958 1.7803 0.4952 1.4702 1.4841 1.9308 
NDUFV2P1 1.3869 0.9627 0.8990 1.0637 0.9711 1.1137 
POU2F2 1.3752 1.4039 0.6660 1.1139 1.3192 1.6336 
IRF2BPL 1.3685 1.4909 0.8284 1.1761 1.5405 1.5229 
HIST1H1C 1.3570 1.1526 0.7836 1.1343 1.4284 1.6114 
WWC3 1.3556 1.4471 0.8071 1.3004 1.4341 1.5725 
GCA 1.3504 1.4956 0.8895 1.2861 1.2737 1.5779 
LINC00115 1.3465 1.2402 1.4528 1.6144 1.6595 1.8522 
PIK3AP1 1.3448 1.4328 0.6350 1.1728 1.3108 1.7847 
AC004383.4 1.3446 1.5725 0.6742 1.3292 1.5102 1.8198 
PLEKHG2 1.3404 1.6499 0.5690 1.1572 1.4677 1.7488 
FZD2 1.3323 1.5077 0.8367 1.1986 1.3310 1.4481 
CNN2 1.3291 1.5923 0.5894 1.0981 1.3292 1.7510 
PDIA4 1.3289 1.4454 0.7269 1.3143 1.3347 1.6515 
DENND3 1.3276 1.6853 0.7676 1.2664 1.3241 1.5704 
ZDHHC20 1.3273 1.4563 0.6042 1.0366 1.2359 1.5179 




TSHZ3 1.3206 1.8097 0.7178 1.1989 1.3143 1.6285 
EBI3 1.3196 1.8948 0.0046 0.5545 0.6097 1.4282 
PLK2 1.3148 1.0428 0.5551 0.7679 1.0889 1.8975 
LRRC63 1.3145 1.4185 1.2807 1.6155 1.4493 1.3330 
PPARG 1.3140 1.7660 0.4834 1.4687 1.6106 2.1663 
IDI1 1.3117 1.5793 0.7587 1.2212 1.4182 2.0094 
CD163L1 1.3074 1.3589 0.5112 0.8043 0.8987 1.0105 
LENG9 1.3065 1.4506 0.1927 0.7120 1.4077 2.0814 
CD44 1.3050 1.3239 0.5718 1.1505 1.3260 1.7874 
ADAMTSL4 1.3048 1.4257 1.0127 1.2768 1.2989 1.2934 
GTDC1 1.3031 1.4637 0.4124 1.1063 1.4266 1.9122 
SLC22A23 1.3019 1.5909 0.2734 1.0466 1.4091 1.9491 
CYTH4 1.3014 1.6228 0.5233 0.9845 1.2261 1.6808 
GPR137B 1.2950 1.4747 0.6236 1.0684 1.3850 1.6853 
LRRC25 1.2949 1.5279 0.8206 1.0962 1.3044 1.6187 
FLOT1 1.2933 1.5276 0.8843 1.3011 1.3364 1.5389 
ANO8 1.2923 1.4237 0.6398 1.0388 1.2515 1.3660 
RHPN1-AS1 1.2900 1.1659 0.5902 1.5439 1.4774 1.5464 
FPGS 1.2827 1.5617 0.6078 1.2395 1.3037 1.6712 
HSD3B7 1.2802 1.6051 0.5534 1.1352 1.4483 1.4912 
PLEKHG6 1.2761 0.7459 0.1735 0.9832 1.2096 0.9933 
S1PR4 1.2739 1.4008 0.4857 0.9739 1.3042 1.3701 
RP11-295G20.2 1.2681 1.6030 1.1085 1.4974 1.3495 1.6025 
CTSL1 1.2640 1.6019 1.0881 1.3162 1.2705 1.2227 
RHOC 1.2610 1.5256 0.6012 1.1176 1.3754 1.7685 
ADAM9 1.2518 1.3278 0.6375 1.0703 1.3132 1.6316 
RP11-568N6.1 1.2492 1.0711 0.7894 1.0184 0.8702 1.1290 
C1orf228 1.2432 0.7208 -0.1530 1.0384 1.1794 1.5255 
CTC-1337H24.1 1.2395 0.3999 0.3219 1.3847 1.0297 1.2730 
PPP1R3B 1.2349 1.3387 0.6479 0.7753 1.0413 1.2198 
RASGRP2 1.2316 1.4793 0.5264 1.1117 1.3558 1.7296 
LILRP1 1.2302 1.1949 0.6283 0.9023 1.1895 1.1746 
STEAP3 1.2254 1.2843 0.4891 1.0422 0.9614 1.5710 
CD59 1.2251 1.4801 0.8972 1.1783 1.3366 1.5166 
CABP4 1.2244 1.2039 0.7177 1.7267 1.6533 1.5472 
BCL2L11 1.2233 0.9273 0.4318 0.8447 1.1425 0.9974 
LAIR1 1.2217 1.4090 0.6269 1.1004 1.2496 1.5331 
PSMC4 1.2183 1.3673 0.2970 0.9878 1.3739 1.9194 
HSPA7 1.2136 1.3784 0.8892 1.2432 1.2379 1.1452 
FCGR2C 1.2101 1.3641 0.8457 1.2519 1.1792 1.1313 
MTSS1 1.2093 1.4539 0.7814 1.1110 1.2504 1.3124 
METRNL 1.2088 1.6331 0.8637 1.0956 1.4395 1.6401 




Mar-01 1.2052 1.3249 0.6414 1.0671 1.1436 1.4498 
MTMR6 1.2045 1.3380 0.5616 0.9322 1.0144 1.4878 
CHCHD2P9 1.1984 1.4538 0.7644 1.2158 1.0214 1.5273 
TUBA1C 1.1964 1.4391 0.6077 1.0797 1.2486 1.6832 
GLTPD2 1.1956 1.1006 0.6420 0.7759 1.1513 1.4803 
HCK 1.1955 1.4509 0.6771 1.1026 1.2515 1.6318 
SEMA3A 1.1912 1.2971 -0.4924 0.1578 0.8831 1.3906 
BTBD19 1.1897 1.4789 0.7525 1.2768 1.0772 1.3200 
ABI1 1.1887 1.3277 0.5832 1.0012 1.2055 1.5802 
PTK2 1.1857 1.2992 0.7399 1.2246 1.3135 1.5091 
LYN 1.1848 1.5440 0.6314 1.1304 1.2250 1.8944 
GSDMA 1.1808 1.6845 1.4454 1.1328 1.4395 1.1961 
CCR2 1.1792 1.0257 0.5621 0.6132 1.0580 1.2262 
CARM1 1.1759 1.4888 0.7522 1.1795 1.2832 1.5409 
RTN2 1.1713 1.4359 0.5333 1.0162 1.5019 1.8289 
INPP4B 1.1639 1.2633 -0.2847 0.7741 1.3356 1.5902 
EIF4G3 1.1593 1.3857 0.6005 1.1592 1.2399 1.3894 
RNF149 1.1588 1.4220 0.5623 0.8475 0.9891 1.4125 
RNF217 1.1553 1.1836 0.9453 1.1154 1.1505 1.1876 
ARAP2 1.1522 1.5983 0.6000 1.1124 1.2154 2.0742 
UBE2J1 1.1502 1.3826 0.6098 1.1423 1.1479 1.6118 
IL4R 1.1442 1.4443 0.7000 1.1532 1.1935 1.4429 
ACTBP11 1.1431 1.3215 0.2645 0.8365 1.2358 1.8674 
TWF1 1.1370 1.4649 0.7121 1.2279 1.0879 1.5526 
HIF1A 1.1308 1.1083 0.5784 0.8494 0.9856 1.3314 
PDE1B 1.1298 1.2868 0.3237 0.9777 1.3819 2.0843 
LDHA 1.1245 1.3979 0.7136 1.1038 1.1296 1.5625 
Sep-06 1.1240 1.2591 0.3251 0.7010 1.0954 1.6555 
TMEM176A 1.1212 1.2520 0.8040 1.0790 1.1173 1.0965 
RFX2 1.1164 1.5428 0.6408 1.1522 1.2796 1.4401 
CTSC 1.1118 1.2114 0.5801 0.9627 1.1040 1.2758 
FAM213A 1.1106 1.1666 0.4475 1.1441 1.3812 1.7071 
ATP13A3 1.1067 1.2061 0.5676 0.9074 1.0838 1.7197 
CLTC 1.1048 1.3395 0.7080 1.0602 1.1950 1.4074 
MLLT1 1.1012 1.3357 0.4529 0.8680 1.1659 1.3979 
TUBB6 1.0994 1.3754 0.5568 1.0543 1.1698 1.6165 
MICAL2 1.0992 1.4719 0.6246 0.9824 1.2925 1.5879 
PNMA1 1.0979 1.4503 0.6597 1.1226 1.1813 1.3716 
RGAG4 1.0965 1.2060 0.7183 1.0454 1.1844 1.1880 
MIDN 1.0949 1.4126 0.7450 0.9525 1.1715 1.4137 
HDGFRP3 1.0947 1.4239 0.7526 0.9170 0.9881 2.2043 
BATF 1.0912 1.5053 0.8575 1.3647 1.2625 1.6314 




DDR1 1.0840 1.1502 0.7402 1.0095 1.3727 1.3170 
UHRF1BP1 1.0779 1.1983 0.5401 0.9195 1.0792 1.2600 
SLCO2B1 1.0762 1.3019 0.6201 0.9420 1.0649 1.1658 
SLC12A9 1.0695 1.3487 0.5890 0.9176 1.0810 1.2873 
PDCD1LG2 1.0690 0.9629 1.0372 1.1196 1.2286 1.4103 
ACTBP2 1.0660 1.5193 0.4063 0.8084 1.4429 1.7501 
CD14 1.0611 1.3351 0.7234 0.8624 1.0525 1.3292 
APIP 1.0601 1.1553 0.5976 1.0152 1.1142 1.4510 
SMPDL3A 1.0538 0.9254 0.3422 0.6609 0.8392 1.4090 
SREBF1 1.0512 1.3519 0.5379 1.0421 1.2188 1.5436 
PAG1 1.0501 1.3825 0.0734 0.7359 0.9257 1.3367 
STOM 1.0493 1.2118 0.5914 0.8958 0.9916 1.3050 
CIC 1.0485 1.1998 0.5393 0.9165 1.0615 1.2444 
EPB41L3 1.0458 1.3386 0.6092 1.0712 1.0776 1.4003 
ENPP4 1.0450 1.1754 0.4086 0.9665 1.0692 1.3720 
FCGR2A 1.0394 1.2464 0.9667 1.0854 1.1106 1.1722 
SLC31A1 1.0373 1.1040 0.5544 0.8952 0.9900 1.2473 
GIMAP6 1.0337 1.1389 0.7702 1.0481 1.2635 1.3654 
ORC6 1.0330 1.3804 0.4863 0.9017 1.2416 1.7591 
NFE2 1.0251 1.2039 -0.2271 0.7144 0.5244 0.6779 
ENG 1.0225 1.2148 0.4766 0.8371 1.0078 1.2064 
RP11-283G6.4 1.0212 1.3287 1.0596 1.3008 1.6174 1.1282 
DIRC3 1.0208 1.3019 0.7395 1.1555 1.4576 1.2025 
BTG2 1.0188 1.1278 0.8438 0.6761 1.2734 1.3507 
ECT2 1.0120 1.0595 0.6589 1.0693 0.9976 1.0416 
RALA 1.0110 1.0776 0.4703 0.6244 0.8327 1.4990 
CYP51P2 1.0022 0.5154 0.3325 0.4315 1.1618 0.9679 
RUNX1 1.0014 1.2734 0.5729 0.9070 1.0755 1.4353 
C3AR1 0.9989 1.0608 0.4487 0.7238 1.0090 1.2428 
PLK3 0.9986 1.4012 0.3947 0.8539 1.0038 1.4929 
MAPRE3 0.9977 1.1282 0.7765 0.9490 1.0442 1.1233 
FYB 0.9954 0.9387 0.5563 0.8736 0.8497 1.0797 
HNRNPKP4 0.9948 0.1413 0.0215 0.2039 0.7310 0.8898 
ATP11C 0.9905 1.2601 0.5333 0.9103 1.0877 1.3469 
CD47 0.9902 1.1538 0.5844 0.9684 1.0923 1.4781 
SEMA4B 0.9902 1.4220 0.6711 0.9246 0.8859 1.0557 
ACSL4 0.9897 1.1355 0.3522 0.8627 0.9980 1.7641 
TBC1D2B 0.9889 0.9252 0.4424 0.6336 0.9392 1.1170 
BCL9 0.9880 1.2977 0.4169 0.5137 0.4153 0.9691 
ABHD3 0.9848 1.2182 0.8147 1.1782 1.1650 1.2193 
CDK2AP1 0.9845 1.2977 0.5010 0.8156 1.2483 1.4426 
ADA 0.9834 1.0924 0.4350 0.7860 1.1096 1.5413 




SLC4A7 0.9797 1.1023 0.3437 0.6273 0.8558 1.1738 
CTSB 0.9781 1.1914 0.7167 1.0774 1.1277 1.1959 
EFHD2 0.9746 1.2847 0.5492 0.8890 1.1033 1.3686 
TM2D2 0.9731 1.0902 0.6169 0.8724 1.0641 1.3200 
VASP 0.9730 1.2927 0.5783 0.9074 1.0811 1.5535 
RNF145 0.9725 1.0794 0.5985 0.9943 1.0547 1.2483 
NUPL1 0.9690 0.9755 0.4200 0.7097 0.7667 1.0894 
LILRB3 0.9668 1.1863 0.7910 0.9676 0.9372 1.0780 
CTC-503J8.6 0.9646 1.2303 0.5880 0.9143 0.9949 1.2639 
PHLPP2 0.9635 0.7083 0.5184 0.6259 0.8218 1.0854 
ARHGAP26 0.9628 1.1229 0.6494 1.0170 0.9781 1.0599 
PIM2 0.9626 0.9350 0.6736 0.8202 0.9622 1.3604 
TP53INP2 0.9589 1.3056 0.6734 1.1608 1.1968 1.5185 
EHBP1L1 0.9579 1.2000 0.4593 0.8290 0.9751 1.1846 
CHD7 0.9574 1.5794 0.5784 1.0488 1.1774 1.6740 
DTNB 0.9567 1.2502 0.9723 1.0940 1.0690 0.8321 
TNFRSF10C 0.9563 1.2001 0.0918 0.9417 0.7538 1.4018 
HSPA6 0.9547 1.2166 1.0867 1.1831 1.0282 0.8763 
RNF141 0.9542 1.1833 0.6533 0.9421 1.1429 1.3835 
ELL2 0.9535 0.9478 0.3295 0.7989 0.9491 1.2977 
SPINT2 0.9492 1.1066 0.7397 0.8214 0.9542 0.9966 
ZNF319 0.9478 1.1253 0.7392 0.9849 1.0428 1.3265 
TMOD2 0.9475 0.8894 0.6842 0.8168 0.9011 0.9932 
KLF3 0.9447 1.1995 0.3831 0.8499 1.0235 1.5322 
NONOP2 0.9442 0.7959 0.8119 0.1782 0.4730 0.6167 
SIPA1L2 0.9413 1.2158 0.4973 0.7863 0.8906 0.9754 
SSH2 0.9366 1.0583 0.4669 0.8154 0.9871 1.1656 
RP11-1024P17.1 0.9363 1.4946 1.1537 1.2029 1.2955 1.6981 
GRIN2D 0.9362 1.0916 0.3944 0.8062 0.9843 1.1150 
MBOAT7 0.9334 0.9918 0.5567 0.6697 0.8704 1.0050 
LRMP 0.9290 1.1123 0.4678 0.7150 0.9520 1.1170 
FURIN 0.9285 1.1365 0.5098 0.6931 0.8504 1.1030 
USB1 0.9271 1.1621 0.6834 0.9124 1.0331 1.2143 
RHOU 0.9268 1.2415 0.7058 0.9057 0.9492 1.1711 
FAM49B 0.9264 1.3064 0.4470 0.8436 1.1247 1.6918 
TRIM8 0.9225 1.0950 0.5030 0.7678 0.9773 1.1598 
ARL3 0.9217 1.1581 0.4822 0.7828 0.9741 1.1907 
EPS8 0.9195 1.0970 0.5459 0.9574 1.2256 1.4061 
CBX6 0.9126 1.0839 0.6108 0.7726 0.9111 1.0302 
VMP1 0.9106 0.9682 1.0399 1.1182 0.9552 0.8723 
PTPRC 0.9103 0.9458 0.4535 0.7473 0.8513 1.1464 
SLC39A1 0.9075 1.0887 0.5727 0.8264 0.9313 1.1913 




ZFP36 0.9058 1.0714 1.1215 0.8478 1.0984 1.2335 
SLC6A8 0.9032 1.1531 0.5963 0.8543 1.1810 1.2892 
CEP85L 0.9016 0.7631 0.5304 0.5903 0.9176 0.8008 
RP11-497H16.4 0.9012 1.5704 1.3283 1.1434 1.0418 0.6729 
SRGAP2C 0.9004 0.8320 0.2959 0.4894 0.7619 1.2266 
DEF6 0.8995 1.1880 0.4094 0.8225 1.0849 1.3564 
TSC22D3 0.8961 1.1817 0.7799 0.7856 0.9482 1.1096 
C1QC 0.8958 1.1739 0.7420 0.9609 1.0078 1.1182 
TBC1D14 0.8949 0.9586 0.5204 0.7457 0.8450 0.8813 
CSK 0.8921 1.1273 0.3896 0.7184 0.9519 1.3190 
PYGL 0.8883 1.1842 0.4580 0.7392 0.8186 1.1407 
MVP 0.8882 1.1580 0.7713 0.9605 0.9750 1.1726 
KCNMB4 0.8880 0.9849 0.8203 0.7704 0.8425 0.9035 
NUF2 0.8794 1.1171 0.5148 0.2177 0.4586 0.2100 
RP13-383K5.4 0.8791 1.1870 0.4030 1.2910 0.9766 1.1813 
TNFRSF1A 0.8790 1.0937 0.6512 0.8468 0.9505 1.0751 
ACSS2 0.8758 1.0140 0.5210 0.8465 0.9292 1.1222 
YBX3 0.8735 1.0587 0.5890 0.7589 0.9251 1.0877 
PLEK 0.8731 1.0048 0.4302 0.8118 0.8446 1.1577 
DUSP1 0.8729 0.8539 0.7585 0.5643 1.0991 1.1493 
MGME1 0.8728 1.1183 0.7701 1.0175 1.0193 1.0771 
NLRC4 0.8727 1.0705 0.2228 0.6942 0.8922 1.3648 
TPTEP1 0.8659 1.0241 0.6358 0.8010 0.9906 1.4195 
ARHGAP32 0.8642 1.0641 0.5045 0.7855 1.2615 1.0588 
SMAD1 0.8623 0.7777 0.3681 0.2088 0.5698 0.9351 
TPM4 0.8607 1.2426 0.4407 0.8556 0.9995 1.5295 
SLC4A8 0.8581 1.3016 0.5539 0.6626 0.8640 1.1054 
ATP6V0A1 0.8574 0.9660 0.4420 0.6657 0.8226 1.0291 
CALR 0.8572 0.9695 0.6170 0.9483 0.8555 1.0737 
VAV1 0.8572 1.0130 0.4735 0.8431 0.9774 1.2757 
LRRC8B 0.8564 1.0698 0.4570 0.8020 1.0427 1.2356 
PIGX 0.8561 1.1506 0.6036 0.8945 1.0281 1.3657 
SLC39A8 0.8519 1.0980 0.8198 1.4630 1.0407 1.4582 
CSGALNACT1 0.8514 0.6438 0.1143 0.9641 0.9125 0.4804 
SNX5 0.8483 1.0624 0.6533 0.8237 0.9757 1.0556 
HSPA5 0.8480 0.8859 0.5802 0.9585 0.7556 1.0538 
LY96 0.8465 1.0466 0.7240 0.9409 0.8687 0.9556 
ACTB 0.8464 1.2790 0.4565 0.8308 1.0001 1.4861 
CCR1 0.8450 1.0762 0.6896 0.8392 0.8894 1.1462 
EAF2 0.8442 1.0305 0.6710 0.8012 0.9216 1.0695 
GTF3C6 0.8406 1.2187 0.6164 0.9879 0.9614 1.1733 
GOLGA6L5 0.8372 1.3047 0.7777 1.0507 0.7899 0.6586 




C2 0.8365 1.1286 0.9065 1.0833 1.0169 1.0808 
CASP4 0.8315 0.7758 0.6365 0.7266 0.7765 1.0045 
JUNB 0.8310 1.0625 1.0962 0.8838 1.0964 1.0434 
MVD 0.8295 1.1618 0.5774 0.9326 0.9761 1.4544 
STXBP5 0.8290 0.8819 0.3612 0.5810 0.6838 1.0110 
TCEB1P2 0.8265 1.1411 0.9843 0.5710 0.5945 0.8578 
STAMBPL1 0.8263 1.3619 0.7521 1.0781 0.9483 1.8757 
ACSL1 0.8259 1.1011 0.6022 0.9968 0.8952 1.4053 
NEDD4 0.8258 0.9721 0.7532 0.7602 1.0726 0.8758 
USP32 0.8253 0.9875 0.4820 0.7542 0.7722 0.9156 
AC026806.2 0.8197 1.0746 0.7682 0.8994 1.0216 1.1140 
RBMS1 0.8188 1.1547 0.5890 0.8662 0.8876 1.0589 
FRMD4B 0.8146 1.3153 0.5845 0.7953 0.8535 1.2201 
APEX2 0.8132 0.9325 0.3870 0.7537 0.7418 0.9581 
MERTK 0.8085 1.4853 0.2769 0.7172 0.7417 1.4743 
DISC1 0.8083 0.9567 0.4735 0.6928 0.8647 0.9475 
SLC39A13 0.8066 1.1337 0.2719 0.7517 0.9864 1.3754 
RP5-1125A11.1 0.8054 0.5514 1.0448 0.5630 0.8210 0.7339 
SEL1L3 0.8038 0.1680 0.3092 0.4900 0.7809 0.6739 
TUBA4A 0.8003 1.1328 0.6775 0.8917 0.9023 0.9716 
STAT3 0.7992 0.9304 0.6914 0.7904 0.8172 0.9310 
RIMKLB 0.7975 1.0933 0.7034 0.9936 0.8800 1.0028 
AQP9 0.7971 0.4875 -0.0457 0.5576 0.7253 0.5698 
PAK1 0.7967 0.8644 0.4080 0.6155 0.8469 1.1371 
MAD2L2 0.7960 1.1164 0.6300 0.9243 0.9270 1.1203 
DNAJC25 0.7954 1.1318 0.6831 1.0252 0.8064 0.9020 
AGFG1 0.7932 1.2151 0.5014 0.8434 0.9057 1.3775 
LCP1 0.7931 0.9540 0.4030 0.7465 0.9489 1.2283 
SGTB 0.7924 1.0889 0.6595 0.9236 0.7818 0.8617 
FOXRED2 0.7917 0.9878 0.5910 0.7292 0.8874 0.8254 
MIR22HG 0.7871 1.3709 0.7218 1.0660 0.8610 1.2036 
TRAM2 0.7782 1.0098 0.8190 0.7875 0.9123 0.9037 
SERPINB1 0.7773 1.0299 0.6169 0.7155 0.7552 0.8995 
CREM 0.7744 0.6244 0.7174 0.6274 0.8239 0.7074 
RAB42 0.7738 1.1592 0.6062 0.9362 0.9000 0.8463 
NBEAL2 0.7738 1.0357 0.4176 0.8352 0.8764 0.9376 
NABP1 0.7726 0.8298 0.4091 0.6325 0.7499 1.0140 
GNA15 0.7724 1.0591 0.5892 0.7928 0.8242 1.0298 
AC109826.1 0.7722 0.9182 0.6522 1.0681 0.7376 0.6405 
PREX1 0.7712 1.0836 0.4592 0.6681 0.7785 1.0020 
ARPC3P1 0.7708 0.5268 0.4405 0.9057 0.7529 0.6964 
ZHX2 0.7694 0.9070 0.5789 0.8881 0.9275 1.1955 




MLXIP 0.7664 0.9319 0.3283 0.6359 0.7899 0.9744 
RP11-497H16.6 0.7646 1.1684 0.7965 0.9038 0.6706 0.3681 
CCDC149 0.7622 1.1750 0.7417 0.9209 0.8645 1.0162 
DPP4 0.7610 -0.0707 1.2136 0.4002 0.7370 0.8126 
ARHGAP33 0.7608 1.1063 0.7175 0.8372 0.7641 0.8485 
VPS9D1 0.7591 1.2610 0.5309 0.8342 0.7424 1.1340 
JAZF1 0.7582 0.8679 0.5564 0.8215 0.8326 0.9855 
KLF16 0.7560 1.0970 0.4425 0.7000 0.9118 1.1405 
PAFAH1B3 0.7553 0.9379 0.5312 0.7491 0.7666 0.8374 
ITPR2 0.7546 0.9154 0.5776 0.7703 0.7907 0.9212 
TUBB 0.7512 1.0557 0.3432 0.7014 0.8398 1.1135 
GNB2 0.7500 1.0750 0.5226 0.6987 0.8529 1.1841 
RBPJ 0.7489 1.1029 0.5410 0.9065 0.8980 1.2011 
C17orf62 0.7489 0.9762 0.4196 0.7575 0.7822 0.8576 
ZNF503 0.7462 1.0728 0.2297 0.4742 1.0149 1.3701 
NACC2 0.7444 0.9627 0.4221 0.6122 0.7925 0.9734 
TPM1 0.7422 1.0091 0.5648 0.7339 0.8547 0.9566 
MS4A7 0.7417 0.8131 0.4778 0.6499 0.6918 0.9195 
CCDC24 0.7414 1.0357 0.7281 0.7537 0.9838 0.9064 
CTD-2382E5.3 0.7409 1.1599 0.7311 0.9102 0.8180 0.8641 
SVIL 0.7400 0.5804 0.2231 0.5299 0.7234 1.2610 
AGO4 0.7367 0.9272 0.5673 0.7596 0.7520 0.8521 
RP11-361D15.2 0.7363 1.2962 1.5652 1.0741 -0.2959 0.4448 
BACH1 0.7361 0.9138 0.4850 0.7325 0.7210 1.2043 
RP11-46D6.1 0.7346 0.6172 0.3833 0.4304 0.7614 0.7750 
ARNTL 0.7326 0.8895 0.4605 0.7283 0.8472 1.0031 
R3HDM4 0.7325 1.0648 0.4846 0.7188 0.9033 1.2146 
AC147651.4 0.7319 0.8734 -0.0784 0.4029 0.5821 0.9931 
NAGS 0.7298 1.1880 0.4040 0.6220 0.8655 1.2735 
OPLAH 0.7289 0.9267 0.3284 0.7039 0.9402 1.1010 
KIAA1841 0.7286 0.8904 0.4159 0.8240 0.7556 1.0563 
GOLPH3 0.7273 0.8120 0.5008 0.6749 0.7689 1.1290 
TSPYL5 0.7273 0.5905 0.7543 0.8796 0.8175 0.9604 
YTHDF1 0.7259 0.9424 0.3428 0.5750 0.6853 1.0515 
FCHSD2 0.7251 0.9235 0.5289 0.7927 0.8485 0.8964 
RP11-848G14.5 0.7234 1.0551 0.7132 0.8811 0.7394 0.5330 
PTGR1 0.7231 0.8897 0.3527 0.4071 0.7893 0.7767 
UCP2 0.7226 1.1092 0.5080 0.7836 0.9091 1.0840 
PLIN3 0.7216 0.9137 0.5106 0.6445 0.7615 1.0217 
HDAC4 0.7201 1.0946 0.6573 0.7875 0.7953 1.1136 
CPEB4 0.7180 0.8734 0.4911 0.7607 0.7019 0.8029 
NDST2 0.7170 0.9531 0.4281 0.6705 0.6181 0.8904 




SAMSN1 0.7155 0.8594 0.5171 0.6889 0.7217 1.0935 
YIPF1 0.7138 0.9331 0.5504 0.7626 0.7980 0.9864 
NMRK1 0.7118 0.8213 0.5209 0.6945 0.7156 0.7306 
GPR141 0.7109 0.6458 0.4868 0.6525 0.8715 0.5262 
EMILIN2 0.7093 1.0131 0.3439 0.5138 0.8046 1.1221 
HIPK2 0.7076 0.8794 0.5077 0.6802 0.8592 0.9179 
SSBP2 0.7056 0.7228 0.5656 0.5802 0.8604 0.7726 
PXN 0.7044 0.9293 0.6437 0.7137 0.6992 0.6593 
YPEL2 0.7028 0.7867 0.2834 0.4850 0.7479 0.8034 
DUSP3 0.7007 0.9841 0.8727 0.7586 0.7151 0.7432 
PTPN6 0.7001 0.9143 0.3538 0.5147 0.6961 1.0802 
DPH3 0.6991 1.0174 0.6051 0.9071 0.8162 1.1363 
SORT1 0.6990 0.7827 0.1460 0.3596 0.6659 0.8475 
FBXO4 0.6977 0.9635 0.6315 0.6765 0.8347 1.0756 
KCNK6 0.6973 0.8445 0.5381 0.6301 0.7984 0.9310 
SMAD7 0.6956 0.8992 0.6544 0.6978 0.7347 0.9962 
TMSB4XP4 0.6951 0.9904 0.5749 0.7104 0.8488 0.8398 
OTUD1 0.6951 0.6693 0.5809 0.4185 0.8293 0.8858 
CBFA2T3 0.6923 0.8169 0.4992 0.6573 0.8116 0.7920 
TMBIM1 0.6917 0.8244 0.4305 0.6099 0.7071 0.8038 
MILR1 0.6905 0.9586 0.5497 0.8290 0.8861 0.9352 
CXCL1 0.6897 0.2470 0.2820 0.1372 0.6022 0.7050 
RERE 0.6871 0.8040 0.5124 0.6416 0.6812 0.7478 
PLD2 0.6867 0.7493 0.3849 0.5923 0.6492 0.8021 
TMCO3 0.6867 0.7907 0.4184 0.5430 0.6769 0.8630 
IER3 0.6856 0.7496 0.7504 0.5953 0.8868 0.6093 
NBEAL1 0.6829 0.5407 0.5654 0.7972 0.9338 0.6697 
NDN 0.6807 1.1104 0.7751 0.5574 1.0341 0.9889 
ZSWIM1 0.6777 1.1300 0.3387 0.7046 0.9396 1.1182 
CSF1R 0.6774 0.6877 0.4496 0.4765 0.6522 0.7491 
CTC-774J1.2 0.6767 0.6754 0.5727 0.8558 0.9414 0.9099 
PRSS36 0.6743 0.9617 0.5468 0.7620 0.8330 0.6475 
MAFB 0.6735 0.9054 0.3905 0.4351 0.7050 0.8624 
PNPLA6 0.6726 0.8693 0.4274 0.6813 0.8004 1.0135 
ATG3 0.6726 0.8045 0.6332 0.7615 0.6106 0.8674 
SNHG15 0.6722 0.9122 0.9958 0.8348 0.8074 0.9766 
ACACA 0.6715 0.8867 0.3472 0.5867 0.9071 1.2644 
LPCAT3 0.6711 0.9134 0.3573 0.6380 0.7763 1.0620 
MANF 0.6710 0.7302 0.5717 0.8491 0.5099 0.7842 
LEPR 0.6666 0.9245 0.6839 0.6440 0.6275 0.5833 
GOSR2 0.6666 1.1023 0.4312 0.6451 0.7052 1.0234 
CLIC1 0.6656 1.0044 0.4666 0.6756 0.7581 1.1301 




RELT 0.6632 1.0289 0.5185 0.7621 0.8355 0.9859 
CDK9 0.6631 0.9179 0.3784 0.6271 0.7237 0.8670 
MCM5 0.6608 0.8070 0.3782 0.5648 0.7239 0.8422 
CTD-2085J24.4 0.6592 0.6958 0.5479 0.7682 0.4495 0.6172 
TMEM70 0.6583 1.0360 0.5283 0.6101 0.7515 1.0175 
TSPAN14 0.6580 0.8836 0.3885 0.5444 0.6575 0.8369 
SELT 0.6564 0.8771 0.4199 0.6724 0.6978 1.0913 
BMP2K 0.6561 1.1138 0.3583 0.6075 0.7851 1.1383 
ME1 0.6527 0.6900 0.8162 0.9191 0.7775 0.8455 
HPS5 0.6491 0.7443 0.6108 0.6940 0.6497 0.6207 
RP11-797A18.3 0.6477 0.5895 0.8732 1.3247 0.6980 0.3118 
PPARD 0.6473 0.9028 0.6298 0.7614 0.7424 0.7852 
RANBP9 0.6466 0.7111 0.4284 0.5544 0.6246 0.9312 
MYO1C 0.6464 0.9951 0.6939 0.6802 0.6943 0.8787 
CNEP1R1 0.6458 0.8708 0.4812 0.6872 0.6449 0.8747 
POLE4 0.6447 1.0276 0.2984 0.6919 0.7172 1.1069 
TMEM88 0.6443 0.7781 1.4797 1.4190 0.8150 1.0678 
C3orf14 0.6417 0.7539 0.4322 0.5116 0.7166 0.7657 
POU6F1 0.6395 0.8684 0.8003 0.7798 0.8271 0.7893 
CEBPB 0.6395 1.0109 0.6231 0.6036 0.8334 0.9510 
TDRKH 0.6374 0.8748 0.4267 0.6930 0.7876 1.0285 
SFT2D2 0.6373 0.7238 0.1946 0.4944 0.6587 0.9689 
ATN1 0.6367 0.6916 0.4962 0.5385 0.6937 0.7344 
FAM89B 0.6367 1.1067 0.5286 0.8244 0.8092 1.0341 
CAB39 0.6361 0.9258 0.3979 0.5494 0.7530 1.0450 
RRBP1 0.6357 0.8900 0.3930 0.6250 0.6703 0.9610 
TNIP2 0.6339 0.8936 0.4570 0.7309 0.7926 1.0417 
TLN1 0.6334 0.8467 0.3745 0.5205 0.6607 0.8291 
HSPA1B 0.6326 0.8898 0.4930 0.8626 0.7751 0.7854 
RAP1B 0.6314 0.8561 0.3748 0.6062 0.7746 1.2048 
TGFBR2 0.6312 0.8053 0.3228 0.3927 0.5950 1.0231 
PCK2 0.6293 0.9295 0.5046 0.6298 0.6251 0.8136 
NRBP2 0.6283 1.0634 0.4106 0.5922 0.7068 0.7462 
CRK 0.6279 0.8950 0.4389 0.6795 0.7033 1.0758 
TRPV2 0.6279 0.8224 0.3476 0.6236 0.7457 1.0395 
RBM47 0.6271 0.9976 0.5939 0.6976 0.7548 0.9430 
ABL2 0.6269 0.7888 0.4200 0.6489 0.6523 0.8176 
SH2D3C 0.6260 0.8684 0.5555 0.5899 0.6556 0.6952 
MPZL1 0.6258 0.8019 0.4347 0.6213 0.7123 0.8997 
NASP 0.6245 0.8564 0.4645 0.7064 0.6133 0.8405 
PRKCB 0.6237 0.8077 0.3255 0.5264 0.8112 1.2318 
CTB-175E5.7 0.6235 0.8783 0.4937 0.3524 0.3269 0.3922 




KIAA0895L 0.6204 0.8033 0.3601 0.7267 0.6223 0.6500 
PFN1P1 0.6204 0.8764 0.3760 0.7693 0.6205 0.8337 
CRADD 0.6198 0.9376 0.4307 0.7439 0.7027 0.7015 
TPM3 0.6181 0.9776 0.4536 0.6865 0.6897 1.0459 
MED16 0.6180 0.8443 0.4800 0.5347 0.7406 1.0608 
PLK4 0.6173 0.3940 0.2828 0.3432 0.5850 0.6306 
PDLIM5 0.6169 0.8768 0.3691 0.6881 0.8044 1.1041 
XRN2 0.6165 0.7187 0.4376 0.5066 0.6016 0.7967 
STOML1 0.6164 0.9075 0.2848 0.5561 0.8277 1.0123 
GPR107 0.6157 0.7278 0.2915 0.4339 0.6554 0.8837 
MYL6 0.6144 0.9583 0.4355 0.6384 0.7334 1.1326 
STK3 0.6133 0.7642 0.4736 0.6225 0.7121 0.8809 
TNFAIP8 0.6130 0.6930 0.5088 0.6895 0.6728 0.8118 
WDR11 0.6124 0.7608 0.2273 0.4586 0.6189 1.0502 
H3F3A 0.6117 0.7975 0.4563 0.5627 0.6388 0.8119 
SMURF2P1 0.6116 1.1496 0.6951 0.7647 1.0065 1.0467 
AIF1 0.6115 0.9148 0.5495 0.6512 0.6422 0.9111 
ATP13A2 0.6094 1.0679 0.5676 0.8515 0.8694 0.9174 
FKBP15 0.6083 0.7879 0.4085 0.5752 0.5996 0.6898 
HYAL2 0.6075 0.8347 0.5713 0.5978 0.7249 0.9933 
MESDC1 0.6074 1.0772 0.5192 0.6271 0.8628 1.1617 
C1orf54 0.6009 0.8420 0.4171 0.6566 0.6220 0.7241 
DDX31 -0.6001 0.1140 -0.0912 -0.2799 -0.4367 -0.1189 
RRP1 -0.6003 -0.1461 -0.0577 -0.3053 -0.3912 -0.2778 
61E3.4 -0.6015 -0.2218 0.0870 -0.0999 -0.3106 -0.5721 
PPOX -0.6021 -0.3129 0.0079 -0.4014 -0.5188 -0.6434 
DCAF17 -0.6023 -0.1601 0.1049 -0.1405 -0.3327 -0.3965 
CASP10 -0.6028 -0.5259 0.1146 -0.5006 -0.4954 -0.6982 
RPP21 -0.6032 -0.4382 0.0195 -0.5152 -0.4797 -0.4739 
RP1-39G22.7 -0.6058 -0.1792 0.1417 -0.2985 -0.6650 -0.3401 
SLC2A11 -0.6061 -0.5179 0.1859 0.0474 -0.3809 -0.6944 
QTRT1 -0.6070 -0.2218 0.1069 -0.3030 -0.3327 -0.3458 
TMEM194A -0.6074 -0.4646 0.0482 -0.3624 -0.4343 -0.8117 
ZSCAN5A -0.6075 -0.2729 0.0419 -0.2470 -0.2442 -0.7882 
GPR132 -0.6082 -0.2156 0.2219 -0.2957 -0.4532 -0.6409 
JMY -0.6086 -0.3782 0.2210 -0.4891 -0.5154 -1.0467 
ITGA6 -0.6095 -0.3620 -0.0997 -0.2417 -0.4254 -0.5412 
RP11-288I21.1 -0.6100 -0.5370 -0.2040 0.1548 -0.6416 -0.9172 
CLUH -0.6101 -0.2515 -0.0402 -0.4229 -0.4048 -0.3083 
NIPAL3 -0.6102 -0.5910 0.1063 -0.4156 -0.3427 -0.8723 
ING5 -0.6115 -0.2782 0.0806 -0.4408 -0.3484 -0.3969 
WDR75 -0.6117 -0.2522 0.0569 -0.3877 -0.4722 -0.4819 




MFNG -0.6134 -0.2338 0.0098 -0.3977 -0.4994 -0.3905 
TIMM9 -0.6144 -0.3006 0.0690 -0.3409 -0.3912 -0.3613 
HIGD2A -0.6144 -0.1966 0.1276 -0.1930 -0.4282 -0.4735 
RPP25L -0.6146 -0.3294 0.0602 -0.3304 -0.3578 -0.4459 
PLEKHG4 -0.6151 -0.6302 -0.3748 -0.1844 -0.3760 -0.7164 
PKD1P1 -0.6153 -1.2004 -0.0723 -0.1373 -0.9791 -0.4207 
HMBS -0.6161 -0.1594 0.0229 -0.1821 -0.6162 -0.3131 
MAN2A2 -0.6163 -0.3292 -0.1268 -0.4227 -0.5355 -0.5872 
DDX11 -0.6170 -0.5463 0.0432 -0.4719 -0.6409 -0.7371 
RP11-640M9.2 -0.6178 -0.4635 0.0851 -0.3293 -0.4750 -0.6314 
RP11-420L9.5 -0.6180 0.1818 0.3489 -0.1134 -0.2183 -0.1901 
TTC3 -0.6181 -0.5035 -0.0403 -0.3886 -0.5279 -0.6490 
SLC25A6 -0.6187 -0.3884 0.0710 -0.4959 -0.4748 -0.5741 
TOMM40 -0.6193 -0.1181 0.0573 -0.3097 -0.3203 -0.1605 
TMPO -0.6196 -0.5001 0.0150 -0.4287 -0.4653 -0.7533 
SLC25A5 -0.6199 -0.2291 -0.0140 -0.4053 -0.4555 -0.3797 
CENPK -0.6202 -0.0070 0.1859 -0.6049 -1.1941 -0.9339 
RRP9 -0.6205 0.0277 -0.1236 -0.2196 -0.2596 -0.1921 
CTB-118N6.3 -0.6211 -0.4991 -0.2323 -0.5901 -0.2299 -0.9403 
WDR89 -0.6219 -0.1472 0.2099 -0.2013 -0.5065 -0.3259 
RNF122 -0.6221 -0.7279 -0.3410 -0.5859 -0.4209 -0.0201 
PTTG1 -0.6222 -0.2622 0.3531 -0.0019 -0.1705 -0.2164 
PPP1R3E -0.6237 -0.3865 0.2611 -0.2936 -0.5082 -0.7813 
MOSPD1 -0.6242 -0.6993 0.2532 -0.3407 -0.6591 -0.8313 
ARHGAP11B -0.6247 -0.0122 0.3643 -0.0787 -0.6869 -0.6688 
KIF11 -0.6248 -0.6705 0.2443 -0.2451 -0.7295 -1.1471 
TRERF1 -0.6250 -0.5334 0.0261 -0.4774 -0.6513 -0.9495 
LENG8-AS1 -0.6253 -0.4834 0.3974 -0.2114 -0.3748 -0.4247 
SKP2 -0.6261 -0.3969 -0.0893 -0.3167 -0.4944 -0.7570 
TAF6L -0.6264 -0.1281 -0.0434 -0.3792 -0.2140 -0.3227 
PTRHD1 -0.6264 -0.5273 0.1608 -0.4021 -0.6166 -0.7428 
SRPRB -0.6270 -0.2751 0.0338 -0.1846 -0.3955 -0.3084 
ZNF649 -0.6273 -0.0625 -0.0425 -0.0806 -0.2072 -0.2749 
RP5-1115A15.1 -0.6284 -0.0885 0.7494 0.0634 0.0289 -0.4700 
SLFN12 -0.6295 -0.4526 0.0110 -0.2803 -0.3720 -0.5694 
POLR3E -0.6296 -0.0648 -0.0866 -0.4477 -0.4189 -0.2520 
NOP14-AS1 -0.6297 -0.2368 -0.2095 -0.5082 -0.8867 -0.5915 
CTC-788C1.1 -0.6303 -0.2918 0.3630 0.1169 -0.6280 -0.5530 
TSPYL1 -0.6304 -0.6086 -0.0258 -0.5472 -0.4632 -0.6699 
EVC -0.6307 -0.6453 -0.2418 -0.5837 -0.7638 -1.0251 
GK5 -0.6316 -0.4345 -0.2958 -0.5238 -0.4131 -0.6066 
L3HYPDH -0.6347 -0.2195 0.0045 -0.1514 -0.2852 -0.5218 




KIF22 -0.6369 -0.3562 -0.0012 -0.4084 -0.5863 -0.6350 
INO80B -0.6377 -0.5374 0.0150 -0.4885 -0.5994 -0.6993 
MRPL2 -0.6379 -0.3042 0.1122 -0.2930 -0.4010 -0.4354 
WDR85 -0.6384 -0.3955 -0.0446 -0.3534 -0.6191 -0.8442 
RMND1 -0.6390 -0.3130 0.0087 -0.4285 -0.3973 -0.3008 
FASTKD1 -0.6392 -0.3653 -0.0887 -0.4426 -0.6682 -0.8421 
CSRP2BP -0.6395 -0.2557 0.0436 -0.2319 -0.4281 -0.3309 
NBPF1 -0.6397 -0.4729 -0.0842 -0.5121 -0.5053 -0.6771 
CCDC86 -0.6404 -0.0714 -0.0307 -0.2990 -0.5168 -0.1558 
NOC3L -0.6418 -0.2329 -0.0659 -0.3799 -0.4665 -0.1989 
ABHD10 -0.6429 -0.4012 0.0427 -0.3949 -0.5028 -0.5568 
TRIB3 -0.6431 0.1085 0.0180 0.1116 -0.2909 -0.1785 
RP11-267J23.4 -0.6433 -0.1871 0.0240 -0.2749 -0.5057 -0.2021 
DLEU1 -0.6435 -0.3619 -0.0899 -0.7916 -0.2188 -0.4252 
S100A13 -0.6446 -0.3786 0.1440 -0.4943 -0.6292 -0.9981 
FAM35A -0.6452 -0.1622 0.1846 -0.3210 -0.3534 -0.4848 
RP11-464F9.1 -0.6454 -0.1549 -0.1397 -0.5938 -0.6307 -0.6943 
PAICS -0.6458 -0.1775 0.0582 -0.2990 -0.3567 -0.1085 
CREB3L2 -0.6465 -0.4483 0.0286 -0.4754 -0.6049 -0.8834 
MBP -0.6470 -0.5072 -0.0931 -0.6302 -0.5886 -0.8459 
CTD-2284J15.1 -0.6472 -0.7665 0.2710 -0.2961 -0.6679 -0.6175 
FTSJ2 -0.6476 -0.2453 0.0553 -0.4281 -0.4907 -0.5430 
FAM86FP -0.6479 -0.7101 0.0338 -0.8242 -0.8282 -0.3370 
NME7 -0.6492 -0.0557 0.2324 -0.4164 -0.6449 -0.5519 
CLEC2D -0.6492 -0.6214 0.1745 -0.2496 -0.4652 -0.9806 
TNK2 -0.6493 -0.3820 0.0096 -0.3917 -0.4844 -0.7796 
MRPL40 -0.6493 -0.1822 0.1100 -0.2310 -0.3648 -0.3336 
RP11-169K16.9 -0.6497 -0.2994 0.3703 -0.1104 -0.3145 -0.5258 
AP4B1 -0.6517 -0.3254 0.2048 -0.1548 -0.3861 -0.5568 
RP11-304L19.11 -0.6523 0.1071 0.7646 0.4209 -0.0528 -0.1406 
ZNF605 -0.6525 -0.3348 0.1743 -0.0656 -0.4235 -0.5056 
CHCHD4 -0.6526 -0.3751 0.0168 -0.3161 -0.2646 -0.4024 
NAP1L1 -0.6534 -0.5648 0.0831 -0.4987 -0.5449 -0.6465 
AC027763.2 -0.6543 -0.0862 0.3052 -0.2333 -0.1750 -0.3133 
THNSL2 -0.6545 -0.6578 0.2769 -0.2856 -0.3388 -0.6454 
HDHD3 -0.6546 -0.4428 0.2195 -0.1449 -0.4241 -0.7907 
HDDC3 -0.6551 -0.2523 0.0671 -0.5103 -0.3499 -0.5471 
DGKD -0.6569 -0.1608 0.1338 -0.2449 -0.3944 -0.3696 
ZNF169 -0.6572 -0.0918 0.1190 -0.2062 -0.3191 -0.3721 
ZNF124 -0.6572 -0.2171 -0.0329 -0.3358 -0.1328 -0.2569 
GGCT -0.6573 -0.2103 0.0459 -0.3434 -0.4690 -0.4364 
NFKBIE -0.6575 -0.4030 -0.0450 -0.2434 -0.3369 -0.3849 




FARSB -0.6577 -0.0621 0.1017 -0.0549 -0.1603 0.0360 
RSL1D1 -0.6581 -0.4116 0.0469 -0.4384 -0.4991 -0.5094 
CD3EAP -0.6589 -0.2832 0.0984 -0.2169 -0.1724 -0.1684 
TMEM38A -0.6596 -0.1196 -0.0114 -0.4892 -0.7514 -0.7595 
HMGN3 -0.6611 -0.3098 0.1614 -0.3015 -0.5234 -0.5619 
ERCC6 -0.6612 -0.5985 -0.0416 -0.5253 -0.7089 -1.0858 
APEX1 -0.6613 -0.3136 -0.0525 -0.4834 -0.5646 -0.4863 
TXLNG -0.6624 -0.1852 0.0804 -0.2872 -0.3057 -0.3362 
Sep-09 -0.6626 -0.3056 -0.0243 -0.5332 -0.6365 -0.6216 
EBAG9 -0.6633 -0.4825 0.2215 -0.2935 -0.6001 -0.4007 
FAM162A -0.6638 -0.3392 0.0061 -0.3438 -0.4749 -0.4965 
HSPBAP1 -0.6647 -0.4809 0.1117 -0.4034 -0.5139 -1.0248 
SLC25A32 -0.6657 -0.1670 0.0070 -0.3346 -0.2972 -0.3947 
GTF2IRD2B -0.6661 -0.6723 0.1208 -0.6297 -0.9945 -0.7783 
NDUFAF4 -0.6664 -0.5097 0.0581 -0.3427 -0.4550 -0.2772 
TRMT10B -0.6668 -0.2095 -0.0383 -0.2099 -0.3885 -0.5302 
RRP15 -0.6677 -0.2402 -0.0346 -0.0889 -0.4685 -0.1739 
SLC5A6 -0.6681 -0.2955 0.0440 -0.3007 -0.4527 -0.4611 
TBC1D24 -0.6686 -0.2769 -0.0558 -0.3437 -0.3329 -0.6947 
IDUA -0.6692 -0.2867 0.0125 -0.3199 -0.4843 -0.6190 
PTPN4 -0.6696 -0.9929 -0.2834 -0.6912 -0.6149 -0.7739 
LBX2-AS1 -0.6700 -0.1636 0.2836 -0.1229 -0.4505 -0.6452 
WDR91 -0.6703 -0.4668 0.0514 -0.4473 -0.5520 -1.0143 
GEMIN8 -0.6705 -0.4741 -0.0197 -0.5199 -0.5865 -0.8011 
DNAJC28 -0.6705 -0.2820 0.4202 -0.1770 -0.1809 0.0333 
MTA3 -0.6709 -0.1110 -0.0244 -0.1601 -0.2198 -0.0630 
ATP5G1 -0.6723 -0.1836 0.0964 -0.2060 -0.4811 -0.3873 
TFB2M -0.6725 -0.4258 0.0688 -0.1772 -0.3429 -0.2116 
IL27RA -0.6736 -0.4363 -0.2298 -0.4291 -0.4129 -0.5886 
WDR4 -0.6736 -0.4011 -0.5381 -0.2365 -0.2895 0.1594 
AC069282.6 -0.6740 -0.4725 0.0594 -0.4399 -0.6287 -0.8020 
BPHL -0.6741 0.1445 -0.2641 -0.1959 -0.2801 -0.4010 
DNPH1 -0.6745 -0.3434 -0.0141 -0.3564 -0.4415 -0.4673 
LRPPRC -0.6747 -0.4559 0.0275 -0.4990 -0.5944 -0.5124 
FAHD2A -0.6748 -0.1930 0.1069 -0.1927 -0.3007 -0.5775 
URI1 -0.6765 -0.3179 0.0410 -0.3305 -0.4067 -0.3409 
CCDC41 -0.6772 -0.2734 -0.1314 -0.1848 -0.7046 -0.2928 
TIMM8A -0.6776 -0.4035 0.1757 -0.5661 -0.4494 -0.3851 
FAM211B -0.6780 -0.2849 -0.0016 -0.5594 -0.1515 -0.1999 
RABL2A -0.6787 -0.3812 0.1170 -0.4649 -0.6479 -0.8241 
JMJD7-PLA2G4B -0.6790 -0.7408 -0.0676 -0.4306 -0.5001 -1.0222 
FAM98A -0.6799 -0.1782 0.0865 -0.0950 -0.3567 -0.4256 




EIF2S3L -0.6810 -0.7689 -0.0730 -0.7088 -0.2035 -0.3931 
TMEM251 -0.6813 -0.4083 0.2071 -0.3969 -0.5105 -0.7561 
TRAPPC6A -0.6815 -0.3254 0.1883 -0.3850 -0.6009 -0.5815 
COX10 -0.6818 -0.2186 0.1376 -0.2784 -0.2621 -0.1799 
SNHG5 -0.6818 -0.5739 0.0671 -0.4543 -0.4920 -0.5607 
DDX51 -0.6820 -0.1871 0.0033 -0.3505 -0.4391 -0.3367 
DDX12P -0.6820 -0.2079 0.1721 -0.2913 -0.6237 -0.7851 
ZNF48 -0.6820 -0.4706 -0.1323 -0.7653 -0.4679 -0.5960 
C12orf66 -0.6825 -0.2632 0.1979 -0.5057 -0.6071 -0.4236 
POLR2J3 -0.6829 -0.4436 -0.0654 -0.1950 -0.5916 -0.3860 
RP1-90J20.12 -0.6831 -0.5118 0.1308 -0.3107 -0.2823 -1.1267 
RP11-733O18.1 -0.6841 0.0115 0.3788 -0.0039 -0.6181 -0.4739 
ALG3 -0.6854 -0.3333 -0.0733 -0.3719 -0.5235 -0.5867 
FKBP14 -0.6855 -0.3595 -0.0652 -0.1631 -0.4284 -0.6290 
PICK1 -0.6857 -0.5389 0.0796 -0.3732 -0.5321 -0.9233 
AC156455.1 -0.6860 -0.0325 0.3835 -0.8869 -0.5007 -0.2988 
SELRC1 -0.6864 -0.2264 -0.0692 -0.5639 -0.3294 -0.4277 
CST3 -0.6865 -0.2767 0.1654 -0.3119 -0.4034 -0.4870 
ISOC1 -0.6873 -0.4211 -0.1835 -0.3915 -0.3364 -0.1226 
ENDOD1 -0.6875 -0.5539 -0.1590 -0.5521 -0.5681 -0.4553 
IARS -0.6875 -0.3498 -0.0348 -0.3393 -0.3633 -0.1489 
ZBTB24 -0.6887 -0.4431 0.0481 -0.4174 -0.4660 -0.6152 
SLC24A4 -0.6891 -0.1086 0.5005 -0.2094 -0.4174 -0.8830 
CLIP4 -0.6899 -0.3387 0.0910 -0.4036 -0.6037 -0.7302 
Mar-01 -0.6903 -0.3778 0.1080 -0.0938 -0.3196 -0.3397 
RAD51D -0.6908 0.0582 -0.0342 0.0260 -0.3815 -0.1665 
VAV2 -0.6926 -0.4547 -0.0515 -0.4343 -0.5400 -0.6478 
FANCD2 -0.6930 -0.3408 0.0518 -0.2914 -0.5945 -0.6597 
AURKA -0.6931 -0.3321 -0.0289 -0.5281 -0.6412 -0.4795 
GPX4 -0.6932 -0.4191 0.1728 -0.2767 -0.5165 -0.7113 
SNX29 -0.6946 -0.4445 0.0652 -0.6230 -0.5959 -0.9172 
SLC25A10 -0.6953 -0.2863 -0.1064 -0.0916 -0.2824 -0.5525 
SYT1 -0.6957 -1.3456 0.2952 -0.8083 -1.2752 -1.8068 
LTV1 -0.6959 -0.1538 0.1511 -0.1420 -0.3093 -0.0638 
UXS1 -0.6964 -0.3609 0.0407 -0.3975 -0.3381 -0.4494 
PPAN -0.6971 -0.3105 0.0120 -0.9724 -0.8731 -0.5195 
RP11-686D22.7 -0.6976 -0.0701 0.3709 -0.2167 -0.4126 -0.7962 
SNHG1 -0.6978 -0.4902 0.0535 -0.3899 -0.5373 -0.5820 
CTD-2270L9.4 -0.6986 -0.2627 0.5714 0.5389 -0.1608 0.4149 
ATL2 -0.6987 -0.3495 -0.0916 -0.4128 -0.6110 -0.5415 
LSMEM1 -0.7002 -0.6823 0.0312 -0.6029 -0.7542 -1.1908 
PSMA6 -0.7006 -0.1233 0.2943 0.0514 -0.5235 -0.4136 




BTG1 -0.7010 -0.5466 0.0562 -0.5645 -0.4675 -0.7192 
RP11-568K15.1 -0.7013 -0.6431 -0.0602 -0.6024 -0.8062 -0.7637 
RASSF2 -0.7013 -0.2857 -0.0374 -0.4827 -0.5198 -0.3639 
TTLL11 -0.7021 -0.1062 -0.1039 -0.2236 -0.2151 -0.0851 
CEP85 -0.7036 -0.2957 -0.0348 -0.3116 -0.4389 -0.4502 
STK32C -0.7038 -0.3763 0.1028 -0.3584 -0.5003 -0.4881 
SPATS2 -0.7041 -0.2905 0.0322 -0.3839 -0.4275 -0.8519 
EIF2D -0.7051 -0.4428 0.1203 -0.5433 -0.5982 -0.5754 
DKC1 -0.7051 -0.2794 0.0205 -0.2399 -0.4207 -0.2836 
C17orf51 -0.7058 -0.3229 0.0852 -0.2289 -0.4987 -0.6397 
RCC2 -0.7067 -0.4791 -0.0725 -0.4316 -0.5388 -0.5623 
MAN2C1 -0.7071 -0.4166 -0.1054 -0.4383 -0.5847 -0.6437 
ASF1B -0.7079 -0.3429 0.1473 -0.4271 -0.4955 -0.8109 
USP36 -0.7087 -0.2092 0.0183 -0.3824 -0.5820 -0.4163 
DUT -0.7092 -0.4911 0.0936 -0.3303 -0.5495 -0.7277 
AC093391.2 -0.7093 -0.7437 0.2404 -0.2057 -0.5887 -1.4884 
ZNF331 -0.7098 -0.5641 0.1481 -0.4285 -0.6033 -0.9755 
SNAPC1 -0.7100 -0.7427 -0.1065 -0.8456 -0.6870 -0.7226 
AL161915.1 -0.7101 -0.7902 0.2332 -0.3595 -0.5113 -1.1798 
FDX1 -0.7114 -0.3556 -0.0969 -0.3925 -0.4371 -0.3140 
CDK10 -0.7115 -0.4043 -0.0517 -0.4170 -0.5904 -0.6986 
WDR43 -0.7123 -0.4511 -0.2463 -0.4756 -0.6476 -0.4246 
E2F6 -0.7124 -0.3218 0.0023 -0.4290 -0.5456 -0.5075 
NEIL1 -0.7139 -0.4078 0.0863 -0.3251 -0.8023 -0.8682 
CALM2 -0.7146 -0.3627 0.0718 -0.4730 -0.5793 -0.5431 
OSBP2 -0.7153 -0.6744 0.1842 -0.4545 -0.6096 -1.1140 
AC008982.2 -0.7162 -0.2869 -0.1282 -0.1992 0.4923 -0.1544 
HEXIM2 -0.7163 -0.9003 0.0397 -0.7410 -0.5095 -1.1143 
TRAP1 -0.7165 -0.4123 -0.0918 -0.4085 -0.3721 -0.5200 
TSC22D1 -0.7171 -0.9077 0.0230 -0.5180 -0.6235 -1.1372 
ENGASE -0.7179 -0.4801 0.0266 -0.3338 -0.6076 -0.9092 
RP11-817O13.6 -0.7183 -0.3108 0.1542 -0.2383 -0.8430 -1.0228 
MCCC2 -0.7187 -0.3377 0.0228 -0.5023 -0.5557 -0.3265 
CAD -0.7189 -0.3875 -0.0772 -0.3790 -0.4243 -0.5513 
MALT1 -0.7190 -0.5035 0.0699 -0.4251 -0.4975 -0.5552 
C19orf24 -0.7210 -0.2122 0.0389 -0.3316 -0.4576 -0.3299 
STIM2 -0.7227 -0.5410 -0.0063 -0.3948 -0.5669 -0.5398 
C3orf62 -0.7239 -0.2989 -0.0153 -0.2541 -0.4883 -0.5814 
THUMPD2 -0.7244 -0.7614 0.0550 -0.4937 -0.7363 -0.8342 
LILRB5 -0.7244 -0.5152 0.3571 0.0231 -0.2555 -0.4394 
CCDC85B -0.7265 -0.1706 0.0539 -0.4803 -0.6077 -0.5328 
THAP9 -0.7266 -0.0497 0.4493 0.1944 -0.3189 0.0741 




DUS3L -0.7275 -0.2406 -0.0556 -0.5419 -0.4310 -0.4052 
ANKRD46 -0.7277 -0.6387 -0.0836 -0.4851 -0.6420 -0.6928 
HMGB2 -0.7278 -0.5938 0.1167 -0.3600 -0.5832 -0.9479 
PUS1 -0.7282 -0.1361 0.0109 -0.3069 -0.3719 -0.0937 
PTK2B -0.7293 -0.5357 0.0089 -0.5062 -0.6920 -0.8287 
RPS26P3 -0.7294 -0.3815 -0.1257 -0.0803 -0.7987 0.2428 
SESN1 -0.7301 -0.7163 0.0398 -0.6453 -0.4762 -0.8706 
OPTN -0.7308 -0.1350 0.3481 -0.1054 -0.5195 -0.8203 
MRPL55 -0.7314 -0.2641 0.0448 -0.4618 -0.6438 -0.5246 
CTD-2228K2.5 -0.7329 -0.4583 -0.1013 -0.7809 -1.2023 -1.1453 
TIAF1 -0.7332 -0.2778 -0.1330 -0.1951 -0.2324 -0.4103 
SIN3B -0.7338 -0.3778 0.0310 -0.3736 -0.6002 -0.6543 
GRWD1 -0.7344 -0.1923 0.0310 -0.3993 -0.3545 -0.0789 
ZSCAN12 -0.7367 -0.1855 -0.2881 -0.6171 -0.6956 -0.7246 
DTWD1 -0.7370 -0.2484 0.1063 -0.1086 -0.4224 -0.1709 
AC009403.2 -0.7375 -0.0336 0.0767 -0.1753 -0.2439 -0.0266 
PSMG4 -0.7387 -0.2024 0.3019 -0.1231 -0.4127 -0.2121 
EARS2 -0.7389 -0.5818 -0.1128 -0.3994 -0.7155 -0.4153 
UAP1L1 -0.7402 -0.2184 0.1465 -0.2390 -0.5707 -0.9175 
LRRC48 -0.7403 -0.3008 0.2285 -0.2015 -0.5363 -0.3013 
RNASEH2B -0.7407 -0.4506 0.1314 -0.4415 -0.6221 -0.9712 
LIPT1 -0.7419 -0.6184 0.0512 -0.3871 -0.6284 -0.8365 
IL6R -0.7425 -0.3819 -0.0601 -0.5962 -0.5747 -0.6852 
ELMSAN1 -0.7428 -0.5240 -0.1264 -0.6328 -0.6541 -0.8839 
POLR1B -0.7428 -0.3667 0.0289 -0.4540 -0.4554 -0.2834 
LRRC69 -0.7432 -0.6547 -0.3729 -0.2269 -0.4393 -0.9783 
DAPK1 -0.7433 -0.4457 0.1171 -0.2852 -0.6015 -0.9261 
SLC25A45 -0.7436 -0.5228 -0.2059 -0.4961 -0.6488 -0.6782 
SLC16A5 -0.7456 -0.3047 0.0355 -0.3184 -0.5372 -0.6079 
HLTF -0.7463 -0.6460 -0.0437 -0.6394 -0.8238 -0.8647 
NAT6 -0.7466 -0.4137 0.1584 -0.4476 -0.8184 -0.5801 
ECSIT -0.7466 -0.6673 -0.0068 -0.5543 -0.6466 -0.7773 
TARSL2 -0.7469 -0.7541 0.2369 -0.4828 -0.6260 -0.9277 
NPM1 -0.7470 -0.5192 0.0254 -0.5028 -0.5618 -0.5981 
COQ9 -0.7472 -0.2888 0.1078 -0.3908 -0.4078 -0.4879 
ALDH3A2 -0.7480 -0.3765 0.2293 -0.3464 -0.5321 -0.8074 
ADORA3 -0.7510 -0.2682 0.0567 -0.4941 -0.8275 -1.1009 
ACCS -0.7543 -0.3835 0.0453 -0.4612 -0.6532 -0.8493 
CD3E -0.7544 -0.0761 0.0222 -0.2800 -0.1889 -0.3345 
PSAP -0.7547 -0.5166 0.0828 -0.4696 -0.6100 -0.7954 
SLC25A40 -0.7547 -0.6444 0.0177 -0.5023 -0.8229 -0.9131 
ZNF717 -0.7550 -0.3969 -0.0896 -0.4605 -0.4808 -0.5976 




CTB-41I6.1 -0.7565 -0.4415 0.1274 -0.4519 -0.5181 -0.8762 
CAMK1D -0.7569 -0.5150 0.0693 -0.5557 -0.5587 -0.6920 
MAGEH1 -0.7574 -0.2619 0.0481 -0.3230 -0.3773 -0.6329 
RPUSD2 -0.7578 0.0107 -0.0374 0.0251 -0.0614 -0.2555 
JARID2 -0.7589 -0.4591 0.0043 -0.4716 -0.5777 -0.8089 
AHCY -0.7596 -0.3608 0.0430 -0.4383 -0.6393 -0.6294 
SLFN11 -0.7607 -0.5634 0.0815 -0.4811 -0.6515 -0.8622 
TMEM39B -0.7609 -0.5163 -0.0028 -0.5806 -0.4998 -0.6133 
MTERFD1 -0.7626 -0.2867 0.1310 -0.1998 -0.3981 -0.3148 
POGLUT1 -0.7643 -0.5149 -0.1148 -0.4466 -0.8034 -0.6384 
MNF1 -0.7649 -0.2127 0.1599 -0.0802 -0.3478 -0.0926 
DPH2 -0.7652 -0.3528 -0.1934 -0.5928 -0.6383 -0.3932 
CCDC154 -0.7661 -0.5114 0.1098 -0.3833 -0.5664 -1.4280 
HGF -0.7665 -0.8460 0.2052 -0.5808 -0.5225 -1.4276 
ZNF706 -0.7668 -0.4942 0.0534 -0.5250 -0.6957 -0.7391 
SIRT4 -0.7672 -0.2847 0.2766 -0.1440 -1.4495 -2.1210 
SPICE1 -0.7672 -0.5089 0.0284 -0.4899 -0.5266 -0.9304 
MSI2 -0.7677 -0.7243 -0.2450 -0.7103 -0.4388 -0.7005 
MPHOSPH9 -0.7677 -0.4765 0.0639 -0.6212 -0.5304 -0.7980 
IGSF6 -0.7679 -0.3785 0.1542 -0.4060 -0.6087 -0.9503 
C17orf76-AS1 -0.7682 -0.5886 -0.1832 -0.6969 -0.6579 -0.6380 
NUDT16P -0.7692 -0.1735 0.2157 -0.3494 -0.3444 -0.5475 
FAM185A -0.7694 -0.2374 0.0339 -0.5510 -0.4944 -0.2893 
HTATSF1P2 -0.7697 -0.6269 0.0313 -0.5099 -0.6544 -1.1399 
CMSS1 -0.7714 -0.7643 -0.1790 -0.6014 -0.6852 -0.3091 
TTC27 -0.7716 -0.2410 -0.0816 -0.3098 -0.2285 -0.3273 
PARP16 -0.7716 -0.5012 -0.0633 -0.6813 -0.5141 -1.0118 
NUDT15 -0.7721 -0.4852 -0.0116 -0.5666 -0.5965 -0.5835 
BAG2 -0.7721 -0.6411 -0.2450 -0.5451 -0.6053 -1.3327 
RP11-154D6.1 -0.7723 -0.6253 0.0925 -0.5113 -0.6422 -0.8092 
RPIA -0.7730 -0.3930 -0.1643 -0.3686 -0.4497 -0.4193 
AMT -0.7736 -0.4295 0.1658 -0.4262 -0.6848 -1.0860 
C2CD2 -0.7738 -0.7769 -0.0243 -0.5014 -0.5036 -0.9230 
ILF3-AS1 -0.7764 -0.2820 0.3765 -0.1733 -0.4535 -0.4939 
NUFIP1 -0.7767 -0.2642 0.0572 -0.4592 -0.7393 -0.4552 
FLNA -0.7774 -0.3441 0.0313 -0.4290 -0.6044 -0.6571 
EFHC1 -0.7778 -0.6704 0.2211 -0.4111 -0.6184 -1.1501 
PEX7 -0.7787 -0.1756 -0.3570 -0.7394 -0.5633 -0.2372 
FBXW8 -0.7788 -0.3094 -0.0683 -0.4482 -0.3490 -0.3727 
IMP3 -0.7793 -0.4849 0.0257 -0.5312 -0.5569 -0.5306 
RPL36A -0.7797 -0.4011 -0.2614 -0.3071 -0.4369 -0.8477 
UTP20 -0.7798 -0.2602 0.0607 -0.4836 -0.2189 -0.1042 




OSBPL3 -0.7814 -0.3679 0.0846 -0.3905 -0.5884 -0.9548 
LIPA -0.7820 -0.6203 -0.2564 -0.6115 -0.6069 -0.8384 
RBFA -0.7821 -0.1640 0.2782 -0.2944 -0.2313 0.0619 
LIMK1 -0.7825 -0.5079 -0.2207 -0.5455 -0.6478 -0.5950 
TP53 -0.7826 -0.5915 -0.0202 -0.5310 -0.6407 -0.7529 
RPL23P8 -0.7833 0.3210 0.4489 0.1550 0.3545 0.0352 
RP11-526I2.5 -0.7834 -0.3089 -0.1238 -0.3508 -0.3915 -0.9249 
DNAJA3 -0.7839 -0.6166 -0.2207 -0.5100 -0.6059 -0.5872 
RP11-452L6.5 -0.7859 -0.2718 0.2176 -0.3313 -0.3025 -0.1877 
PDE7A -0.7859 -0.6442 -0.0102 -0.4372 -0.6694 -0.9598 
LINC00338 -0.7883 0.2173 0.7115 0.1904 -0.3059 -0.1625 
MYADM -0.7888 -0.7588 -0.3774 -0.9288 -0.6991 -0.7961 
ZNF852 -0.7909 -0.3812 -0.1461 -0.4719 -0.3818 -0.6362 
UNC5CL -0.7919 -0.4316 -0.1298 -0.4071 -0.7164 -0.9885 
GS1-124K5.4 -0.7926 -1.0514 -1.4133 -0.9951 -0.5766 -0.5170 
ANKMY1 -0.7927 -0.4437 -0.0364 -0.5698 -0.6332 -0.8742 
RP11-473M20.14 -0.7941 -0.5879 -0.0236 -0.4929 -0.5681 -0.6417 
STARD13 -0.7957 -0.2867 0.1400 -0.4122 -0.7035 -0.9513 
KBTBD6 -0.7959 -0.3331 0.0798 -0.2373 -0.4930 -0.3527 
ADSSL1 -0.7960 -0.3999 0.1573 -0.6559 -0.7609 -1.2170 
C2CD5 -0.7984 -0.3927 0.0241 -0.5473 -0.5829 -0.5409 
ZNF519 -0.8001 -0.8250 -0.1531 -0.6747 -0.6615 -1.1273 
MMD -0.8005 -0.4099 -0.1305 -0.3211 -0.6558 -0.4885 
GSE1 -0.8007 -0.6097 -0.0128 -0.5767 -0.5982 -0.7631 
IRS2 -0.8009 -0.5958 0.0566 -0.5480 -0.4637 -0.9694 
RCSD1 -0.8042 -0.6464 -0.0168 -0.6190 -0.6799 -0.6760 
MCM4 -0.8050 -0.0887 0.0025 -0.4817 -0.4434 -0.6616 
LMTK2 -0.8063 -0.4838 0.0790 -0.1952 -0.5754 -0.5948 
VAV3 -0.8071 -0.2277 0.2554 -0.2534 -0.5897 -0.8072 
ERMAP -0.8076 -0.6350 -0.0572 -0.4572 -0.6203 -0.9388 
AC133528.2 -0.8078 -0.3288 0.3338 0.0250 -0.2674 -0.3058 
RP11-248J18.3 -0.8121 -0.2287 0.1085 -0.0035 -0.5753 -0.5941 
ESPL1 -0.8123 -0.4638 0.1959 -0.3075 -0.3132 -0.4673 
AC073043.2 -0.8132 -0.1624 0.5638 0.0353 -0.4790 -0.3936 
ZNF566 -0.8134 -0.4598 0.0992 -0.3849 -0.4329 -0.4480 
FAM78A -0.8135 -0.4420 0.0100 -0.5324 -0.6174 -0.8796 
RP11-85F14.5 -0.8146 -0.3048 0.2614 -0.3463 -0.5695 -1.1143 
PPAT -0.8153 -0.4438 -0.0002 -0.6421 -0.9321 -0.7893 
NPM3 -0.8154 -0.3312 -0.2805 -0.3357 -0.4479 -0.2701 
ACRC -0.8159 -1.0824 -0.2192 -0.7806 -0.7836 -1.4332 
LYRM4 -0.8169 -0.4626 0.0702 -0.6384 -0.5506 -0.5973 
CKS2 -0.8176 -0.7810 0.1979 -0.3247 -0.4928 -0.9096 




MDN1 -0.8208 -0.4453 -0.1180 -0.5466 -0.7095 -0.6986 
RP11-153A23.6 -0.8219 -0.3201 -0.2258 -0.2780 -0.4646 -0.9209 
PRDM1 -0.8228 -0.7682 0.0491 -0.6608 -0.7714 -1.1394 
CDK4 -0.8247 -0.4155 0.0828 -0.4247 -0.5327 -0.6151 
ADK -0.8248 -0.5361 -0.0017 -0.7187 -0.8481 -0.9732 
ZNF570 -0.8258 -0.1634 -0.0345 -0.4203 -0.1870 -0.4149 
SCARF1 -0.8263 -0.5526 0.0410 -0.4758 -0.8028 -1.1091 
ANO9 -0.8267 -0.3295 0.0357 -0.1627 -0.0729 -0.4904 
MTFR2 -0.8270 0.2183 0.0681 -0.4214 0.0118 -0.5059 
MXI1 -0.8271 -0.8448 0.1738 -0.6773 -0.8385 -1.2168 
RPL21P28 -0.8298 -0.4157 0.0705 0.0730 -0.2382 -0.8059 
DAGLA -0.8307 -0.5518 -0.0818 -0.5253 -0.5920 -0.8894 
BTN3A1 -0.8307 -0.6912 0.1038 -0.4443 -0.6811 -1.1884 
CDCA7L -0.8325 -0.2385 -0.1556 -0.7293 -0.7528 -0.7331 
IL8 -0.8338 -1.3359 0.1519 -0.8609 -0.7783 -1.3517 
MRTO4 -0.8348 -0.3221 0.0179 -0.3729 -0.4608 -0.0860 
ANGEL1 -0.8350 -0.6113 -0.1053 -0.5310 -0.6426 -0.8163 
RSG1 -0.8354 -0.5005 0.0264 -0.3277 -0.6045 -0.6632 
SETDB2 -0.8367 -0.5453 0.0506 -0.4749 -0.7451 -1.1630 
PRKAG2-AS1 -0.8367 -0.4124 0.1055 -0.5551 -0.6253 -0.8190 
ASAH1 -0.8369 -0.5348 0.0766 -0.5246 -0.6968 -0.9524 
RP11-296I10.6 -0.8380 -0.3754 0.1828 -0.3213 -0.7606 -0.7176 
61E3.4 -0.8387 0.0564 0.0672 -0.0557 -0.4161 -0.4989 
CAMKK2 -0.8388 -0.6204 -0.0675 -0.5260 -0.6249 -0.7188 
EPB41 -0.8388 -0.7791 -0.1007 -0.7410 -0.7113 -0.9492 
CTD-2349P21.9 -0.8392 -0.9891 -0.6002 -0.9645 -0.3847 -1.5159 
CTPS1 -0.8393 -0.3674 -0.1622 -0.2895 -0.2619 0.5630 
ZSCAN18 -0.8410 -0.6263 0.1282 -0.2069 -0.3656 -0.6018 
GGT1 -0.8411 -0.6195 -0.1922 -0.6382 -0.7608 -0.7985 
RP3-473L9.4 -0.8418 -0.5679 -0.0069 -1.4854 -1.8729 -2.1597 
LRRN2 -0.8429 -1.2985 -0.2164 -0.3650 -0.5852 -1.6078 
ZNF33B -0.8434 -0.3362 0.0704 -0.6304 -0.7304 -0.9127 
RP11-705C15.3 -0.8455 -0.5391 0.1033 -0.2784 -0.2663 -0.5387 
AGAP9 -0.8477 -0.4383 0.1271 -0.3737 -0.8076 -0.8415 
RP11-876N24.4 -0.8478 -0.6061 -0.2562 -0.5394 -0.5694 -1.2078 
TDRD6 -0.8480 -0.6974 0.0128 -0.2647 -0.6320 -1.1661 
POLR1C -0.8516 -0.1905 0.0123 -0.4308 -0.6600 -0.5699 
INO80C -0.8520 -0.6272 0.1208 -0.4145 -0.8192 -0.4914 
LTA4H -0.8524 -0.8117 -0.0008 -0.6072 -0.7627 -1.0851 
CCDC101 -0.8536 -0.4380 0.1639 -0.3501 -0.5988 -0.6440 
THADA -0.8538 -0.5950 0.0351 -0.5390 -0.6635 -0.8632 
CECR5 -0.8540 -0.5053 0.0278 -0.5311 -0.7547 -0.8125 




PPT2 -0.8547 -0.0835 0.0810 -0.3984 -0.4742 -0.1756 
TCF7 -0.8562 -0.3205 0.0908 -0.9356 -0.5378 -0.8081 
CFLAR-AS1 -0.8566 -0.7271 -0.2077 -0.3086 -0.1529 -0.9460 
TP53I11 -0.8570 -0.4383 -0.2849 -0.3304 -0.8008 -0.7723 
LDHB -0.8587 -0.4561 0.0361 -0.4573 -0.6203 -0.6129 
ZNF835 -0.8589 -0.7112 -0.6075 -1.2381 -1.2928 -1.5369 
WBSCR27 -0.8600 -0.7747 0.2260 -0.5865 -0.6011 -1.2525 
PFAS -0.8625 -0.4738 -0.1177 -0.6280 -0.7081 -0.6897 
SHMT2 -0.8627 -0.5960 -0.0548 -0.5624 -0.6982 -0.7474 
PRC1 -0.8633 -0.5860 -0.1135 -0.4358 -0.9190 -0.6897 
GRN -0.8641 -0.5840 0.0180 -0.6108 -0.7315 -0.9017 
FAM117B -0.8648 -1.0298 -0.1204 -0.8216 -0.6042 -1.1627 
MYBBP1A -0.8654 -0.2435 -0.1473 -0.4078 -0.4673 -0.2847 
BCL11A -0.8659 -0.3993 -0.2675 -0.5558 -0.8812 -0.8386 
CTB-41I6.2 -0.8660 -0.5527 -0.1325 -0.5954 -0.6666 -1.0982 
GTF2IRD2 -0.8667 -0.5681 0.1498 -0.2466 -0.3846 -0.6776 
TYSND1 -0.8675 -0.7462 -0.0986 -0.6797 -0.7532 -0.8186 
DUSP28 -0.8677 -0.4660 -0.1609 -0.7588 -0.6879 -0.6784 
PLD6 -0.8678 -0.3356 -0.0470 -0.2782 -0.7630 -0.9018 
TBC1D8 -0.8685 -0.7819 -0.3889 -0.6058 -0.5468 -0.8451 
ACVR2A -0.8692 -0.4546 -0.0241 -0.3549 -0.4994 -0.5261 
PEAK1 -0.8693 -0.7685 0.0841 -0.5110 -0.6998 -1.1437 
WDR27 -0.8703 -0.8303 -0.2660 -0.6975 -0.7529 -1.0750 
CYP2U1 -0.8711 -0.7926 0.1034 -0.5200 -1.0505 -0.9014 
ENOSF1 -0.8728 -0.5170 0.1067 -0.3768 -0.6797 -0.9927 
ATF3 -0.8754 -1.0840 -0.4833 -1.1020 -0.4946 -0.5655 
RUNX3 -0.8760 -0.5070 0.0133 -0.6553 -0.7164 -0.7595 
CCDC125 -0.8775 -0.5562 -0.2990 -0.6826 -0.7011 -0.7713 
SLC1A4 -0.8775 -0.5475 -0.4657 -0.7243 -0.8994 -0.8471 
ZNF137P -0.8782 -0.1179 0.0245 -0.3496 -0.3563 -0.6427 
DHX57 -0.8821 -0.5545 -0.0453 -0.5162 -0.8570 -0.7807 
ZNF490 -0.8830 -0.5943 -0.2132 -0.5248 -0.2714 -0.8462 
CD6 -0.8837 -0.7110 -0.4019 -0.2740 -0.1680 -0.4783 
DCBLD1 -0.8879 -0.8121 -0.1196 -0.5318 -0.8945 -1.0818 
PSPH -0.8887 -0.6592 0.0940 -0.3214 -0.3860 -0.6860 
RP11-849H4.2 -0.8889 -0.8986 -0.1141 -0.2499 -0.4910 -1.0304 
RNF166 -0.8892 -0.4839 -0.0973 -0.4883 -0.5767 -0.8470 
CPED1 -0.8928 -0.7372 0.0870 -0.4801 -0.6976 -0.8626 
RP11-62J1.3 -0.8928 -0.1185 -0.0579 -0.8858 -0.4726 -0.0360 
MICAL1 -0.8972 -0.5271 0.0843 -0.5657 -0.8136 -1.2612 
MYH7B -0.8973 -0.4276 -0.0448 -0.8673 -0.9288 -1.0589 
SVIP -0.9002 -0.6007 0.1699 -0.7769 -0.8385 -0.9410 




PDLIM1 -0.9034 -0.3411 1.2051 0.4751 -0.9465 -0.2938 
WDR92 -0.9047 -0.0840 0.4898 0.0433 -0.1797 -0.0886 
ZZZ3 -0.9053 -0.6642 -0.0871 -0.6746 -0.7640 -0.8995 
TMEM201 -0.9055 -0.5997 -0.1037 -0.4724 -0.5242 -0.3911 
DDHD1 -0.9059 -0.6875 0.1313 -0.4445 -0.6948 -0.8590 
ADAM1A -0.9092 -0.4768 -0.1522 -0.8940 -0.7757 -0.8303 
FSCN1 -0.9097 -0.0702 0.1245 -0.3895 -0.4636 -0.1197 
AGAP8 -0.9113 -0.3953 0.2483 0.0083 -0.1548 -0.8608 
FAM217B -0.9123 -0.7414 -0.0665 -0.4712 -0.7899 -0.8985 
SMIM4 -0.9160 -0.4011 0.1167 -0.4247 -0.7311 -0.8097 
GAS5 -0.9166 -0.6127 0.1143 -0.5377 -0.5144 -0.6796 
YJEFN3 -0.9172 -0.6084 -0.0345 -0.1617 -1.0496 -1.1037 
COQ4 -0.9172 -0.4649 0.0107 -0.4888 -0.5809 -0.7042 
ZNF10 -0.9183 -0.6827 0.1030 0.1075 -0.7371 -0.8847 
HSD17B14 -0.9184 -0.4816 0.2748 -0.2097 -0.4772 -0.6079 
GABPB1-AS1 -0.9200 -0.5273 -0.4210 -0.4828 -0.7365 -1.1969 
ATP2A3 -0.9202 -0.8583 -0.1504 -0.8770 -0.8645 -1.2377 
PLCD4 -0.9205 -0.0865 0.1948 -0.1399 -0.4996 -0.4889 
NT5DC1 -0.9207 -0.8038 0.1320 -0.4577 -0.7298 -1.1838 
MICALL2 -0.9217 -0.6972 -0.2786 -0.6154 -0.6791 -1.3453 
GINS1 -0.9219 -0.0592 0.1273 -0.3627 -0.7652 -0.9611 
RP5-864K19.4 -0.9221 -0.5963 -0.2058 -0.6307 -0.8616 -1.5992 
MARVELD1 -0.9222 -0.6100 0.0071 -0.6945 -0.8134 -1.1734 
DAK -0.9244 -0.6278 -0.0947 -0.6614 -0.8383 -0.9896 
NMNAT3 -0.9250 -0.7587 0.1995 -0.5728 -0.3113 -0.5100 
TRGV5 -0.9259 -0.8986 -0.0601 -0.9547 -1.0995 -0.2426 
FNDC3A -0.9275 -0.8510 -0.0304 -0.6546 -0.8044 -1.0219 
REPIN1 -0.9282 -0.6324 -0.0598 -0.5814 -0.6726 -0.8578 
RBM38 -0.9285 -0.4963 -0.1353 -0.6313 -0.8778 -0.6863 
C18orf32 -0.9296 -0.1464 -0.3007 -0.3730 -0.5374 -0.2522 
PDXP -0.9298 -0.7199 -0.7338 -1.1719 -0.7594 -0.5235 
ZNF600 -0.9302 -0.4331 0.0738 -0.3920 -0.8562 -0.8658 
TTC7A -0.9309 -0.7083 0.0574 -0.7133 -0.9198 -1.1959 
UBAP1L -0.9312 -0.7443 -0.0425 -0.3674 -0.4417 -1.0783 
URB2 -0.9314 -0.3009 -0.0804 -0.4250 -0.4899 -0.1897 
CLDN12 -0.9325 -0.9707 -0.4693 -0.5800 -0.6243 -0.9642 
PHYH -0.9325 -0.5339 -0.0715 -0.5408 -0.5328 -0.6386 
CDR2 -0.9327 -0.4108 0.0147 -0.2536 -0.6218 -1.0314 
CPNE9 -0.9347 -0.1771 0.4502 -0.2728 -0.9504 -1.1556 
IQGAP2 -0.9359 -0.6041 0.1660 -0.5870 -0.7778 -1.2485 
RP11-395P17.3 -0.9368 -0.2732 0.2019 -0.3520 -0.6524 -0.7443 
POPDC2 -0.9375 -0.4589 -0.1661 -0.7822 -0.7963 -1.3822 




M1AP -0.9383 -0.6766 0.2493 -0.6689 -0.6906 -1.5790 
C14orf79 -0.9384 -0.1897 0.2260 -0.2510 -0.5422 -0.4495 
MCM2 -0.9407 -0.4662 0.1021 -0.4952 -0.5356 -0.7111 
RP11-403I13.8 -0.9425 -0.6020 0.1206 -0.2151 -0.6595 -0.4505 
LRRC8D -0.9434 -0.6956 -0.0144 -0.6157 -0.6829 -0.8427 
RPS6KA5 -0.9445 -0.5895 -0.0843 -0.7791 -0.3179 -0.9541 
ATG4C -0.9445 -0.8977 0.0717 -0.5427 -0.8040 -1.2136 
HMGA1 -0.9458 -0.5032 -0.1014 -0.6039 -0.6465 -0.5908 
NIT2 -0.9463 -0.3724 -0.0243 -0.3802 -0.6565 -0.6325 
TBC1D2 -0.9470 -0.5430 0.0959 -0.6960 -0.8901 -1.5341 
DHRS3 -0.9471 -0.7120 0.0734 -0.5174 -0.7299 -1.2982 
RP11-264B17.4 -0.9491 -0.9367 -0.6122 -1.5366 -1.4396 -1.6034 
ATG16L2 -0.9498 -1.0100 -0.0987 -0.8215 -0.9189 -1.3935 
SNHG8 -0.9507 -0.6046 -0.2599 -0.7007 -0.7543 -0.6563 
UBXN11 -0.9524 -0.6873 -0.0427 -0.4771 -0.8580 -1.1769 
MMP19 -0.9531 -1.1018 0.0675 -0.5328 -0.7308 -1.1716 
ZNF296 -0.9533 -0.2211 -0.0728 -0.6908 -0.8703 -0.7797 
BTN3A2 -0.9536 -0.8079 0.2094 -0.4475 -0.7661 -1.2367 
NHSL1 -0.9540 -0.2115 0.0951 -0.0706 -0.4446 -0.4757 
SH3BP5-AS1 -0.9553 -0.8024 0.1501 -0.4964 -0.8741 -1.1654 
NCF2 -0.9560 -0.6622 0.0702 -0.6558 -0.9348 -1.2765 
TSPAN4 -0.9560 -0.4617 0.0914 -0.5240 -0.7556 -1.1113 
TTYH2 -0.9564 -0.8567 -0.1655 -0.9203 -0.9444 -1.3242 
PNPLA7 -0.9565 -0.5974 0.2587 -0.7355 -0.8722 -1.6610 
OSGIN1 -0.9597 -0.2353 0.1655 -0.0361 -0.5099 -0.6327 
PRPF40B -0.9602 -0.3884 0.2014 -0.4306 -0.5254 -0.5104 
ACVRL1 -0.9602 -0.5509 0.1947 -0.4236 -0.6576 -0.3238 
GPR35 -0.9632 -0.4267 -0.4362 -0.8506 -0.7673 -0.7244 
SNRPEP4 -0.9636 -0.1826 0.1306 -0.0563 -0.0567 -0.6097 
PFKM -0.9653 -0.6475 0.0342 -0.5332 -0.7532 -0.9276 
COQ10A -0.9654 -0.8604 -0.1990 -0.7277 -1.0160 -1.6569 
RP11-10K16.1 -0.9664 -0.7544 -0.2010 -0.5426 -0.5317 -1.1940 
RP11-390P2.4 -0.9664 -0.3185 0.0764 -0.3643 -0.3224 -0.4621 
PRR22 -0.9685 -0.6697 -0.1022 -0.4643 -1.0043 -0.7874 
KLHDC8B -0.9697 -0.6224 -0.0201 -0.7115 -0.9503 -1.5731 
SMYD3 -0.9717 -0.4022 -0.0520 -0.5886 -0.4654 -0.4631 
CTD-2373H9.6 -0.9722 -0.8754 -0.6919 -1.6902 -0.9181 -1.5389 
TRGV4 -0.9726 -0.4827 0.3126 -0.3616 -0.7394 -0.5872 
IVD -0.9742 -0.8389 -0.1336 -0.7924 -0.9488 -0.9818 
CENPP -0.9751 -0.2626 -0.0483 -0.2664 -0.4641 -0.7129 
SAMD3 -0.9758 -0.9985 -0.4727 -1.0592 -0.8833 -0.6334 
RP11-496I9.1 -0.9770 -0.7234 -0.2917 -0.4860 -1.1132 -1.0794 




SPR -0.9789 -0.6692 0.2426 -0.3034 -0.4844 -0.9554 
CTD-2337J16.1 -0.9801 -0.5268 0.4632 0.0122 -0.3189 -0.6027 
TMEM104 -0.9811 -0.3296 -0.0396 -0.5024 -0.6778 -0.7736 
RP11-350G8.5 -0.9821 -0.4998 0.3509 -0.5514 -0.8966 -1.4222 
TRIM16L -0.9823 -0.9440 0.1591 -0.5007 -0.5614 -0.9872 
PLA2G7 -0.9840 -0.7011 -0.0339 -0.5003 -0.8536 -1.2435 
EID2B -0.9841 -0.5363 0.1117 -0.3777 -0.4005 -0.4102 
MOK -0.9843 -1.0415 -0.1176 -0.7609 -0.5645 -0.7790 
GSTP1 -0.9844 -0.6926 0.1057 -0.5873 -0.8782 -1.0845 
ZNF404 -0.9852 -0.6660 0.2250 -0.7045 -0.5492 -1.4001 
DDX47 -0.9858 -1.0257 0.0262 -0.4752 -0.9840 -1.0761 
THEM4 -0.9887 -0.4396 -0.0937 -0.3881 -0.7462 -0.8114 
AHRR -0.9898 -0.7304 -0.0929 -0.5773 -0.8913 -1.1129 
LRRC37A4P -0.9899 -0.8934 -0.3421 -0.7867 -0.8016 -0.9287 
MAP4K1 -0.9917 -0.5855 -0.0352 -0.6055 -0.7567 -1.1117 
SFXN4 -0.9937 -0.7129 -0.1349 -0.5669 -0.6749 -0.8920 
FXYD5 -0.9939 -0.5566 0.1058 -0.5677 -0.8265 -0.9486 
CDC42EP3 -0.9940 -0.6093 -0.0034 -0.6210 -0.8563 -1.0307 
KAT2A -0.9954 -0.6638 0.0148 -0.6494 -0.8661 -1.2311 
AKAP1 -0.9959 -0.6331 -0.1529 -0.6357 -0.7204 -0.8556 
FBXO36 -0.9967 0.5311 -0.0123 -0.3698 -0.2931 -0.0662 
ABCA5 -0.9968 -0.5279 0.1936 -0.3797 -0.5454 -1.3049 
TUBE1 -1.0009 -0.6274 -0.1058 -0.4013 -0.7855 -0.5990 
XRCC6BP1 -1.0020 -1.0522 -0.1639 -0.6874 -0.8108 -1.3798 
GADD45A -1.0022 -0.8308 0.1232 -0.6697 -0.9718 -1.2107 
AC005082.12 -1.0023 -0.4478 0.0816 -0.4780 -0.4411 -0.9010 
OXER1 -1.0024 -0.7284 0.1855 -0.3138 -0.7656 -1.3304 
DTX4 -1.0039 -1.1531 -0.3664 -1.1996 -1.2273 -1.3223 
TYW1B -1.0046 -0.4067 -0.5246 -0.9712 -0.8336 -0.7782 
ZHX3 -1.0076 -0.5234 -0.0757 -0.5643 -0.8385 -0.7977 
THG1L -1.0082 -0.8710 -0.0585 -0.6153 -0.5893 -0.6432 
ADCK1 -1.0085 -0.6295 -0.0526 -0.5893 -0.7306 -0.9106 
LA16c-390E6.4 -1.0097 -0.6796 -0.2057 -0.4482 -0.8234 -1.8323 
ALKBH2 -1.0119 -0.2124 -0.1244 -0.3606 -0.3986 -0.1866 
TRIM59 -1.0128 -0.6301 0.3694 -0.3759 -0.4222 -0.5803 
PABPC4 -1.0139 -0.7908 -0.0918 -0.8561 -0.8797 -1.1434 
CCL4L2 -1.0165 -1.8241 -0.0171 -0.3809 -0.7773 -1.6306 
C9orf41 -1.0169 -0.7989 -0.0664 -0.4373 -0.3841 -0.5234 
AMICA1 -1.0185 -0.8850 0.0692 -0.7937 -1.0147 -1.6551 
NFE2L3 -1.0198 -0.9848 0.2170 -0.3537 -0.5471 -0.6934 
EPDR1 -1.0212 -0.7480 0.4211 -0.2291 -0.4448 -1.0474 
EVL -1.0224 -1.0599 -0.4674 -1.0264 -0.8952 -1.3231 




DPH1 -1.0242 -0.8383 -0.1754 -0.6634 -1.0225 -0.8603 
EPB41L4A-AS1 -1.0248 -0.8453 0.1528 -0.7350 -0.9710 -1.0305 
TIPARP -1.0254 -0.7154 -0.3110 -0.8649 -0.9873 -0.9566 
FAM69A -1.0255 -1.0020 0.1805 -0.7506 -1.0808 -1.3223 
SRSF7 -1.0270 -0.6192 0.0167 -0.5440 -0.8664 -0.9781 
CD109 -1.0272 -1.9329 -0.3462 -1.1237 -1.0755 -1.9060 
TMEM71 -1.0280 -0.9869 0.2393 -0.8567 -0.9376 -1.2193 
KNSTRN -1.0283 -0.4659 0.0377 -0.5376 -0.5719 -0.8537 
URB1 -1.0293 -0.6280 -0.1020 -0.8295 -0.9964 -0.6166 
RAB37 -1.0296 -1.3742 0.0217 -1.0683 -1.2545 -1.9819 
MARS2 -1.0307 -0.3410 0.2271 -0.2408 -0.0806 -0.5266 
MUSTN1 -1.0309 -1.3593 -0.4181 -1.3056 -0.6285 -1.5760 
PKD1P1 -1.0309 -0.6480 1.2728 -0.9912 -0.7309 0.4352 
NLRP1 -1.0310 -0.9888 -0.0117 -0.9789 -0.9434 -1.4916 
FUCA1 -1.0329 -0.4567 0.0489 -0.5640 -0.8960 -1.2234 
RP11-66N11.8 -1.0352 -0.1027 -0.0797 -0.2917 -0.8957 -1.1562 
SLC19A2 -1.0362 -0.6222 -0.2256 -0.6550 -0.9298 -0.9604 
HOMER2 -1.0379 -0.7231 -0.0054 -0.3928 -1.0486 -1.0033 
RRP7B -1.0382 -0.5003 -0.2864 -0.4252 -0.8312 -0.6504 
TMEM120B -1.0387 -0.7313 -0.2153 -0.6018 -0.8149 -1.0543 
EPM2A -1.0393 -0.5772 -0.1791 -0.5017 -0.6370 -0.6433 
GATM -1.0409 -0.6872 -0.1003 -0.7765 -0.9738 -1.1171 
RP11-626A5.2 -1.0413 -0.4471 -0.2449 -1.5939 -0.9691 -1.7445 
LFNG -1.0427 -0.5522 -0.0686 -0.8511 -0.8111 -0.8615 
CD82 -1.0429 -1.0058 -0.5605 -1.1722 -1.0036 -0.8967 
MGLL -1.0429 -0.4568 0.0608 -0.3691 -0.7977 -0.9360 
PYROXD2 -1.0434 -0.6170 0.1406 -0.5612 -0.9741 -1.1875 
CCNB1 -1.0443 -0.6589 0.0556 -0.7037 -1.2302 -1.0855 
GOLPH3L -1.0453 -1.0688 0.0246 -0.7352 -0.7400 -1.4614 
SLC12A2 -1.0462 -0.6282 0.1137 -0.4113 -0.6468 -0.2722 
CSTA -1.0472 -0.6975 0.1988 -0.4946 -0.8413 -1.1323 
AC026740.1 -1.0473 -0.0246 0.1032 -0.3295 -0.4965 -0.9931 
WLS -1.0490 -0.6425 0.1093 -0.6639 -0.7873 -1.0984 
CCDC34 -1.0491 -0.9990 0.1056 -0.6828 -1.4723 -2.0351 
IRF5 -1.0505 -0.4953 0.0423 -0.5819 -0.9015 -1.0769 
ZRANB3 -1.0519 -0.5267 0.0259 -0.9711 -0.5382 -1.1079 
XYLB -1.0522 -0.8681 -0.3179 -1.1909 -0.6798 -0.8167 
ARRDC5 -1.0542 -0.6928 -0.0393 -0.6514 -0.8645 -1.3019 
RNF144A -1.0558 -0.8845 0.2532 -0.4722 -0.8876 -0.8650 
AC010980.2 -1.0573 -0.5924 0.2295 -0.2198 -0.6745 -1.4435 
NBPF11 -1.0594 -0.7795 0.1450 -0.5083 -1.1033 -0.9809 
CLYBL -1.0617 -0.9425 0.1293 -0.8474 -1.1554 -1.3768 




RGCC -1.0644 -0.7305 -0.6794 -1.1771 -0.7270 -1.0210 
WDR52 -1.0657 -0.9593 0.1305 -0.4947 -1.0291 -1.5095 
HEXA -1.0667 -0.6672 0.0449 -0.6893 -0.8882 -1.1071 
BUB1 -1.0676 -0.6904 -0.0387 -1.1147 -0.9469 -1.1409 
ARHGAP10 -1.0681 -0.8423 -0.1012 -0.6396 -0.8815 -1.2630 
FGL2 -1.0683 -0.8579 -0.1987 -0.8234 -0.9554 -0.9027 
RP11-229P13.20 -1.0684 -0.8309 0.2475 -0.2421 -0.7191 -1.5282 
SMAD3 -1.0694 -0.9795 -0.4849 -1.1015 -1.1225 -0.4162 
HCST -1.0699 -0.9223 -0.0740 -0.8334 -1.0400 -1.1743 
LINC00865 -1.0701 -0.7295 0.1475 -0.3170 -0.1764 -1.1111 
PLAU -1.0722 -0.5110 0.1059 -0.4585 -1.0185 -1.4468 
ZNF607 -1.0737 -0.3158 -0.0982 -0.3742 -0.4389 -0.4571 
NOB1 -1.0740 -0.7225 -0.2016 -0.6738 -0.7594 -0.6335 
RPH3AL -1.0746 -0.3379 -0.4221 -0.6825 -0.6525 -0.7050 
CEBPA -1.0749 -0.4690 -0.4501 -1.2437 -0.6382 -0.6324 
ZNF132 -1.0757 -0.7045 -0.4763 -1.1427 -0.5180 -0.8212 
VWF -1.0762 -0.9204 -0.3672 -1.1550 -0.8079 -1.4205 
MUC20 -1.0768 -0.8482 0.1109 -0.3981 -0.9483 -1.0160 
RAB40B -1.0780 -0.5051 -0.0570 -0.2669 -0.9680 -0.9023 
SLC16A1 -1.0794 -0.6097 -0.1806 -0.5339 -0.7485 -0.6414 
RP11-474P12.5 -1.0812 -0.3906 0.3366 -0.0977 -0.0763 -0.0159 
EXOSC5 -1.0827 -0.8125 -0.1150 -0.7508 -1.0622 -1.0608 
CTD-2020K17.1 -1.0831 -1.0421 0.0327 -0.7366 -0.9907 -1.3848 
RRS1 -1.0859 -0.0758 -0.3635 -0.3367 -0.4042 -0.1224 
GCLC -1.0871 -0.8455 -0.2451 -0.8398 -0.9123 -1.1922 
LGALS3 -1.0883 -0.6039 -0.0355 -0.6081 -0.9477 -1.1718 
DDX10 -1.0889 -0.7581 -0.1651 -0.5337 -0.6340 -0.5839 
SLC25A5-AS1 -1.0928 -0.4598 0.0064 -0.5779 -0.5537 -0.8363 
ICAM3 -1.0933 -0.8572 -0.3362 -0.9100 -1.1093 -1.1863 
RP11-793H13.11 -1.0939 -0.2693 -0.4291 -0.8845 -0.6866 -1.1232 
PTCH2 -1.0941 -1.0835 -0.1369 -0.3641 -0.7873 -1.7945 
RRN3P1 -1.0950 -0.6053 0.2219 -0.4778 -0.8541 -1.3219 
EIF4EBP3 -1.0965 -1.2363 -0.3943 -1.1696 -1.0115 -1.5582 
MAFF -1.0975 -1.1054 -0.2668 -0.9433 -0.7475 -0.7117 
PPFIBP2 -1.0985 -0.8362 -0.1287 -0.7902 -0.8805 -1.1366 
CYB5RL -1.1018 -0.5782 -0.0970 -0.6099 -0.7612 -0.8946 
RP11-443P15.2 -1.1057 -0.8795 0.3714 -0.2683 -0.8211 -1.1127 
TEX2 -1.1074 -0.8431 -0.1032 -0.6300 -0.8532 -1.1862 
LA16c-316G12.2 -1.1085 0.1748 1.2074 0.2675 0.6367 -0.1831 
CTD-2228K2.7 -1.1106 -1.1068 -0.1532 -0.5097 -0.9805 -1.1942 
OSBPL1A -1.1112 -0.7472 0.0450 -0.4962 -0.8573 -1.2521 
SERPINF2 -1.1143 -1.0227 -0.0934 -1.0810 -1.2343 -1.7480 




LDHD -1.1159 -0.6455 -0.1852 -0.8340 -1.0179 -0.9722 
TNFSF8 -1.1195 -0.8392 0.1337 -0.5358 -0.6477 -1.0209 
ADAT2 -1.1205 -0.3202 -0.2173 -0.3495 -1.1402 -0.8272 
GM2A -1.1208 -0.7748 -0.0503 -0.8233 -1.0680 -1.4199 
IL11RA -1.1222 -0.8210 0.0295 -0.4964 -0.7361 -1.3011 
IL18 -1.1234 -0.7316 0.0931 -0.2864 -0.8392 -1.2476 
RRN3P2 -1.1256 -0.8119 -0.2955 -0.8978 -0.8134 -1.3189 
AC093627.10 -1.1257 -1.1422 -0.2173 -1.1399 -1.2254 -1.4835 
RP11-329L6.1 -1.1270 -0.5643 -0.0677 -0.1783 -0.7031 -0.6278 
PRKXP1 -1.1270 -0.5672 -0.2609 -1.0961 -1.1105 -0.9026 
COX7A1 -1.1304 0.0028 -0.4003 0.0412 -0.0355 -0.9659 
MTAP -1.1316 -0.8207 -0.0583 -0.7556 -0.9261 -1.0307 
NUSAP1 -1.1336 -0.6807 0.2620 -0.6619 -1.1593 -1.6315 
MYH3 -1.1348 -0.6128 0.2726 -0.4470 -0.7441 -0.9938 
GRAMD4 -1.1353 -0.7605 0.0898 -0.6707 -0.9211 -1.5493 
CHCHD6 -1.1364 -0.9132 0.0442 -0.9105 -1.1298 -1.4065 
MORN1 -1.1378 -1.3917 0.4651 -0.6838 -0.0933 -1.2437 
RP11-111M22.3 -1.1379 -0.5461 -0.1894 -0.7835 -0.7397 -1.5389 
CTD-2086O20.3 -1.1390 -0.2724 -0.2299 -0.6799 -0.5494 -0.5871 
AEN -1.1408 -0.5926 -0.1562 -0.5606 -0.5280 -0.1778 
RDH13 -1.1411 -0.7503 -0.3170 -0.6451 -0.6630 -0.9732 
FANCA -1.1411 -0.7725 0.2782 -0.4903 -0.9222 -1.1178 
CDK14 -1.1428 -1.4766 -0.6488 -1.0921 -0.8439 -0.8193 
FABP4 -1.1440 -1.4513 -1.1015 -1.2328 -0.2173 -1.5217 
CENPF -1.1445 -1.1224 0.5193 -0.4904 -1.6098 -1.0745 
CTD-2002H8.2 -1.1462 -0.4183 0.0652 -0.6056 -0.9487 -1.0818 
TVP23A -1.1466 -0.4804 -0.0392 -0.0581 -1.3783 -0.6003 
CHCHD10 -1.1510 -0.5905 -0.1637 -0.8593 -0.8750 -0.9252 
ACSS1 -1.1518 -0.9484 -0.0441 -0.7657 -0.9334 -1.1217 
CHIT1 -1.1537 -1.6467 -1.2316 -1.5843 -1.4921 -1.5995 
CTC-203F4.1 -1.1545 -0.6889 1.0393 0.2050 -1.0713 -0.9939 
SNAI3 -1.1551 -0.8309 -0.0768 -0.8605 -0.8872 -1.0168 
CCNB1IP1 -1.1553 -0.8354 -0.2648 -0.7597 -0.9781 -1.1117 
TOB1-AS1 -1.1564 -1.7200 0.0725 -1.1699 -1.2522 -1.3806 
ARL5C -1.1578 -0.1623 0.4678 -0.7778 -0.3631 -1.9242 
KB-431C1.3 -1.1596 -1.6272 -0.6746 -1.1692 -2.0286 -2.5850 
AF127936.5 -1.1596 -0.6903 0.0765 -0.6310 -0.8250 -0.9366 
SIGLEC14 -1.1602 -0.5146 0.0432 -0.5634 -0.8118 -1.0545 
CHST13 -1.1649 -0.7365 -0.1255 -1.0279 -1.0371 -1.4045 
CDKN2B -1.1655 -0.6815 -0.6107 -0.4833 -0.3959 -0.4970 
RP11-488C13.5 -1.1675 -0.6882 0.0927 -0.7461 -0.8511 -1.0883 
MREG -1.1681 -0.8886 -0.8061 -1.1783 -0.5205 -1.3528 




RP11-107F6.3 -1.1690 -1.2196 -0.5805 -0.5841 -0.9652 -1.7990 
TRIM6 -1.1700 -0.6471 -0.2945 -0.4820 -0.6079 -0.9300 
RPS6KA2 -1.1723 -0.8792 -0.0380 -0.9652 -1.1813 -1.7245 
TIGD2 -1.1739 -0.8194 -0.1486 -0.3793 -0.4764 -0.7470 
ASCL2 -1.1739 -0.6465 0.1119 -0.7136 -0.7578 -1.1507 
RP11-108P20.1 -1.1739 -0.6371 -0.2904 -0.3907 -0.7483 -0.6274 
CTD-2639E6.9 -1.1739 -0.1580 0.2939 -0.7730 -0.3455 -0.7624 
LONRF3 -1.1758 -0.3370 -0.2539 -0.4872 -0.9240 -1.0858 
MAD2L1 -1.1769 -0.4640 -0.0049 -0.5172 -1.1809 -1.0946 
KCNAB2 -1.1772 -0.7229 -0.0823 -0.8140 -1.0544 -1.5115 
ARSG -1.1779 -0.7663 -0.1646 -0.8622 -1.2231 -1.1475 
CXorf24 -1.1806 -0.6333 0.1566 -0.4924 -0.4967 -0.5024 
CD9 -1.1809 -0.9803 -0.0137 -0.9485 -1.0881 -1.7153 
NCF1 -1.1814 -0.9212 0.1682 -0.7722 -0.9893 -1.5022 
LSR -1.1821 -0.8612 -0.4171 -0.8938 -1.0258 -1.5756 
ZNF74 -1.1831 -0.8330 -0.2037 -0.7646 -0.8394 -1.5349 
IRF2BP2 -1.1851 -0.8724 0.0441 -0.6579 -0.7906 -1.1687 
FAM195A -1.1859 -0.6690 -0.2024 -0.8183 -1.0063 -0.9723 
SFMBT2 -1.1861 -0.7685 0.0538 -0.3750 -0.7894 -1.0571 
NCOA7 -1.1867 -1.0972 0.1040 -0.7884 -0.8994 -1.2469 
AC108488.4 -1.1888 -1.0382 -0.2779 -0.7869 -1.2051 -1.1255 
NPM1P25 -1.1907 -0.7910 -0.1820 -0.4470 -1.0407 -1.1424 
GALNT3 -1.1910 -0.9426 -0.0853 -0.8838 -1.5145 -1.5303 
ADAL -1.1924 -0.5509 -0.1229 -0.6267 -0.6966 -0.6308 
CERS4 -1.1940 -0.8984 0.0150 -0.6968 -0.9257 -1.0678 
CAPG -1.1959 -0.7516 0.0287 -0.7178 -1.1523 -1.4100 
TMEM48 -1.1964 -0.8901 -0.0504 -0.6967 -0.7932 -0.7268 
AC079250.1 -1.2000 -0.1538 0.2945 -0.2102 -0.1684 -1.0814 
DHODH -1.2005 -0.6880 -0.1410 -0.5799 -0.8643 -0.9509 
RP4-800G7.2 -1.2024 -0.9218 0.0097 -0.5441 -0.9369 -0.9865 
COL23A1 -1.2052 -1.0448 -0.0869 -1.3571 -1.5437 -1.9048 
TRAF5 -1.2064 -0.6508 -0.2181 -0.8069 -1.1020 -1.2572 
SETD6 -1.2080 -0.8654 -0.4573 -0.8840 -1.0948 -1.4117 
RHOBTB1 -1.2110 -0.8391 -0.2256 -0.9064 -0.8496 -0.9654 
TMEM220 -1.2128 -0.8705 -0.1563 -0.5956 -1.1734 -1.6414 
CC2D2A -1.2153 -0.3943 0.3945 -0.6662 -1.1829 -1.0850 
KIF17 -1.2197 -1.5109 -0.1186 -0.8600 -1.0297 -2.2671 
RP11-468E2.9 -1.2222 -1.0830 -0.4124 -0.9196 -0.9848 -1.7383 
SOX12 -1.2231 -1.0614 -0.2340 -1.4261 -1.0027 -1.4373 
KIF27 -1.2249 -0.4008 -0.4830 -0.9910 -0.7131 -0.9826 
LL22NC03-86G7.1 -1.2273 -1.0729 -0.3129 -0.6601 -0.7392 -1.5979 
AGPAT5 -1.2296 -0.9794 -0.1808 -0.8504 -1.0171 -1.3153 




ANKH -1.2324 -0.9518 -0.1474 -1.0696 -1.1544 -1.4010 
RP11-254F7.2 -1.2368 -0.8320 -0.1956 -0.9257 -1.0736 -1.3315 
SNED1 -1.2382 -1.1631 -0.2006 -1.2785 -0.5304 -1.8570 
OSBPL7 -1.2383 -0.9110 -0.0670 -0.7699 -1.1440 -1.0814 
SLC25A38 -1.2419 -0.8260 -0.0808 -0.6416 -0.8287 -0.9044 
CTD-2037K23.2 -1.2440 -0.9310 0.1168 -0.7440 -1.0340 -0.8770 
FAAH -1.2471 -0.8844 -0.1199 -0.6769 -1.0820 -1.0232 
SLC9A3 -1.2490 -1.3015 -0.2315 -1.0907 -0.9520 -1.0374 
NUP210 -1.2494 -1.0022 -0.3195 -0.9918 -1.2125 -1.5673 
SLC25A27 -1.2494 -0.9810 -0.0737 -0.7691 -1.4228 -1.3473 
FBP1 -1.2521 -1.5048 -0.6481 -1.2710 -1.0823 -1.4473 
CITED4 -1.2525 -0.7184 0.2249 -0.3690 -0.6894 -0.3284 
RP11-334C17.5 -1.2535 -1.0327 -0.1699 -0.8644 -1.2672 -1.7808 
CTSD -1.2550 -0.7775 -0.2089 -0.8854 -1.0850 -1.2040 
ACACB -1.2550 -1.2379 -0.2459 -0.9629 -1.1386 -1.8061 
CTD-2619J13.8 -1.2562 -1.0066 -0.0651 -0.9391 -1.1688 -1.2314 
RP5-1103G7.4 -1.2572 -0.9227 -0.1525 -1.0951 -1.0935 -0.8199 
NR4A1 -1.2586 -1.2313 -0.1757 -0.8557 -0.4701 -0.9804 
RAB11FIP4 -1.2592 -1.3751 -0.6397 -1.2250 -0.8055 -1.3833 
COLQ -1.2634 -1.4009 -0.5600 -1.0213 -1.2137 -2.5285 
GPR82 -1.2658 -1.3632 -0.1707 -1.2322 -1.6054 -2.5851 
CARD14 -1.2668 -1.0094 -0.2901 -1.6149 -1.6986 -2.0444 
EREG -1.2750 -3.3626 0.3865 -1.4131 -0.8937 -2.0653 
RP11-368P15.3 -1.2764 -0.9413 0.0184 -0.4716 -1.0134 -1.6005 
EME1 -1.2773 -0.3971 0.3330 -0.8538 -1.0016 -0.8384 
FARP1 -1.2785 -1.0345 0.1909 -0.7087 -1.0602 -1.1146 
BACE1 -1.2812 -1.1459 -0.3421 -0.8508 -1.1278 -1.3445 
CDIP1 -1.2818 -0.9810 -0.2046 -1.0820 -1.0493 -1.1907 
NCF1B -1.2865 -1.0525 0.1706 -0.8757 -1.0765 -1.6185 
IL18BP -1.2883 -0.7193 -0.1824 -0.7370 -1.2108 -1.4776 
C3orf18 -1.2909 -1.0906 -0.4669 -0.9967 -1.3218 -1.7091 
C11orf1 -1.2915 -0.6032 -0.3121 -0.7708 -1.0408 -0.6412 
C14orf159 -1.2928 -0.9572 0.0545 -0.8469 -1.3245 -1.7032 
CCL22 -1.2932 -1.8220 -0.4359 -0.8071 -0.8785 -1.9108 
AL592284.1 -1.2935 -1.0365 0.1282 -0.5174 -0.5125 -1.1093 
RASL10A -1.2946 -0.7737 -0.2817 -0.9918 -0.9352 -1.2078 
GFOD1 -1.2966 -0.5673 -0.0026 -0.7274 -1.3978 -1.1003 
ECE2 -1.2980 -0.3407 0.3343 -0.3318 -0.6004 -0.4723 
DDO -1.2995 -0.8193 0.0837 -0.3037 -0.6221 -0.9084 
IRF4 -1.3005 -0.6771 -0.0529 -0.8147 -0.9858 -1.1881 
RP11-430C7.5 -1.3049 -0.9587 -0.0951 -0.8532 -1.1323 -1.3828 
SLC26A11 -1.3114 -0.9628 -0.3922 -1.0213 -1.2182 -1.4688 




FAH -1.3124 -0.6569 -0.0135 -0.6216 -1.1904 -1.2967 
OAF -1.3155 -1.1020 -0.0605 -0.8948 -1.1544 -1.4206 
SLC29A3 -1.3171 -0.9611 -0.3825 -0.9937 -1.0824 -1.2669 
CD244 -1.3222 -1.2391 -0.3791 -0.9619 -1.5408 -1.5213 
AC004840.9 -1.3223 -0.9288 -0.5478 -0.8975 -1.3360 -1.3978 
RP11-472N13.3 -1.3260 -1.0185 0.2123 -0.9672 -1.5189 -2.4734 
SAMD4A -1.3287 -0.6296 -0.0326 -0.6876 -0.7550 -0.8187 
RP11-196G11.2 -1.3332 -0.7308 -0.0074 -0.4824 -0.6136 -1.1249 
DNAJC5B -1.3341 -2.2156 -0.0719 -1.3027 -1.4644 -2.6696 
RP3-395M20.8 -1.3355 -1.2669 -0.2547 -1.0641 -1.3013 -1.9940 
IFITM10 -1.3389 -0.7630 -0.1017 -0.9829 -1.0359 -1.5196 
CTC-471J1.2 -1.3431 -0.0383 0.3155 -0.5209 -0.3739 -0.2836 
ABCC3 -1.3458 -1.1971 0.0802 -0.7840 -1.0184 -1.8510 
SLC9A7 -1.3491 -1.5534 -0.6699 -1.2266 -1.5821 -1.8906 
P2RY8 -1.3494 -1.3028 -0.1437 -0.9673 -1.2284 -1.7281 
BAIAP2 -1.3498 -0.9436 -0.1010 -0.9222 -1.0204 -1.6411 
TXNRD3 -1.3501 -1.1367 -0.4424 -0.5824 -1.1283 -1.1698 
TNFAIP2 -1.3544 -1.0499 0.0625 -0.8368 -1.1299 -1.6275 
C10orf128 -1.3550 -0.9855 0.0167 -0.7816 -1.0214 -1.5855 
IQCH-AS1 -1.3566 -1.0004 -0.2840 -1.0393 -0.9630 -1.5455 
PPM1H -1.3569 -0.7118 -0.2121 -0.5951 -0.7084 -0.9762 
EEPD1 -1.3602 -0.7634 -0.0555 -0.8587 -1.0301 -1.1578 
AC068580.5 -1.3635 -1.3303 -1.0995 -0.6498 -1.6304 -1.4987 
AP001258.4 -1.3647 -0.6243 -0.1229 -0.8584 -1.5441 -1.3179 
TRABD2A -1.3655 -0.4980 -0.1662 -0.6452 -1.0676 -1.1647 
SLC16A6 -1.3682 -0.7781 0.2183 -0.8627 -1.1634 -1.1711 
NREP -1.3682 -0.8349 -0.1704 -0.9980 -1.1488 -1.4961 
ALCAM -1.3722 -1.2712 -0.4354 -0.9672 -1.0680 -1.3983 
SOX13 -1.3731 -0.5725 -0.0521 -0.9819 -1.1864 -1.7809 
GALM -1.3741 -0.9551 -0.4495 -1.0523 -1.3211 -1.7426 
PDK4 -1.3754 -1.4439 -0.9674 -1.2057 -1.1176 -1.5625 
ST6GALNAC2 -1.3775 -1.1851 0.0830 -0.6122 -0.7612 -1.6520 
CCL3L1 -1.3783 -1.4288 -0.7007 -0.9268 -0.8879 -1.8228 
GRASP -1.3794 -0.5273 0.0094 -0.6725 -0.5252 -0.8261 
NUPR1 -1.3838 -0.9521 0.3108 -0.8068 -1.1687 -1.7988 
RP11-278C7.1 -1.3860 -0.3736 0.6556 -0.0218 -0.1651 -0.5214 
FAM177B -1.3862 -1.0749 0.4897 -0.2567 -1.2115 -2.0571 
RPL7AP10 -1.3887 -1.1423 -0.1927 -0.7653 -0.4954 -1.0942 
SLC17A9 -1.3966 -0.8531 -0.1819 -0.7246 -1.1514 -1.3544 
ITGAX -1.3970 -1.2861 -0.1024 -1.0225 -1.2405 -1.8491 
RP11-611D20.2 -1.3973 -0.8452 0.0234 -0.7850 -1.0371 -1.5895 
MPZL2 -1.3979 -1.2981 0.0417 -1.2737 -0.9797 -1.3931 




LRFN4 -1.4049 -0.5184 -0.1188 -0.6978 -1.0629 -1.4185 
ZNF704 -1.4084 -1.5405 -0.0071 -1.0321 -1.3653 -2.0493 
FXN -1.4089 -1.0661 -0.3708 -0.7079 -1.1700 -0.7334 
PPM1K -1.4093 -1.5135 -0.1642 -1.2553 -0.8348 -2.1279 
CALCRL -1.4159 -0.9815 0.4115 -0.3190 -0.7648 -0.8196 
TMCC3 -1.4197 -1.1796 0.0228 -1.2442 -1.2913 -1.4733 
CLEC12A -1.4207 -1.1539 0.1015 -0.9175 -1.2125 -2.0683 
KBTBD11 -1.4214 -0.8464 -0.5010 -1.2102 -1.2251 -1.1150 
PDE4DIP -1.4221 -1.3455 0.0503 -0.8105 -1.3183 -2.0383 
AC025335.1 -1.4233 -0.7974 -0.0169 -1.0471 -1.0206 -1.4086 
FAM86B3P -1.4236 -0.4934 -0.4010 -0.9840 -1.1225 -1.0532 
SLC7A11 -1.4243 -2.0178 0.2926 -1.0453 -0.8581 -1.9134 
RP11-368J21.3 -1.4263 -0.6334 0.2577 -0.6787 -1.0959 -1.6228 
APOBR -1.4263 -0.8428 -0.3162 -1.2077 -1.5762 -1.6062 
RP11-213H15.3 -1.4290 -1.1982 0.1778 -0.3135 -0.9167 -1.2437 
A2M -1.4299 -1.8694 -0.3022 -1.4953 -1.3568 -2.3976 
C1orf127 -1.4382 -1.2863 0.0917 -0.7628 -1.1507 -1.8305 
UBE3D -1.4384 -1.0957 -0.4935 -1.2459 -1.2492 -0.8880 
H2AFY2 -1.4432 -1.2561 -0.3666 -0.9610 -1.5092 -1.3553 
DNM1 -1.4453 -0.5158 0.1023 -0.5209 -1.0893 -1.3341 
HPSE -1.4484 -1.0351 -0.0541 -1.0912 -1.3885 -1.9694 
CHST7 -1.4496 -1.2106 -0.1476 -0.8202 -1.0102 -1.6489 
CD83 -1.4529 -1.3090 -0.5358 -0.9299 -0.9837 -1.1111 
ZC3H12C -1.4540 -1.1970 -0.0751 -0.8504 -1.2702 -1.6544 
SEMA4D -1.4546 -1.0427 -0.1914 -0.9357 -1.1641 -1.3429 
RP11-152N13.5 -1.4616 -1.6790 -0.4902 -0.1680 -1.6680 -0.1661 
AC074289.1 -1.4752 -0.6106 -0.0578 -1.0050 -1.4068 -1.9657 
GPNMB -1.4754 -1.1398 -0.0913 -1.0904 -1.3566 -1.9231 
TAGAP -1.4778 -0.8771 -0.1300 -0.6292 -1.0717 -1.2520 
PUS7 -1.4790 -0.8078 -0.2680 -0.9949 -1.1781 -0.6642 
ICOSLG -1.4810 -0.9770 -0.2569 -0.9739 -1.3588 -1.4907 
TNFAIP3 -1.4843 -1.4616 0.0162 -0.6633 -1.0161 -1.5646 
C1orf134 -1.4847 -0.3382 -0.0324 -1.0464 -1.1614 -0.8839 
CECR1 -1.4874 -1.1753 -0.1158 -1.0330 -1.2949 -1.8279 
AC093162.5 -1.4891 -0.2800 -0.0661 -1.1180 -0.9676 -1.3658 
MATK -1.4901 -2.1347 -1.2779 -1.8924 -1.3716 -2.0712 
F11R -1.4931 -1.1816 -0.0924 -0.9752 -1.1897 -1.6616 
CCDC88B -1.4933 -1.2421 -0.5454 -1.0674 -1.2399 -1.3677 
KITLG -1.4940 -1.0291 0.0152 -0.3359 -1.1866 -1.4399 
LINC00869 -1.4978 -1.8720 -0.2741 -1.3350 -0.6359 -0.7895 
CPAMD8 -1.4997 -1.1799 -0.1201 -1.0227 -1.4391 -1.9114 
PMAIP1 -1.5016 -1.1148 -0.6568 -2.0084 -1.7940 -1.6038 




SSX2IP -1.5064 -0.5507 -0.2068 -0.6188 -0.8830 -0.9041 
NCF1C -1.5188 -1.2305 0.0379 -0.8387 -1.1491 -1.8077 
DIP2C -1.5241 -1.1364 -0.2645 -1.6149 -0.9336 -2.0765 
OTOA -1.5256 -1.1714 0.0416 -0.8390 -1.3934 -1.6433 
HK2 -1.5281 -1.4115 -0.3905 -1.4503 -1.6407 -1.9867 
CLEC1B -1.5286 -0.7999 -0.1460 -1.2430 -1.3425 -1.7904 
EXTL2 -1.5337 -1.1346 -0.5072 -1.2870 -1.7443 -2.0236 
CRTAM -1.5363 -1.3397 -0.0571 -1.2493 -1.1847 -2.1868 
COL6A1 -1.5461 -1.5868 -0.2915 -1.1542 -1.6677 -1.9727 
SH3PXD2A -1.5471 -1.4909 -0.0767 -1.3107 -1.3880 -2.1147 
TARBP1 -1.5475 -1.0728 -0.2485 -0.8392 -1.3859 -1.7308 
SPAG8 -1.5520 -1.5587 -0.3121 -1.0303 -1.2805 -1.8888 
A2M-AS1 -1.5545 -1.0121 -0.1380 -0.3327 -1.0495 -0.9094 
METTL1 -1.5644 -0.6237 -0.5455 -0.8464 -0.8485 -0.8147 
SIK1 -1.5691 -1.2097 -0.5482 -0.6614 -1.2002 -1.0629 
CCDC88C -1.5692 -1.3387 -0.2948 -1.0913 -1.2641 -1.8285 
FAM46A -1.5715 -1.4229 -0.2993 -1.2863 -1.3831 -1.8314 
AVPI1 -1.5786 -1.2497 -0.3181 -1.3885 -1.4386 -2.3904 
RP11-264B17.3 -1.5824 -0.9640 -0.2885 -0.5513 -0.8615 -1.7133 
ARHGAP22 -1.5865 -1.2187 -0.1046 -0.9730 -1.3227 -1.8531 
ATP8A1 -1.5951 -1.4067 -0.1521 -1.0810 -1.2828 -2.0063 
AC093620.5 -1.6045 -0.7214 -0.4802 -0.9718 -0.5340 -0.9189 
RP11-212I21.2 -1.6058 -0.9098 -0.5380 -0.4925 -1.1099 -2.0788 
CDH23 -1.6058 -1.1674 -0.2503 -1.1730 -1.2087 -1.9909 
IL3RA -1.6089 -2.0289 -0.0080 -1.2487 -1.2092 -1.3946 
CD1D -1.6091 -1.3297 -0.5250 -1.0547 -1.4410 -1.4837 
AKR1C3 -1.6094 -1.3555 0.3238 -0.9022 -0.6371 -1.0622 
RP11-120K18.3 -1.6118 -1.8682 0.2164 -1.0512 -1.1671 -2.6851 
MTMR9LP -1.6127 -1.5077 -0.0472 -1.1699 -1.6724 -2.2550 
C10orf2 -1.6149 -0.4378 -0.3467 -0.7050 -0.7937 -0.1141 
PPARGC1B -1.6150 -1.1013 -0.4706 -1.1106 -1.4131 -1.6861 
PHYHD1 -1.6152 -0.4395 0.4766 -0.5580 -0.9563 -1.4956 
RNASEH2B-AS1 -1.6165 -0.8225 -0.8246 -0.7881 -1.3919 -1.8634 
ZNF589 -1.6279 -1.2809 -0.3993 -1.1899 -1.3908 -1.7866 
ZBED3 -1.6361 -0.9645 -0.3333 -1.2902 -1.4852 -1.6352 
AP001056.1 -1.6401 -0.9178 0.0060 -1.3513 -1.3408 -1.3314 
PDE6G -1.6409 -0.9430 -0.4698 -1.0191 -1.4695 -1.9299 
CABLES1 -1.6460 -1.3164 -0.1420 -0.7530 -1.0606 -1.4515 
PIK3C2B -1.6460 -1.1394 -0.2768 -1.1896 -1.0497 -1.4978 
GRAMD1B -1.6542 -1.3332 -0.0372 -1.0222 -1.2053 -1.8253 
AC079767.4 -1.6589 -1.3065 -0.0042 -1.0233 -1.7629 -2.3994 
PHLDA3 -1.6628 -2.1532 -0.8497 -1.8251 -1.7367 -1.5704 




XYLT1 -1.6640 -1.3131 -0.1923 -1.2733 -1.3295 -1.9424 
RASGRP3 -1.6667 -1.3148 -0.1490 -1.0106 -1.4060 -2.1731 
RP11-54C4.1 -1.6711 -1.1085 0.1118 -0.1409 -1.5021 -1.2255 
PDGFB -1.6733 -0.7407 0.1392 -0.9211 -1.2328 -1.8383 
CTD-2516F10.2 -1.6733 -1.3869 -0.5370 -1.3933 -1.4705 -2.2445 
CTSF -1.6746 -1.9353 -0.1364 -1.6737 -1.2903 -2.3698 
CTC-329D1.2 -1.6771 -0.0965 -0.3447 -0.6413 -0.4020 -0.8050 
AC006272.2 -1.6800 -1.4537 0.0401 -0.9372 -1.1516 -1.1478 
PLA2G16 -1.6808 -1.0945 -0.2314 -0.6366 -0.9272 -1.1625 
MYCL1 -1.6840 -1.7164 -0.2369 -1.1515 -1.1895 -1.7713 
CTB-31N19.3 -1.6856 -1.4780 -0.1159 -0.8429 -1.8126 -2.1001 
APOC1 -1.6938 -2.7498 -1.0649 -1.9594 -1.8460 -2.8946 
IGF1 -1.7126 -1.1229 0.1421 -0.8725 -1.4653 -2.1272 
DCSTAMP -1.7161 -2.0377 -1.5155 -2.3400 -1.2238 -2.9403 
PIK3R3 -1.7194 -1.1800 -0.5156 -1.4036 -1.4803 -1.6060 
JAG1 -1.7287 -0.9401 0.0164 -1.1789 -1.4540 -1.8949 
AP000783.1 -1.7326 -0.5843 0.2662 -0.6480 -0.8688 -1.2774 
SMPD3 -1.7391 -1.5056 -0.3364 -1.0569 -1.5399 -1.7112 
FAIM3 -1.7414 -2.1860 -1.2557 -1.9233 -1.7494 -2.3963 
CDK18 -1.7493 -1.6199 -0.1168 -1.2033 -1.3391 -1.6731 
Sep-03 -1.7494 -1.5719 -0.0195 -0.8826 -1.1978 -2.0272 
SPTBN1 -1.7512 -1.7308 -1.0409 -1.6384 -1.8012 -1.6988 
ACP5 -1.7534 -1.6232 0.0406 -1.2305 -1.4462 -2.3945 
RP11-471B22.2 -1.7593 -0.5665 0.1186 -0.1881 -0.4893 -0.4899 
AP001053.11 -1.7627 -1.5266 -0.1491 -1.2597 -1.6800 -2.4762 
QPRT -1.7652 -1.3534 -0.3862 -1.2284 -1.4382 -1.4708 
AP001007.1 -1.7736 -1.2065 -0.0337 -1.0381 -1.5081 -2.0220 
RP11-465B22.3 -1.7764 -1.0537 0.1226 -0.3216 -1.0815 -2.0462 
SELL -1.7900 -1.6557 -0.1852 -1.2929 -1.6386 -1.8375 
AL353354.1 -1.7902 -0.6839 0.2605 -0.0793 -0.0984 0.1013 
RP11-389C8.2 -1.7917 -1.1232 -0.6472 -0.9709 -0.8155 -1.0560 
RP11-672A2.6 -1.7977 -0.7559 0.4555 -1.1910 -2.4376 -1.0113 
KCNC4 -1.7984 -1.4442 -0.2922 -0.8220 -1.5701 -2.0761 
CHST15 -1.7997 -1.1269 -0.1549 -1.0720 -1.6100 -1.7917 
TNNI2 -1.8027 -1.4753 -0.4566 -1.3946 -1.6203 -2.0397 
AC022007.5 -1.8119 -1.0507 -0.1996 -1.3898 -1.1627 -1.1705 
SLC37A2 -1.8164 -1.5334 -0.2717 -1.3925 -1.6464 -2.1774 
GYPC -1.8177 -1.1214 -0.1513 -0.9436 -1.3488 -1.7583 
HTRA1 -1.8194 -2.2689 -0.1195 -1.3758 -1.6403 -2.0554 
RP11-356N1.2 -1.8386 -0.9756 -0.0193 -0.5895 -1.4297 -1.6058 
CD52 -1.8477 -1.6511 -1.0093 -1.7252 -1.3255 -2.0261 
ESCO2 -1.8524 -1.1830 -0.0551 -0.6806 -1.5160 -2.1446 




CENPV -1.8638 -1.0287 -0.1948 -0.1855 -0.6200 -1.0072 
JUP -1.8681 -1.8634 -0.1990 -1.4882 -1.6532 -2.4046 
PHACTR1 -1.8902 -1.4848 -0.1607 -0.9293 -1.6116 -2.3472 
TNFRSF18 -1.8926 -1.1378 -0.3648 -0.7376 -0.9525 -1.1128 
HBEGF -1.8943 -2.5356 -0.2749 -1.7525 -1.5199 -2.6471 
NLE1 -1.9076 -0.7335 -0.6033 -1.3953 -1.0971 -0.8577 
HSH2D -1.9353 -1.6958 -0.1674 -1.4383 -1.6342 -2.1414 
MMP2 -1.9445 -1.7336 0.0651 -1.3041 -1.5222 -1.6593 
U62631.5 -1.9460 -2.3963 -0.7179 -1.4358 -3.1210 -5.4429 
FCN1 -1.9519 -1.5700 -0.1262 -1.2329 -1.8502 -2.4076 
SOX4 -1.9641 -1.6948 -0.6093 -1.4775 -1.4311 -2.0945 
DNM3 -1.9737 -1.4236 -0.2835 -1.5291 -1.5718 -2.2591 
MGST1 -1.9753 -1.5946 -0.2076 -1.1174 -1.2426 -1.9296 
PTPN22 -1.9776 -1.7223 -0.1778 -1.5998 -1.7486 -2.5548 
TM4SF19 -1.9854 -2.4014 -1.6866 -2.2449 -2.0103 -3.0511 
TFAP4 -1.9858 -1.3980 -0.4761 -1.3491 -1.6662 -2.0176 
MTSS1L -1.9889 -1.5257 -0.4164 -1.5231 -1.2776 -1.5135 
PYHIN1 -2.0000 -1.5291 0.1618 -1.4258 -1.1399 -2.0428 
RASAL1 -2.0004 -2.0981 -0.4983 -1.6658 -1.9433 -3.1476 
CMBL -2.0009 -1.5162 0.4486 -0.8944 -1.2904 -2.1491 
NQO1 -2.0066 -1.5108 -0.1342 -1.0301 -1.5903 -1.7638 
MMP23A -2.0086 -5.8826 1.3821 0.6414 0.6415 -1.0272 
ADORA2B -2.0255 -0.8247 -0.3249 -1.2571 -1.2734 -1.8876 
GRIP1 -2.0312 -1.5337 -0.0445 -1.1354 -1.6740 -1.9391 
ZMIZ1-AS1 -2.0326 -2.6775 -0.5043 -1.7343 -2.2272 -2.7200 
ZFP36L2 -2.0371 -1.7525 -0.3107 -1.6487 -1.6648 -2.4112 
MARCKSL1 -2.0576 -1.3653 -0.4575 -1.0479 -1.3164 -1.2832 
AP001055.6 -2.0684 -1.4222 -0.1864 -1.5972 -1.9359 -2.1900 
LSP1 -2.0697 -1.9761 -0.6057 -1.9558 -2.0537 -2.6122 
CAMKK1 -2.1018 -1.3557 -0.6533 -1.4878 -1.9825 -1.8155 
RGS1 -2.1048 -2.1277 -0.7695 -1.8138 -1.8441 -2.0153 
LHFP -2.1184 -2.2477 -0.9025 -1.4729 -0.7643 -1.3606 
NINL -2.1235 -1.5901 0.2537 -1.1941 -1.5269 -2.7849 
METAP1D -2.1307 -1.0632 -0.4302 -1.2308 -1.2933 -1.2237 
GCSAM -2.1383 -0.9083 -0.4820 -1.7701 -1.6506 -1.9718 
SULF2 -2.1414 -1.6080 -0.0936 -1.5486 -2.0161 -3.0181 
ITGA11 -2.1549 -1.9527 -0.8161 -1.3800 -2.1702 -2.2488 
OASL -2.1618 -0.4357 0.4407 -0.5716 -1.0594 -1.2843 
CTB-179K24.4 -2.1699 -0.8934 -0.4479 -0.7462 -0.9965 -1.3326 
NOTCH3 -2.1711 -3.0792 -0.6103 -1.7905 -1.4514 -2.5500 
CSF1 -2.1767 -2.4318 -1.3890 -2.0395 -2.1182 -2.2309 
AC100830.5 -2.1791 -1.7706 -2.1470 -1.5322 -1.2354 -1.9023 




PTPLAD2 -2.1875 -1.8747 -0.1292 -1.5082 -1.8438 -2.2304 
SLC40A1 -2.2057 -2.2115 -0.0255 -1.8039 -1.9584 -3.0381 
CRABP2 -2.2173 -2.0727 -1.4868 -2.6704 -2.0901 -3.0998 
RP11-760H22.2 -2.2190 -1.2514 -0.0004 -1.0466 -1.6075 -1.2746 
CCL5 -2.2317 -1.4890 -0.4268 -1.3292 -1.7709 -2.1781 
DHDH -2.2357 -0.5100 -0.4337 -0.7216 -2.0602 -1.4530 
OLFML3 -2.2425 -2.8423 0.1947 -1.0708 -1.6433 -1.6372 
C11orf21 -2.2448 -1.5823 -0.3625 -1.6555 -1.8856 -2.7427 
SPARC -2.2456 -2.4241 -0.1890 -1.6693 -1.7275 -2.4925 
SPN -2.2551 -1.6704 -1.2091 -2.1453 -1.6057 -1.8434 
ZNF618 -2.2610 -2.3659 -0.3827 -1.8049 -2.2025 -2.8419 
TSPAN32 -2.2778 -1.3229 -0.2805 -1.4474 -2.2090 -2.1551 
SERPINB2 -2.2870 -1.5040 0.4382 -1.0071 -2.1156 -2.4707 
TNFRSF21 -2.2945 -1.6464 -0.4722 -1.7350 -2.3279 -2.9423 
LEPREL4 -2.2999 -1.9499 -0.1733 -1.6070 -2.0753 -3.3944 
GDF15 -2.3012 -1.7687 -0.6631 -1.7131 -1.6913 -2.2542 
C11orf89 -2.3062 -2.4119 -0.5612 -1.7455 -2.0550 -2.9592 
ITGA3 -2.3095 -2.9016 -1.8753 -2.5354 -2.6351 -3.1889 
GADD45G -2.3312 -2.0569 -0.7070 -1.6439 -1.6988 -2.5630 
CD22 -2.3494 -2.0273 -0.5244 -1.7080 -2.3287 -2.8698 
LPL -2.3678 -2.7169 -2.0010 -2.2033 -1.7561 -2.6725 
TMEM255A -2.3680 -1.7316 -0.1499 -1.3913 -1.7114 -2.4647 
TREM2 -2.3812 -3.0239 -1.1318 -2.2048 -2.1961 -3.6716 
CTSL2 -2.3840 -2.5168 -0.9242 -2.4816 -3.1719 -2.7831 
TNFSF14 -2.3887 -1.9018 -1.6732 -2.8704 -2.0787 -1.8973 
FRMD3 -2.4361 -2.3885 -0.3538 -1.5574 -2.5236 -4.0631 
IFI44L -2.4447 -1.0274 0.2750 -0.3983 -1.8559 -2.3738 
RP11-1260E13.4 -2.4599 -1.6083 -0.6215 -1.2141 -2.1666 -2.5850 
MYO1A -2.4693 -2.4031 0.1355 -2.1584 -2.0512 -3.4416 
USP18 -2.4915 -1.8604 -0.0600 -0.7819 -2.0219 -2.1948 
ALK -2.4973 -1.7311 -0.1673 -1.7437 -1.9432 -3.0794 
SEMA3C -2.5004 -2.1409 -0.8025 -2.0116 -2.8499 -2.9524 
ATP6V0D2 -2.5295 -2.2272 -0.3822 -2.0006 -2.5508 -3.0746 
CFP -2.5776 -2.2071 -0.2516 -1.6525 -2.3815 -2.9519 
ALOX5AP -2.6213 -1.8704 -0.3174 -1.5775 -2.5151 -2.7369 
IL24 -2.6257 -2.7697 -0.4186 -1.4730 -1.1473 -1.5641 
CBX3P2 -2.6465 -1.5586 -0.8394 -0.8387 -0.5111 -0.6603 
AL449209.1 -2.6471 -0.9398 -0.2170 -0.6195 -1.3390 -2.2053 
ALDH1A1 -2.6713 -2.1661 -0.0521 -1.5844 -2.0970 -3.1700 
AC007246.3 -2.7146 -2.3318 -0.5096 -1.8938 -2.6542 -2.7196 
CCND1 -2.7655 -2.7012 -1.5657 -2.5212 -2.9646 -3.0416 
RP11-288L9.4 -2.7886 0.0430 1.2915 -0.7266 -2.3145 -1.5499 




AP1S3 -2.8171 -0.8369 -0.8883 -1.7554 -1.8462 -1.8705 
RP1-80N2.2 -2.8516 -2.3157 -2.1434 -2.6568 -2.2122 -2.2412 
APOBEC3A -2.8564 -2.5169 -0.4961 -1.4506 -2.0444 -4.6562 
TNFRSF4 -2.8659 -2.2249 -0.0836 -1.1162 -1.4767 -2.3054 
COL9A2 -2.8666 -2.0965 -1.4737 -2.4621 -2.2868 -1.9919 
LY9 -2.8710 -2.4180 -0.5010 -2.3775 -2.6490 -3.6717 
MRC2 -2.9054 -2.5990 -1.1321 -2.6319 -2.7152 -4.1015 
KCP -2.9120 -2.5200 -1.1729 -2.3575 -2.9433 -3.2314 
RTN4R -2.9189 -2.3038 -1.3436 -2.6451 -2.5805 -3.6773 
MFSD2A -3.0294 -2.5196 -0.5754 -1.7159 -2.6920 -2.6385 
RP11-807H22.7 -3.0342 -1.0811 -0.0420 -0.9997 -0.6443 -2.8741 
CXCL10 -3.0420 -2.5960 0.4020 -1.5867 -1.6642 -3.3523 
FXYD6 -3.1965 -2.5918 -0.1558 -1.9298 -2.6013 -3.4171 
OLR1 -3.2818 -3.2235 -1.1488 -2.4463 -2.8566 -4.1260 
TMEM119 -3.3012 -2.9825 -0.4152 -2.5178 -2.8776 -3.8565 
AC017104.6 -3.3012 -1.5098 -0.9882 -3.8111 -3.0958 -5.0444 
CD300LB -3.3156 -3.1967 -0.7679 -2.2065 -2.4894 -3.1478 
TREML1 -3.4098 -3.3347 -1.1630 -4.0354 -2.0991 -5.4429 
BTF3P7 -3.5354 -2.4433 -0.3445 -1.6150 -2.8702 -3.5178 
TIMP3 -3.5392 -3.5546 -2.7013 -2.6459 -2.9676 -4.2373 
F2RL3 -3.6576 -2.5196 -0.5871 -2.3784 -3.2661 -3.8013 
RUFY4 -3.6764 -3.1260 -0.3640 -2.0054 -2.4985 -4.2213 
SLC45A3 -3.7387 -2.2321 -0.9056 -2.5673 -2.8461 -3.6644 
AFF3 -3.8015 -3.6531 -1.3869 -3.5694 -3.9496 -4.1254 
CXCL11 -3.9025 -3.7815 0.8892 -1.3020 -1.6147 -3.0461 
RP11-511P7.2 -4.0081 -4.4181 -2.8192 -2.2895 -3.8345 -2.4566 
ALOX15B -4.0536 -3.9283 -1.1122 -3.4972 -4.6491 -5.6333 
AC104809.3 -4.1004 -7.1997 -1.2767 -3.5815 -3.1965 -4.5518 
TRPC2 -4.3699 -3.8579 -0.5387 -2.4160 -2.6706 -2.6027 
PADI2 -4.6922 -3.9667 -0.7430 -2.9882 -4.3534 -4.6289 






Appendix Table 2. CD8 RNA sequencing. Log2 fold change of genes 
significantly upregulated by WTD 50 nM > 0.6 log2 fold change and significantly 
downregulated by WTD 50 nM <-0.6 log2 fold change compared to non-IL-10 
treated cells and their corresponding regulation by the IL-10 variants. Only those 
in the WTD 50 nM were filtered for significance, other conditions were not filtered 
for significance. Fold change is the average of three biological replicates. 
WTD50= WTD 50 nM, R5D50= R5A11D 50 nM, WTM50= WTM 50 nM, R5M50= 
R5A11M 50nM, WTD01= WTD 0.1 nM, R5D01= R5A11D 0.1 nM 
 
Gene Name WTD50/US  R5D50/US  WTM50/US  R5M50/US  WTD01/US R5D01/US  
S100A9 4.4094 3.2977 -1.2630 4.2730 0.5025 2.1699 
SULT1B1 4.2299 3.3821 1.6337 3.7013 3.1997 3.5394 
EGFL7 3.7169 2.7309 1.1376 3.3331 1.5145 1.9995 
CTD-3094K11.1 3.6912 3.3808 1.1699 4.2977 2.3923 3.0732 
IGJ 3.5861 4.0461 2.7624 4.0041 2.6657 3.2909 
RCAN2 3.5411 2.7266 -0.0557 3.2525 1.6658 2.2109 
IGKV3-20 3.4951 4.4571 3.4509 4.3973 3.8051 4.5718 
ADD2 3.3725 2.8491 0.5555 2.4331 2.0101 2.5842 
SOCS3 3.3709 2.8327 0.5112 3.0319 1.4259 2.2220 
PAX5 3.2763 2.4840 0.3909 2.3487 0.3268 0.5540 
GPR34 3.2079 2.6507 -0.0706 2.8482 1.8133 2.6033 
CLU 2.7920 2.2149 0.3947 2.5114 1.3217 1.5630 
ACE 2.6878 1.9319 -0.8079 1.9458 1.0810 1.2853 
TDRD9 2.6821 1.4537 0.5574 2.1710 1.7762 1.3848 
GREM2 2.6649 1.4546 -0.4868 2.3499 0.6581 1.0092 
GZMB 2.6646 2.3496 0.6876 2.5717 1.1565 1.8722 
COX6B2 2.6125 0.9366 -0.0484 2.2121 0.1468 0.4479 
FES 2.5459 2.3636 0.2708 2.4099 1.2293 1.8744 
GNG7 2.4761 0.5796 0.5580 1.9889 0.8346 1.0987 
GSDMA 2.4736 2.0911 1.2572 1.9767 1.8279 2.2243 
MIAT 2.4432 2.1121 0.0646 2.1398 0.9752 1.1958 
RASL11A 2.4384 1.0710 0.3994 2.0397 1.0945 1.3859 
TIAM1 2.2790 2.0540 0.2696 1.9303 1.3945 1.9266 
EPHB3 2.2691 1.7559 1.0458 2.3564 2.6963 2.6132 
MAPK11 2.1734 1.6714 0.1249 1.8337 0.9150 1.2469 
SLC7A8 2.1413 1.5014 0.2086 2.1413 1.5611 1.7281 
HKDC1 2.1287 2.1329 0.7867 1.9741 2.1126 2.2474 
ZNRF1 2.1068 1.7068 0.2786 1.9822 0.7158 1.2224 
AC010761.13 2.0536 1.5436 0.0849 1.3863 1.4570 1.3283 
AC092566.1 2.0389 2.0219 0.3324 1.7894 1.5988 1.3415 




ITGAX 1.9691 1.7123 0.3466 1.7964 0.9428 0.9857 
SBNO2 1.9673 1.5933 0.0594 1.6784 0.7011 1.2169 
FUT7 1.9654 1.7857 0.3842 1.8594 1.2036 1.2750 
IGKV4-1 1.9296 0.7370 -0.1444 1.1312 1.0671 0.3890 
RCN3 1.8850 1.4973 0.4495 1.8546 0.6433 0.3424 
NPTX1 1.8184 1.5628 0.4170 1.5842 2.1250 2.1069 
RP3-324O17.4 1.7999 0.8050 0.9309 1.3542 1.0808 0.4719 
FURIN 1.7736 1.5611 0.3169 1.7164 0.7967 1.1583 
PRRG2 1.7488 0.7843 -0.2481 1.5509 1.1004 1.2743 
PI16 1.7385 1.6099 0.1877 1.5812 1.3659 1.0925 
ITGA6 1.7337 1.4634 0.1567 1.4830 1.0394 1.2745 
BCL3 1.7205 1.5895 0.2036 1.5766 0.8556 1.2078 
HSD3B7 1.7082 1.3484 0.4698 1.4350 0.7922 1.0456 
SPEG 1.6401 1.2444 0.3490 1.4453 1.3099 1.4755 
KIRREL2 1.6011 1.3146 0.2373 1.5493 0.6791 1.1171 
SERF1B 1.5933 1.7310 1.5485 2.3930 2.4012 1.8457 
JUN 1.5860 0.9438 -0.1648 1.2656 0.1007 0.6053 
SSTR3 1.5206 1.0241 0.2898 1.2268 -0.3034 0.4940 
CD9 1.5196 1.1217 0.3709 1.4080 0.9896 0.8136 
NPAS2 1.5081 1.3959 0.5483 1.4661 0.9190 1.2365 
KDSR 1.4818 1.1475 0.1212 1.2880 0.4423 0.7335 
INPP5A 1.4810 1.3779 0.2150 1.3680 0.8126 0.9554 
ROM1 1.4560 1.1574 -0.2438 1.2258 0.7410 0.7977 
RP11-17G12.2 1.4448 1.2429 0.8301 1.3867 1.4389 0.5452 
RP11-295G24.5 1.4301 0.0247 0.3495 0.4700 -0.0902 0.5130 
LGALSL 1.3902 0.8043 0.7960 1.5675 1.0288 0.7948 
INSL3 1.3900 1.2612 0.4182 1.6391 1.0651 1.1906 
PDGFRB 1.3653 1.3198 0.2413 1.4025 0.8092 0.8145 
IFNGR2 1.3585 0.9299 0.1628 0.9093 0.9391 1.2789 
TRAJ10 1.3536 1.6630 0.9594 1.1155 0.5305 0.7370 
FGFBP2 1.3482 1.2525 0.0764 1.4396 0.7234 0.8967 
S100B 1.3328 1.1100 0.2813 1.0464 0.9234 1.2346 
ITGA3 1.3320 1.0106 -0.1118 1.1482 0.3699 0.5161 
FAM110C 1.3301 0.8398 0.2130 1.0303 -0.0086 0.5843 
TCF7 1.3236 0.9537 0.1481 0.9756 0.9931 1.2439 
BCL7A 1.3185 1.0474 0.1887 1.0568 1.1669 0.9897 
RP11-18I14.7 1.3095 1.1202 0.2327 0.8171 1.0863 0.8439 
VWA5A 1.2811 0.9487 0.3038 1.2047 0.5081 0.6113 
TBXA2R 1.2783 1.1081 -0.0496 1.2509 1.3776 1.1460 
AL137059.1 1.2697 0.9772 -0.0778 1.3508 1.6858 1.6430 
RP11-798K23.5 1.2610 1.0886 0.1721 1.5493 0.9733 -0.6742 
CXCR6 1.2531 0.8268 0.0009 1.1064 0.1322 0.6068 




JAK3 1.2422 1.1410 0.2273 1.2091 0.7764 0.7726 
PSD 1.2354 0.6408 0.0237 1.3282 0.4114 0.8628 
SEMA4G 1.2165 0.8921 -0.3999 0.9769 0.6303 0.5201 
CCR7 1.2159 0.9578 0.1922 0.9602 0.8711 1.1020 
TRERF1 1.2044 0.9518 -0.0400 1.0553 0.3921 0.4744 
AC108463.1 1.2002 1.1762 0.2456 1.1444 0.4986 0.1033 
PARP9 1.1907 1.1381 0.2381 1.1899 0.7765 0.8959 
GPR35 1.1889 0.8570 0.0915 1.0670 0.4892 0.6918 
ZNF853 1.1825 0.8540 0.1145 0.9191 0.7261 0.6475 
ANKRD35 1.1751 0.6902 0.0312 0.7292 0.3775 0.5045 
GLDC 1.1429 0.8102 -0.0525 0.8904 -0.2524 0.3972 
LL0XNC01-237H1.2 1.1349 1.0437 0.9364 1.1176 0.5531 0.6858 
PLXNB2 1.1320 0.9518 0.0670 1.0217 0.5429 0.6374 
IL21R 1.1315 0.6832 -0.1596 0.9011 0.1775 0.2580 
TMEM150A 1.1271 0.7198 0.0730 0.9348 0.3139 0.5562 
PPP1R3B 1.1219 0.8598 -0.0504 0.9462 0.1917 0.5570 
AC108004.3 1.1204 1.4604 0.5452 1.5119 0.3326 0.3949 
CTD-2020K17.4 1.1136 0.8301 0.2730 0.6219 1.1592 0.1806 
SMARCD3 1.1096 0.9999 0.0917 1.1483 0.4083 0.4315 
MVP 1.1081 0.9638 0.1467 1.0498 0.7572 0.8055 
RP11-439L18.2 1.0997 0.7204 0.4360 0.9433 0.1018 0.7012 
CTA-445C9.15 1.0997 1.1687 -0.0109 1.1171 0.7020 0.7955 
RP13-977J11.8 1.0977 -0.2052 0.7468 0.4713 0.2910 0.3985 
LINC00852 1.0954 1.3142 0.7714 1.2331 0.9939 0.3815 
TMEM229B 1.0936 0.8268 -0.0570 0.9014 0.9322 0.8091 
GP5 1.0919 1.1886 0.3863 1.3571 0.8863 0.8545 
AC004383.4 1.0818 1.7152 0.7442 0.3785 0.8005 0.7261 
CD7 1.0754 0.8389 0.0852 0.9246 0.7013 0.7083 
PTGDS 1.0746 1.0545 -0.3026 1.1139 1.1691 0.9937 
BATF 1.0732 0.7648 0.0719 0.9647 0.2772 0.4741 
CMTM8 1.0703 0.3392 0.0520 0.9367 0.5016 0.4115 
MGAT3 1.0648 0.8014 0.1747 0.7618 1.0333 0.9251 
MAP3K6 1.0614 1.0319 0.0258 0.9861 0.4695 0.4677 
RAB38 1.0590 0.2681 0.1010 0.9361 -0.1583 0.0160 
REG4 1.0472 0.7948 -0.0298 0.9173 0.9651 1.0876 
MUC1 1.0430 1.0857 0.1959 0.9253 0.8550 0.6496 
AGXT2L2 1.0429 0.8361 -0.0557 0.9632 0.4062 0.4923 
HRH2 1.0225 0.8887 0.1537 1.0063 0.3871 0.4707 
HAPLN3 1.0124 0.9586 0.1082 0.9593 0.7764 0.8346 
LRP5 1.0122 0.8306 -0.0319 0.8136 0.6776 0.7277 
PMEL 1.0008 0.4556 -0.0539 0.6612 0.8659 0.3306 
RP11-270C12.3 0.9985 0.4567 0.7635 0.7274 0.0744 0.4584 




SEMA7A 0.9841 0.8361 0.0442 0.8499 0.3841 0.5796 
CCR1 0.9822 1.1451 0.2395 1.1530 0.5359 0.7528 
ARHGEF4 0.9805 1.0210 0.1638 0.9219 1.1913 0.8690 
RAB15 0.9735 0.9260 0.0046 0.7382 0.6742 0.6727 
DLGAP4 0.9714 0.9211 0.0557 0.9864 0.6001 0.5761 
ARL5B-AS1 0.9577 0.5621 0.5638 0.8333 -0.2152 -0.2855 
IL17RA 0.9566 0.8755 -0.0837 0.8976 0.6165 0.5524 
GIMAP7 0.9540 0.7672 0.0279 0.8782 0.4981 0.6637 
IGLV2-14 0.9475 0.4004 -0.4772 0.5179 0.0944 -0.0052 
GAL3ST4 0.9456 0.7478 0.1109 0.5788 0.6992 0.6382 
EEPD1 0.9395 0.5194 -0.3001 0.5674 0.1944 0.2578 
RIMS3 0.9209 0.8199 -0.0710 0.8422 0.3558 0.5881 
TREX2 0.9204 0.8561 0.0336 0.6366 0.5743 0.3745 
GIMAP8 0.9001 0.7038 -0.1031 0.7712 0.3967 0.6407 
DAPK2 0.8957 0.8517 0.4130 1.2003 0.4024 0.5792 
SERTAD1 0.8946 0.6558 0.1545 0.8265 0.4717 0.5013 
STAT3 0.8872 0.7916 0.0883 0.8129 0.5037 0.5756 
RP11-796G6.2 0.8810 0.3029 -0.1386 0.7609 -0.0116 0.4130 
SH3BP5 0.8666 0.7316 -0.1544 0.8829 0.3186 0.4360 
RENBP 0.8654 0.6442 0.1251 0.7790 0.5984 0.6536 
ADORA2B 0.8578 0.4718 -0.1532 0.3534 0.2765 0.6638 
TPST2 0.8498 0.8178 0.0406 0.8720 0.5381 0.5513 
MAST4 0.8360 0.7024 -0.0829 0.8743 0.3908 0.2315 
MAP3K5 0.8341 0.6513 -0.0975 0.7405 0.2332 0.4236 
LAG3 0.8316 0.7183 0.0851 0.8984 -0.0010 0.3322 
DENND6B 0.8315 0.5382 0.0226 0.6214 0.2287 0.2584 
FLVCR2 0.8312 0.4693 0.0672 0.5335 -0.0684 -0.2824 
MEMO1P1 0.8265 0.7054 0.4417 0.9349 0.2899 1.5536 
RAB3A 0.8243 0.9115 0.3148 0.8929 0.5641 0.4353 
PADI4 0.8233 0.8298 0.2115 0.4394 0.5919 0.7858 
ROGDI 0.8217 0.6839 -0.3264 0.6528 0.4789 0.3700 
GIMAP5 0.8165 0.6635 -0.0141 0.7376 0.2966 0.5281 
PHOSPHO1 0.8133 0.8594 -0.2631 0.6131 0.1884 0.6288 
PLEKHN1 0.8133 0.7060 0.1998 0.8718 0.0565 0.5190 
IL18RAP 0.8073 0.7668 -0.0491 0.8499 0.0823 0.4445 
PITPNM2 0.8024 0.7558 -0.0955 0.7925 0.4488 0.4785 
UBASH3B 0.7886 0.6245 0.0755 0.7865 0.4724 0.4459 
RP1-257I20.14 0.7867 0.5640 0.7124 1.0400 0.6015 0.2331 
APBA2 0.7858 0.4662 -0.1082 0.4862 0.3480 0.4800 
APOL1 0.7854 0.7229 0.0430 0.7996 0.4504 0.4503 
IMPDH1 0.7836 0.6201 0.1028 0.7298 0.4984 0.4173 
C19orf35 0.7778 0.4423 -0.0687 0.1149 0.5501 0.4732 




LINC00035 0.7702 0.3306 -1.1393 0.6877 0.6345 0.2730 
RP11-61L23.2 0.7699 0.5962 0.2994 0.7096 0.1793 -0.0850 
RP11-289I10.2 0.7673 1.2903 -0.1993 0.7644 0.8994 0.8798 
SPHK1 0.7627 0.5053 0.1780 0.7440 0.6423 0.5322 
ABCA2 0.7537 0.7962 -0.0213 0.7470 0.3635 0.3267 
STOM 0.7492 0.6328 -0.0334 0.7740 0.1804 0.3851 
IL18R1 0.7480 0.7600 0.0816 0.7811 0.3333 0.6962 
CTD-2267D19.3 0.7438 0.3207 0.1048 0.3953 0.6307 0.3137 
RAB11FIP5 0.7408 0.7306 0.0436 0.8760 0.3367 0.2161 
NOL3 0.7383 0.9188 0.9970 1.1162 0.4394 0.5300 
NBEAL2 0.7376 0.7801 -0.1070 0.7631 0.4502 0.3562 
FBXO32 0.7369 0.3694 -0.1456 0.6327 0.1839 0.1119 
GOLGA7B 0.7355 0.7015 -0.0259 0.7414 0.7162 0.5613 
DTNBP1 0.7265 0.5340 0.0926 0.7365 0.2363 0.2647 
NECAB3 0.7254 0.6713 -0.0541 0.7291 0.5883 0.5883 
LIMS2 0.7249 0.6265 0.2844 0.6005 0.8015 0.6104 
WNT11 0.7245 0.5758 -0.3878 1.1123 -0.2859 0.0034 
BRSK1 0.7228 0.6330 0.1429 0.6095 0.2743 0.4406 
SIAE 0.7195 0.4620 -0.0030 0.6741 0.3190 -0.0753 
SNX29 0.7184 0.4159 -0.1522 0.6078 -0.0237 -0.1148 
MAN2A2 0.7173 0.7191 -0.1009 0.7039 0.2896 0.2257 
NBPF16 0.7115 1.1618 0.0593 0.2825 0.9437 0.5372 
SLC12A9 0.7069 0.6832 -0.1131 0.6717 0.2959 0.2017 
PRPS1P2 0.7065 0.5003 0.3010 0.7730 0.6453 0.2265 
IGSF9B 0.7052 0.8180 -0.0863 0.6767 0.7907 0.7674 
DECR2 0.7028 0.2114 0.0791 0.7317 0.0955 -0.1808 
SLC6A8 0.7014 0.7260 0.6051 1.0311 0.4129 0.4599 
FBXO2 0.6966 0.4855 0.2254 0.7315 0.4711 0.5675 
RP5-1028K7.2 0.6963 0.5563 -0.0858 0.6444 0.3452 0.3765 
KLHDC8B 0.6953 0.5103 0.6644 0.3170 0.4633 -0.1097 
GNPDA1 0.6874 0.4903 0.0629 0.6814 0.4065 0.4537 
JUNB 0.6874 0.4737 -0.0685 0.6268 0.0128 0.1589 
NARF 0.6791 0.4733 -0.1012 0.6356 0.1192 0.1483 
AC002310.12 0.6786 -0.0495 0.4857 0.4757 0.5158 -0.0636 
TRIB2 0.6730 0.4687 -0.2087 0.5774 0.3663 0.2908 
TRAJ3 0.6695 0.6608 -0.4475 0.5804 1.0671 -0.9505 
DTX3L 0.6693 0.7203 0.0700 0.7338 0.4903 0.5259 
LGALS3BP 0.6606 0.6118 0.1214 0.6004 0.6319 0.6408 
TTC21A 0.6596 0.5599 -0.0671 0.7725 0.2442 -0.0959 
MIDN 0.6586 0.6857 0.0100 0.6526 0.4420 0.4314 
NBPF15 0.6578 0.6932 -0.0770 0.6951 0.3582 0.3248 
LINS 0.6541 0.5601 -0.0775 0.6282 0.2292 0.2948 




CA6 0.6499 0.5920 0.1107 0.7425 0.8401 0.4063 
CLIP3 0.6466 0.1786 0.2669 0.7381 0.3148 0.2502 
NOTCH2NL 0.6457 0.9326 -0.0573 0.7531 0.1313 0.4725 
TXK 0.6434 0.5188 -0.1173 0.6191 0.2076 0.3067 
COL6A2 0.6401 0.4132 -0.1206 0.5348 0.4651 0.5491 
PGS1 0.6318 0.6094 -0.0374 0.6892 0.2195 0.1618 
RHPN2 0.6312 0.3257 0.1909 0.8957 0.7089 0.2674 
RP11-561C5.4 0.6300 0.4768 0.3768 0.8122 -0.1203 0.1705 
APOL2 0.6299 0.5907 -0.0119 0.5485 0.3699 0.3853 
NOSIP 0.6288 0.5559 0.0381 0.6767 0.6146 0.4102 
NPDC1 0.6280 0.5936 -0.0225 0.6944 0.4000 0.0994 
COL18A1 0.6259 0.5108 0.0294 0.6974 0.3461 0.1631 
SLC24A6 0.6251 0.5131 -0.2912 0.5244 0.2108 0.2369 
GRASP 0.6165 0.4547 0.0896 0.7128 0.6311 0.6218 
ABLIM1 0.6154 0.5887 -0.0430 0.7321 0.4713 0.3518 
SEMA4B 0.6132 0.6353 -0.0310 0.6384 0.2786 0.3122 
C14orf64 0.6113 0.5473 -0.1850 0.4344 0.2833 0.3204 
RPP21 0.6019 0.7528 -0.4003 0.6969 0.5090 0.5733 
CPEB4 0.6015 0.6300 -0.0052 0.5740 0.3698 0.2981 
SYNJ2 0.6013 0.6717 0.0408 0.6775 0.4735 0.3614 
NPM1P27 -0.6005 -0.3284 -0.1394 -0.2552 -0.2794 -0.5053 
ZNF286B -0.6005 -0.1049 -0.6019 -0.7846 -0.4986 -0.8367 
QPCTL -0.6013 -0.3373 -0.0184 -0.2465 -0.2963 -0.5474 
FBXO34 -0.6018 -0.3662 -0.1905 -0.3096 -0.3398 -0.5169 
PPAP2A -0.6018 -0.4165 -0.0342 -0.3823 -0.0318 -0.3230 
TRMT11 -0.6025 -0.3088 -0.1153 -0.2956 -0.3635 -0.5610 
STAT4 -0.6031 -0.3063 -0.0946 -0.2503 -0.1327 -0.3403 
SDC4 -0.6035 -0.3336 -0.0774 -0.3245 -0.2890 -0.3849 
ARHGAP10 -0.6039 -0.3067 -0.0917 -0.3968 -0.2698 -0.6143 
DUSP6 -0.6049 -0.3177 -0.0928 -0.2209 -0.1804 -0.4381 
FAM69A -0.6050 -0.4698 -0.1339 -0.2992 -0.1173 -0.4665 
CHEK1 -0.6055 -0.3137 -0.0867 -0.3116 -0.2078 -0.5291 
SLC4A10 -0.6058 -0.3026 -0.0829 -0.0851 -0.4620 -0.4856 
RP11-495P10.2 -0.6060 -0.0622 -0.1890 -0.2048 -0.1176 -0.5086 
SLC25A40 -0.6073 -0.2636 -0.0766 -0.2947 -0.2404 -0.4814 
RAD51B -0.6082 -0.2603 0.0018 -0.2440 -0.3111 -0.3853 
LIM2 -0.6084 -0.3503 -0.1626 -0.4638 -0.6467 -0.2217 
RP11-10O17.2 -0.6086 -0.5203 -0.0472 -0.2083 -0.2705 -0.3996 
AC069282.6 -0.6099 -0.0654 -0.5122 -0.5131 -0.6171 -0.8820 
TEX30 -0.6101 -0.3862 -0.0539 -0.3073 -0.1756 -0.5856 
TIFA -0.6103 -0.4148 -0.2492 -0.5162 -0.3496 -0.5680 
KLHDC2 -0.6105 -0.4587 -0.1817 -0.4109 -0.3760 -0.5570 




GPHN -0.6109 -0.3993 -0.0809 -0.1176 -0.1871 -0.5048 
HBEGF -0.6124 -0.1363 0.2958 0.2060 -0.3876 -0.4452 
AMIGO2 -0.6130 -0.2646 -0.1966 -0.2763 -0.2828 -0.4220 
C17orf75 -0.6139 -0.3293 -0.1037 -0.2563 -0.1979 -0.5573 
USP13 -0.6140 -0.2775 -0.1476 -0.3268 -0.2475 -0.5318 
FOXO3 -0.6140 -0.3099 -0.3485 -0.3159 -0.2715 -0.5121 
SNX16 -0.6154 -0.1280 -0.0137 -0.2255 -0.2241 -0.3975 
TMEM154 -0.6156 -0.3784 -0.2141 -0.3859 -0.5950 -0.7775 
RP11-815I9.4 -0.6164 -0.1908 -0.0735 -0.1397 -0.4794 -0.1986 
CACNA2D4 -0.6183 -0.3905 -0.3534 -0.7456 -0.4601 -0.4843 
PER1 -0.6187 -0.3303 -0.1992 -0.2450 -0.3088 -0.5281 
BPHL -0.6188 -0.3577 -0.3491 -0.4536 -0.2185 -0.4062 
AP001877.1 -0.6189 0.5070 -0.2611 0.4020 0.1624 -0.3949 
TNFRSF10B -0.6189 -0.4588 -0.2469 -0.5245 -0.3477 -0.6097 
ZNF85 -0.6190 -0.2208 -0.2001 -0.5348 -0.3269 -0.5383 
TMEM116 -0.6193 -0.4096 -0.1300 -0.5089 -0.3504 -0.6693 
BRPF3 -0.6205 -0.2769 -0.2255 -0.3284 -0.2505 -0.5126 
AUNIP -0.6222 -0.3117 -0.0812 -0.3376 -0.1965 -0.5169 
SOX12 -0.6225 -0.8855 -0.1170 -0.4052 -0.3736 -0.8175 
KB-431C1.4 -0.6226 -0.1731 -0.0950 -0.3026 -0.3140 -0.4240 
ADAM9 -0.6231 -0.2597 0.0657 -0.2810 -0.4900 -0.6808 
C11orf1 -0.6231 -0.4318 -0.1703 -0.3541 -0.3713 -0.7032 
RP3-475N16.1 -0.6239 -0.3738 -0.3895 -0.2487 -0.3792 -0.6670 
B4GALT2 -0.6241 -0.2980 -0.0615 -0.2003 -0.1935 -0.5220 
ZCCHC14 -0.6241 -0.2390 -0.3660 -0.5761 -0.4081 -0.6076 
DUSP1 -0.6242 -0.4222 -0.1132 -0.3658 -0.1087 -0.4848 
HNRPLL -0.6244 -0.3653 -0.2124 -0.3133 -0.3530 -0.5319 
DERL3 -0.6244 -0.1555 -0.1693 -0.3015 -0.1598 -0.5889 
ADAMTS1 -0.6248 -0.0799 -0.1863 -0.1312 -0.1948 -0.5145 
LINC00674 -0.6252 -0.4075 -0.4368 -0.4667 -0.4048 -0.5564 
TBKBP1 -0.6269 -0.2467 -0.1951 -0.1938 -0.3537 -0.7359 
USP22 -0.6271 -0.3454 -0.2131 -0.3457 -0.2885 -0.5467 
SPINT1 -0.6272 -0.4832 -0.1152 -0.2306 -0.2149 -0.2913 
RAD50 -0.6273 -0.3046 -0.1853 -0.2737 -0.3599 -0.5948 
DUSP5 -0.6279 -0.2802 -0.1857 -0.1519 -0.4475 -0.5696 
DNAJC1 -0.6281 -0.4468 -0.2774 -0.4213 -0.4538 -0.4528 
AL450992.2 -0.6290 -0.3518 -0.3960 -0.3978 -0.4546 -0.6456 
RPL22L1 -0.6293 -0.3607 0.0025 -0.2184 -0.3688 -0.7901 
ZFP69B -0.6294 -0.4417 -0.2425 -0.3434 -0.6007 -0.6789 
APP -0.6300 -0.5119 -0.0854 -0.4666 -0.4692 -0.6249 
NCF4 -0.6301 -0.3959 -0.2073 -0.3295 -0.4714 -0.6015 
ITGB1P1 -0.6318 -0.3720 -0.2487 -0.2992 -0.3195 -0.6127 




SNX9 -0.6337 -0.4079 -0.2420 -0.3706 -0.5636 -0.6176 
RP5-886K2.3 -0.6343 -0.5169 -0.7513 -0.4732 -0.5804 -0.6016 
ITGB1 -0.6345 -0.3392 -0.2668 -0.3563 -0.3389 -0.5364 
ACYP1 -0.6348 -0.2714 -0.1412 -0.2789 -0.0256 -0.4083 
MTO1 -0.6355 -0.4394 -0.1646 -0.3770 -0.4455 -0.6098 
ACCS -0.6359 -0.4921 -0.2879 -0.3176 -0.3186 -0.6076 
HLA-DPA1 -0.6361 -0.3658 -0.1753 -0.2657 -0.4504 -0.6592 
NAP1L1 -0.6363 -0.3663 -0.1547 -0.3225 -0.3042 -0.5770 
RNF135 -0.6372 -0.4704 -0.2477 -0.3786 -0.4369 -0.6678 
SIGLEC9 -0.6376 -0.4675 -0.4619 -0.6703 -0.0393 -0.8488 
ADRB2 -0.6377 -0.2219 -0.2234 -0.3111 -0.2433 -0.3207 
EBP -0.6389 -0.2591 -0.0174 -0.1537 -0.1051 -0.4044 
MLF1IP -0.6397 -0.3513 -0.1734 -0.4338 -0.2694 -0.5122 
DOCK7 -0.6402 -0.5990 -0.2535 -0.4607 -0.4410 -0.7508 
TMEM121 -0.6402 -0.5507 -0.1876 -0.3249 -0.2299 -0.6237 
FAM110A -0.6402 -0.3290 -0.1487 -0.4918 -0.3295 -0.5220 
FSTL3 -0.6405 0.0669 -0.2878 -0.2082 -0.2643 -0.2223 
NETO2 -0.6406 -0.2224 0.0096 -0.2610 -0.4575 -0.6912 
GTSF1 -0.6406 -0.1275 -0.0431 -0.2002 -0.3135 -0.3476 
P2RX7 -0.6408 -0.2394 -0.2920 -0.2035 -0.3287 -0.5733 
AHR -0.6414 -0.3756 -0.1548 -0.3773 -0.3737 -0.4799 
RTN4R -0.6416 -0.1177 -0.1788 -0.2167 -0.1718 -0.3935 
RPSAP9 -0.6418 -0.5468 0.3828 -0.1801 0.0261 -0.5871 
ERBB2 -0.6425 -0.0880 -0.1522 -0.0953 -0.4416 -0.5923 
SFR1 -0.6427 -0.3338 -0.1107 -0.2312 -0.2273 -0.4418 
INPP4B -0.6427 -0.3367 -0.2380 -0.4487 -0.3685 -0.6094 
AC125232.1 -0.6431 -0.3144 0.0112 -0.3031 -0.4415 -0.4278 
ERN1 -0.6445 -0.4341 -0.4223 -0.4248 -0.7295 -0.8623 
FAM212A -0.6452 -0.3583 -0.3852 -0.6275 0.4273 -0.6521 
MNAT1 -0.6452 -0.3126 -0.0118 -0.2497 -0.2512 -0.4841 
TMEM107 -0.6452 -0.3411 -0.2386 -0.4052 -0.2533 -0.5515 
CENPH -0.6453 -0.4529 -0.1242 -0.4094 -0.2753 -0.5799 
FBXO43 -0.6466 -0.3659 -0.4267 -0.3341 -0.1881 -0.6638 
HIBADH -0.6469 -0.5187 -0.2860 -0.3985 -0.4971 -0.6355 
SLC35F2 -0.6472 -0.2394 -0.1404 -0.2563 -0.4016 -0.4808 
FAM3C -0.6480 -0.2832 -0.2240 -0.2625 -0.5894 -0.6211 
PLEKHO1 -0.6481 -0.4411 -0.2276 -0.3744 -0.1639 -0.4465 
ZNF702P -0.6487 -0.0231 0.1286 -0.0487 0.1993 0.3762 
TRIM16 -0.6488 -0.3986 -0.1390 -0.2279 -0.3233 -0.8126 
AP1AR -0.6488 -0.3473 -0.1986 -0.3454 -0.4836 -0.4587 
AFMID -0.6491 -0.4783 -0.2241 -0.3366 -0.3728 -0.4686 
P2RY11 -0.6496 -0.3326 -0.3369 -0.2927 -0.2645 -0.3970 




SMIM19 -0.6516 -0.3703 -0.3265 -0.4601 -0.2471 -0.4884 
OXR1 -0.6523 -0.3255 -0.2397 -0.3896 -0.3499 -0.5119 
C4orf33 -0.6527 -0.3408 -0.0970 -0.3212 -0.3067 -0.4421 
FABP5 -0.6538 -0.3255 0.0020 -0.2863 -0.2824 -0.5234 
TREML2 -0.6539 -0.1515 0.0746 -0.1612 0.0638 -0.3212 
DYRK4 -0.6543 -0.3533 -0.0957 -0.2670 -0.3600 -0.4683 
CCDC7 -0.6544 -0.5610 -0.0765 -0.7052 -0.6906 -0.6721 
HOXC4 -0.6553 -0.4404 -0.4474 -0.2975 -0.4845 -0.7303 
AC073046.25 -0.6556 -0.1696 -0.0274 -0.1909 -0.2384 -0.3054 
TCTN3 -0.6557 -0.4001 -0.1454 -0.3620 -0.4492 -0.6103 
SIAH2 -0.6567 -0.4300 -0.1653 -0.3193 -0.4520 -0.5854 
PPM1L -0.6570 -0.3807 -0.2636 -0.2894 -0.3353 -0.6510 
IQCG -0.6573 -0.2624 -0.0784 -0.4061 -0.2324 -0.5185 
C17orf53 -0.6578 -0.4352 -0.2270 -0.3609 -0.2201 -0.5960 
ECI1 -0.6579 -0.4555 -0.1342 -0.4267 -0.3983 -0.5957 
LONP1 -0.6584 -0.3171 -0.1746 -0.3718 -0.4273 -0.6419 
ZNF230 -0.6587 -0.3445 -0.0542 -0.3332 -0.1195 -0.5994 
TTC32 -0.6588 -0.2615 -0.2733 -0.3790 -0.3569 -0.5305 
GJB6 -0.6591 -0.5029 0.0071 -0.2432 -0.0373 -0.3829 
PSMG1 -0.6594 -0.4423 -0.1589 -0.4074 -0.3548 -0.6420 
RHOC -0.6598 -0.5002 -0.1183 -0.3381 -0.4437 -0.5455 
P4HA1 -0.6603 -0.3314 -0.0868 -0.2579 -0.2308 -0.6249 
ZNF347 -0.6607 -0.1100 -0.3369 -0.2494 -0.1691 -0.2122 
IMMP2L -0.6607 -0.9340 -0.2982 -0.6911 -0.5323 -0.7784 
CTC-260E6.6 -0.6612 -0.6421 -0.2175 -0.0811 -0.5058 -0.5161 
GRAMD3 -0.6625 -0.4140 -0.2342 -0.1928 -0.6083 -0.5531 
SAV1 -0.6627 -0.3896 -0.1783 -0.3259 -0.4703 -0.7704 
ZSCAN20 -0.6632 -0.3346 -0.2194 -0.3413 -0.5799 -0.7880 
ETV2 -0.6633 -0.3682 -0.2614 -0.5979 -0.1108 -0.2854 
THNSL1 -0.6642 -0.5584 -0.0759 -0.4092 -0.1914 -0.6591 
DHRS4 -0.6643 -0.3357 -0.1662 -0.1934 -0.1988 -0.3721 
EXOC6B -0.6645 -0.2303 -0.2671 -0.1985 -0.2089 -0.4401 
SNRPEP4 -0.6645 -0.4267 0.0734 0.0462 0.0043 0.0209 
RP11-809O17.1 -0.6646 0.2445 0.1407 0.1727 -0.2186 -0.1752 
CDCA7 -0.6646 -0.3696 -0.2038 -0.4497 -0.1295 -0.5604 
LYST -0.6648 -0.2667 -0.2776 -0.4145 -0.4979 -0.5423 
XPOT -0.6649 -0.3649 -0.1869 -0.3947 -0.4465 -0.6862 
CCNG1 -0.6650 -0.3612 -0.1973 -0.4004 -0.3042 -0.5505 
RAB8B -0.6656 -0.3579 -0.2239 -0.3741 -0.2520 -0.5173 
ATP2B1 -0.6663 -0.2533 -0.2016 -0.2893 -0.1673 -0.4784 
NEDD4L -0.6676 -0.6102 -0.2113 -0.4084 -0.2792 -0.6730 
AL161915.1 -0.6679 -0.0932 -0.3596 -0.0279 0.0514 -0.2122 




KLF11 -0.6682 -0.4796 -0.2201 -0.3009 -0.2293 -0.4393 
TNFRSF10A -0.6685 -0.4391 -0.3219 -0.3375 -0.2790 -0.5604 
STAMBP -0.6697 -0.4073 -0.2090 -0.3121 -0.3253 -0.4885 
MAP4K2 -0.6698 -0.3259 -0.1242 -0.3686 -0.1840 -0.5177 
IMPDH2 -0.6710 -0.3486 -0.0925 -0.3377 -0.2975 -0.5957 
MUT -0.6716 -0.3503 -0.0819 -0.2921 -0.2875 -0.5046 
NCR3 -0.6718 -0.2372 -0.0378 -0.1668 0.0264 -0.3892 
PAQR8 -0.6726 -0.4222 -0.1966 -0.4999 -0.0800 -0.3714 
C4orf32 -0.6729 -0.5480 -0.2326 -0.4485 -0.5105 -0.5192 
AC017002.1 -0.6739 -0.4770 -0.0373 -0.2080 -0.6405 -0.7914 
RASA4DP -0.6744 0.1998 0.1532 0.1430 -0.3492 -0.1934 
PDE4B -0.6750 -0.4814 -0.1927 -0.4061 -0.5281 -0.6928 
FBXO48 -0.6753 -0.3104 -0.0568 -0.1627 -0.1567 -0.7108 
SAMSN1 -0.6754 -0.3868 -0.1088 -0.3950 -0.4275 -0.4808 
CCDC28A -0.6764 -0.3027 -0.2721 -0.3235 -0.3730 -0.5408 
ARNTL2 -0.6779 -0.3014 -0.0404 -0.3557 -0.3204 -0.4640 
HSPD1P1 -0.6782 -0.3704 -0.1250 -0.4048 -0.2363 -0.6639 
PDCD4-AS1 -0.6798 -0.4845 -0.3684 -0.5708 -0.3353 -0.6234 
ZNF616 -0.6800 -0.2345 -0.1559 -0.1995 -0.3092 -0.4534 
AP000640.10 -0.6805 -0.1871 -0.2469 -0.9437 -0.2270 -0.1582 
GLCE -0.6812 -0.3512 -0.2342 -0.2133 -0.2304 -0.5509 
SCML2 -0.6814 -0.5047 -0.0939 -0.4141 -0.2312 -0.4049 
JMY -0.6817 -0.5208 -0.4596 -0.5876 -0.8291 -0.9346 
ACSF2 -0.6821 -0.4736 -0.1296 -0.3289 -0.1970 -0.5709 
RP11-463M16.4 -0.6824 -0.4773 -0.3709 -0.3540 -0.1935 -0.2793 
CHIC2 -0.6825 -0.2759 -0.2517 -0.2310 -0.5770 -0.5735 
C17orf76-AS1 -0.6843 -0.5296 -0.1583 -0.3766 -0.5005 -0.6846 
GADD45A -0.6845 -0.5284 -0.1562 -0.4878 -0.3601 -0.5901 
DPYD -0.6849 -0.4811 -0.3246 -0.4217 -0.2466 -0.5979 
SLC29A2 -0.6855 0.0185 -0.1453 -0.1057 -0.2270 -0.4177 
CCNG2 -0.6856 -0.5143 -0.3768 -0.4772 -0.4178 -0.7773 
CITED2 -0.6864 -0.4686 -0.2759 -0.3771 -0.4226 -0.7749 
MAPK13 -0.6866 -0.3469 -0.1392 -0.3027 -0.2908 -0.5859 
MAP2K6 -0.6872 -0.3219 -0.1220 -0.3641 -0.2485 -0.6300 
TBXAS1 -0.6874 -0.6185 -0.1588 -0.6461 -0.7131 -0.7170 
ZCCHC7 -0.6880 -0.4289 -0.2157 -0.4702 -0.3858 -0.5580 
AC018816.3 -0.6883 -0.1823 -0.5968 -0.4769 -0.1455 -0.2965 
NT5DC1 -0.6884 -0.3769 -0.2799 -0.3590 -0.3030 -0.5763 
FANCL -0.6884 -0.3772 -0.1028 -0.3757 -0.1872 -0.6488 
RP11-764K9.2 -0.6891 -0.4244 -0.3774 -0.3738 -0.6898 -0.7808 
TATDN1 -0.6893 -0.4348 -0.2450 -0.2789 -0.3245 -0.7252 
ZFAS1 -0.6895 -0.5692 -0.1727 -0.3641 -0.4595 -0.7572 




RNF32 -0.6901 -0.3049 -0.6299 -0.0987 -0.6253 -0.4233 
TLE1 -0.6907 -0.5717 -0.5561 -0.8906 -0.6938 -0.6202 
ZSCAN16 -0.6909 -0.2192 -0.1865 -0.2437 -0.2325 -0.3855 
PYHIN1 -0.6919 -0.4547 -0.2356 -0.5157 -0.5017 -0.6030 
WDR41 -0.6924 -0.3005 -0.0449 -0.2677 -0.2390 -0.6807 
SGK1 -0.6925 -0.3623 -0.1391 -0.3827 -0.6561 -0.6322 
AAED1 -0.6939 -0.1942 -0.1185 -0.0722 -0.2556 -0.4795 
GALM -0.6942 -0.4573 -0.1855 -0.3942 -0.6287 -0.7466 
MEOX1 -0.6954 -0.4838 -0.4562 -0.6354 0.1091 -0.4001 
PIK3AP1 -0.6971 -0.4302 -0.3836 -0.4663 -0.6934 -0.5770 
TNK2 -0.6975 -0.3453 -0.1957 -0.3782 -0.3635 -0.6319 
XRCC6BP1 -0.6977 -0.5053 -0.1088 -0.3636 -0.3899 -0.5950 
NBR2 -0.6983 -0.5269 -0.4064 -0.5332 -0.5562 -0.8459 
NFE2L3 -0.6988 -0.4027 -0.0945 -0.4115 -0.4855 -0.5093 
CCDC28B -0.6991 -0.3845 -0.0693 -0.3392 -0.0779 -0.4432 
CCR4 -0.6997 -0.7026 -0.3974 -0.7690 -0.6743 -0.8237 
C19orf48 -0.7000 -0.4271 -0.1863 -0.4840 -0.3562 -0.6265 
EIF4BP6 -0.7009 -0.4598 -0.1153 -0.2595 -0.2517 -0.6837 
TMEM44 -0.7010 -0.2979 -0.0045 -0.4684 -0.1347 -0.6419 
FBXO4 -0.7017 -0.4118 -0.1943 -0.4314 -0.4760 -0.6214 
MYO6 -0.7018 -0.4140 -0.1887 -0.3680 -0.8596 -0.6595 
ZNF219 -0.7026 -0.6278 0.0068 -0.4614 -0.6246 -0.6730 
KLF9 -0.7026 -0.3712 -0.1228 -0.3086 -0.4787 -0.7832 
CTC-788C1.1 -0.7031 -0.7488 0.0233 -0.4459 0.0273 -0.4852 
MRPL45P2 -0.7034 -0.3651 -0.2189 -0.4857 -0.1632 -0.8444 
KIF3C -0.7035 -0.4124 -0.1960 -0.4248 -0.2760 -0.6009 
GNAQ -0.7036 -0.3021 -0.1652 -0.3599 -0.3116 -0.5116 
AIF1 -0.7044 -0.5273 -0.0091 -0.3405 -0.3041 -0.5753 
AKAP3 -0.7047 -0.5223 -0.2970 -0.1873 -0.2613 -0.8586 
CDK6 -0.7049 -0.1508 -0.1529 -0.3110 -0.3196 -0.5516 
CRIM1 -0.7052 -0.3592 -0.2402 -0.3285 -0.3489 -0.5545 
C2CD4D -0.7061 -0.3442 -0.1815 -0.3058 -0.3069 -0.8121 
FOXN3 -0.7066 -0.3633 -0.3283 -0.4226 -0.3913 -0.5393 
FADS3 -0.7073 -0.4480 -0.2559 -0.5254 -0.3708 -0.4360 
NEIL3 -0.7076 -0.4319 -0.1714 -0.4021 -0.2791 -0.5210 
RP11-521C20.4 -0.7080 -0.4415 -0.2838 -0.3811 -0.8167 -0.1656 
DMC1 -0.7082 -0.3134 -0.0659 -0.3210 -0.2769 -0.4259 
AP3M2 -0.7084 -0.4306 -0.1353 -0.4211 -0.3604 -0.6508 
CDCA7L -0.7090 -0.4392 -0.1021 -0.3760 -0.2845 -0.5223 
VAV3 -0.7092 -0.3694 -0.1962 -0.2954 -0.2402 -0.4948 
PARVB -0.7095 -0.3661 -0.0586 -0.3525 -0.3648 -0.5856 
POC1B -0.7099 -0.3650 -0.1096 -0.3311 -0.3866 -0.6327 




HYLS1 -0.7115 -0.5159 -0.1872 -0.5014 -0.1913 -0.6019 
AC010733.5 -0.7115 -0.4173 -0.7363 -0.3483 -0.7247 -0.4187 
ZNF607 -0.7125 -0.6541 -0.1081 -0.4284 -0.5657 -0.7203 
ZNF90 -0.7133 -0.4176 0.0013 -0.5774 -0.4735 -0.7236 
PGBD1 -0.7137 -0.2597 -0.0740 -0.3527 -0.2424 -0.4636 
EOMES -0.7137 -0.4351 -0.2651 -0.4825 -0.4695 -0.4701 
AP1S2 -0.7137 -0.5165 -0.2280 -0.4334 -0.3263 -0.5716 
USP44 -0.7139 -0.4331 -0.1187 -0.3266 -0.3877 -0.7838 
NR4A2 -0.7150 -0.5650 -0.3288 -0.8140 -0.9180 -1.0218 
AC009299.3 -0.7162 -0.4967 -0.3212 -0.6126 -0.5665 -0.6036 
DOK4 -0.7163 -0.3548 -0.0455 0.0136 -0.1807 -0.6812 
BBS12 -0.7189 -0.2186 -0.2649 -0.4467 -0.3940 -0.7485 
FAM216A -0.7200 -0.4426 -0.1624 -0.3710 -0.4135 -0.7831 
LINC00484 -0.7206 -0.0637 -0.1412 -0.5501 -0.5005 -0.4319 
MYO1E -0.7212 -0.2567 -0.0343 -0.2569 -0.1047 -0.4877 
CCDC171 -0.7212 -0.0500 0.1919 -0.4002 -0.0195 -0.3118 
RHBDL3 -0.7214 -0.6416 -0.3063 -0.8031 -0.2294 -0.3819 
CHST2 -0.7248 -0.6702 -0.2879 -0.6250 -0.4880 -0.8685 
KLRB1 -0.7249 -0.5851 -0.4052 -0.6570 -0.5834 -0.5657 
CTBP2 -0.7259 -0.2061 -0.1264 -0.5858 -0.2768 -0.3513 
FBLN5 -0.7269 -0.4960 -0.2964 -0.3636 -0.6026 -0.7661 
CDC14A -0.7271 -0.4082 -0.3044 -0.4574 -0.3629 -0.5745 
KHDC1 -0.7277 -0.6905 -0.4245 -0.5804 -0.3660 -0.7562 
RP3-527F8.2 -0.7284 -0.2799 -0.0728 -0.1317 -0.2597 -0.4304 
ITGA4 -0.7287 -0.3227 -0.2340 -0.3851 -0.2403 -0.5619 
ARHGEF39 -0.7291 -0.2536 -0.1596 -0.4329 -0.3679 -0.5959 
KIAA0101 -0.7300 -0.3858 -0.1829 -0.4246 -0.2232 -0.5501 
AGAP3 -0.7302 -0.4243 0.0042 -0.4391 -0.4639 -0.6756 
MRPL10 -0.7306 -0.4393 -0.2711 -0.4339 -0.4522 -0.6350 
SH2B3 -0.7308 -0.4391 -0.3155 -0.6009 -0.1317 -0.3749 
PPIAP29 -0.7316 -0.4213 -0.2762 -0.3612 -0.2760 -0.7335 
EFCAB2 -0.7320 0.1259 -0.0038 0.2333 -0.2299 -0.1649 
RNLS -0.7344 -0.5390 -0.0683 -0.4350 -0.3015 -0.4334 
GJB2 -0.7351 -0.3226 -0.1586 -0.4447 -0.4765 -0.8220 
CBX7 -0.7355 -0.6523 -0.4076 -0.5406 -0.6024 -0.8359 
PRIM1 -0.7358 -0.3897 -0.0786 -0.4353 -0.2297 -0.5609 
MVK -0.7360 -0.4182 -0.2060 -0.4560 -0.2857 -0.6198 
IL2RA -0.7382 -0.3740 -0.0544 -0.2981 -0.5842 -0.7033 
TNC -0.7384 0.1451 -0.3269 -0.3742 -0.1964 -0.5707 
C9orf66 -0.7388 -0.0567 -0.1797 -0.1465 -0.2430 -0.3315 
PLAUR -0.7394 -0.0358 -0.0883 -0.2987 -0.4153 -0.4803 
PDCD4 -0.7401 -0.6375 -0.3937 -0.5668 -0.5732 -0.7304 




PDE4A -0.7412 -0.3937 -0.2268 -0.4668 -0.3731 -0.5334 
SCCPDH -0.7426 -0.4783 -0.1711 -0.4193 -0.4084 -0.4918 
SLC1A4 -0.7433 -0.4775 -0.3161 -0.5218 -0.4642 -0.6881 
RP11-214C8.5 -0.7435 -0.4328 -0.4519 -0.4568 -0.7564 -0.8173 
CCNB1IP1 -0.7439 -0.5304 -0.1939 -0.5205 -0.4123 -0.7054 
ENC1 -0.7455 -0.3395 -0.2809 -0.3974 -0.5735 -0.5864 
C12orf57 -0.7459 -0.5555 -0.2186 -0.4600 -0.2955 -0.5879 
LIMA1 -0.7463 -0.3958 -0.1344 -0.4454 -0.4620 -0.6486 
RPL4P1 -0.7481 -0.0036 -0.0864 -0.1120 -0.3299 -0.7626 
IFI27L1 -0.7484 -0.4533 -0.2748 -0.5729 -0.2704 -0.6496 
LINC00623 -0.7487 -0.4834 -0.5578 -0.7745 0.6437 -0.6364 
CARD17 -0.7509 -0.4017 0.0074 -0.5227 -0.5013 -0.2501 
SPATA7 -0.7513 -0.2255 -0.2782 -0.2170 -0.5344 -0.6160 
ZNF391 -0.7514 -0.2945 -0.2720 -0.5938 -0.2804 -0.3696 
AMZ2P1 -0.7514 -0.4155 -0.3278 -0.5755 -0.2863 -0.5125 
DGCR6 -0.7517 -0.2246 -0.4147 -0.3432 -0.5933 -0.7298 
ICAM2 -0.7529 -0.3725 -0.2364 -0.3733 -0.0967 -0.6207 
LRRCC1 -0.7534 -0.3171 -0.0900 -0.2847 -0.2893 -0.4976 
GPD2 -0.7548 -0.4074 -0.2865 -0.4055 -0.5104 -0.6270 
DAK -0.7561 -0.5791 -0.3769 -0.4166 -0.3904 -0.7467 
C17orf51 -0.7561 -0.3676 -0.0666 -0.4470 -0.5799 -0.7074 
RP11-24B19.3 -0.7562 -0.3626 -0.3548 -0.2075 -0.3774 -0.7185 
ZC3HAV1L -0.7564 -0.4274 -0.2046 -0.3000 -0.4472 -0.7491 
AKIP1 -0.7578 -0.5343 -0.0589 -0.4713 -0.2167 -0.5847 
PATL2 -0.7584 -0.5994 -0.3702 -0.6367 -0.6260 -1.1634 
SPRY4 -0.7610 -0.5089 0.0299 0.1652 -0.3169 -0.4453 
CERKL -0.7613 -0.3565 -0.2285 -0.3712 -0.3018 -0.5500 
RP11-430B1.2 -0.7613 -0.6401 -0.6011 -1.0001 -0.5891 -1.5799 
RP4-659J6.2 -0.7615 -0.5276 -0.4910 -0.4314 -0.6148 -0.6779 
SSBP2 -0.7619 -0.4395 -0.1660 -0.5024 -0.0709 -0.5052 
TBC1D19 -0.7634 -0.5089 -0.4514 -0.4322 -0.5347 -0.4924 
PIGV -0.7643 -0.5085 -0.2648 -0.4526 -0.5011 -0.7929 
ARL4A -0.7645 -0.5268 -0.3268 -0.3608 -0.2564 -0.6125 
MAPK8 -0.7646 -0.3970 -0.0941 -0.3348 -0.5693 -0.6869 
CTB-131B5.4 -0.7648 -0.6494 -0.6064 -0.0884 -0.2746 -0.5350 
ACP6 -0.7653 -0.3959 -0.0524 -0.3378 -0.3318 -0.5902 
PRELID2 -0.7654 -0.4667 -0.0299 -0.8992 -0.8436 -1.4027 
AC004381.6 -0.7655 -0.4190 -0.0994 -0.5011 -0.6161 -0.4405 
AP001816.1 -0.7663 -0.4832 -0.2596 -0.5872 -0.5224 -0.7859 
RAB31 -0.7676 -0.0322 -0.1034 -1.0908 -0.5548 -1.5476 
MCOLN2 -0.7678 -0.3822 -0.2757 -0.4141 -0.5265 -0.6906 
SPIN1 -0.7682 -0.3612 -0.1325 -0.3460 -0.2576 -0.6004 




DUSP4 -0.7707 -0.4500 -0.2435 -0.4293 -0.6223 -0.8291 
CDKN2A -0.7709 -0.5445 -0.2289 -0.5231 -0.2176 -0.5698 
SH3TC1 -0.7716 -0.3702 -0.2916 -0.8297 -0.4670 -0.6563 
TMEM2 -0.7717 -0.3134 -0.2275 -0.3468 -0.4648 -0.5704 
PALD1 -0.7726 -0.5606 -0.1397 -0.5142 -0.2211 -0.6287 
MYO5C -0.7744 -0.4250 -0.1331 -0.3951 -0.0847 -0.8338 
RTN2 -0.7745 -0.1911 -0.4218 0.0219 0.0444 -0.1879 
PBLD -0.7750 -0.6399 -0.4525 -0.5249 -0.6066 -0.8082 
FXYD7 -0.7752 -0.6290 -0.1885 -0.7642 -0.4138 -0.5400 
AC016747.3 -0.7764 -0.4996 -0.2509 -0.4273 -0.4436 -0.6624 
NAT6 -0.7766 -0.3226 -0.1713 -0.3117 -0.0973 -0.7372 
CTSH -0.7773 -0.3854 -0.0341 -0.2801 -0.1293 -0.5390 
KLRG1 -0.7774 -0.5350 -0.4106 -0.5308 -0.4591 -0.5550 
NR1H3 -0.7775 -0.3557 -0.3172 -0.3498 -0.1959 -0.3985 
RP11-393B14.1 -0.7783 -0.3744 -0.2388 -0.4024 -0.7723 -0.6718 
DHRS4L2 -0.7795 -0.4337 -0.1033 -0.3533 -0.3772 -0.5971 
RP11-89M16.1 -0.7799 -1.0826 -0.3773 -1.1140 -1.3245 -1.3427 
NFIL3 -0.7801 -0.4521 -0.2007 -0.3542 -0.4998 -0.7679 
RP11-968A15.2 -0.7804 -0.3887 -0.3700 -0.7244 -0.2368 -1.5351 
AC092295.7 -0.7819 -0.3492 -1.2658 -0.9178 -0.4843 -1.1167 
MAP3K7CL -0.7823 -0.2382 0.0205 0.0666 -0.1311 -0.7211 
CCPG1 -0.7831 -0.5127 -0.2429 -0.5254 -0.4169 -0.7109 
CTB-186H2.2 -0.7831 0.1166 0.1234 0.2330 -0.0384 -0.0638 
AC104820.2 -0.7832 -0.1122 -0.1230 -0.5070 -0.5089 -0.5646 
TP53I11 -0.7860 -0.6454 -0.2368 -0.8101 -0.5578 -0.8066 
SIRPG -0.7870 -0.4074 -0.1829 -0.3868 -0.1951 -0.5335 
AIM2 -0.7875 -0.5760 -0.1282 -0.5270 -0.8941 -0.7022 
CREB3L4 -0.7883 -0.4244 -0.1764 -0.3699 -0.4190 -0.6801 
NEDD9 -0.7892 -0.4348 -0.2572 -0.4531 -0.3759 -0.5761 
SLC43A1 -0.7895 -0.5570 -0.3346 -0.5460 -0.4245 -0.8257 
PPP1R15A -0.7915 -0.5669 -0.2636 -0.5156 -0.6927 -0.7775 
CPNE7 -0.7921 -0.7660 -0.4275 -0.5892 -0.3557 -0.9372 
BTG1 -0.7923 -0.5804 -0.2802 -0.5684 -0.5134 -0.7209 
FAR2 -0.7946 -0.3868 -0.1523 -0.4992 -0.3396 -0.4536 
PAM -0.7953 -0.5278 -0.3226 -0.5602 -0.6642 -0.6753 
CPNE8 -0.7958 -0.5449 -0.0555 -0.3647 -0.3436 -0.5526 
ZNF35 -0.7959 -0.6881 -0.0712 -0.4742 -0.6803 -0.5547 
GPR15 -0.7981 -0.4614 -0.3387 -0.4103 -0.4520 -0.6981 
RPL12P4 -0.7984 -0.5104 -0.0579 -0.2216 -0.6517 -0.4798 
MBNL2 -0.8009 -0.5886 -0.2684 -0.4815 -0.5115 -0.7373 
RP1-152L7.5 -0.8010 -0.5774 -0.2840 -0.5176 -0.3726 -0.7809 
NAMPT -0.8013 -0.4707 -0.1094 -0.3956 -0.5625 -0.7501 




ZC3H6 -0.8036 -0.4883 -0.4323 -0.3720 -0.6074 -0.5852 
SLC38A2 -0.8038 -0.4670 -0.1945 -0.4564 -0.4492 -0.7751 
ATP6AP1L -0.8044 -0.3579 -0.3777 -0.5927 -0.6107 -0.9665 
AKT3 -0.8051 -0.5179 -0.3009 -0.4371 -0.6430 -0.8416 
TGFBR3 -0.8057 -0.4314 -0.3378 -0.4340 -0.4253 -0.6499 
TIMD4 -0.8059 -0.2562 0.2607 -0.2154 -0.0601 -0.3241 
KIF3A -0.8061 -0.4245 -0.1265 -0.3487 -0.5586 -0.7360 
EAF2 -0.8068 -0.3033 -0.2143 -0.5005 -0.6501 -0.7009 
RAVER2 -0.8071 -0.6162 -0.1026 -0.5316 -0.6322 -1.0362 
AVPI1 -0.8101 -0.7288 0.0960 -0.5016 0.0322 -0.1572 
SLC26A4-AS1 -0.8139 -0.5379 0.2678 0.1963 -0.8044 -1.5368 
PPIAP11 -0.8139 -0.3723 -0.2621 -0.2192 -0.3728 -0.8088 
CEP128 -0.8155 -0.4375 -0.2799 -0.6185 -0.3509 -0.7188 
C20orf197 -0.8157 -0.2322 -0.3456 -0.3518 -0.3168 -0.5347 
RMI2 -0.8161 -0.4927 -0.1545 -0.5513 -0.3292 -0.5556 
HVCN1 -0.8166 -0.4907 -0.1521 -0.5550 -0.2256 -0.5379 
RBM38 -0.8186 -0.3608 -0.1070 -0.2654 -0.1971 -0.5735 
ADAM22 -0.8194 -0.5477 -0.3135 -0.6504 -0.3417 -0.9658 
RND1 -0.8209 -0.4539 -0.0466 -0.2141 -0.0409 -0.1222 
NAMPTL -0.8212 -0.3781 -0.1660 -0.3240 -0.5121 -0.6206 
EGR1 -0.8214 -0.5560 -0.2627 -0.5895 -0.7285 -0.7813 
EFCAB4A -0.8220 -0.4903 -0.1158 -0.5857 -0.0813 -0.9611 
LRRC1 -0.8224 -0.4899 -0.1055 -0.4318 -0.5562 -0.6802 
GAB2 -0.8227 -0.5131 -0.1487 -0.6614 -0.5042 -0.7244 
TMEM55A -0.8231 -0.7792 -0.2625 -0.6690 -0.4018 -0.7965 
APOBEC3H -0.8238 -0.3602 -0.1224 -0.4450 -0.3206 -0.5225 
HSPB1 -0.8250 -0.5465 -0.1438 -0.4302 -0.2857 -0.7317 
EPS8 -0.8256 -0.5450 -0.2568 -0.2965 -0.1913 -0.8268 
HSPA6 -0.8261 -0.5022 -0.2913 -0.8466 -0.6404 -0.7189 
ABHD17C -0.8272 -0.7127 -0.2331 -0.5831 -0.8461 -0.7847 
SMS -0.8273 -0.4632 -0.0950 -0.4589 -0.3086 -0.5631 
EDARADD -0.8279 -0.7005 -0.1804 -0.6956 -0.7125 -0.9128 
C7orf41 -0.8292 -0.4673 -0.3301 -0.4210 -0.5937 -0.6106 
RP11-1415C14.4 -0.8302 -0.2722 -0.5480 0.2961 -0.0291 0.4501 
SLC18B1 -0.8315 -0.5777 -0.2292 -0.4626 -0.3982 -0.7149 
TPM2 -0.8315 -0.5347 -0.4177 -0.4153 -0.0832 -0.6761 
ATXN1 -0.8328 -0.4229 -0.3823 -0.5704 -0.6122 -0.7585 
C5orf34 -0.8339 -0.4980 -0.3756 -0.5199 -0.3108 -0.6027 
NAB2 -0.8347 -0.4328 -0.1760 -0.5530 -0.3755 -0.6470 
C12orf60 -0.8350 -0.5324 -0.1162 -0.1369 -0.3128 -0.6661 
AUH -0.8357 -0.5027 -0.1948 -0.5293 -0.4901 -0.8328 
IFT81 -0.8358 -0.4737 -0.2553 -0.2701 -0.5318 -0.4553 




SLC22A18 -0.8361 -0.3665 -0.4786 -0.5079 -0.2888 -0.5903 
TFAP2E -0.8361 -0.5261 -0.2024 -0.3389 -0.6936 -0.6372 
CCDC141 -0.8372 -0.4041 -0.3017 -0.4128 -0.4380 -0.7231 
INPP5F -0.8385 -0.3670 -0.2521 -0.3976 -0.4212 -0.5841 
CDT1 -0.8396 -0.5181 -0.2434 -0.6112 -0.3258 -0.7066 
H1FX -0.8413 -0.6276 -0.2806 -0.4958 -0.4779 -0.7535 
CXCR4 -0.8420 -0.4735 -0.1130 -0.5027 -0.2344 -0.4810 
GEM -0.8436 -0.3158 -0.4811 -0.5428 -0.5837 -0.4158 
TESK2 -0.8455 -0.5514 -0.3282 -0.4464 -0.5460 -0.7920 
RIPK2 -0.8474 -0.6212 -0.3898 -0.6322 -0.5641 -0.7325 
CTPS2 -0.8485 -0.5142 -0.2806 -0.5026 -0.4952 -0.8051 
S100A5 -0.8487 -0.4524 -0.4435 -0.2411 -0.5825 -0.5387 
ABCA3 -0.8491 -0.5033 -0.2616 -0.7012 -0.5539 -0.8074 
RP4-575N6.4 -0.8499 -0.3689 -0.4154 -0.4452 -0.4504 -0.9311 
RAB39B -0.8549 -0.6355 -0.2118 -0.4334 -0.6681 -0.8706 
CTA-292E10.6 -0.8553 0.1707 0.1752 0.1598 -0.0360 -0.4979 
FGR -0.8571 -0.4598 -0.0825 -0.4947 -0.5497 -0.7305 
ZFP69 -0.8597 -0.3928 -0.1808 -0.3298 -0.5187 -0.5702 
SNX10 -0.8609 -0.3541 -0.0576 -0.3795 -0.3082 -0.5845 
BCAR3 -0.8613 -0.8805 -0.6167 -0.4414 -0.6660 -1.0523 
NFKBIL1 -0.8623 -0.4575 -0.3299 -0.3586 -0.4395 -0.7019 
COCH -0.8638 -1.4347 -0.1387 -0.3514 -0.5329 -0.6007 
AC147651.4 -0.8643 -0.4067 -0.2093 -0.4271 -0.5260 -0.7323 
RBMS2 -0.8674 -0.5899 -0.3437 -0.4328 -0.7181 -1.0053 
APOLD1 -0.8684 -0.4777 -0.3605 -0.5978 -0.3261 -0.7151 
MAFG-AS1 -0.8698 -0.8036 -0.3719 -0.3903 -0.3347 -1.0930 
CTC-303L1.1 -0.8709 -0.6170 -0.4106 -0.6054 -0.7060 -1.0080 
BACE1 -0.8714 -0.5563 -0.2624 -0.3658 -0.7073 -0.5603 
FAM84B -0.8715 -0.5622 -0.2553 -0.5243 -0.5901 -0.9045 
CMAHP -0.8726 -0.5426 -0.2420 -0.6533 -0.7171 -0.8602 
SAP30 -0.8733 -0.5627 -0.2141 -0.4051 -0.6118 -0.7014 
GPR174 -0.8738 -0.4463 -0.2398 -0.5716 -0.5082 -0.5766 
KIR3DX1 -0.8741 -0.1782 -0.2312 -0.4542 -0.8321 -0.7872 
LRMP -0.8744 -0.6414 -0.2733 -0.7296 -0.4875 -0.7170 
CCDC50 -0.8745 -0.5271 -0.1040 -0.3027 -0.7359 -0.7658 
KB-1027C11.4 -0.8750 -0.2722 -0.2190 0.0489 -0.6059 -0.1858 
COLQ -0.8759 -0.6474 -0.6087 -0.3856 -0.4579 -0.8351 
HIST1H2BG -0.8762 -1.0740 -0.1232 0.0802 -0.9426 -1.1353 
SLC27A5 -0.8798 -0.5768 -0.0473 -0.2109 -0.7008 -0.9311 
EVA1B -0.8802 -0.5681 -0.3383 -0.6043 -0.4459 -0.6882 
ZBTB16 -0.8806 -0.6783 -0.2606 -0.6582 -0.3841 -0.5178 
CREM -0.8811 -0.5621 -0.1694 -0.4536 -0.6270 -0.6240 




CCDC74A -0.8819 -0.4690 -0.2838 -0.6084 -0.5469 -0.7396 
FAM172BP -0.8821 -0.4965 -0.2318 -0.7078 -1.1834 -0.6844 
EVC -0.8833 -0.8110 -0.4485 -0.7745 -1.0277 -0.7340 
IRF4 -0.8846 -0.4151 -0.1993 -0.4592 -0.5333 -0.7893 
HOMER2 -0.8853 -0.4893 -0.0748 -0.4735 -0.2268 -0.5401 
THG1L -0.8911 -0.6268 -0.1432 -0.5090 -0.5311 -0.7338 
GPX4 -0.8920 -0.6471 -0.1082 -0.5920 -0.2479 -0.7389 
MICALCL -0.8922 -0.3605 -0.2466 -0.3817 -0.5645 -1.2432 
LEPR -0.8993 -0.4603 0.0335 -0.1865 -0.7849 -0.9532 
SPEF2 -0.9020 -0.3941 -0.3541 -0.3660 -0.5550 -0.6534 
LST1 -0.9021 -0.3602 -0.1197 -0.2938 -0.0333 -0.2939 
RP11-620J15.3 -0.9023 -0.8771 -0.3587 -0.5671 -0.6632 -0.8325 
TCEAL1 -0.9028 -0.4249 -0.0919 -0.5233 -0.4661 -0.6313 
CTD-2162K18.5 -0.9030 -0.8043 -0.4625 -0.5403 -0.3135 -0.5042 
CMC1 -0.9051 -0.6116 -0.2784 -0.6061 -0.5552 -0.7701 
LYN -0.9056 -0.4974 -0.3280 -0.6531 -0.8132 -0.8586 
NUDT6 -0.9061 -0.5311 -0.2294 -0.4939 -0.4036 -0.7963 
PMAIP1 -0.9063 -0.6012 -0.0856 -0.4637 -0.5451 -0.7891 
TRGC1 -0.9067 -0.5681 -0.2697 -0.6339 -0.5367 -0.6942 
IQGAP3 -0.9069 -0.5916 -0.1962 -0.5388 -0.1729 -0.6383 
ZCCHC18 -0.9080 -0.5295 -0.3473 -0.5342 -0.5006 -0.7132 
PLD1 -0.9093 -0.0854 -0.4081 -0.2204 -0.5622 -0.7748 
MYO18B -0.9109 -0.4138 -0.9072 -0.4960 -1.0174 -0.9636 
PLK1S1 -0.9122 -0.5810 -0.3517 -0.5688 -0.5768 -0.8378 
COQ2 -0.9125 -0.4566 -0.3079 -0.5567 -0.4037 -0.5951 
FCGR3A -0.9132 -0.5681 -0.3295 -0.6285 -0.7699 -0.6382 
JUP -0.9153 -0.4640 -0.2382 -0.5149 0.0354 -0.3939 
RP11-25K19.1 -0.9164 -0.5636 -0.0315 -0.8897 -0.5866 -0.7286 
NMB -0.9172 -0.9074 -0.4767 -0.7348 -0.4856 -0.7217 
GZMK -0.9201 -0.5918 -0.2826 -0.6436 -0.7210 -0.5687 
CTD-2006C1.2 -0.9204 -0.6425 -0.2946 -0.3606 -0.4409 -0.5317 
FCRLB -0.9204 -0.7073 -0.2205 -1.1962 -0.3160 -0.8529 
RP11-254F7.2 -0.9220 -1.1516 -0.4992 -0.5492 -1.0510 -1.2625 
MND1 -0.9222 -0.5315 -0.1943 -0.4083 -0.2561 -0.6835 
PTGER4 -0.9240 -0.5178 -0.2317 -0.5527 -0.3262 -0.6191 
FAM115B -0.9264 -0.2257 -0.8110 -0.6854 -1.0138 -0.5671 
NCALD -0.9266 -0.4916 -0.1528 -0.4428 -0.4273 -0.6286 
PAQR7 -0.9268 -0.5630 -0.0390 -0.6168 -0.4993 -0.5250 
RP11-104G3.2 -0.9275 -0.5485 -0.3732 -0.6449 -0.9893 -1.3363 
C18orf56 -0.9276 -0.7060 -0.2293 -0.9650 -0.6788 -0.6163 
RP11-446H18.3 -0.9298 -1.1454 -0.9266 -0.7006 -0.9697 -1.0216 
TRGV8 -0.9300 -1.0936 -0.2737 -0.7293 -0.4317 -0.7185 




MYO1D -0.9316 -0.6886 -0.2296 -0.3484 -0.7290 -0.6064 
ACTN1 -0.9321 -0.4716 0.0180 -0.4833 -0.1409 -0.6898 
TRIB3 -0.9337 -0.6691 -0.1741 -0.5911 -0.6781 -0.9640 
RP11-458F8.2 -0.9343 -0.5280 -0.0206 -0.1419 -0.2363 -0.7826 
NDFIP2 -0.9362 -0.5855 -0.0385 -0.5749 -0.5824 -0.5354 
TNFSF9 -0.9364 -0.5480 -0.1547 -0.5441 -0.6143 -0.7173 
CTB-55O6.8 -0.9378 -0.4216 -0.0774 -0.3106 -0.3752 -0.7528 
CLECL1 -0.9381 -0.4265 -0.2485 -0.4802 -0.6887 -0.5657 
TNFSF4 -0.9382 -0.8270 -0.2027 -0.7933 -0.6523 -0.7179 
GPR63 -0.9402 -0.3556 -0.2684 -0.7307 -0.5422 -0.6840 
PYROXD2 -0.9412 -0.3788 -0.2142 -0.3858 -0.2965 -0.8041 
PDE8A -0.9423 -0.4406 -0.2166 -0.4623 -0.5661 -0.7992 
DUSP10 -0.9429 -0.5739 -0.2905 -0.5573 -0.5322 -0.7487 
IRF5 -0.9431 -0.7214 -0.1472 -0.5792 -0.7666 -0.8129 
NECAB1 -0.9444 -0.4302 -0.4356 0.0520 -0.5317 -0.8986 
GFOD1 -0.9464 -0.4273 -0.1468 -0.6230 -0.5980 -0.7276 
ZNF821 -0.9465 -0.6686 -0.4442 -0.6040 -0.5812 -1.0079 
AVIL -0.9470 -0.4383 -0.4751 -0.3081 -0.4628 -1.4419 
MGLL -0.9493 -0.6771 -0.1920 -0.1405 -0.1928 -0.8726 
CCL5 -0.9557 -0.6420 -0.3520 -0.6026 -0.5856 -0.7732 
RP5-995J12.2 -0.9565 -0.7685 -0.3685 -0.6405 -0.3966 -0.6606 
SMAD7 -0.9565 -0.4744 -0.2194 -0.6134 -0.5402 -0.6791 
EXD2 -0.9571 -0.5975 -0.1643 -0.5421 -0.4992 -0.5184 
AC009948.5 -0.9599 -0.6574 -0.3231 -0.6232 -0.7392 -0.9683 
TRAV25 -0.9610 -0.5150 -0.2701 -0.2676 -0.0365 -0.4953 
SHMT2 -0.9642 -0.6055 -0.2165 -0.6524 -0.5508 -0.8768 
TGIF1 -0.9659 -0.6468 -0.3321 -0.7322 -0.7915 -0.9344 
PLCB1 -0.9666 -0.3503 -0.1421 -0.4534 -0.4987 -0.3778 
AC006369.2 -0.9669 -0.1211 -0.3534 -0.4607 -0.3796 -0.7545 
TRGV10 -0.9678 -0.5530 -0.2307 -0.6486 -0.4569 -0.8422 
NPM2 -0.9712 -0.2593 -0.3907 -0.2468 -0.8279 -0.4682 
LINC00426 -0.9713 -0.5463 -0.4298 -0.4631 -0.5140 -0.8789 
RHBDD2 -0.9717 -0.6062 -0.2596 -0.6938 -0.5934 -0.7780 
C1orf21 -0.9722 -0.8076 -0.4620 -0.6379 -0.6587 -0.7751 
CTD-2325M2.1 -0.9722 -0.8064 -0.3854 -1.4249 -0.5444 -0.2551 
CXCL16 -0.9737 -0.5764 -0.2141 -0.5264 -0.6948 -0.6658 
SLC41A2 -0.9744 -0.5745 -0.3402 -0.5362 -1.1079 -0.7856 
SLC4A4 -0.9755 -0.5056 -0.1983 -0.6021 -0.6348 -0.6444 
ARSD -0.9771 -0.5369 -0.4066 -0.9709 -0.5211 -0.8333 
ALCAM -0.9780 -0.5863 -0.0177 -0.4858 -0.4868 -0.9364 
TIAM2 -0.9786 -0.4754 -0.2541 -0.5481 -0.5405 -0.7345 
MAF -0.9797 -0.6097 -0.2933 -0.4744 -0.6436 -0.7000 




DNAJC18 -0.9800 -0.5756 -0.4065 -0.5753 -0.5918 -0.9241 
ATP5G2P4 -0.9812 -0.5403 0.0773 -0.6230 0.1596 -0.6759 
AHI1 -0.9831 -0.4610 -0.2201 -0.5875 -0.5833 -0.9250 
FAM43A -0.9841 -0.8798 -0.4553 -0.9699 -0.7356 -1.0938 
GMPR -0.9849 -0.7963 0.1461 -0.4972 -0.2998 -0.9514 
CDKN2B-AS1 -0.9856 -0.5220 -0.3670 -0.4698 -0.6043 -0.7888 
GAS2L1 -0.9862 -0.3901 -0.0522 -0.3336 -0.1682 -0.3810 
IFI44 -0.9881 -0.4294 0.0709 -0.3195 -0.4615 -0.7131 
C5 -0.9898 -0.7143 -0.3097 -0.6163 -0.1599 -0.9160 
IVNS1ABP -0.9917 -0.5307 -0.1718 -0.6263 -0.5960 -0.7710 
SCPEP1 -0.9953 -0.8215 -0.3789 -0.6033 -0.8020 -0.9362 
AP001055.6 -0.9959 0.0977 -0.7847 -0.7449 -0.0111 -0.8712 
PLEKHA5 -0.9981 -0.6318 -0.2077 -0.4782 -0.5780 -0.8378 
SLC44A1 -1.0003 -0.7311 -0.1992 -0.7601 -0.5821 -0.7734 
ABCG2 -1.0007 -0.3029 -0.4403 -0.6980 -0.3525 -0.2088 
ELL2 -1.0026 -0.6028 -0.3241 -0.6452 -0.9214 -0.9849 
CTC-378H22.2 -1.0041 -0.3913 0.1260 -0.7653 -0.2882 -0.8084 
GSTA4 -1.0044 -0.4236 -0.1256 -0.2516 -0.7353 -0.9220 
ROCK1P1 -1.0086 -0.8959 0.0079 -0.3740 -0.8033 -1.5254 
LAYN -1.0103 -0.9362 0.1232 -0.8808 -0.8750 -0.9945 
RP11-312J18.5 -1.0105 -0.6714 -0.0057 -0.6012 -0.5192 -0.5228 
ZEB2 -1.0141 -0.5024 -0.2687 -0.5271 -0.8771 -0.8445 
ZSCAN9 -1.0149 -0.7543 -0.4578 -0.9910 -0.9921 -1.0940 
GPR27 -1.0235 -0.4687 -0.3065 -0.4527 -1.2466 -1.3917 
FEZ1 -1.0256 -0.4195 -0.2393 -0.8741 -0.8579 -0.6344 
PRSS30P -1.0284 -0.8800 -0.2088 -0.6710 -0.8427 -1.1550 
MDFIC -1.0286 -0.6026 -0.2788 -0.5917 -0.4223 -0.7279 
GK -1.0336 -0.6271 -0.2429 -0.7017 -0.5852 -0.9126 
NEO1 -1.0339 -0.5443 -0.2311 -0.5271 -0.7643 -0.8842 
AMOTL1 -1.0357 -0.9210 -0.6758 -0.9175 -0.5355 -0.8182 
CRNDE -1.0379 -0.5973 -0.1459 -0.7977 -0.5565 -0.9504 
IFNLR1 -1.0388 -0.5116 -0.2582 -0.5525 -0.5823 -0.8901 
PRSS16 -1.0426 -0.1514 -0.4317 -0.3436 -0.0555 -0.1969 
RP3-340N1.5 -1.0433 -0.1770 -0.1271 0.0673 -0.3393 -0.6190 
CCDC112 -1.0464 -0.6134 -0.2200 -0.6547 -0.5482 -0.8734 
BTN2A3P -1.0466 -0.2804 -0.1146 -0.1575 -0.3198 -0.9183 
B4GALNT3 -1.0483 -0.2175 0.0136 -0.1085 -0.1590 -0.2537 
IL12RB2 -1.0507 -0.4447 -0.0840 -0.5394 -0.7227 -0.7008 
HLA-DQB1 -1.0511 -0.7634 -0.2574 -0.5127 -0.5267 -0.9206 
SLC11A1 -1.0528 -0.3796 -1.1520 -0.8886 -0.1580 -0.9550 
PEG10 -1.0542 -0.6568 0.0264 -0.7809 -1.1749 -1.4651 
EIF4EBP1 -1.0562 -0.7315 -0.2616 -0.7275 -0.7070 -0.9068 




CCNI2 -1.0579 -0.9104 -0.1259 -0.7655 -0.5149 -0.8695 
HMGN5 -1.0608 -0.6344 -0.1075 -0.7109 -0.6457 -1.1629 
CTD-3014M21.4 -1.0611 -0.7625 -0.4665 -0.4141 -0.1890 -0.7369 
SLMO1 -1.0614 -0.0169 -0.3981 -0.4299 -0.9964 -0.9884 
VSIG10 -1.0644 -0.6429 -0.2427 -0.7972 -0.7642 -0.9924 
APLF -1.0663 -0.2987 -0.5085 -0.4753 -0.4917 -0.7576 
MAMLD1 -1.0671 -0.5699 -0.4218 -0.8691 -1.0127 -0.9957 
METTL7A -1.0746 -0.6642 -0.3026 -0.6540 -0.3991 -0.9733 
RHEBL1 -1.0748 -0.4985 -0.0766 -0.4364 -0.5815 -0.8242 
AC012146.7 -1.0762 -0.4181 -0.1742 -0.5631 -0.3710 -0.6749 
B3GALNT1 -1.0797 -0.6729 -0.1062 -0.8096 -0.3738 -0.7048 
RP11-383H13.1 -1.0815 -0.8411 -0.3852 -0.9540 -1.0578 -1.3062 
PLA2G4C -1.0866 -0.1445 -1.8614 -1.1831 -1.6059 -1.6937 
PTGES3P2 -1.0907 -0.9132 -0.4234 -0.5791 -0.6904 -0.8822 
SYK -1.0920 -0.5639 -0.7501 -1.0299 -0.5618 -0.5277 
CAMK1D -1.0949 -0.7536 -0.5449 -0.7717 -0.5324 -0.7810 
TMEM170B -1.0955 -0.1976 -0.1873 -0.2790 -0.5129 -0.5990 
PIR -1.0966 -0.3337 0.2857 -0.1327 -0.4002 -0.9907 
HIST1H1E -1.0978 -0.5031 -0.4598 -0.3013 -0.7480 -0.7303 
RP11-472B18.2 -1.0981 -0.8205 -0.0602 -0.8755 -0.9035 -0.3129 
ADPRH -1.0987 -0.7638 -0.1888 -0.8312 -0.6739 -1.0050 
DUSP2 -1.1025 -0.8431 -0.3562 -0.7326 -0.5906 -0.8281 
TRGV9 -1.1029 -0.8260 -0.0780 -0.5666 -0.7259 -0.7346 
TRGC2 -1.1055 -0.6691 -0.3648 -0.6690 -0.6726 -0.7584 
METRNL -1.1094 -0.8312 -0.3241 -0.6128 -1.2386 -1.1003 
HIST3H2BA -1.1127 -0.2065 -0.8114 -0.5850 -0.6993 -1.3392 
NCKAP1 -1.1225 -0.8584 -0.3796 -1.1250 -1.0039 -1.0680 
CD70 -1.1229 -0.7910 -0.2550 -0.7290 -0.7603 -0.8095 
RAB37 -1.1235 -0.6439 -0.2755 -0.7974 -0.4106 -0.8551 
TNFRSF11A -1.1286 -0.7345 -0.0967 -0.5766 -0.9100 -0.7714 
SESN2 -1.1301 -0.8452 -0.2605 -0.8592 -0.9971 -1.1113 
TNFRSF4 -1.1310 -0.6405 0.0517 -0.6151 -0.7874 -0.9308 
IFIT2 -1.1353 -0.4056 0.0935 0.2264 -0.3918 -0.7373 
DYNC2H1 -1.1385 -0.6396 -0.4455 -0.6617 -1.0524 -0.8315 
SH2D1B -1.1396 -0.4223 -0.0895 -0.6172 -0.5718 -0.6650 
CCR2 -1.1401 -0.5956 -0.1507 -0.4739 -0.4071 -0.7041 
MYBL1 -1.1467 -0.5758 -0.3581 -0.7437 -0.4385 -0.6751 
INSR -1.1506 -0.3107 -0.3851 -0.2592 -0.1701 -0.6426 
ACTA2 -1.1552 -1.0147 -0.5222 -1.1455 -0.9442 -1.1134 
MLLT4 -1.1594 -0.7544 -0.2912 -0.6205 -0.7758 -0.9440 
MAN1C1 -1.1604 -0.8965 -0.4237 -0.8476 -0.8399 -1.0815 
AJUBA -1.1606 -0.8321 -0.6456 -0.8861 -0.2594 -0.8358 




MRC2 -1.1636 -1.2592 -0.6949 -1.1983 -1.0344 -1.5590 
BSPRY -1.1642 -0.7079 -0.0991 -0.6830 -0.6264 -0.8745 
TNFAIP3 -1.1680 -0.8008 -0.4336 -0.7914 -0.8607 -0.9098 
FHL1 -1.1688 -0.8842 -0.3027 -0.7966 -0.5378 -0.6743 
B3GALT2 -1.1698 -0.5224 -0.3698 -0.7097 -0.5100 -0.7114 
EPDR1 -1.1714 -0.6064 -0.2063 -0.5862 -0.6270 -0.7953 
GAS7 -1.1735 -1.0006 -0.4346 -1.1916 -0.9122 -0.8443 
CDKN2B -1.1774 -0.7044 -0.3784 -0.6718 -0.3166 -0.6060 
SLC9A7 -1.1822 -0.7845 -0.3137 -0.6391 -0.6823 -0.9232 
ENTPD1 -1.1849 -0.7830 -0.2690 -0.7225 -0.9330 -0.9457 
SETD7 -1.1874 -0.9758 -0.2889 -0.8475 -1.0544 -1.1214 
BATF3 -1.1905 -0.7254 -0.0767 -0.6541 -0.9180 -0.9594 
TCEAL4 -1.1923 -0.8481 -0.1607 -0.8418 -0.6098 -0.7595 
AC018642.1 -1.1947 -0.6848 -0.3360 -0.6299 -0.9548 -0.7109 
NR4A1 -1.1957 -0.4924 -0.1192 -0.5678 -0.7738 -1.0409 
TOX -1.1960 -0.7130 -0.3825 -0.8689 -0.7264 -0.9312 
APOBEC3B -1.1998 -0.6485 -0.3663 -0.9088 -0.6058 -0.9727 
CDCP1 -1.2034 -0.3278 -0.0201 -0.4705 0.2930 -0.2924 
AXIN2 -1.2053 -0.5088 -0.3546 -0.5048 0.0154 -0.2117 
KCNQ5 -1.2056 -0.6473 -0.2311 -0.7453 -0.4424 -0.8083 
AC016708.2 -1.2065 -1.1699 -0.2566 -0.6590 -0.1284 0.0369 
RP11-693N9.2 -1.2123 -0.6090 -0.3256 -0.4206 -0.5817 -0.7506 
RP11-132A1.4 -1.2144 -0.6970 -0.0462 -0.5017 -0.5079 -0.6012 
POU2AF1 -1.2151 -0.1676 -0.1263 -0.4787 -0.4801 -0.9110 
MIR155HG -1.2226 -0.7508 -0.0078 -0.7125 -0.8550 -1.2320 
EPHX4 -1.2226 -0.5465 -0.1635 -0.2820 -0.5292 -0.8859 
CKAP4 -1.2299 -1.0042 -0.2771 -0.8272 -0.5996 -1.1564 
IL17RB -1.2360 -0.9601 -0.2853 -0.7889 -0.7148 -1.2235 
RASGEF1B -1.2474 -0.4596 -0.3368 -0.8874 -0.6419 -0.6810 
EGFL6 -1.2528 -0.8208 -0.2479 -0.9859 -0.7659 -1.0421 
SPRED2 -1.2541 -0.8151 -0.2059 -0.6399 -0.4009 -0.7513 
RP11-474B16.1 -1.2559 -0.7732 -0.0763 -0.9169 -0.9811 -1.0703 
F8 -1.2581 -0.8077 -0.3116 -0.8486 -0.8033 -0.8952 
BCAT1 -1.2584 -0.8829 -0.3051 -0.7956 -1.1441 -1.3593 
RP4-781K5.8 -1.2659 -0.5769 -0.1520 -0.5102 -0.4046 -0.9734 
KRT7 -1.2725 -1.3567 -0.0896 -1.0814 -0.5743 -0.6434 
TPRG1 -1.2748 -0.6175 -0.2617 -0.8114 -1.0183 -1.1460 
HDAC5 -1.2779 -0.8205 -0.4643 -0.8380 -0.7123 -1.0872 
IFIT3 -1.2846 -0.4207 0.2119 0.3346 -0.4909 -0.7948 
XCL2 -1.2881 -1.2481 -0.3500 -1.0923 -1.0899 -0.8851 
FAM49A -1.2907 -0.7672 -0.4102 -0.8472 -0.9915 -0.8734 
RP11-162J8.3 -1.2919 -0.9105 -0.1054 -0.6311 -1.2332 -0.9083 




CTC-378H22.1 -1.2976 -1.1284 -0.5269 -0.4786 -0.0996 -0.5273 
WWTR1 -1.2983 -0.3122 -0.4057 -0.3543 -0.8637 -1.5122 
CYBRD1 -1.2986 -0.5258 -0.5521 -1.3167 -0.8889 -2.1404 
VNN2 -1.2993 -0.9042 -0.5054 -1.0233 -0.7790 -0.9869 
RP1-43E13.2 -1.3020 -0.0881 -0.5299 -0.2630 -1.2251 -0.5454 
ETV1 -1.3043 -0.8577 -1.0352 -0.8344 -1.4861 -1.4161 
LAIR2 -1.3086 -1.1228 -0.3466 -1.3713 -1.0570 -0.3454 
LINC00263 -1.3105 -0.7779 -0.1188 -0.5981 -0.6977 -1.2534 
NUDT7 -1.3166 -0.3268 -0.5024 -0.3364 -0.0286 -0.6730 
PHLPP1 -1.3170 -0.7770 -0.3778 -0.7446 -1.0504 -1.2423 
PLXNC1 -1.3174 -0.7495 -0.3946 -1.0818 -0.6087 -0.7583 
AK4 -1.3187 -0.4917 0.2902 -0.3425 -0.6017 -1.0114 
GYLTL1B -1.3215 -1.2056 -0.8919 -0.4455 -0.3223 -1.1960 
C10orf128 -1.3238 -0.8586 -0.2400 -0.7988 -0.8268 -1.0190 
Sep-03 -1.3265 -0.7457 -0.2100 -0.6143 -0.8005 -0.7949 
KB-1460A1.1 -1.3343 -0.4657 -0.4271 -1.2162 -1.2185 -1.4870 
SIGLEC12 -1.3405 0.0038 0.1870 -0.5491 -0.3251 -0.3957 
FAM174B -1.3406 -0.1719 -0.8388 -0.8115 -0.1979 -0.7510 
CCL3 -1.3421 -0.6336 -0.1543 -0.5365 -1.2904 -0.9831 
GCSAM -1.3424 -0.9424 -0.4625 -0.9965 -0.8708 -1.1202 
CLIC4 -1.3437 -0.8821 -0.2122 -1.0044 -1.0370 -1.1768 
ANGPTL6 -1.3482 -1.0289 -0.4290 -0.9754 -0.9246 -0.8690 
MYB -1.3484 -0.8321 -0.2097 -0.8881 -0.9349 -1.2411 
RP4-728D4.2 -1.3526 -0.9781 -0.2101 -1.0290 -0.7171 -1.1584 
RP1-111D6.3 -1.3596 -0.7157 -0.1849 -0.9442 -1.2849 -0.7554 
CCBP2 -1.3687 -1.2006 -0.5823 -0.9972 -1.3576 -1.4388 
SMIM14 -1.3723 -1.0382 -0.4189 -0.8210 -0.9167 -1.1369 
EGR2 -1.3762 -0.9219 -0.3495 -1.0966 -1.1224 -1.2070 
TSC22D3 -1.3818 -1.0942 -0.4126 -0.9601 -0.9773 -1.2869 
ELOVL4 -1.3835 -0.9316 -0.3317 -0.7515 -1.1304 -1.2774 
AC092580.3 -1.3886 -1.0533 -0.3070 -2.0557 -1.5760 -1.4657 
RHOB -1.3921 -1.1356 -0.1555 -0.8726 -1.3802 -1.3018 
ATF3 -1.3931 -0.9571 -0.0327 -0.6744 -1.0521 -1.2321 
CFH -1.4026 -0.8837 -0.3753 -0.5734 -1.1187 -1.4285 
HLA-DQA1 -1.4066 -0.9560 -0.4891 -0.8221 -1.2236 -1.1190 
CD109 -1.4124 -0.8244 -0.3425 -1.1258 -0.5692 -1.0603 
FGFR1 -1.4153 -0.8627 -0.2346 -1.0570 -0.6093 -0.9869 
TRGV7 -1.4158 -0.7115 -0.3514 -1.2096 -0.5730 -0.8149 
hsa-mir-146a -1.4170 -0.8152 -0.8279 -1.4166 -1.2540 -1.2757 
AC069363.1 -1.4228 -0.2498 -0.5210 -0.6996 -0.5588 -0.4213 
FBP1 -1.4244 -1.8977 -0.9626 -1.2072 -1.7289 -0.8864 
TRAJ44 -1.4258 0.3090 -0.5261 0.5525 -1.1168 0.4797 




SOCS2 -1.4314 -0.9425 -0.2548 -0.9190 -0.8299 -1.0778 
MLK4 -1.4352 -1.1642 -0.0814 -1.0524 -1.1240 -1.5616 
CD160 -1.4444 -0.7051 -0.3348 -0.5844 -0.5431 -0.5951 
CTD-2514K5.2 -1.4564 -1.1785 -0.9946 -1.2828 -1.5298 -1.3325 
PRSS57 -1.4624 -0.8750 -0.2270 -0.6563 -0.3216 -1.1403 
RP11-227H4.4 -1.4779 -0.3095 0.1755 -0.5343 -1.0964 -0.7870 
DTHD1 -1.4800 -1.0326 -0.9152 -1.0638 -1.4542 -0.9688 
ZC2HC1A -1.4801 -0.7638 -0.4372 -0.7825 -0.9992 -1.0169 
PTPRM -1.4840 -1.0722 -0.8763 -1.4519 -1.3766 -1.1615 
MCAM -1.4860 -1.3015 -0.0471 -1.0263 -0.5455 -1.0635 
RDH10 -1.4878 -1.0086 -0.2603 -1.1148 -1.1887 -1.2586 
IL4I1 -1.4938 -1.3972 -0.4019 -0.8572 -1.1717 -1.2718 
TRAJ47 -1.5015 -0.7294 -2.1444 -3.5850 -1.9773 -2.4854 
PROK2 -1.5040 -0.6492 -0.1082 -0.5634 -1.1225 -1.2357 
EXTL2 -1.5140 -1.1609 -0.3020 -0.8646 -0.7777 -1.4891 
GNA11 -1.5237 -0.5081 -0.3320 -0.6979 -0.9607 -1.5614 
CACNA1I -1.5238 -1.3133 -0.7530 -1.1700 -0.8889 -1.2881 
RGS2 -1.5298 -1.1999 -0.5421 -1.1337 -1.1262 -1.5239 
ABCG1 -1.5307 -0.9766 -0.2904 -1.0410 -0.7223 -1.1715 
AC002331.1 -1.5390 -1.9962 -0.3282 -1.2615 -1.7754 -1.1028 
MLF1 -1.5421 -0.3104 -0.1943 -0.4154 -0.6614 -0.3751 
HLA-DQA2 -1.5455 -0.8591 -0.6125 -0.6288 -1.2978 -1.3029 
ST8SIA6 -1.5505 -1.1986 -0.5889 -1.2688 -1.5947 -1.3733 
VLDLR -1.5589 -0.9198 -0.2018 -1.1129 -0.9962 -1.4626 
COLGALT2 -1.5613 -0.7899 -0.9097 -1.3545 -1.4156 -1.7317 
SHC4 -1.5633 -0.5787 0.0376 -0.7634 -1.4710 -1.1053 
CD86 -1.5659 -0.9087 -0.3431 -0.9812 -1.2651 -1.3400 
SMOX -1.5689 -1.2219 -0.2226 -1.0511 -1.2073 -1.7268 
AC013460.1 -1.5733 -0.9653 -0.6377 -0.0345 -0.2147 -1.4282 
TNFRSF9 -1.5843 -0.9899 -0.3567 -0.9718 -1.2482 -0.9954 
LIF -1.5955 -0.9217 0.0394 -0.9779 -0.4472 -0.9116 
FILIP1L -1.5965 -1.1477 -0.3689 -0.9775 -0.6716 -0.8103 
ZDHHC14 -1.6029 -1.0677 -0.4594 -1.1336 -0.9652 -1.1009 
COL9A2 -1.6112 -0.7269 -0.2882 -0.9545 -0.8801 -0.8838 
SMKR1 -1.6173 -1.1514 0.0641 -1.0061 -0.7246 -0.8368 
ZNF826P -1.6206 -0.5070 0.0502 -0.3824 -0.8595 -0.8104 
NXPH4 -1.6431 -1.3705 -0.3764 -1.5653 -1.5850 -1.2930 
SHROOM1 -1.6453 -0.6577 -0.0887 -0.9376 -0.9913 -0.8844 
PTGIR -1.6482 -0.8085 -0.4503 -1.1422 -0.3349 -1.5684 
SOCS2-AS1 -1.6518 -1.0139 -0.4065 -1.2032 -0.6335 -1.1046 
PLAU -1.6676 -1.0243 0.1098 -0.8621 -0.7045 -1.3599 
NEK6 -1.6741 -1.0744 -0.3981 -1.2551 -0.5816 -1.0958 




CADM1 -1.6789 -1.2384 -0.4143 -1.0012 -1.3205 -1.2550 
SLC35F3 -1.6899 -1.1424 -0.1352 -1.0789 -0.6915 -1.1864 
HECW2 -1.7053 -0.9592 -0.5627 -0.8310 -1.5299 -1.3848 
RP3-395M20.9 -1.7061 -1.5222 -1.4009 -0.5006 -0.0910 -0.3793 
EPAS1 -1.7120 -0.9578 -0.1830 -0.9356 -1.1528 -1.2467 
EEF1A2 -1.7120 -1.6435 -0.4626 -1.7315 -1.4138 -1.4783 
GNAO1 -1.7165 -1.1909 -0.7546 -1.5552 -1.0881 -1.2471 
HDAC9 -1.7167 -0.9668 -0.6865 -0.8029 -0.9934 -1.0500 
CD83 -1.7176 -1.3224 -0.2412 -1.5508 -0.8559 -1.0636 
SLC14A1 -1.7269 -1.1190 -0.8137 -0.9786 -0.7623 -0.7589 
SGCE -1.7364 -0.7304 0.0607 -0.3269 -1.2241 -1.1203 
CD80 -1.7406 -1.1692 -0.1166 -1.0225 -0.4186 -0.9834 
ZSCAN31 -1.7793 -1.3082 -0.1915 -0.8850 -1.0263 -1.0563 
CCR8 -1.7985 -1.2059 -0.1731 -1.3214 -0.7736 -1.1042 
AKR1C3 -1.7994 -1.4972 -0.4658 -1.1240 -0.8013 -1.1070 
AARD -1.8024 -1.2760 -0.5285 -1.3027 -1.2862 -1.2029 
FTH1P22 -1.8028 -1.0590 -0.1801 -1.5404 -1.0945 -1.4604 
TRPC1 -1.8035 -1.1752 -0.2691 -1.1442 -0.8229 -1.4157 
RNASE6 -1.8080 -1.7054 -0.3879 -1.3982 -0.8195 -1.9551 
CHN2 -1.8207 -1.0994 -0.5884 -1.1232 -1.1580 -1.2906 
LMCD1 -1.8385 -0.6898 -0.0995 -0.8901 -0.8362 -0.7263 
PRKCE -1.8409 -1.3543 -0.3779 -1.0875 -1.6272 -1.6496 
SERPINE2 -1.8535 -1.0326 -0.3384 -1.3788 -1.1319 -1.5569 
PTPLA -1.8588 -1.7630 -0.2154 -0.7628 -1.2143 -1.7761 
RP11-316P17.2 -1.8651 -1.2230 -0.6473 -1.0875 -1.2775 -1.7980 
HNRNPA1P21 -1.8785 -1.4646 -0.4509 -1.4415 -0.9763 -1.6186 
H1F0 -1.8977 -1.2063 -0.3541 -1.2197 -1.1443 -1.5898 
ISL2 -1.9011 -1.2745 -0.2716 -1.0804 -1.8711 -1.0231 
EVI5 -1.9022 -1.5972 -0.2422 -0.6511 -1.6150 -1.6371 
CLDN12 -1.9152 -0.9874 -0.4896 -1.3885 -1.3741 -1.5814 
GPT2 -1.9171 -1.2710 -0.3134 -1.4451 -1.4411 -1.7199 
TMEM63C -1.9202 -1.1188 -0.2807 -0.9474 -0.8550 -1.3003 
APBA1 -1.9345 -1.0309 -0.4154 -1.2701 -1.4183 -1.4878 
SH3RF2 -1.9535 -1.8396 -0.9633 -0.7729 -1.0455 -1.8322 
ETV5 -1.9557 -1.9587 -0.2133 -1.5994 -1.5368 -1.8280 
HHLA2 -1.9611 -1.0700 -0.1601 -1.0144 -1.2236 -1.5596 
FAM211B -1.9646 -1.2337 -0.3112 -1.0984 -1.1872 -1.2321 
TIGIT -1.9650 -1.3866 -0.4877 -1.4175 -1.5224 -1.4713 
CCR3 -1.9676 -0.9073 -0.5284 -0.7120 -1.0178 -1.0756 
RAMP1 -1.9946 -1.0380 -0.2428 -1.0469 -0.4671 -0.7803 
UST -2.0027 -1.2015 -0.3294 -1.5175 -0.9537 -1.2755 
SBF2-AS1 -2.0080 -1.1594 -0.3368 -1.2521 -1.1931 -1.3161 




RP11-305L7.1 -2.0231 -0.9927 -0.3709 -0.8816 -1.1277 -1.3266 
PDGFD -2.0343 -1.6644 -0.6563 -1.1761 -1.4919 -1.3524 
ILDR1 -2.0503 -1.4728 -0.3440 -1.5307 -1.3562 -2.2420 
MARVELD1 -2.0643 -1.5342 -0.3659 -1.3757 -1.0159 -1.0925 
ETV4 -2.0689 -1.0382 -0.1188 -0.8342 -1.1752 -1.1530 
TRIB1 -2.0731 -1.2947 -0.4780 -1.2525 -1.3242 -1.6648 
RGS16 -2.0775 -1.6428 -0.5862 -1.4204 -1.8280 -1.9300 
PACSIN1 -2.0970 -1.2859 -0.2482 -1.4204 -1.3939 -1.6956 
CDC14B -2.1269 -1.4621 -0.3226 -1.0596 -1.7175 -1.8913 
S100P -2.1550 -1.1307 -0.6680 -1.6559 -1.2599 -1.0507 
RGS1 -2.1847 -1.6731 -0.5279 -1.5413 -1.8283 -1.6738 
CCL23 -2.1963 -2.0948 -0.8879 -0.7789 -1.9587 -1.3470 
RP11-324I22.3 -2.2246 -1.2847 -0.7059 -0.6587 -1.4423 -0.3626 
CTH -2.2264 -1.6956 -0.4262 -1.5990 -2.0658 -1.9254 
EBI3 -2.2566 -2.2613 -0.0471 -2.2934 -1.8330 -1.8334 
GNG8 -2.2662 -1.5955 -0.2884 -1.5850 -0.6521 -1.3395 
BCAS2P2 -2.4106 -1.5035 -0.4204 -1.4667 -1.2065 -1.9103 
NKD2 -2.4574 -1.4123 -0.7114 -1.6986 -0.9969 -1.1621 
COL5A2 -2.5477 -1.5462 -0.5162 -1.6741 -1.1936 -1.7579 
CHDH -2.5647 -1.6016 -0.4837 -1.3150 -1.8133 -2.7518 
PTK2 -2.5670 0.1284 -0.4194 -1.2568 -2.4050 -2.0315 
FAM167A -2.6891 -1.8819 -0.5494 -1.4746 -1.1248 -2.2974 
IL13 -2.7009 -1.5728 -0.0258 -1.6228 -1.5817 -1.2959 
COX20P2 -2.8300 -1.8444 0.1314 -2.0255 -1.7658 -2.2441 
STC2 -2.8577 -1.9295 -0.1391 -1.5322 -2.0535 -2.4257 
DAPK1 -2.9233 -1.2684 0.0361 -2.6856 -0.7090 -1.9053 
AKR1C7P -3.0840 -1.9061 -0.5085 -1.8559 -0.7414 -2.1831 
AC099552.4 -3.0950 -1.3288 -0.1326 -1.5604 -1.7862 -2.4010 
DNAJC12 -3.2696 -2.2876 -0.4569 -2.0108 -2.0944 -2.5067 






Appendix Table 3. Genes associated with an exhausted CD8 T cell 
phenotype. List of genes previously identified as upregulated (1) or 
downregulated (-1) in exhausted CD8 T cells (Bengsch et al., 2018). Their 
corresponding log2 fold change induced by WTD at 50 nM in this study is shown 








S100A9 1 4.409391 
ACE 1 2.687795 
LGALSL 1 1.390236 
CD7 1 1.07537 
DAPK2 1 0.895695 
STAT3 1 0.887183 
RENBP 1 0.865449 
LAG3 1 0.831617 
UBASH3B 1 0.788562 
LIM2 1 -0.608384 
TIFA 1 -0.61033 
ADAM9 1 -0.62308 
DERL3 1 -0.624422 
NCF4 1 -0.630144 
DOCK7 1 -0.640155 
AFMID 1 -0.649064 
OXR1 1 -0.65231 
SAMSN1 1 -0.675389 
SGK1 1 -0.69247 
CDK6 1 -0.704876 
SUOX 1 -0.710546 
EOMES 1 -0.713721 
NR4A2 1 -0.715028 
MYO1E 1 -0.721196 
CHST2 1 -0.724764 
KLRB1 1 -0.724909 
CDC14A 1 -0.727093 
GJB2 1 -0.735064 
GPD2 1 -0.754813 
PRELID2 1 -0.765364 
DUSP4 1 -0.770669 
TMEM2 1 -0.771667 




CEP128 1 -0.815531 
EGR1 1 -0.821417 
ATXN1 1 -0.832809 
RAB39B 1 -0.854936 
FGR 1 -0.857058 
MYO18B 1 -0.910937 
GZMK 1 -0.920116 
PTGER4 1 -0.923961 
NDFIP2 1 -0.936174 
TNFSF4 1 -0.938183 
ALCAM 1 -0.978035 
AHI1 1 -0.983066 
IFI44 1 -0.988114 
GSTA4 1 -1.004397 
MDFIC 1 -1.02861 
CCDC112 1 -1.046438 
HLA-DQB1 1 -1.051093 
SUV39H2 1 -1.091967 
SYK 1 -1.091967 
TMEM170B 1 -1.095479 
METRNL 1 -1.109433 
SH2D1B 1 -1.139647 
MYBL1 1 -1.146663 
GAS7 1 -1.173454 
ENTPD1 1 -1.184866 
TOX 1 -1.196013 
POU2AF1 1 -1.215056 
CKAP4 1 -1.229929 
IFIT3 1 -1.284612 
C10orf128 1 -1.323768 
ZC2HC1A 1 -1.480093 
CD86 1 -1.565925 
PPFIBP1 1 -1.674597 
CD83 1 -1.717614 
CD80 1 -1.74058 
TRPC1 1 -1.8035 
RNASE6 1 -1.807966 
CHN2 1 -1.820656 
TIGIT 1 -1.965003 
ILDR1 1 -2.050287 
TRIB1 1 -2.073117 
RGS16 1 -2.077546 




RCN3 -1 1.884982 
TCF7 -1 1.323565 
CCR7 -1 1.215875 
IL17RA -1 0.956607 
FAM69A -1 -0.604967 
ACYP1 -1 -0.634779 
HIBADH -1 -0.646926 
PPM1L -1 -0.657046 
PSMG1 -1 -0.659389 
NEDD4L -1 -0.667623 
GLCE -1 -0.681181 
TLE1 -1 -0.690656 
AAED1 -1 -0.693927 
C12orf57 -1 -0.74589 
MAPK8 -1 -0.764629 
THG1L -1 -0.891135 
SPEF2 -1 -0.901969 
SMAD7 -1 -0.956494 
RAB37 -1 -1.123516 
AXIN2 -1 -1.205297 
EEF1A2 -1 -1.711985 
 
 
